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 Hyperuricaemia, pathologically defined as the presence of higher levels of serum 
urate, results from a compromise in the delicate balance between the production and 
excretion of urate primarily in the liver and the kidneys, respectively. Hyperuricaemia is a 
prerequisite for gout, a painful inflammatory arthritis. The symptoms of gout arise from 
the body’s immune response to monosodium urate crystals that accumulate in the 
synovial fluid of the joints. Hyperuricaemia and gout are complex traits. A number of 
genetic loci confer risk to develop hyperuricaemia. Genome-wide association studies 
(GWAS), an indispensable tool in population genetics, has identified at least twenty eight 
genomic loci that contain variants affecting serum urate concentration. Gene-environment 
interactions also play a significant role in this context. Exogenous factors such as the 
intake of purine-rich foods increase the frequency of gout flares. Population-specific 
genetic effects on gout are as evident, if not more, as for other complex phenotypes. 
 The prevalence of gout is much higher in the New Zealand Polynesian population 
compared to other populations. Approximately 7% of New Zealand Māori and Pacific 
Island people and 3% of New Zealand Europeans are affected by gout. The coexistence of 
metabolic conditions with gout, usually called gout-comorbidities, adds another level of 
complexity. However, not many studies have attempted to address the causal relationship 
between these traits. In fact, my research project was instigated as an attempt to study the 
causal associations between gout and its comorbidities and fill in some gap in the 
scientific literature. The research was, however, limited to three metabolic 
conditions/comorbidities of gout – imbalanced iron homeostasis, metabolic syndrome and 
disrupted lipid metabolism. 
 My study shows an association between increased serum ferritin and the risk of 
gout and seeded an idea that the consumption of iron-rich diet may play a role in 
increasing the frequency and severity of gout flares. Genetic association analysis using 
two variants in the HFE gene was done to confirm the association between ferritin and 
urate, which showed positive association in a smaller dataset and provoked the idea to 
investigate the causality, if it exists, between gout and iron metabolism. Using the robust 
‘Two-sample Mendelian randomisation’ approach and exploiting summary statistics data 
from two large GWA studies, I was able to find an evidence of a causal effect of iron on 
urate metabolism, but not urate on iron metabolism. 
 
 ii 
 In the context of the metabolic syndrome, the role of variants within/near the 
ADRB3, MC3R, MC4R and ADTRP genes were investigated. The positive effects 
identified for these variants supported the possible involvement of obesity and insulin 
resistance-related genes in gout pathophysiology. 
 With the help of gene sequencing-based rare variant analyses, several novel 
population-specific association signals were found within the coding regions of two lipid-
related genes, LRP2 and A1CF. Polynesian-specific novel genetic effects were identified 
to be predictive for gout for common variants within the LRP2 gene. Rare variants within 
the LRP2 gene were also identified and a higher prevalence of non-synonymous 
polymorphisms that can increase the risk of hyperuricaemia was observed in European 
individuals compared to Polynesians. These results indicated LRP2 to contribute to the 
difference in gout prevalence between Māori and Pacific Island individuals compared to 
the New Zealand European population. 
 Collectively, my study reports a causal role of iron and ferritin in increasing 
serum urate concentration and the involvement of imbalanced iron homeostasis in 
hyperuricaemia. Also, positive genetic associations indicated that genes contributing to 
metabolic syndrome and lipid metabolism can increase the risk of gout, and also have 
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SECTION 1.1 INTRODUCTION TO URATE, GOUT AND 
METABOLIC DISEASE 
1.1.1 Background 
 The uric acid story began several centuries ago when the German-Swedish 
chemist, Karl Wilheim Scheele (in 1776), isolated the substance from a bladder stone. He 
called it ‘lithic acid’ by virtue of its acidic properties (reviewed in Richet (1995)). The 
name was later changed to ‘uric acid’ by George Pearson and Antoine Fourcroy, 
reflecting its presence in normal urine (Fourcroy, 1804). Since then, researchers across 
the globe have been intrigued to establish the physiological and pathophysiological roles 
of uric acid in the human body, especially following the scientific speculation of the 
crucial significance of uric acid homeostasis in the prevention and/or management of 
several disorders including gout. The story particularly relevant to disorders other than 
gout, however, remains incomplete and merits further exploration. 
1.1.1.1 Basic chemical properties of uric acid 
 Uric acid (C5H4N4O3; 2,6,8-trihydroxypurine) is a weak diprotic acid with pKa1 
~5.4 and pKa2 ~10.3. Under physiological pH (~7.4), it is mostly present in the form of 
monovalent urate anion formed by the dissociation of a proton from the molecule (Figure 
1.1). Therefore, the term urate is often used in literature to denote the dissociated 
monovalent anionic state of uric acid in the extracellular fluid. The terms uric acid and 
urate are interchangeably used to refer to the total uric acid pool in the body (Bobulescu 
and Moe, 2012). 
Figure 1.1: Formation of urate from uric acid via dissociation of one proton. Uric acid and urate are used 




1.1.1.2 Urate handling - evolutionary insight 
 Although purine degradation is conserved across species, the end product of 
degradation is species dependent. In several organisms including most other mammals, 
urate is only an intermediary product of metabolism and is further subjected to oxidative 
degradation by the enzyme uricase (urate oxidase) in the peroxisomes of hepatocytes to 
form allantoin. Allantoin, being water soluble, is relatively easily excreted by the kidneys 
(Briggs et al., 1977). However, birds, reptiles and some primates including humans, lack 
the uricase enzyme as a consequence of mutational silencing of the uricase gene. 
Evolutionary evidence suggests the occurrence of multiple missense and frameshift 
mutations in the promoter and coding regions of the gene during hominoid evolution, 
gradually decreasing the expression of the uricase gene and rendering the protein non-
functional (Kratzer et al., 2014; Masako et al., 2013; Oda et al., 2002). As a result, urate 
remains the end product of purine metabolism in these species and it is excreted as such 
by the kidneys (Rafey et al., 2003). Figure 1.2 illustrates the uricase mutations during the 
early hominoid evolution. 
 
Figure 1.2: Uricase mutation in early hominoid evolution. Figure illustrates the process of loss of uricase enzyme 
through space and time. Source: (Johnson et al., 2008). 
 The mechanism for the clearance of urate from the body largely depends on the 
presence or absence of functional catabolic enzymes in the pathway and varies from 




Figure 1.3: Flow sheet for conserved purine degradation and its variable end product metabolism among animal 
taxa. 1 indicates the end product of purine (AMP, IMP, GMP) metabolism in humans and other higher primates 
due to the evolutionary loss of uricase (indicated by red cross). Steps 2 to 9 illustrate the variation in end 
excretory products of purine metabolism between different species. Redrawn from Johnson et al. (2009b) and 
Lee et al. (2013).  
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1.1.1.3 Urate homeostasis in humans 
 In the human body, urate is the final breakdown product of purine catabolism. 
Degradation of endogenous (derived from nucleic acid metabolism) and exogenous 
purines (derived from dietary sources) result in the intracellular production of urate. In 
order to maintain a relatively constant (desirable) level of circulating urate in the body, a 
homeostatic mechanism functions to create a balance between the net production and 
excretion of urate. Urate homeostasis involves three determinants- its production in the 
liver, renal excretion and intestinal secretion (Rafey et al., 2003). The production of uric 
acid occurs primarily in the liver by the action of a molybdenum metalloenzyme called 
xanthine oxidase. This poorly soluble intracellular product enters the body’s circulation 
(as urate) by cellular efflux and is delivered to the kidney for excretion (Brondino et al., 
2006). Renal excretion of urate contributes to two-third of total urate excretion. A small 
proportion of urate that gains entrance to the intestine is degraded by the colonic bacteria 
and eliminated (Bobulescu and Moe, 2012; Rafey et al., 2003). This process, termed 
intestinal/extra-renal uricolysis, is especially significant when renal handling of urate is 
compromised (Sorensen and Levinson, 1975). 
Figure 1.4: Schematic representation of the key determinants of urate homeostasis in humans. Redrawn from 
Bobulescu and Moe (2012).  
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1.1.2 Renal handling of urate and hyperuricaemia 
 Once urate in circulation reaches the kidney, it is freely filtered. However, under 
normal conditions, bidirectional transport of urate occurs in the renal proximal tubules, 
resulting in > 90% of the filtered urate being reabsorbed and < 10% of the filtered urate 
being excreted. The proportion of filtered urate eventually excreted in the urine (as uric 
acid) is termed as fractional excretion of uric acid (FEUA) (Fushimi et al., 1990). The 
physiological value of FEUA under normal conditions is approximately 10% and is 
higher in females than males (Bobulescu and Moe, 2012). Fractional excretion of uric 
acid is indicative of renal function. 
 The serum urate level in humans is about ten times higher than in other mammals 
(Mandal and Mount, 2015). This can be attributed to the absence of the uricase enzyme 
and the urate reabsorption system in the kidney. The fact that the kidney invests resources 
in reabsorption of a large proportion of filtered urate compels us to speculate that urate is 
beyond an inert metabolic product in humans. Indeed, urate does have more roles to play 
in the human body apart from the undoubtedly important role of shuttling purine waste to 
the exterior (Richet, 1995). There is overwhelming evidence for its role as a respiratory 
and circulatory antioxidant (Carocho and Ferreira, 2013; Kang and Ha, 2014; Peden et al., 
1990). 
 Since the urate reabsorption system operates in the kidney, renal handling of urate 
is critical to maintain the desirable level of serum urate. The presence of a lower than 
normal level of serum urate is termed hypouricaemia. Hypouricaemia is defined as a 
serum urate concentration of < 0.2 mmol L-1 (Martín and Nieto, 2011). Defective urate 
reabsorption in the kidney has been shown to cause hereditary renal hypouricaemia 
characterised by hypouricaemia and increased FEUA (Windpessl et al., 2016). Hereditary 
renal hypouricaemia is caused by mutations in two genes encoding renal transporters in 
the proximal renal tubule, SLC22A12 (Solute carrier family 22 member 12) and SLC2A9 
(Solute carrier family 2 member 9) (Dinour et al., 2010; Komoda et al., 2004; Windpessl 
et al., 2016). Conversely, hyperuricaemia is described as the presence of a greater than 
normal level of circulating urate in the blood stream. 
 Hyperuricaemia can be caused by either increased production of uric acid in the 
liver and/or reduced excretion by the kidney and gut. This in turn may be a consequence 
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of excessive intake of purine rich foods, and/or defective endogenous purine metabolism 
and/or endogenous defects in the urate reabsorption/secretion system. A lower FEUA is 
indicative of hyperuricaemia. The commonly used threshold values to define 
hyperuricaemia in adults include serum urate concentration of > 0.41 mmol L-1 in males 
and > 0.35 mmol L-1 in females (Dalbeth et al., 2016). 
 Hyperuricaemia has been linked to diseases such as kidney stones and chronic 
uric acid nephropathy, evidence for causation being limited (Bobulescu and Moe, 2012). 
The relevance of hyperuricaemia in disease is most evident from its causal link with gout. 
Hyperuricaemia has also been described to be associated with gout-related comorbidities 
especially hypertension and diabetic renal disease (Doria and Krolewski, 2011; Perlstein 
et al., 2006) and found to be a concomitant of the metabolic syndrome (MetS) that 
encompasses hypertension, obesity, insulin resistance and dyslipidaemia (Mandal and 
Mount, 2015). Hyperuricaemia observed in non-symptomatic patients is described as 
asymptomatic hyperuricaemia (aHU) (Richardson, 1991). 
1.1.3 Gout 
 Gout being a complex disease is influenced by multiple genetic, environmental 
and interlinking risk factors (Robinson and Horsburgh, 2014). It is a painful inflammatory 
arthritic disease characterised by hyperuricaemia, hyperuricaemia being a necessary, 
although not sufficient, parameter for gout. Gout is the most common form of 
inflammatory arthritis in the elderly population. The global prevalence of gout is 
gradually increasing, which may be attributed partly to population aging, a rise in obesity 
and insulin resistance as well as changing lifestyle and dietary practices (Dalbeth et al., 
2016). The factors determining gout in the presence of hyperuricaemia are diverse and 
not completely understood (Dalbeth et al., 2016). 
 The basic pathophysiological feature of gout is the deposition of monosodium 
urate (MSU) crystals in the synovial fluid of the joints following longstanding 
hyperuricaemia. Gout is therefore referred to as a urate crystal deposition disease. Joints 
at the extremities/periphery are commonly affected (Underwood, 2006), especially the 
metatarsal phalangeal joint of the big toe (Dalbeth et al., 2016). The clinical features of 
gout arise due to the body’s innate immune response to the accumulated crystals. 
Diagnosis of gout includes an inspection of clinical history, microscopic examination, 
1| Introduction 
 9 
imaging and laboratory testing (Peláez-Ballestas et al., 2010). The presence of tophus, 
defined as chronic inflammatory granulomatous lesions formed in response to crystal 
deposition (Dalbeth et al., 2016) and elevated serum urate concentration, are strongly 
suggestive of gout (Janssens et al., 2010). 
Figure 1.5: Pathophysiology of gout: Acute gout is characterised by redness, swelling and severe pain due to 
formation of monosodium urate (MSU) crystals within the synovial spaces of joints and an inflammatory 
response, while longstanding untreated hyperuricaemia can lead to deposition of MSU crystals (tophi) and 
subsequent permanent damage to the joints. 
 Acute gouty arthritis, the most common clinical presentation of gout, is 
characterised by severe pain, redness, tenderness, heat and swelling of the affected joint 
and causes restricted joint movement (Rome, 2012). Exogenous factors that trigger gout 
flares are diverse and include dehydration, starvation, alcohol consumption and intake of 
purine rich foods (Choi et al., 2004b; Zhang et al., 2012a)An acute gout flare peaks 
within the first day of attack and typically lasts for about a week, in the absence of 
treatment (Bellamy et al., 1987; Lindsay et al., 2011; Snaith, 2003). 
 If left untreated, acute gout may progress to advanced stage gout commonly called 
‘chronic gout’. Chronic gout is essentially characterised by continuous low-level pain and 
frequent intermittent attacks (flares) of severe pain. Despite having low pain, the severity 
of gout may keep increasing over time (Choi et al., 2005b; Lindsay et al., 2011). This can 
lead to joint disability due to the formation of large deposits of MSU crystals in the joints 
called ‘tophi’ (singular: tophus) (Figure 1.5). Formation of tophi not only may be visually 
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distressing but can also cause irreparable damage to the joints in addition to restricted 
mobility (Choi et al., 2005b). 
1.1.3.1 Immunological perspective 
 Monosodium urate crystals are extremely potent elicitors of inflammation. A local 
immune response is evoked at the site of MSU crystal deposition via the recruitment of 
neutrophils, production of inflammatory mediators and proinflammatory cytokines (So, 
2008). This process involves components of the innate immune system that can detect 
cellular products released by damaged cells in the body. The initial inflammatory 
response is triggered by two components, the toll-like receptors (TLRs) namely TLR2 
and TLR4 (Akira and Takeda, 2004; Lim and Staudt, 2013), and the pattern recognition 
molecule called CD14 (Cluster of differentiation 14) (Fujihara et al., 2003). Multiple 
intracellular processes lead to the formation of an inflammasome complex that triggers 
the maturation of interleukin 1-beta (IL1-ß) from pro-IL1-ß, which is the major mediator 
of the inflammatory effect (So, 2008) (Figure 1.6). 
Figure 1.6: Immunological perspective of gout: MSU crystals activate monocytes via the Toll-like receptor 
(TLR) pathway and the inflammasome. Binding to TLR and CD14 promotes phagocytosis and cell activation 
through MYD88-dependent signalling mechanisms. In the cytosol, MSU crystals induce the formation of the 
NALP-3/NLRP3 (NACHT, LRR, and pyrin domain-containing-3) inflammasome and lead to caspase-1 
processing of pro-IL-1β. Activation of the endothelium by IL-1β increases trafficking of neutrophils to the 
inflammatory site. ASC, apoptosis-associated speck-like protein containing a caspase-associated recruitment 
domain; IL, interleukin; NF-κB, nuclear factor-kappa-B. Modified and redrawn from So (2008). 
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1.1.4 Genetics of hyperuricaemia and gout 
 Hyperuricaemia is a complex trait. Variants in dozens of genes play a role in 
conferring risk to develop the phenotype. The interplay between the genetic risk variants 
and environmental risk factors is of crucial significance (Robinson and Horsburgh, 2014). 
Genome-wide association studies (GWAS), typically used to scan the genome to identify 
common genetic variants, mostly single nucleotide polymorphisms (SNPs), causally 
associated with a given phenotype/trait, is a methodology that has significantly improved 
our understanding of the genetic basis of complex traits including hyperuricaemia. At 
least 28 loci conferring risk to develop hyperuricaemia have been identified to date. Two 
major urate loci, namely SLC2A9 and ABCG2, have been shown to collectively explain 3-
4% of variance in serum urate concentration and thereby strongly influence serum urate 
levels in the body (Köttgen et al., 2013). 
 Genome-wide association studies before 2013 identified a total of 11 urate loci, 
collectively explaining 5-6% variance in serum urate (Dehghan et al., 2008a; Döring et 
al., 2008; Kolz et al., 2009; Yang et al., 2010b). The loci were identified either in or near 
these genes; PDZK1, GCKR, SLC2A9, ABCG2, RREB1, SLC17A1, SLC16A9, SLC22A11, 
NRXN2, INHBC. The most recent serum urate GWAS data comes from Köttgen et al. 
(2013), who identified 18 novel urate related loci using the data from a population of 
>110,000 European individuals. The loci were identified in or near the TRIM46, INHBB, 
SFMBT1, TMEM171, VEGFA, BAZ1B, PRKAG2, STC1, HNF4G, A1CF, ATXN2, 
UBE2Q2, IGF1R, NFAT5, MAF, HLF, ACVR1B/ACVRL1, and B3GNT4 genes and 
collectively explained ~7% variance in serum urate concentration (Köttgen et al., 2013). 
 Given that hyperuricaemia is a prerequisite for the development of gout, it is 
highly likely that urate-associated genes are also associated with gout (Hollis-Moffatt et 
al., 2012a; Hollis‐ Moffatt et al., 2009; Köttgen et al., 2013; Phipps-Green et al., 2010). 
Recently 28 urate-associated loci, identified by Köttgen et al. (2013), were tested for their 
association with gout at the Merriman Laboratory (Phipps-Green et al., 2016) using data 
from > 4,000 New Zealand European and Polynesian individuals. In addition to SLC2A9, 
ABCG2, SLC17A1 and GCKR, significant associations with gout were identified, 
especially for four novel gout loci in or near IGF1R, PDZK1, MAF and HLF (Phipps-
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Green et al., 2016). These results also indicated a possible role of non-urate transporter 
genes in the development of gout. 
1.1.5 Prevalence of hyperuricaemia and gout 
 As mentioned before, serum urate concentration of ≥ 0.41 mmol L-1 in men and ≥ 
0.35 mmol L-1 in women is used to define hyperuricaemia (Dalbeth et al., 2016). The fact 
that average recorded levels of serum urate may fall differently within this range for 
different populations (explained hereafter) means that the prevalence of hyperuricaemia 
varies between different regions of the world (Table 1.1). For example, the average serum 
urate concentrations have been recorded to be as low as 0.24 mmol L-1 and as high as 
0.46 mmol L-1 in Brazilian and Taiwanese Aborigine males, respectively. For females, 
this range varies between 0.22 mmol L-1 to 0.37 mmol L-1 for Brazilian and Tibetan 
populations, respectively (Acheson and Florey, 1969; Chou and Lai, 1998; Gosling et al., 
2014). This average makes some populations to fall within the hyperuricaemic range e.g., 
Tibetans, Taiwanese Aborigine, Cook Island and New Zealand Māori (Brauer and Prior, 
1978; Chou and Lai, 1998; Evans et al., 1968). This, in turn, results in higher prevalence 
of hyperuricaemia in these populations (Chang et al., 2001; Prior et al., 1966). 
Table 1.1: Country specific prevalence of hyperuricaemia 
Country Prevalence (%) Country Prevalence (%) 
Brazil 13 Philippines 25 
China 6 to 25 Russia 17 
Indonesia 18 Samoa 33 
Iran 8 Saudi Arabia 8 
Italy 9 to 12 Seychelles 25 
Japan 20 to 26 South Korea 5 
Marshall Islands 85 Spain 5 to 11 
Mexico 11 Sweden 10 to 16 
Mongolia 5 to 18 Taiwan 10 to 52 
New Zealand 8 (non-Māori)/17 to 19 (Māori) Thailand 9 to 11 
Nigeria 17 Turkey 12 
Papua New Guinea 1 USA 21 to 22 
Source: (Smith and March, 2015). 
 Although hyperuricaemia is essential for the development of gout, their 
prevalence may differ for the same population. The reason behind is evident – not all 
individuals with hyperuricaemia develop gout. For example, Taiwanese Aborigines have 
the highest prevalence of hyperuricaemia while the prevalence of gout has been recorded 
to be highest in Australasian populations (explained in the subsequent paragraph). The 
average level of urate is higher in males than females, and so is the prevalence of gout 
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(reviewed in Kuo et al. (2015)). An approximate range of the worldwide prevalence of 
gout was recorded to be 0.02% (for countries in South Asia: Afghanistan, Bhutan, India, 
Nepal and Pakistan) to 0.39% (Australasian countries; Australia and New Zealand) in a 
2014 World Health Organisation (WHO) survey (Smith et al., 2014), however this is 
likely to be an underestimate owing to the method of data capture. According to a recent 
study by Kuo et al. (2015), the overall prevalence of gout was recorded to be > 1% in 
most developed countries (especially in Europe and North America) (Figure 1.7). The 
overall prevalence of gout was recorded to be 3.9% in the adult US population (age ≥ 20 
years) in the National Health and Nutritional Examination Survey (NHANES 2007-2008) 
(Zhu et al., 2011). For Canada, an estimated general prevalence was suggested to be ~3% 
in adults (Badley and DesMeules, 2003; O'Donnell et al., 2015). In Europe, Greece has 
been reported to have the highest prevalence of gout, at 4.75%, in the adult population 
(Anagnostopoulos et al., 2010). Kuo et al. (2014b) provided the latest estimate of gout 
prevalence to be 3.22% in the adult (age ≥ 20 years) UK population, with an overall 
population estimate to be 2.49%. The overall estimates are similar to what have been 
reported for other European countries i.e., 3.3% for Spain (Sicras-Mainar et al., 2013) and 
3.7% for the Netherlands (Picavet and Hazes, 2003). On the other side of the picture, 
within Europe, the lowest prevalence of gout (0.3%) has been reported for the adult 
population of Portugal (Reis and de Queiroz, 2014) and Czech Republic (Hanova et al., 
2006). 
Figure 1.7: The estimated prevalence of gout across the world showing higher prevalence of gout in developed 
countries, especially in Oceania populations (Australia and New Zealand). Source: Kuo et al. (2015). 
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 As illustrated in Figure 1.7 (Kuo et al., 2015), the prevalence of gout is highest in 
Australasian countries i.e., Australia and New Zealand. Two equivalent studies indicated 
an overall prevalence of gout to be 1.5% for Australian (Robinson et al., 2015) and 3.75% 
for New Zealand (Winnard et al., 2012) adults. Interestingly, the prevalence and severity 
of gout differ strikingly among diverse ancestral groups in these regions, with Pacific 
Islanders and Māori having a higher prevalence of gout than people of European decent. 
About 3.8% of adults have been reported to have gout in an Australian aboriginal 
community in North Queensland, with 22% cases being identified as having severe gout 
(presence of subcutaneous tophi) (Minaur et al., 2004). In contrast, an overall prevalence 
of 1.44% (all-age) was reported in Australian National Health Survey (ANHS) data 
(Skinner, 1997). For New Zealand, using data from the Aotearoa New Zealand Health 
Tracker (ANZHT), the prevalence of gout has been reported to be 3.2% in European 
individuals (Winnard et al., 2012). In comparison, the prevalence of gout was as high as 
7.6 and 6.1% for Pacific Island and Māori individuals, respectively (Winnard et al., 2012). 
This indicated the rate of gout to be almost double in Pacific Island and Māori 
populations than Europeans. Over the passage of time, the prevalence of gout has 
progressively increased in the New Zealand Māori and European individuals (Figure 1.8), 
with a minimum rate of 2.7% and 0.3% recorded in 1958 to 6.06% and 3.24% in 2009 in 
both populations, respectively (Klemp et al., 1997; Lennane et al., 1960; Prior and Rose, 
1966; Winnard et al., 2012). 
Figure 1.8: The estimated prevalence of gout in the New Zealand Māori and European population over time. 
Note: All values in the graph are presented for the year(s) when data were collected from the respective 
populations, which may differ from the year(s) it was published. A prevalence of ‘zero’ does not represent the 
absence of data.  
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1.1.6 Urate, gout and metabolic disease 
1.1.6.1 Foreword 
 As mentioned earlier, gout has a high rate of co-occurrence with other metabolic 
conditions. These co-occurring conditions are generally referred to as ‘comorbidities’. 
Considering hyperuricaemia and gout as index diseases under study, comorbidity is 
defined following Feinstein’s definition (Feinstein, 1970) in my thesis. According to this 
definition: 
“A comorbidity is any distinct additional entity that has existed or may occur during the 
clinical course of a patient who has the index disease under study.” 
 Ample evidence is available linking gout to metabolic syndrome (or its 
components) (Puig and Martinez, 2008), renal disease (Kramer et al., 2003; Kramer and 
Curhan, 2002; Yu et al., 2012), hyperlipidaemia (reviewed in Kuo et al. (2014a)) and 
cardiovascular disease (CVD) (Choi and Curhan, 2007b; Krishnan et al., 2006; Kuo et al., 
2013). However, evidence for its possible association with other, relatively less studied 
comorbidities, is still limited e.g., hypothyroidism (Durward, 1976; Kuzell et al., 1955), 
cancer (Boffetta et al., 2009; Kuo et al., 2012) and anaemia (McAdams-DeMarco et al., 
2012). 
 The clinical guidelines and recommendations approved by American College of 
Rheumatology (ACR) (Nuki, 2014), American College of Physicians (ACP) (Shekelle et 
al., 2017), European League against Rheumatism (EULAR) (Richette et al., 2017) and 
the British Society for Rheumatology (BSR) (Roddy, 2016) have insisted and discussed 
more about the diseases that are pathophysiologically related to gout. Their guidelines 
also recommend urate-lowering therapy (ULT) only to the patients with either a high 
urate load or kidney-related comorbidities. Although it is understandable that a great 
focus was placed on comorbidities that are causally correlated with gout, multiple 
metabolic conditions may appear simply as co-occurring ailments rather than causes in 
many patients. Such metabolic conditions that may or may not indicate a direct (or 
causal) relationship with gout still merit provision of management guidelines. 
1| Introduction 
 16 
 Although the above-described observational studies have been useful in providing 
proof for a possible association between gout and other metabolic conditions, yet the 
information provided in these studies cannot ascribe the causality between cause and 
effect relationship. The main reason behind this uncertainty is that the data presented in 
such studies are purely observational based on the co-occurrence of the two conditions, 
which may in turn be prone to biases due to additional metabolic conditions as potential 
confounders of cause (exposure) and effect (disease) relationship (Bowden et al., 2017). 
As complex traits (like gout) are affected by a number of environmental factors, getting 
false positive associations without accounting for confounders is highly likely (Hayden et 
al., 2013; Shrank et al., 2011). Unaccounted confounding is a reason why such studies 
may fail to replicate the reported associations or prove any causality when tested in 
randomised controlled trials (RCTs) (Kovesdy and Kalantar-Zadeh, 2012; Smith and 
Ebrahim, 2001, 2008). However, it may not always be possible to carry a large 
randomised controlled trial due to several social reasons. In such scenarios, Mendelian 
randomisation (MR) can be used as a successful approach, analogous to RCT, to infer a 
possible causal relationship between cause and effect (Iturrieta-Zuazo and Walter, 2015; 
Smith and Hemani, 2014). Mendelian randomisation makes use of genetic variants 
robustly associated with exposure (e.g., body iron levels) as instruments to identify their 
predictive effect on the outcome (e.g., serum urate/gout), adjusting simultaneously for 
potential confounders (Smith and Ebrahim, 2003). The MR exploits the basic principle of 
random assignment of alleles at conception that are not prone to confounding via 
environmental factors as well as reverse causation due to unidirectional flow of biological 
information i.e., information can be only translated from genome to protein and not in the 
reverse direction. Hence, exploring new information between gout and other metabolic 
conditions not only requires broadening the range of coexisting conditions being 
considered but also a more robust approach, like genetic association analysis and/or MR, 
to explain ‘which is driving which’ relationship between them. 
1.1.6.2 Gout and metabolic disease in New Zealand 
 Aotearoa New Zealand has one of the highest documented prevalence of gout 
worldwide (as mentioned above) as well as its related comorbidities (Winnard et al., 
2013); worth mentioning is the co-prevalence of obesity, kidney disease, type 2 diabetes 
(T2DM) and CVDs, occurring individually or as components of the metabolic syndrome, 
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with hyperuricaemia or gout. Gout has generally been associated with all-cause mortality, 
mostly due to death from renal disease or CVD (Choi and Curhan, 2007b; Stamp and 
Chapman, 2013; Teng et al., 2012). Despite their utmost clinical importance and 
subsequent increased demand for health care resources, studies exploring metabolic 
disease(s) as a comorbidity of gout have been seldom carried out in the New Zealand 
population. In the following paragraphs, using the data available in the literature, I have 
summarised the history of the prevalence of some well-known metabolic conditions. The 
summary is structured to specifically outline these comorbidities in the context of their 
coexistence with hyperuricaemia and gout, both globally and in New Zealand. 
1.1.6.2.1 Obesity 
 Ranking first in the list of gout-associated comorbidities is obesity. Generally, a 
body mass index (BMI) > 30 kg/m2 is referred as a cut off to specify obesity. Obesity, 
particularly visceral obesity, is also a well-recognised risk factor for other metabolic 
diseases e.g., T2DM and CVD (Després and Lemieux, 2006; Mokdad et al., 2003). Being 
obese has also been reported to increase the xanthine oxidase (XO) catabolism of purines 
and, thereby, enhanced production of urate in adipose tissues (Tsushima et al., 2013). 
High BMI measures and obesity have been described to be associated with increased 
urate levels in several human-based studies, mostly as components of metabolic 
syndrome (Billiet et al., 2014; Johnson et al., 2013b; Nejatinamini et al., 2015). In 
addition, data from MR studies have also described a causal association between 
genetically determined adiposity measures and higher urate levels. These studies have 
described an elevation in urate to occur as a consequence of an increase in triglycerides, 
BMI, adiposity and its associated risk factors (Lyngdoh et al., 2012; Palmer et al., 2013; 
Rasheed et al., 2014). Moreover, in a study including the data of 15,533 American 
individuals from a community-based cohort (Campaign Against Cancer and Heart 
Disease/CLUE II), McAdams-DeMarco et al. (2011) reported the onset of gout to be 3 
years earlier on an average in obese (age > 21 years) compared to non-obese participants. 
An analysis of the US population data from NHANES 2007-2008 showed that 53% of the 
individuals with gout (age > 20 years) were obese (Zhu et al., 2012). 
 An early survey of 115 Māori men revealed that individuals with hyperuricaemia 
and gout tend to be heavier than their comparative normouricaemic controls (Gibson et 
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al., 1984). In general, New Zealand is facing a continuous rise in the prevalence of 
obesity. Recent data from the New Zealand Ministry of Health reported an overall 31% of 
the individuals to be obese and 34% still overweight (www.health.govt.nz/). New Zealand 
has also been ranked as 3rd in the 2014 OECD (Organisation for Economic Co-operation 
and Development) report for the worldwide prevalence of obesity (Ng et al., 2014). 
According to this survey, Polynesians largely contributed to the burden of obesity in New 
Zealand (www.oecd.org/). The New Zealand Ministry of Health further confirmed the 
prevalence of obesity for different ancestral groups in New Zealand, with Pacific 
Islanders being at the top (66.2%) followed by Māori (46.5%) and Europeans (and other 
ethnicities (29.2%) (Figure 1.9) (www.stats.govt.nz/ and www.health.govt.nz/). 
Figure 1.9: Graphical illustration of the proportion of the New Zealand obese population, stratified by ethnicity 
and gender. Source: www.stats.govt.nz/ and www.health.govt.nz/). 
1.1.6.2.2 Renal impairment and chronic kidney disease 
 Renal dysfunction is common in patients with hyperuricaemia or gout. Increased 
serum creatinine and decreased glomerular filtration rate (GFR) are indicative of reduced 
kidney function. Higher serum creatinine levels have been classically associated with 
higher levels of serum urate in gout patients (Nishida, 1992). Contradictory to this, a 
Mendelian randomisation (MR) study found a causal association between genetically 
higher levels of serum urate and decreased serum creatinine (Hughes et al., 2014). 
Evidence has also indicated reduced GFR to be associated with higher urate levels 
(Johnson et al., 2013a; Mohandas and Johnson, 2008; Suliman et al., 2006). A study 
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including data from NHANES 2009-2010 reported a 2-3 fold increase in the prevalence 
of gout for a decrease in GFR (data for every 30 mL/min/1.73m2 decrease in GFR) 
(Krishnan, 2012). Several studies have reported an elevation in urate to be predictive for a 
progressive increase in pre-established chronic kidney disease (CKD) (Shi et al., 2011) or 
the development of renal impairment in individuals with normal renal function (Ohno et 
al., 2001; Shi et al., 2011; Syrjänen et al., 2000). Chronic hyperuricaemia has strongly 
been associated with CKD (Johnson et al., 1999; Johnson et al., 2013a). Higher 
prevalence of CKD has also been reported in gout patients. Data from the large US 
population-based study, NHANES 2007-2009, revealed about 71% of the gout patients to 
have CKD at stage 2 or higher (Zhu et al., 2012). In a recent meta-analysis of data from 
17 large studies including multiple populations, the global co-prevalence of gout with 
advanced stage CKD was found to be 24% (Roughley et al., 2015). In contrast, two other 
recent studies reported a prevalence of gout in CKD patients to be 6.8% and 24.3% in the 
US and Dutch populations, respectively (Jing et al., 2014; Wang et al., 2015). In addition, 
a possible relationship of increased urate concentration has been marked as an 
independent predictor for the development of CKD in patients with T2DM (Altemtam et 
al., 2011; Zoppini et al., 2012). Having chronic kidney disease has also been regarded as 
a factor that increases the risk for the development of diabetes, CVD and other heart-
related complications (Go et al., 2004). 
 Likewise, a few studies have also reported the co-prevalence of gout with CKD in 
the New Zealand (NZ) population. A study reported a 3.5-fold higher rate of ESRD (end-
stage renal disease) in Māori and Pacific Islanders than Europeans (Collins, 2010). 
Robinson et al. (2012) found that ~16-27% of gout patients who were admitted in any of 
the New Zealand hospitals between 1999 and 2009 had renal complications, with most 
patients being either Māori or Pacific Islanders. Although exact figures are still unknown, 
a 2014 national consensus statement from the New Zealand Ministry of Health 
(www.health.govt.nz/) suggested about 7% of the adult New Zealand population to be 
CKD sufferer (NZMH, 2014). 
1.1.6.2.3 Type 2 diabetes 
 Type 2 Diabetes (T2DM) is another metabolic condition that has been consistently 
reported for its coexistence with hyperuricaemia and gout (Winnard et al., 2013). 
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Elevated levels of serum urate have been shown to be strongly associated with an 
increased risk of T2DM (Sluijs et al., 2015). However, the same study was unable to find 
a causal relationship between genetically high serum urate and T2DM using the MR 
approach (Sluijs et al., 2015). Moreover, hyperuricaemia has been generally associated 
with a high risk of T2DM (Billiet et al., 2014; Johnson et al., 2009a). In contrast, the 
relationship between gout and diabetes is rather complex (Stamp and Chapman, 2013), 
with one study showing reduced risk of developing gout in patients with advanced T2DM 
(was ascribed to increased urination leading to increased urate excretion) (Choi and Ford, 
2008). Additionally, a large study in the US population showed a higher risk of 
developing T2DM in male gout patients with higher risk of CVD (Choi et al., 2008). 
Another study in the UK based population also found a similar relationship between gout 
and the risk of developing T2DM (Rho et al., 2016). However, the risk ratio (RR) was 
higher in females (RR = 10.1) than males (RR = 9.5) (Rho et al., 2016). 
 Consistent with the aforementioned study findings, a higher risk of developing 
T2DM has also been observed in the New Zealand individuals, with disproportionate 
adverse effects in the Polynesian populations (explained hereafter). According to a recent 
report from the New Zealand Ministry of Health (www.health.govt.nz/), being a Māori or 
Pacific Islander increases the risk of developing T2DM by 3-fold in comparison to other 
ancestral backgrounds. An overall prevalence of T2DM has been reported to be 6.6% in 
the New Zealand population (Winnard et al., 2013), while other studies reported the 
prevalence to be highest in Pacific Islanders (Chan et al., 2014). A recent study by 
Coppell et al. (2013), using data from the 2008/09 New Zealand Adult Nutrition Survey 
(NZANS), found an overall prevalence of prediabetes and diabetes to be 25.5% and 7.0%, 
respectively. The study also reported the prevalence of diabetes to be higher in males 
(8.3%) than females (5.8%). Winnard et al. (2013) reported a higher co-prevalence of 
gout and T2DM, with 25.6% of the gout patients (n = 119,234) in the ANZHT database 
also having T2DM. 
1.1.6.2.4 Cardiovascular disease 
 A high prevalence of CVD and T2DM travels concomitantly with gout (Winnard 
et al., 2013). Linking the above mentioned comorbidities, elevated levels of urate have 
been associated with an increased risk of cardiovascular mortality in patients with CKD 
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(Kanbay et al., 2012; Madero et al., 2009) and T2DM (Ito et al., 2011). Hyperuricaemia 
has been described as a potential risk factor for a number of heart-related problems 
including hypertension (Grayson et al., 2011), coronary heart disease (CHD)/ischemic 
heart disease (IHD) (Kim et al., 2010), heart failure (Huang et al., 2014), stroke (Kim et 
al., 2009) and peripheral vascular disease (Baker et al., 2007). More recent MR studies 
have reported a causal relationship between genetically predicted serum urate and adverse 
cardiovascular outcomes including sudden cardiac death (Kleber et al., 2015). However, 
other studies using the same approach were unable to find such causal associations, 
between serum urate and CHD (Palmer et al., 2013; White et al., 2016) or biomarkers of 
CHD (Rasheed et al., 2014). Despite these findings, hyperuricaemia has been associated 
with all-cause cardiovascular mortality in several populations (Chen et al., 2015a; Li et 
al., 2016; Moulin et al., 2017). In line with these studies, gout has also been described to 
be strongly associated with cardiovascular mortality (Kuo et al., 2009), especially CHD 
associated mortality (Choi and Curhan, 2007b; Clarson et al., 2013) and myocardial 
infarction (Kuo et al., 2013). 
 An overall prevalence of CVD in the New Zealand population has been reported 
to be 5.4%, with ~22.7% co-prevalence of gout and cardiovascular events (Winnard et al., 
2013). Heart failure and CVD were reported as potential comorbid conditions, 
respectively, in 27.6% and 39.1% of the gout patients who were admitted to the New 
Zealand hospitals between the years 1999-2009 (Robinson et al., 2012). In the context of 
the New Zealand population, CHD has been declared as most common type of CVD. 
According to the 2014 data from the New Zealand Ministry of Health 
(www.health.govt.nz/), one in every eighteen adults has been diagnosed with CHD, with 
a death rate of one every 40 minutes. Again, the prevalence of CHD is higher in Māori 
(6.2%) and Pacific Islanders (5.04%) in comparison to the individuals of European 
descent (4.2%) (Thornley et al., 2011). Bramley et al. (2004) showed that Māori had risk 
ratios of 1.9 and 5.7 for death by IHD and diabetes, respectively, when referenced against 
the non-indigenous New Zealand population. Data from The Auckland Region Coronary 
or Stroke Study (ARCOS) further supported this fact, in which Māori (Death rate = 68%) 
and Pacific Island (Death rate = 64%) individuals had higher death rates caused by a 
coronary event compared to Europeans (Death rate = 44%) (Bullen and Beaglehole, 
1997). Another more recent analysis in the same database revealed that heart stroke 
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occurs at a comparatively younger age in Polynesians (61.9 years) than Europeans (74.6 
years) (Feigin et al., 2006). 
1.1.7 Metabolic disease/comorbidities included in this study 
 The research in my thesis was broadly conducted and limited to the occurrence of 
(or changes in) the following three metabolic conditions/comorbidities of gout. These 
metabolic conditions have been abundantly reported for their possible coexistence with 
hyperuricaemia and/or gout as potential comorbidities. 
1. Imbalanced iron homeostasis 
2. Metabolic syndrome 
3. Imbalanced lipid metabolism (dyslipidaemia) 
 To make this section precise for the readers and due to the discrete nature of 
selected comorbidities, extensive cumbersome text explanations are avoided here. Instead, 
section 1 of each chapter (Chapter 2 to Chapter 5) is dedicated to a detailed description of 
the history, background concept and biological mechanisms for each of the metabolic 
diseases plus rationale for its possible relationship with urate metabolism and gout, as 
described in the literature per se. The following paragraphs provide only a summary 
background for each of these comorbidities in a bigger picture before explaining the aims 
of this study. 
1.1.7.1 Iron homeostasis and gout 
 Iron is an essential element of the human body and is vital for an array of 
metabolic functions, such as oxygen transport and oxidative phosphorylation. The human 
body is specialised to strictly maintain the normal blood levels of iron within a narrow 
range of 3 to 4 grams (3.8 g in males and 2.3 g in females) of the total body weight 
(Leong and Lonnerdal, 2012). However, the range may vary between 4 and 5 grams for 
well-nourished people (Gropper and Smith, 2013). 
 Food is the primary source of iron, providing heme and non-heme iron through 
animal and plant sources, respectively. In comparison to non-heme iron derived from 
plants, heme iron derived from animal sources (meat, fish and seafood) is more readily 
absorbable in the body. Dietary heme iron accounts for two-thirds of the average person’s 
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total iron stores (Bezwoda et al., 1983; Carpenter and Mahoney, 1992; West and Oates, 
2008) and due to its high bioavailability, the absorption of heme iron is 5 to 7 times 
higher than that of non-heme iron in the gastrointestinal tract (Björn-Rasmussen et al., 
1974; Reizenstein, 1979). The amount of iron gained from a non-heme source is totally 
dependent upon the individual’s body iron status (Hurrell and Egli, 2010). 
 Maintaining iron in strict limits is crucial due to its biological toxicity and 
catalytic activity. Iron in its free floating form can primarily cause oxidative stress and, 
thereby, destruction and/or death of otherwise healthy cells due to the increased 
production of reactive oxygen species (ROS) (Bresgen and Eckl, 2015; Dixon and 
Stockwell, 2014). The human body is specialised to not only regulate its pre-existing 
endogenous iron pools but also the amount of iron from the diet, which is regulated at 
both the systemic and cellular levels (Ganz, 2013; Wang and Pantopoulos, 2011). The 
regulation of iron homeostasis involves a number of proteins, enzymes, and other cellular 
structures to properly distribute and store the metal. After reaching the stomach, iron in 
the food is absorbed by the duodenal enterocytes in a controlled fashion (Fuqua et al., 
2012). Once it enters the circulatory blood pool, the transport of iron in the blood is 
controlled by a glycoprotein named transferrin, which reversibly binds iron ions and 
carries them to the surrounding tissues (Rouault, 2003). The cellular uptake of iron is 
mainly governed by transferrin receptor mediated import from transferrin into the cells 
(Moos, 2002). As the human body does not possess any specialised excretory mechanism 
for the removal of iron, at each successive stage of its distribution, any extra amount of 
iron is required to be liganded and stored. This exceptionally important need to sequester 
iron in a suitable liganded form is fulfilled via ‘ferritin’. Ferritin is a hollow globular 
protein, synthesised in the liver and specialised for the storage of excess iron in a non-
toxic form and its release in a controlled fashion (Harrison et al., 1986). 
 Failure to maintain normal body iron levels may end up with negligible iron 
imbalance to severe iron-related disorders. Two disorders of abnormal iron levels in the 
body are iron deficiency – too low iron, and iron overload – too high iron. In aggregate, 
iron deficiency and haemochromatosis (iron overload) have been reported to affect over 1 




1.1.7.1.1 Body iron profile 
 Ferritin reflects cumulative iron stores in the body and is measured under regular 
laboratory practices as a surrogate marker to determine iron levels in the blood and iron-
related disorders (WHO, 2011). In addition, body iron profile is reflected via the amount 
of total blood (serum) iron, serum transferrin, total iron binding capacity (TIBC) and 
transferrin saturation (TSAT). Total iron binding capacity (TIBC) is the capacity of the 
blood to bind iron with transferrin, that in turn indicates the maximum amount of iron that 
blood can carry and is an indirect measure of blood transferrin (Yamanishi et al., 2003). 
Transferrin saturation (TSAT), on the other hand, is an indirect estimate of the amount of 
transferrin available for iron to bind. It is calculated as the ratio between total blood iron 
and TIBC and represents the percentage of transferrin’s iron-binding sites occupied by 
iron i.e., a TSAT of 10% indicates that 10% of the iron-binding sites on the transferrin 
possess bound iron while 90% of the sites are still free for the iron to bind. 
1.1.7.1.2 Iron homeostasis, urate and gout 
 Urate is a well known iron chelator i.e., it has the ability to bind to and protects 
the body tissues from metal (iron)-mediated free radical damage (Davies et al., 1986; 
Ghio et al., 1994). Iron, in turn, is known for its ability to modulate the activity of 
xanthine oxidase and subsequently the production of urate (Ghio et al., 2002). Ferritin, 
TIBC and TSAT have been positively correlated with urate in the US National Health and 
Nutrition Examination Survey (NHANES III) (Ghio et al., 2005; Mainous et al., 2011) 
with elevation in serum urate suggested as an indicator of iron overload (Mainous et al., 
2011). 
 Supportive evidence for iron as a trigger for gout flares is provided by the ability 
of iron to form complexes with MSU crystals in vitro, their presence in the synovial fluid, 
stimulation of oxidative stress through the generation of ROS, granulocyte and 
complement activation and production of lymphocytes (Ghio et al., 1994). Association of 
iron with a number of pro-inflammatory activities in animal models (Dabbagh et al., 
1992) and a decrease in gouty flares following phlebotomy to attain near iron-deficient 
levels in hyperuricaemic patients (Facchini, 2003) are also suggestive of its role in gouty 
arthropathy. Consistent with these observational studies, a recent study reported the 
association of a genetic variant in the transferrin receptor (TFRC: rs1466085) with gout. 
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Individuals carrying the risk allele of this variant also self-reported a higher likelihood of 
an iron-rich food as a trigger of flares (Merriman et al., 2015). 
 Interestingly, purine-rich foods from  animal-based diet have been associated with 
increased risk of recurrent gout attacks while purine-rich foods from plant-based diet did 
not show a strong correlation (Zhang et al., 2012b). These observations, combined with 
the other observational and intervention data (Facchini, 2003; Ghio et al., 2005; Mainous 
et al., 2011), are consistent with the idea that iron in purine-rich foods (red meat for 
example) could be a causal factor of gout. 
 Despite the presence of evidence in literature suggesting a possible role of iron 
and its related disorders in predicting hyperuricaemia and gout, this important 
relationship has been excessively neglected in New Zealand population-based studies. In 
fact, apart from studies that are more observational and conventional, data providing 
information on a causal relationship between these two important metabolic components 
are not available in the literature. Therefore, imbalanced iron homeostasis was selected as 
one of the major metabolic complications of gout in my thesis. My research was 
conducted with the hope of shedding light on a possible causal relationship between these 
two metabolic conditions and to fill in the substantial gap in literature, especially in the 
context of the New Zealand population. 
1.1.7.2 Metabolic syndrome and gout 
 Almost all of the metabolic diseases described in Section 1.1.6 are collectively 
considered as ‘metabolic syndrome’ or MetS. However, the debate of inclusion of 
hyperuricaemia per se in the definition is still controversial (Nejatinamini et al., 2015; 
Wei et al., 2015). The main reason for considering hyperuricaemia as one of the MetS 
components is the presence of plentiful data in a number of epidemiological studies 
reporting co-occurrence of and/or association between hyperuricaemia and MetS 
components (detailed in Section 1.1.6) (Billiet et al., 2014; Chen et al., 2007; Liu et al., 
2015; Yamasaki and Tomita, 2008). 
 Most of the epidemiological studies have suggested hyperuricaemia to be a 
condition occurring secondary to hyperinsulinaemia (Muscelli et al., 1996; Soltani et al., 
2013) and thereby its positive association with insulin resistance and diabetes (Li et al., 
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2013; Lippi et al., 2008). Additionally, data for its positive association with other MetS 
components is abundant too e.g., obesity (Han et al., 2014; Tang et al., 2010), 
cardiovascular disorders and hypertension (Borghi et al., 2014; Nakanishi et al., 2003). A 
more recent study has indicated a positive correlation between elevated serum urate and a 
collection of risk factors that culminates as MetS (Nejatinamini et al., 2015). 
 Components of MetS and the data for their possible relationship with 
hyperuricaemia and gout are already detailed in Section 1.1.6. However, despite the 
above-mentioned observational data (and data provided in Section 1.1.6), the number of 
studies providing a genetic association between gout and the metabolic syndrome are 
scarce. The research in my thesis was structured not only to fill in this substantial gap in 
the literature but also to provide a genetic basis to this observational relationship between 
the two metabolic conditions, especially with an emphasis given to the New Zealand-
based ancestral population groups. 
1.1.7.3 Lipid metabolism and gout 
 A number of lipid biomarkers and their transport proteins collectively make the 
blood lipid profile. However, most of this profile is characterised by two types of lipids, 
cholesterol and triglycerides (TG) and their carrier proteins called ‘lipoproteins’. 
Lipoproteins are generally categorised by their density, the amounts of lipids and proteins 
in the molecule and the type of lipid biomarker they tend to transport through circulation. 
Whilst very low-density lipoproteins (VLDL) mainly transport TG, low-density 
lipoproteins (LDL) and high-density lipoproteins (HDL) are the major transporters of 
cholesterol (Voet et al., 2006). An abnormal amount (hypo or hyper) of lipids in the 
blood is referred to as ‘dyslipidaemia’. 
  As mentioned earlier, hyperuricaemia has been associated with dyslipidaemia as 
part of the metabolic syndrome (Mandal and Mount, 2015). A number of reports 
explained an association of hyperuricaemia and gout with all-cause and CVD mortality 
and myocardial infarction independent of confounders (Chen et al., 2009a; Krishnan et al., 
2006; Kuo et al., 2009). In addition, a recent MR study has provided evidence for a 
causal role of elevated triglyceride levels in raising serum urate in European individuals 
(Rasheed et al., 2014). However, the biochemical basis for the causal relationship 
between serum urate and lipids is still poorly understood. 
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 Genome-wide association studies have successfully identified hundreds of 
common variants with a significant association with the studied phenotype/disease. These 
variants, however, usually explain a relatively small proportion of disease heritability 
with a large proportion still ‘missing’ or ‘hidden’ (Goldstein et al., 2013). For example, 
the most recent genome-wide association study from Köttgen et al. (2013), that combined 
data from > 110,000 European-ancestry individuals, provided evidence for association of 
28 loci that collectively explain 7.0% of the variance in urate. Albeit considering all 
common variants included in the Köttgen et al. (2013) GWAS could collectively explain 
~27-41% variance in urate, a significant portion of variance still remains unexplained. 
Non-urate loci (besides those involved in urate transport) may not only be helpful in 
exploring the ‘missing’ part of the urate variance but would also help to characterise the 
shared genetic basis of gout or urate with other metabolic conditions. Two lipid-related 
genes, LRP2 (lipoprotein receptor-related protein 2/megalin) and A1CF (apolipoprotein B 
mRNA-editing enzyme 1 (APOBEC1) complementation factor) (explained below), are 
examples of such non-urate loci that have been selected to study in this thesis. 
1.1.7.3.1 LRP2 and A1CF 
 Lipoprotein receptor-related protein 2 (LRP2) or megalin is a protein which in 
humans is encoded by the LRP2 gene (Fisher and Howie, 2006; Saito et al., 2005). 
Lipoprotein receptor-related protein 2 gene is a non-urate transport locus that has been 
identified for its predominant function in lipid metabolism (Cabezas et al., 2011; 
Christensen and Birn, 2002) and reabsorption and metabolism of glomerular-filtered 
substances (Hosaka et al., 2009). The T allele of a common variant (rs2544390) within 
the LRP2 gene has been reported to be associated with higher serum urate concentration 
in Japanese individuals (Hamajima et al., 2012; Kamatani et al., 2010). A more recent 
study (Rasheed et al., 2013b) was able to identify the population-specific effects for the T 
allele of the rs2544390 variant with an increased gout risk in New Zealand Māori and 
Pacific Island individuals but not Europeans. The study further indicated that alcohol 
intake in New Zealand Polynesian population over-rides the otherwise protective role of 
the C allele of this variant and thus causes increase in gout risk due to a non-additive gene 
(C allele of LRP2 SNP rs2544390)-environment (alcohol intake) interaction (Rasheed et 
al., 2013b). Consistently, Dong et al. (2015) also reported the T allele of rs2544390 to be 
associated with increased susceptibility to gout in the Han Chinese population. 
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 In addition to common variants, low frequency (or rare) variants within the LRP2 
gene have been reported for their association with several other disease phenotypes. A 
study identified disease mutation clusters of rare variants within LRP2 to be associated 
with Autism Spectrum Disorders (ASD) in three different datasets (Ionita-Laza et al., 
2012). A more recent study that measured 13 urinary biomarkers in the Framingham 
Heart Study (FHS) Offspring Cohort (n = 2,640) reported a cluster of rare variants in the 
LRP2 gene to be associated with urinary levels of Trefoil Factor-3 (TFF3; gene encoding 
the TFF3 protein, expressed in gastrointestinal mucosa and possibly involved in 
protecting, stabilizing and healing of mucus layer) along with multiple common variants 
of LRP2 to be associated with TFF3 levels in urine and kidney injury molecule 1 
(McMahon et al., 2014). 
 Another emerging candidate in the non-urate transport gene list is apolipoprotein 
B mRNA-editing enzyme 1 (APOBEC1) complementation factor or A1CF, which plays a 
role in the production of two different protein isomers, apo B-48 and apo B-100 from one 
nuclear gene (Chen et al., 1987; Powell et al., 1987). In the recent GWAS, the A1CF 
variant (rs10821905) was associated with serum urate levels in Europeans (Köttgen et al., 
2013), along with significant association with gout risk in New Zealand Europeans 
although not in Māori and Pacific Islanders (Phipps-Green et al., 2014). In terms of data 
from fine mapping and whole genome or exonic sequencing, no study has yet reported 
any disease-based association for other variants within A1CF. 
 Both, LRP2 and A1CF, have also been reported as loci associated with kidney 
function in a recent GWAS (LRP2 = 3.5E-08; A1CF = 1.07E-12) that included the data 
from > 130,000 European individuals (Pattaro et al., 2016). Despite evidence for the 
involvement of LRP2 and A1CF in a number of physiological processes, little is known 
about the effect of their possible causal variants on biological pathways, particularly those 
leading to gout. Based on the above described literature, it was hypothesised that other 
less common variants within LRP2 and A1CF coding regions could contribute to gout risk 
in New Zealand Māori and Pacific Islanders and Europeans, which may prove helpful in 
explaining some part of the ‘unexplained heritability’ for gout. 
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1.1.8 Specific aims of the study 
 The research was carried out to add new data to the repository of ‘gout and 
metabolic disease’, especially by focusing on those coexisting metabolic conditions that 
have been regularly ignored and/or the data for which are scarce/absent in relation to 
hyperuricaemia and gout. While the broader aim of this study was to test the biochemical 
and genetic association of metabolic diseases with gout and hyperuricaemia in the 
European and New Zealand Polynesian populations, the specific aims were based on 
discrete hypotheses, outlined as follows: 
1. To characterise iron profile biomarkers (total iron, transferrin, ferritin, transferrin 
saturation and total iron binding capacity) and test the hypothesis that changes in 
these markers are linearly correlated with a change in serum urate concentration 
and are predictable for hyperuricaemia and gout in the New Zealand European 
and Polynesian (Māori and Pacific Islanders) individuals. 
2. To test the hypothesis that variants in the haemochromatosis gene (HFE) are 
independently involved in gout risk in the New Zealand Polynesian and European 
individuals. 
3. To exploit the summary statistics data from recent genome-wide association 
studies (European population) and test the hypothesis that there is a causal 
relationship between the above-mentioned serum iron biomarkers and urate 
concentrations using the Mendelian randomisation approach. 
4. To test the hypothesis that variants in metabolic syndrome related genes are 
independently involved in gout risk in Polynesian (Māori and Pacific Island) and 
European New Zealanders. 
5. To identify and characterise other common variants obtained from exon 
sequencing of two lipid-related genes (LRP2 and A1CF) and use a replication-
based approach to test the hypothesis that common variants in these genes have an 
independent association with hyperuricaemia and gout in European and/or New 
Zealand Polynesian individuals. 
6. To identify and characterise the rare and non-synonymous variants obtained from 
exon sequencing of two lipid-related genes (LRP2 and A1CF) and test the 
hypothesis that these rare and/or non-synonymous variants collectively have an 
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influence on hyperuricaemia in European and New Zealand Polynesian 
individuals. 
1.1.9 Thesis structure 
 This thesis is divided into six chapters. Each chapter, whilst describing 
experimental results/findings (Chapter 2 to Chapter 5), has its own comprehensive 
introduction and specified aims. This is primarily an attempt to bridge the distinct 
background of each comorbid condition as well as to provide a logical rationale in the 
context of hyperuricaemia and gout. Chapter 2 to Chapter 5 also provides relevant 
information available in literature, for the different ancestral groups in New Zealand. 
 The next two chapters (Chapter 2 and Chapter 3) provide the biochemical and 
genetic association analysis results of hyperuricaemia and gout with abnormal iron 
homeostasis as a coexisting potentially causal phenomenon. The findings explained in 
these two chapters mostly are ‘first time ever’ findings, especially within the New 
Zealand setting. 
 Chapter 2 was exclusively designed to provide information about the initial 
biochemical association analyses for blood iron biomarkers with hyperuricaemia and gout. 
In addition, the genetic association analysis for two well-known iron overload-related 
variants was carried out to assess their association with hyperuricaemia and/or gout 
within the NZ Polynesian and European populations. The positive observational 
outcomes from this chapter were the basic prompts to extend this work to Chapter 3. 
 Chapter 3 presents findings of the first-ever Mendelian randomisation analysis 
done using summary statistics from genome-wide association studies (GWAS) to find a 
possible causal relationship between serum iron biomarkers and urate concentrations. 
 Chapter 4 deals with the second comorbid condition, metabolic syndrome. This 
chapter provides outcomes of genetic association analyses to describe a relationship 
between several components of the metabolic syndrome, urate and gout. It also provides 
genetic evidence for an involvement of MetS components in the aetiology of gout for the 
first time in the New Zealand population. 
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 Chapter 5 provides an extensive ‘rare variant analyses’ for exon sequencing data 
from the two well-recognised lipid-related genes (LRP2 and A1CF). This study for the 
first time reports population-specific findings for common variants associated with 
hyperuricaemia and gout in the New Zealand population. The study also reports for the 
first time the population-specific rare variant burden of hyperuricaemia for LRP2. 
 Finally, Chapter 6 includes the overall discussion and conclusion of the thesis. 
 Anywhere in this thesis, unless specified in the footnotes, I performed all wet lab 
experiments and statistical analyses plus in silico data handling for Chapter 3 for MR 
software. 
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SECTION 1.2 POPULATION DATASETS USED IN THIS 
STUDY 
 Data of the participants collected from different regions of the world, including 
diverse populations, were used for demographic and clinical information and subsequent 
analyses. In order to avoid the unnecessary repetition of the text explaining the same 
details, a comprehensive summary of each dataset is provided here. In general, this 
summary provides the information about the recruitment criteria, gross total number, 
ancestral background and ethical approval for each study group. Hence these details are 
avoided while referring to these data sets in different chapters of this thesis. 
1.2.1 Gout Case-Control Cohorts 
1.2.1.1 New Zealand Gout Cohort 
 For the most part of this thesis, demographic and clinical data of subjects within 
the New Zealand Gout Cohort have been analysed. The New Zealand Gout Cohort is a 
case-control cohort that was developed for the evaluation of environmental and genetic 
risk factors for gout and hyperuricaemia in the New Zealand-resident European and 
Polynesian populations. Currently, the cohort contains data from > 1,800 European and > 
2,800 Polynesian individuals. 
 For this cohort, the recruitment of gout cases was initiated back in 2001 at The 
University of Auckland, New Zealand, under the supervision of Dr. Lachy McLean. The 
project supervision was transferred to Professor Tony Merriman (University of Otago, 
Dunedin, New Zealand) in 2006. Under his overall supervision, the gout cases were 
initially recruited from two North Island cities, Auckland and Rotorua. The gout case 
recruitment was then extended to healthcare facilities within four major regions of New 
Zealand including Auckland, Wellington, Canterbury and Otago. The recruitment of the 
control group began in 2009, following which data of non-gout individuals were 
convenience sampled from above four regions of New Zealand. In 2010, the recruitment 
of a gout case-control sample set began in collaboration with Ngati Porou Hauora (NPH: 
operates in the rohe of Ngati Porou Hauora (tribal territory) located in the East Coast 
region (Te Tai Rāwhiti) of New Zealand) in collaboration with Ngati Porou Hauora 
Charitable Trust (NPHCT: www.nph.org.nz). The NPH cohort currently contains the data 
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of > 450 individuals. The purpose of the study was explained and a written informed 
consent was obtained from participants for the collection of their blood. In conjunction to 
this, every participant was asked to manually fill out a questionnaire about their socio-
demographic status, family history of gout, grand-parental ancestry information, medical 
history and certain dietary habits. The American College of Rheumatology (ACR) gout 
criteria (Wallace et al., 1977) were followed to ascertain the diagnosis of gout. 
Participants who fulfilled the ACR criteria were further asked to fill out a questionnaire to 
provide details of particular gout characteristics e.g., use of diuretics or other urate-
lowering therapy (ULT), the frequency of acute attacks and presence of tophus/tophi 
(information about presence of tophi were obtained by physical examination). All gout 
participants were also asked to name and provide detailed information about the 
particular foods/drinks that trigger their gout flares. Following the questionnaires, blood 
and urine samples were collected from each participant and were sent to the Merriman 
Laboratory (University of Otago, Dunedin, New Zealand) for further processing. At the 
Merriman Laboratory, a portion of each serum and urine sample was sent to southern 
Community Laboratory (SCL), Dunedin (www.sclabs.co.nz) for biochemical analysis, 
and the remainder of the serum samples were aliquoted and were stored at -80°C for 
future use. Serum urate was measured using the uricase oxidation method (details in 
Section 2.2), while the DNA extraction was done using a standard chloroform/ethanol 
extraction protocol (Sambrook and Russell, 2006). All experimental procedures were 
followed in accordance with the ethical standards of the responsible committee on human 
experimentation and with the Helsinki Declaration of 1975, as revised in 1983. 
 The Lower South Ethics Committee (OTA/99/11/098) and the New Zealand 
Multi-Region Ethics Committee (MEC/05/10/130) granted ethical approval for the 
recruitment and subsequent study. The ethical approval for the Ngati Porou Hauora 
Cohort recruitment was granted by the Northern Y Region Committee (NTY/07/07/074) 
and University of Otago Human Ethics Committee (13/117). The formation and 
continued recruitment of the New Zealand Gout Cohort were funded by several funding 
bodies within New Zealand i.e., the New Zealand Health Research Council 
(www.hrc.govt.nz), University of Otago (www.otago.ac.nz), Arthritis New Zealand 
(www.arthritis.org.nz) and Lottery Heath Research New Zealand 
(www.communitymatters.govt.nz). 
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 For the purpose of analysis at several instances in this thesis, the Polynesian data 
set in New Zealand Gout Cohort was divided into three ancestral sub-groups as described 
by Hollis-Moffatt et al. (2012a): Eastern Polynesian (EP: primarily included Cook Island 
and NZ Māori), Western Polynesian (WP; primarily included individuals from Samoa, 
Tonga, Tuvalu, Niue and Tokelau) and mixed Eastern and Western Polynesian (EPWP). 
Eastern Polynesian participants were further subdivided into two sub-groups: EPN 
(subjects with high EP ancestry) and EPZ (subjects with low EP ancestry). 
1.2.1.2 Additional Gout Cohorts from Europe & Australia 
 Two additional, relatively smaller, European gout case-only cohorts were 
recruited from the Merriman Lab's collaborating institutes of Europe and Australia. The 
participants in these groups were recruited to increase the number of gout cases and also 
analyse them, treating non-gout samples from NZ Gout Cohort as their respective 
controls. The first group was recruited in collaboration with European Crystal Network 
(Eurogout Consortium) (Lioté et al., 2013) and included the data of 827 individuals of 
European ancestry. The samples in the Eurogout Cohort were mainly recruited at the 
collection centres of these institutes; 1) University of Edinburgh, Keele University, Queen 
Elizabeth Hospital and City Hospital in the UK, 2) Universitario de Alicante, Hospital De 
Cruces, 3) Rijnstate Hospital, Radboud University Medical Centre, University Medical 
Centre Utrecht in Netherlands and 4) Universitätsklinikum Carl Gustav Carus an der 
Technischen Universität Dresden in Germany. Ethical review boards of the respective 
institutes granted ethical approval for the subject recruitment and subsequent analyses for 
the Eurogout Cohort. The details of ethical approvals are; Ethikkommission, Technische 
Universität Dresden (EK 8012012), South East Scotland Research Ethics Committee 
(04/S1102/41), Commission Cantonale (VD) D'éthique de la Recherche sur l'être Humain, 
Université de Lausanne, Commissie Mensgebonden Onderzoek regio Arnhem—
Nijmegen and Partners Health Care System Institutional Review Board. The second 
group was recruited in collaboration with Arthritis Genomics Recruitment Initiative in 
Australia (AGRIA) and included data from 215 individuals of European ancestry. The 
samples in the AGRIA Cohort were mainly recruited at the collection centres of these 
institutes within Australia; 1) the University of Queensland and Diamantina Institute at 
the University of Queensland, 2) The University of New South Wales, St. Vincent's 
Hospital and 3) The University of Adelaide. The details of ethical approvals are: 
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Research and Ethics Committee, Repatriation General Hospital, South Australia (32/08); 
Research Ethics Committee, University of New South Wales. All subjects in these two 
cohorts had gout clinically ascertained using ACR criteria described above (Wallace et al., 
1977). A written informed consent was obtained from all subjects in Eurogout and 
AGRIA Cohorts. 
1.2.1.3 UK Biobank Cohort 
 The UK Biobank is a large, non-commercial, repository that was established in 
the United Kingdom (UK) in 2007 (www.ukbiobank.ac.uk/). It was established (in 
Stockport, Greater Manchester, UK) to facilitate the investigation of the contribution of 
genetic predisposition and environmental exposure to the development of a range of 
diseases including heart disease, cancer, dementia, diabetes, osteoporosis, arthritis, eye 
disorders and forms of depression. The UK Biobank is a 25-year follow-up study that 
includes data from ~500,000 volunteers in the UK. All individuals in the study ranged 
from 40 to 69 years of age at the time of initial recruitment (2006-2009). The participants 
were invited to visit different assessment centres based in the UK and were interviewed 
about baseline demographic variables, medical history, lifestyle and nutritional habits. 
 For the purpose of this study, the gout case-control genotype and phenotype data 
were sourced and analysed from the UK Biobank Cohort under approval number 12611 
(Ollier et al., 2005). 1  The samples in the UK Biobank were genotyped using the 
Affymetrix Axiom array for 820,967 markers. The data of the participants were selected 
for analysis based on the European ancestry and availability of genotype information. 
Data of individuals that failed to either fulfil the genotype quality control assessment, had 
self-reported sex mismatch with genetic sex or had hospital diagnosed kidney disease 
(ICD10 I12, I13, N00-N05, N07, N11, N14, N17-N19, Q61, N25.0, Z49, Z94.0, Z99.2) 
were excluded from the study. Applying these selection criteria, genotyping data of 
~73.3M SNPs were imputed using SHAPEIT3 and IMPUTE2 platforms and UK10K and 
1000 Genomes as the combined reference panel. 
                                                 
1 Professor Tony R Merriman (PhD supervisor) and Professor Nicola Dalbeth (Collaborator: The University 
of Auckland, New Zealand) supervised the UK Biobank project-associated work and a staff member of the 
Merriman Laboratory, Murray Cadzow (Assistant Research Fellow), determined the gout definitions and 
carried out the association analyses in the UK Biobank data. 
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 For the UK Biobank Cohort, the diagnosis of gout was not ascertained following 
ACR criteria (described above). Therefore, gout status was defined following a 
combination of definitions (Cadzow et al., 2016) provided in the previous 
epidemiological literature (Colhoun et al., 2003; Dalbeth et al., 2016; Köttgen et al., 
2013). The gout diagnosis criteria were broadly divided into four categories; self-reported, 
hospital diagnosed, use of ULT and Winnard-defined gout (Winnard et al., 2012). Self-
report of gout was defined as ‘participant reporting as having gout at the time of 
interview’. Hospital diagnosed gout was defined as ‘having a primary or secondary 
hospital discharge coding for gout (ICD10 M10 including subcodes). Use of ULT was 
defined as ‘participant reporting as being on any ULT (allopurinol, febuxostat or 
sulphinpyrazone) and not being diagnosed as having leukemia or lymphoma (ICD10 C81-
C96) by the hospital’. Winnard-defined gout was defined as ‘having a hospital diagnosis 
of gout or being on gout-specific medication (any ULT or colchicine)’ as described by 
Winnard et al. (2012). 
1.2.2 Non-Gout (Control only) Cohorts 
1.2.2.1 Jackson Heart Study Cohort 
 The Jackson Heart study is a population-based longitudinal study based in the 
City of Jackson, US (United States) state of Mississippi. The Jackson Heart Study was 
established in 1997 as a partnership among three major institutes in Jackson (Jackson 
State University, the University of Mississippi Medical Centre and Tougaloo College, 
Jackson Mississippi) and the National Institutes of Health’s National Heart, Lung, and 
Blood Institute (NHLBI) and Office of Research on Minority Health, while the initial 
recruitment of the subjects was started in the year 2000. The JHS was designed to identify 
the risk factors for the cardiovascular disease and its associated manifestations including 
obesity, hypertension, diabetes, stroke, coronary heart disease and chronic kidney disease 
in more than 5000 African American individuals from Jackson, Mississippi (Taylor, 
2005). The JHS represents the largest single-site, prospective study conducted in African 
Americans to investigate the inherited (genetic) factors that affect above defined 
metabolic conditions and to develop potential treatments that do more good and less harm 
than treatments that are available today. The JHS Cohort currently has data from ~5,300 
male and female adults aged 35 to 84 years, from more than 400 families. The 
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information provided on the JHS official website (www.jacksonheartstudy.org/) indicates 
3 phases (Exam 1 to 3) of the subject recruitment (information of year of recruitment was 
not provided). Publicly-accessible data includes demographic, clinical, dietary and social 
information of the recruited subjects in three directories (visit 1 to 3). Permission to 
access the data was granted to Professor Merriman under the dbGaP controlled access 
agreement (project name: “Genetic Basis of Gout”; project approval #384). The 
phenotype data for iron profile and baseline health information from Exam 1 phase 1 
(visit 1) was used in this thesis for several analyses in Chapter 2 (Section 2.2). 
1.2.2.2 Third National Health and Nutrition Examination Survey Cohort 
 The US Third National Health and Nutrition Examination Survey (NHANESIII) 
is a nationwide population-based study that was designed to investigate the prevalence 
and risk factors of multiple common diseases in the US population 
(www.cdc.gov/nchs/nhanes). The National Centre for Health Statistics (NCHS) and 
Centres and Disease Control and Prevention (CDC) are the supporting bodies for 
NHANESIII. The study contains data from 39,695 male and female individuals (at least 2 
months of age or older), with the data being considered as illustrative for the general US 
population. The study started in 1988 and includes data from more than 85 regions within 
the US. The subjects in the NHANESIII were recruited in two phases. Phase 1 was 
conducted between the years 1988 to 1991 and collected data from 44 counties, while 
Phase 2 was conducted between the years 1991 to 1994 and collected the data from 45 
different counties. Within the time period of six years, a total of 33,994 participants were 
interviewed at their home about their demographic status, dietary habits and medical 
histories followed by a visit for medical examination in a mobile examination centre 
(examination response rate was 78%). The phenotype data for NHANESIII is publicly 
available at their official website (www.cdc.gov/nchs/nhanes/nhanes3.htm) and can be 
downloaded without permission requirements. The phenotype data for iron profile and 
baseline health information from Phase 1 and 2 (European and African American 
individuals) were downloaded for various analyses in Chapter 2 (Section 2.2). 
1.2.2.3 Atherosclerosis Risk in Community Study Cohort 
 The Atherosclerosis Risk in Community (ARIC) Study is a population-based, 
longitudinal study designed to investigate established and new risk factors for 
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atherosclerosis in the US population (www2.cscc.unc.edu/aric/; Database of Genotype 
and Phenotype/dbGaP; www.ncbi.nlm.nih.gov/gap accession # phs000280). The study 
includes data from 15,485 male and female adults mainly from four different 
communities in the US – Forsyth County, North Carolina; Northwest Minneapolis, 
Minnesota, Jackson, Mississippi and Washington County, Maryland. The subject 
recruitment for the study started in 1987. All individuals who agreed to participate in the 
study were interviewed in Exam 1 between 1987 and 1989 about the baseline 
demographic and clinical characteristics along with details of food intake. The average 
age of participants ranged between 45 and 64 years. The study then followed the clinical 
information of the participants on re-examination every 3-years along with annual 
detailed telephone interviews. The ARIC study currently has the data for a total of five 
clinical examinations completed – Exam 1: 1987-1989, Exam 2: 1990-1992, Exam 3: 
1993-1995, Exam 4: 1996-1998 and Exam 5: 2011-2013. The study also had whole-
genome genotyping performed as part of the GENEVA (Gene-Environment Association 
Studies) initiative (dbGaP accession #phs000090). The genotyping was performed for 
~934,930 SNPs using the Affymetrix 6.0K Chip genotyping platform. Four major 
funding bodies - NHLBI: #N01-HC-55015, N01 HC-55016, N01-HC-55018, N01-HC-
55019, N01-HC-55020, N01-HC-55021, N01-HC-55022, R01HL087641, R01HL59367 
and R01HL086694, National Human Genome Research Institute/NHGRI: 
#U01HG004402, National Institute of Health/NIH: #HHSN268200625226C and 
University of Carolina, Chapel Hill, collectively support the ARIC study. The permission 
to access the data was granted to Professor Merriman under the dbGaP controlled access 
agreement (project name: “Genetic Basis of Gout”; project approval #384). For the 
purpose of various analyses in this thesis (Chapter 4: Section 4.2), the phenotype and 
genotype data were obtained from visit 1 (1987-1989) only. 
1.2.2.4 Framingham Heart Study Cohort (Offspring & Generation 3) 
 The Framingham Heart study (FHS), established in 1948, is a population-based 
longitudinal study aimed to identify and investigate common genetic and environmental 
risk factors that contribute to cardiovascular disease (www.framinghamheartstudy.org/; 
dbGaP accession # phs000007). The FHS cohort also includes data for other metabolic 
conditions including gout, hyperuricaemia, osteoporosis and diabetes. The current data in 
the FHS cohort were established over a period of time following a large number of 
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asymptomatic male and female individuals for the development of CVD or related 
symptoms. The original FHS cohort consisted of 5,209 individuals from Framingham, 
Massachusetts; all aged 28 to 62 years. Since the recruitment of the Original FHS cohort 
in 1948, two more cohorts were recruited – the Offspring and Generation 3 cohorts. The 
Offspring cohort was established in 1971, which essentially included 5,124 offspring of 
the participants in the ‘Original’ cohort and their spouses. The Generation 3 cohort was 
established in 2002 and included 4,148 grandchildren of the ‘Original’ cohort. 
Participants in both the Offspring (1971-1975) and Generation 3 (2002-2005) cohorts 
were asked to give written consent for the study. All interested participants were then 
interviewed about baseline demographic, social and clinical aspects. The individuals in 
the FHS cohort were also genotyped as part of the SNP Health Association Resource 
(SHARe) project (dbGaP accession # phs000342). The genotyping was performed for 
~934,500 SNPs using the Affymetrix 500K mapping array. Two funding bodies - NHLBI 
and Boston University (www.bu.edu), collectively support the FHS. Permission to access 
the data was granted to Professor Merriman under the dbGaP controlled access agreement 
(project name: “Genetic Basis of Gout”; project approval #384). For the purpose of 
various analyses in this thesis (Chapter 4: Section 4.2), the phenotype and genotype data 
were obtained from examination 1 (Offspring: 1971-1975 and Generation 3: 2002-2005). 
1.2.2.5 Cardiovascular Health Study Cohort 
 The Cardiovascular Health Study (CHS) is a prospective population-based 
observational study that was established to evaluate the risk factors, development and 
progression of cardiovascular disease (www.chs-nhlbi.org; dbGaP accession # 
phs000287). The CHS subject recruitment was started in 1989 with coverage of four 
major regions; California, Maryland, North Carolina and Pennsylvania. A total of 5,582 
participants were interviewed and underwent extensive annual clinical examinations 
between the years 1989 and 1999. The cohort was divided into two age groups - Senior: 
aged between 65 and 79 years, and Aged: 80 years or older. The measurements included 
socio-demographic status, dietary habits and measurements of potential CVD risk factors 
such as hypertension, complete lipid profiles and the presence of subclinical disease 
(echocardiography, carotid ultrasound and cranial magnetic resonance imaging/MRI). 
During the follow-up, participants were contacted via phone calls to update their health 
status and hospitalisation. The main outcomes recorded in the follow-up were coronary 
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heart disease, heart failure, angina, heart stroke, transient ischemic attack and mortality. 
The CHS cohort was genotyped as part of SNP Typing for Association with Multiple 
Phenotypes from Existing Epidemiologic Data (STAMPEED; dbGaP accession # 
phs000226) using the Illumina HumanCNV370 duo bead chip as the genotyping platform. 
The National Institutes of Health’s National Heart, Lung, and Blood Institute (NHLBI) is 
the main funding body for the CHS cohort. Permission to access the data was granted to 
Professor Merriman under the dbGaP controlled access agreement (project name: 
“Genetic Basis of Gout”; project approval #384). For the purpose of various analyses in 
this thesis (Chapter 4: Section 4.2), the phenotype and genotype data were obtained from 
visit 1 (1989-1991). 
1.2.2.6 Coronary Artery Risk Development in Young Adults Study Cohort 
 The Coronary Artery Risk Development in Young Adults (CARDIA) Study was 
designed ‘to examine the determinants and development of clinical and sub-clinical 
cardiovascular disease and its risk factors’ (www.cardia.dopm.uab.edu; dbGaP accession 
# phs000285). The study began in 1985 with recruitment of 5,115 adult males and 
females aged 18-30 years. The participants were selected with equal numbers in sub-
groups of race, ethnicity, gender, age and education. The recruitment was done in four 
centres - Birmingham, Alabama; Minneapolis, Minnesota; Chicago, Illinois and Oakland, 
California. After the initial interview about demographic and clinical history between 
1985 and 1986, all participants were asked to participate in follow-up at year 2 (1987-
1988), year 5 (1990-1991), year 7 (1992-1993), year 10 (1995-1996), year 15 (2000-
2001) and year 20 (2005-2006). At a re-examination success rate of 72%, the current 
cohort includes the data completed for 3,622 individuals. The data collected were mainly 
for risk factors of cardiovascular disease e.g., blood pressure, glucose, cholesterol and 
other lipids. Baseline characteristics included the measurement of weight, skinfold fat, 
exercise pattern, dietary habits and alcohol consumption. Genotyping of the CARDIA 
cohort was also performed as a part of GENEVA initiative (dbGaP accession # 
phs000309) using the Affymetrix 6.0K genotype platform at Boston Massachusetts. In 
addition to NHLBI and NIH, the CARDIA study is funded by University of Alabama, 
Birmingham (www.uab.edu). Permission to access the data was granted to Professor 
Merriman under the dbGaP controlled access agreement (project name: “Genetic Basis of 
Gout”; project approval #384). For the purpose of various analyses in this thesis (Chapter 
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4: Section 4.2), the phenotype and genotype data were obtained from visit 2 of CARDIA 
cohort. 
1.2.3 ReSequencing Cohort 
 In addition to a subset selected from NZ Gout Cohort for resequencing (details in 
Chapter 5), samples from two small European cohorts were also selected for resequencing. 
A description of these cohorts is provided below. The combined resequencing data set 
including all three subsets is referred to as ‘ReSequencing Cohort’ in the thesis text. 
1.2.3.1 Nurse’s Health Study Cohort 
 The Nurse’s Health Study (NHS) is a female-based longitudinal study that was 
established in 1976 (www.channing.harvard.edu/nhs). The initial aim of the study was to 
investigate long-term health effects of oral contraceptives in female population of the 
USA. A total of 121,700 female nurses, aged between 30 and 55 years, were recruited 
from 11 different states of the USA. All participants were sent a questionnaire via email 
to record their demographic, medical and lifestyle details with success return rate of 
~70%. Every two years, participants in the Nurse’s Health Study are mailed a 
questionnaire to detail their medical history, hormonal medication usage, menopausal 
status and quality of life. The National Institute of Health (www.nih.gov), Brigham and 
Women’s Hospital, and Harvard School of Public Health and Harvard Medical School 
(Boston, Massachusetts) are funding bodies for NHS. 
1.2.3.2 Health Professionals Follow-up Study Cohort 
 The Health Professionals Follow-Up Study (HPFS) is a men’s health based 
longitudinal study that began in 1986 (http://www.hsph.harvard.edu.hpfs). The aim of the 
study was to evaluate the potential link between nutritional factors and men’s health via 
relating diet with incidence of serious illnesses e.g., heart disease, cancer, pulmonary and 
vascular disease. The HPFS all-male study was established to complement the all-female 
Nurse’s Health Study (NHS; explained above in section 1.2.3.1), which inspects similar 
hypotheses in a population of females. More than 51,000 males, aged between 40 and 75 
years, were recruited from different regions of United States of America (USA). 
Professions of the males included in the study were recognised as being pharmacists, 
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dentists, osteopaths, podiatrists, optometrists or veterinarians. All participants are mailed 
a questionnaire to provide their health, medication and exercise history every two years. 
The Harvard School of Public Health and the National Cancer Institute (www.cancer.gov) 
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SECTION 2.1 IRON HOMEOSTASIS, URATE AND GOUT: AN 
INTRODUCTION 
2.1.1 Background 
 Iron is an essential element of the human body and is vital for an array of 
metabolic functions, such as oxygen transport and cellular respiration (oxidative 
phosphorylation). The importance of this metal lies in its ability to act as an electron 
donor in its ferrous (Fe2+) state and acceptor in its ferric (Fe3+) state. When present in 
abnormally excess amounts, iron can create potential hazards to the surrounding cells by 
catalysing the reaction of production of free radicals from hydrogen peroxide. These free 
radicals can end up in damaging a wide range of cellular structures, and ultimately killing 
the cells. While our body needs the right amount of iron for several metabolic functions, 
it also needs to protect its cells from the harm done by free floating iron. Being a trace 
element, iron is required only in small amounts in the body. This is why the human body 
is specialised to strictly maintain the normal blood levels of iron within a narrow range of 
3 to 4 grams (3.8 g in males and 2.3 g in females) of the total body weight (Leong and 
Lonnerdal, 2012). For well-nourished people, this range may vary from 4 to 5 grams 
(Gropper and Smith, 2013). 
2.1.2 Forms of dietary iron 
 Diet acts as the major source of iron for an adult human being. Food-based iron is 
typically categorised into heme and non-heme forms (Sharp, 2010). The readily 
absorbable heme is abundantly found in animal-based foods (meat, fish and seafood) as 
part of hemoproteins, myoglobin and hemoglobin. Studies estimate that dietary heme iron 
accounts for two-thirds of the average person’s total iron stores (Bezwoda et al., 1983; 
Carpenter and Mahoney, 1992; West and Oates, 2008). Due to its high bioavailability, the 
absorption of heme iron is 5 to 7 times higher in the gastrointestinal tract than non-heme 
iron (Björn-Rasmussen et al., 1974; Reizenstein, 1979). The presence of proteolytic 
enzymes and low pH (which increases iron solubility) in the stomach and small intestine 
makes an ideal environment for the release of heme from hemoproteins (Collins and 
Anderson, 2012). Once entered into the enterocytes, iron is released from heme to be 
transported to the blood. In a meat-eating population, heme iron is estimated to contribute 
10 to 15% of the total iron intake. However, it can contribute > 40% of the absorbed iron 
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due to its simpler form and higher absorption (Carpenter and Mahoney, 1992; Hunt, 
2002). Non-heme iron, which comes from both plant and animal-based foods is much less 
well absorbed than heme iron. Heme iron being preferentially absorbed in the intestine, 
the amount of iron gained from a non-heme source is totally dependent upon the 
individual’s iron status (Hurrell and Egli, 2010). 
2.1.3 Mechanism of iron regulation 
 Iron homeostasis is a tightly regulated set of biochemical processes. A number of 
proteins, enzymes, and other cellular structures are involved in maintaining the normal 
body iron concentration. Figure 2.1 illustrates the series of mechanisms and their 
components involved in human iron homeostasis. In addition to the regulation of 
endogenous iron pools, the amount of iron from the diet is regulated in the body at two 
different levels namely systemic and cellular (Ganz, 2013; Wang and Pantopoulos, 2011). 
2.1.3.1 Systemic regulation 
 The control of iron concentrations at the systemic level is accomplished by its 
precise uptake, distribution and storage. Duodenal enterocytes work in a controlled 
fashion to absorb a specific amount of the dietary iron via the villi/brush border (Fuqua et 
al., 2012). The heme is directly imported inside the enterocytes via the enterocyte’s cell 
membrane protein called divalent metal ion transporter 1/DMT1 (Collins and Anderson, 
2012; Courville et al., 2006). Conversely, the non-heme iron needs to be reduced to its 
ferrous form to act as DMT1 substrate. Two metalloreductases, duodenal cytochrome 
B/DCYTB and STEAP2 are known to perform this function (McKie, 2008), yet the exact 
mechanism involved in this reduction process is unknown (Zhang et al., 2012a). In 
addition, a human cell culture study also presented some evidence of absorption of 
dietary ferritin in the enterocyte through endocytosis (San Martin et al., 2008). Once the 
enterocyte uptake of heme or non-heme is completed, it is broken down to release iron 
(ferrous/Fe2+ form) by heme oxygenases (Fuqua et al., 2012; Raffin et al., 1974). Iron has 
two fates at this stage, either stored inside endogenous ferritin or exported out of the 
enterocytes into the circulation for its transport to other tissues of the body. A 
transmembrane protein at the basolateral surface of the enterocytes, ferroportin (FPN1), is 
the only known mammalian protein that makes this export possible (Anderson and Vulpe, 
2009). Ferroportin exports iron in its ferrous form, but before release into the blood, it is 
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oxidised to its ferric form (only form that can bind the iron transporting protein) by 
ferroxidases (e.g., hephaestin) (De Domenico et al., 2007). Once  it reaches the 
circulatory blood pool, the transport of iron in the blood is controlled by a glycoprotein 
named transferrin/TF. Transferrin reversibly binds iron ions absorbed from the duodenum 
and carries them to the surrounding tissues (Rouault, 2003). 
Figure 2.1: Steps involved in maintiaing iron balance in the human body. 
 The human body does not possess any specialised excretory mechanism for the 
removal of iron. Thus, it is essential to have tight regulation of iron absorption in order to 
match the body iron requirements. In conjunction to its absorption, two major 
mechanisms help to maintain the body iron levels within the normal range i.e., recycling 
and loss. The reticuloendothelial system, mainly comprised of monocytes and tissue 
macrophages, efficiently recycles iron through the breakdown of senescent (aged) red 
blood cells. In addition, a small but steady quantity of iron is lost through faeces, 
epithelial cell sloughing, sweating and menstrual bleeding in women (Knutson and 
Wessling-Resnick, 2003). According to a survey, the total amount of the average daily 
iron loss is 1 mg for men, 1.5 to 2 mg for pre- and 1 mg for postmenopausal women 
(Hunt et al., 2009). A 25 amino acid peptide hormone ‘hepcidin’ is known for its ability 
Possibly contributing to 
serum ferritin 
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to inhibit the over-efflux of iron through intestinal enterocytes and reticuloendothelial 
cells (Knutson, 2010; Nemeth and Ganz, 2009). Hepcidin is a hepatic hormone, which 
freely circulates in the blood and can bind, internalise and degrade the iron exporter FPN1 
to decrease blood iron release (Nemeth et al., 2004). 
2.1.3.2 Cellular regulation 
 Cellular iron levels are controlled differently by different cell types via the 
expression of particular iron regulatory and transport proteins. The cellular uptake of iron 
is mainly governed by transferrin receptor 1/TFR1 and transferrin receptor 2/TFR2 
mediated import from transferrin into cells (Moos, 2002). In contrast to TFR2, TFR1 
possesses 30 times higher affinity for transferrin-bound iron and is known to play the 
main role in iron uptake at the cellular level (Kawabata et al., 2000; West et al., 2000). 
Transferrin receptors can only recognise transferrin-bound iron, which means any free 
floating (unliganded) iron is not transported inside the cells via TFRs. This specific 
recognition is necessary to cause a conformational change on the cell surface to begin 
endocytosis of the iron and formation of endosome (Hentze et al., 2010). The DMT1 and 
ZIP14 (Zrt-Irt-like protein) also allow iron to directly enter the cells via the plasma 
membrane (Lane et al., 2015). As ferric iron can potentially introduce toxicity to cellular 
organelles, it needs to be reduced to its ferrous state before entering the cytoplasm. Two 
components, the DMT1 and STEAP family reductases, perform the functions of reduction 
and import, respectively (Hentze et al., 2010). The ferrous form of iron imported into the 
cell makes up a labile iron pool where it stays in a soluble and chelateable state (Yehuda 
and Mostofsky, 2010). 
 Like enterocytes, iron is also exported out of other cells (neurons, erythrocytes 
and macrophages) that ultimately determine the systemic iron levels. The iron exporter 
FPN1 transports ferrous iron out of the cell (Ganz, 2005), simultaneously assisted with 
conversion of ferrous to ferric state before releasing it in the cytoplasm (Hentze et al., 
2010). Hepcidin performs its function of internalisation and degradation of FPN1 to 
regulate iron efflux at the cellular level. The exact mechanism being unknown, hepcidin 
may also downregulate TFR1 and DMT1 (Du et al., 2011). 
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2.1.4 Iron storage in the body 
 Due to the high potential for biological toxicity and catalytic activity, iron ions 
should never stay ‘free’ or unliganded. This exceptionally important need to sequester 
iron in a suitable liganded form is fulfilled via ‘ferritin’. Ferritin is a hollow globular 
protein, made of 24 subunits of heavy (FtH1) and light (FtL) chains (Arosio and Levi, 
2010). Ferritin is the only protein specialised for the storage of excessive iron in a non-
toxic or redox inactive form and its release in a controlled fashion (Harrison et al., 1986). 
The ability of cells to regulate their iron uptake by modulating the conformation 
(endocytosis) and expression of the receptors (TFRs) on the cell surface and storage of 
excess iron as ferritin is one of the major features that tightly maintains iron homeostasis. 
Synthesis of ferritin mainly takes place in hepatocytes (liver cells), with minor amounts 
being synthesised by other cells (Anderson and Shah, 2013; Theil, 1987). It has been 
estimated that ferritin contains about 2 grams of the total iron (out of 3 to 4 grams) in the 
body, most of which is commonly found in blood regulatory tissues/organs i.e., bone 
marrow, spleen, liver, duodenum and skeletal muscle (Gropper and Smith, 2013; Saito, 
2014). Iron stored in the heptaocytes makes up the primary physiologic iron reserve that 
can be mobilised to release iron according to the systemic metabolic demands (Anderson 
and Shah, 2013). Serum ferritin reflects cumulative iron stores in the body and it is 
measured under regular laboratory practices to determine the blood levels of iron (Saito et 
al., 2013; Shoden et al., 1953). 
 Hemosiderin is another iron storage complex, that works alongside ferritin to 
decrease and increase the iron supply to the cells under iron overload and deficiency, 
respectively. Mostly referred as ‘inactive ferritin’, hemosiderin is created by macrophages 
as an ill-defined complex of denatured ferritin and iron (Fischbach et al., 1971). Any iron 
contained in hemosiderin has a minimal chance to be delivered to the body tissues. 
Ferritin has been shown to be actively converted to hemosiderin to protect cells from 
damage caused by iron overload (Saito and Hayashi, 2015). Also, as a protective 
mechanism towards iron deficiency, any drastic decrease in iron levels can instantly 
convert hemosiderin back to ferritin to normalise the total body iron concentration (Saito 
et al., 2013). 
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2.1.5 Disorders of iron metabolism 
 Two disorders of abnormal body iron levels are iron deficiency – too low iron, 
and iron overload – too high iron. In aggregate, iron deficiency and overload have been 
reported to affect over 1 billion people around the globe (Hentze et al., 2004). More 
recent studies indicated haemochromatosis (iron overload) to be more prevalent in men 
with an occurrence of 0.6% in European populations (Crownover and Covey, 2013). In 
contrast, a study based on 1995-2011 data collected from several populations (children 
and adult women only) estimated 800 million children (43% of total) and women (29% of 
total) to be affected with iron deficiency or anaemia globally (WHO, 2015). 
2.1.5.1 Iron deficiency 
 Iron deficiency occurs when body iron concentrations drastically decrease to a 
level that could create potential hazards to health and life (CDC, 2006). Malnutrition is 
the most common cause of iron deficiency worldwide, especially in children and pre-
menopausal women (Dlouhy and Outten, 2013; Robert and Xiaole, 2013). When dietary 
intake and systemic and cellular regulatory mechanisms are not able to compensate 
sufficiently for iron loss, the body develops a state of iron deprivation over time. The 
continuous deprivation could clinically manifest as iron deficiency anaemia (Njajou et al., 
2006) – a condition characterised by low levels of iron, reduced production of 
haemoglobin and oxygen supply to the tissues and microcytic erythrocytes. An iron-rich 
diet may be sufficient to treat mild iron deficiency, while anaemia may only be corrected 
following an appropriate therapy i.e., oral or parenteral iron intake (Camaschella, 2015; 
Lopez et al., 2016). 
2.1.5.2 Iron overload and haemochromatosis 
 Iron overload is characterised by accumulation of iron in the body due to genetic 
or environmental causes (Hider and Kong, 2013). Repeated blood transfusions and 
excessive intake of iron-rich supplements can lead to iron overload (Barton et al., 2006; 
Robert and Xiaole, 2013). On the other hand, hereditary haemochromatosis (HHC) occurs 
due to one or two autosomal recessive mutations in the HFE (Human haemochromatosis) 
gene (Feder et al., 1996) i.e., rs1800562 (Cys282Tyr: replaces cysteine to tyrosine at 
amino acid 282) and rs1799945 (His63Asp: replaces histidine with aspartate at amino 
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acid 63) (Merryweather-Clarke et al., 1997). Haemochromatosis is considered the most 
common form of iron overload in Europeans (Merryweather-Clarke et al., 1997; Powell 
et al., 2016), however it accounts for less than 5% of known impaired iron metabolism 
conditions (Cherfane et al., 2013). In addition, Pacific Islanders and Asians have been 
shown to have the highest geometric mean levels of ferritin and TSAT despite having 
lowest prevalence of C282Y homozygotes (Adams et al., 2005). The presence of 
haemochromatosis mutations can disrupt a pathway of iron homeostasis and may 
manifest as reduced hepcidin production and increased intestinal iron absorption in the 
body (Powell et al., 2016). Either through iron overload or haemochromatosis, too much 
iron in the blood could eventually overwhelm the storage capacity of the body. This can 
result in iron-mediated oxidative tissue damage, organ disease and complete organ failure 
(Kohgo et al., 2008; Powell et al., 2016). 
2.1.6 Iron profile, urate and gout – evidence presenting possible 
correlation 
 Urate is well known for its physiological role as an antioxidant with an estimated 
60% contribution to antioxidant activity in the human body (Nieto et al., 2000). In 
addition, it is also known to protect body tissues from iron-mediated free radical damage 
via iron chelation (Davies et al., 1986; Ghio et al., 1994). Iron, in turn, can modulate the 
activity of xanthine oxidase and thereby the production of urate (Ghio et al., 2002). 
 A number of studies have provided evidence for imbalanced iron homeostasis in 
renal and joint diseases e.g., chronic kidney (Macdougall et al., 2016; Zumbrennen-
Bullough and Babitt, 2014) and rheumatic disease (Baker and Ghio, 2009; Hachem and 
El-Zimaity, 2007). Ferritin, iron binding capacity and transferrin saturation have been 
positively associated with urate in European and African American individuals from the 
US National Health and Nutrition Examination Survey (NHANES) (Ghio et al., 2005; 
Mainous et al., 2011). One of these studies also suggested serum urate to be a potential 
indicator of iron overload (Mainous et al., 2011). 
 There are a number of possible ways that iron could contribute to gouty 
inflammation. Iron is able to form complexes with MSU crystals in vitro, stimulate 
oxidative stress through the generation of reactive oxygen species, contribute to 
granulocyte and complement activation and production of lymphocytes (Ghio et al., 
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1994). Association of iron with a number of pro-inflammatory activities in animal models 
(Dabbagh et al., 1992) and a decrease in gouty flares following phlebotomy to attain near 
iron-deficient levels in hyperuricaemic patients (Facchini, 2003) are also suggestive of a 
role in gouty arthropathy. Consistent with these observational studies, data from an 
immune-focused GWAS over 450 NZ Europeans indicated a causal association of a 
variant in the transferrin receptor (TFRC: rs1466085) with an increased risk of gout 
(Merriman et al., 2015). Individuals carrying the risk allele of this variant also self-
reported a higher likelihood of an iron-rich food as a trigger of gout flares (Merriman et 
al., 2015). 
 Food, as the basic source of iron for an adult human, provides heme (from animal-
based food) and non-heme (from animal and plant-based foods) iron to the body, with 
dietary heme iron contributing two-thirds of a person’s average iron stores (Bezwoda et 
al., 1983; Carpenter and Mahoney, 1992; West and Oates, 2008). Diet is also a key 
source of purines. Interestingly, purine-rich foods from an animal-based diet have been 
associated with increased risk of recurrent gout attacks while purine-rich foods from a 
plant-based diet did not show a strong correlation (Zhang et al., 2012b). These 
observations, combined with the other observational and intervention data (Facchini, 
2003; Ghio et al., 2005; Mainous et al., 2011), are consistent with an alternative 
hypothesis that iron in purine-rich foods (red meat for example) could be a causal factor 
in gout. 
 This part of the thesis was based on an observational and genetic association study 
to test for any possible correlation of total iron, transferrin, ferritin, total iron binding 
capacity (TIBC) and transferrin saturation (TSAT) with serum urate and/or gout in 
individuals with different ancestries. The specific aims of this study were; 
1. To evaluate any difference in the average levels of total iron, transferrin and 
ferritin between people with and without gout. 
2. To replicate the association of serum ferritin with urate and to test for its 
association with hyperuricaemia in European and African American populations. 
3. To test for an association of other blood iron profile markers (total iron, 
transferrin, TIBC and TSAT) with urate in NZ European and Polynesian datasets. 
4. To test for association of serum ferritin with gout and flare frequency in European 
and NZ Polynesian individuals. 
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5. To analyse the genetic association of two haemochromatosis variants, rs1800562 
and rs1799945, within the HFE gene with urate and gout in NZ European and 
Polynesian populations. 
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SECTION 2.2 ASSOCIATION OF IRON BIOMARKERS AND 
HAEMOCHROMATOSIS VARIANTS WITH URATE AND GOUT 
2.2.1 Background 
 As mentioned in Section 2.1, blood levels of total iron, transferrin and ferritin 
collectively make-up an adult body’s iron profile and are measured in daily laboratory 
practices to assess a person’s iron status (Sajeevan et al., 2016). Ferritin directly reflects 
cumulative iron stores in the body and thereby acts as a reliable surrogate indicator of an 
iron-related disorder (WHO, 2011). In conjunction to these, the capacity of blood to bind 
iron with transferrin is calculated as total iron binding capacity (TIBC). Total iron 
binding capacity mirrors the maximum amount of iron that blood can carry and is an 
indirect measure of blood transferrin (Yamanishi et al., 2003). Another important 
measure for iron status is transferrin saturation (TSAT), which indirectly estimates the 
amount of transferrin available for iron to bind. Calculated as a percentage, TSAT is a 
ratio between total iron and TIBC that represents the percentage of transferrin’s iron-
binding sites occupied by iron i.e., a TSAT of 20% means that, 80% sites on the 
transferrin are still free for iron to bind. Table 2.1 below shows the normal reference 
range for each of these parameters. 
Table 2.1: Standardised normal levels/reference range for iron profile markers 




65-177 μg dL-1 
(11.6-31.7 μmol L-1) 
50-170 μg dL-1 
(9.0-30.4 μmol L-1) 
Serum ferritin 20-250 μg L-1 (ng mL-1) 15-150 μg L-1 (ng mL-1) 
TIBC 250-370 μg dL-1 (45-66 μmol L-1) 
TSAT 20-50% 15-50% 
Note: Reference range for each biomarker is presented as average for European population only. Source: (Fauci, 2008). 
 As described in section 2.1, elements of the iron profile have been positively 
associated with serum urate (SU) and present a possible relationship with gout and gout 
flares. The association of TFRC: rs1466085 with gout in NZ Europeans somewhat 
provides the genetic basis to these observations (Merriman et al., 2015). Despite such 
evidence, no study has yet provided a direct measure of iron markers in the context of 
their association with urate or gout in NZ populations. This part of my thesis is 
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specifically based on the hypothesis that body levels of iron contribute to gout risk, either 
by increasing serum urate or via another independent unknown metabolic route. 
 This section represents the biochemical and genetic association analyses carried 
out to investigate the association of iron with gout and urate in NZ European, Polynesian 
and African American populations. First a preliminary observational analysis was done, 
based on measuring serum levels of total iron, ferritin, transferrin, TSAT and TIBC and 
investigating their possible relationship with urate and gout. To support the previously 
reported findings of the intake of iron-rich food to be a possible factor in gout (Choi et al., 
2004b; Öztürk et al., 2013; Williams, 2008), the observational analysis was further 
extended and food-based data collected from NZ individuals were analysed. 
 Given that ferritin has been reported as a marker of acute inflammation (Kell and 
Pretorius, 2014), C-reactive protein (CRP) was included as an adjustor in the regression 
models to rule out the possibility that any likely association between ferritin and risk of 
gout and flare frequency could be a consequence of inflammation. C-reactive protein is 
an acute-phase protein, which increases in inflammation and has previously been 
demonstrated to elevate in hyperuricaemia (Ruggiero et al., 2006) and gout (Roseff et al., 
1987). Also, to rule out the possibility of getting biased results due to inflammation via 
liver damage, any participant with hepatic disease was excluded from the various 
analyses. 
 In addition, genetic association analysis of two haemochromatosis variants, 
rs1800562 and rs1799945, was also done to test for any possible association with urate 
and gout in NZ European and Polynesian populations. 
2.2.2 Methods 
2.2.2.1 Biochemical analysis 
2.2.2.1.1 Study participants 
 Four different datasets were used for this study, comprising two gout case-control 
sets from NZ and US (The United States of America) and two subsets of non-gout 
individuals selected from two publicly available cohorts, The Jackson Heat Study (JHS) 
and The US Third National Health and Nutrition Examination Survey (NHANES III) 
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(Chapter 1: Section 1.2). Table 2.2 and 2.3 report the demographic and clinical details for 
these study groups. The NZ data set included 320 European and Polynesian male 
individuals and was selected as a sub-set of New Zealand Gout Cohort (Chapter 1: 
Section 1.2). The US data set included 249 male individuals (gout and non-gout), 
recruited during 2014-2016 from community-based settings in the US2. The NZ sample 
set comprised male NZ European (100 cases and 60 controls) and Polynesian (100 cases 
and 60 controls) individuals. The data for consumption of iron-rich food (red meat, 
seafood and fish) were determined as previously reported (Flynn et al., 2015). The US 
group comprised a mixture of Latino, African Americans and Europeans (189 cases and 
60 controls). All US gout cases had crystal proven or clinically diagnosed gout, with no 
active acute gout at the time of sample draw (no NSAID or colchicine usage within 2 
weeks before the sample draw). New Zealand participants without gout (controls) 
included in this study were convenience sampled from the Auckland, Otago and 
Canterbury regions of NZ. The US control group comprised sex- and ancestrally-matched 
volunteers. Individuals with a history of liver damage or disease were excluded from the 
NZ and US case groups and US control participants were included if they had never been 
diagnosed with gout and were not currently taking any non-steroidal anti-inflammatory 
drugs (NSAIDs) or colchicine. The Independent Ethics Committee E6 Good Clinical 
Practice granted ethical approval for the US samples. The collection was done in 
accordance with the Declaration of Helsinki (October 2008), and applicable local 
regulatory requirements (including Institutional Review Board approval). Written 
informed consent was obtained from all subjects for the collection of samples and 
subsequent analyses. 
 Publicly-available data from two larger cohorts, JHS and NHANES III, were used 
only for serum ferritin versus urate association analyses. These data sets have been 
detailed in Chapter 1 (Section 1.2). The JHS data included a total of 1,260 African 
American individuals, while the NHANES III data were comprised 4,355 African 
American and 5,112 European individuals. All individuals recruited from the JHS and 
                                                 
2 Drs Jeffrey N Miner and Cory N Iverson (Biology, Ardea Biosciences, Inc., AstraZeneca Group, San 
Diego, US) kindly provided demographic and clinical information for the US data set. 
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NHANES III cohorts were at least 21 years of age. Subjects who self-reported as taking 
any diuretic or other urate-lowering medication, or had kidney disease or gout, or had 
first-degree relatives with gout were excluded from the serum/plasma urate association 
analyses. This categorisation was made to assess urate association only in non-gout 
subjects and to remove any chances of getting biased results due to gout or other potential 
factors affecting urate concentration and thus differed from the criteria applied to the 
previous study that used the NHANES III data (Ghio et al., 2005). Additionally, none of 
the participants used here overlapped with Ghio et al. (2005), and the data were analysed 
separately in the NHANES III European and African American participants. In order to 
assess the association with hyperuricaemia, both cohorts were stratified on the basis of 
serum urate levels with a cut-off value of ≥ 0.41mmol L-1 between hyperuricaemic cases 
(serum urate ≥ 0.41 mmol L-1) and normouricaemic controls (serum urate ≤ 0.37mmol L-
1). 
 The iron profile marker data provided for the US group included only ferritin, 
while the data sourced from JHS and NHANES III included total iron, ferritin, TIBC and 
TSAT. 
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Table 2.2: Demographic and clinical information for NZ, US, JHS and NHANES III data sets 





Group Non-gout Gout Non-gout Gout Non-gout Gout Non-gout Non-gout Non-gout 
Baseline Information 
Total Participants (n) 60 100 60 100 60 193 1260 5112 4355 
Males, n (%) 60 (100) 100 (100) 60 (100) 100 (100) 60 (100) 189 (97.92) 567 (45.00) 2460 (48.09) 1925 (44.41) 
Age (years)^ 53.41 ± 14.95 64.3 ± 11.73 41.98 ± 13.71 48.18 ± 13.42 52.1 ± 6.89 56.55 ± 10.76 47.59  ± 10.82 52.95 ± 19.87 41.90 ± 17.63 
BMI (kg/m2)^ 26.30 ± 3.02 30.05 ± 4.46 31.09 ± 5.68 36.32 ± 7.75 - - 31.16 ± 7.23 26.01 ± 5.05 27.65 ± 6.58 
Serum Urate (mmol L-1)^ 0.33 ± 0.07 0.38 ± 0.10 0.32 ± 0.03 0.49 ± 0.10 0.35 ± 0.08 0.38 ± 0.11 0.31 ± 0.08 0.31 ± 0.07 0.32 ± 0.09 
CRP (mg dL-1)^ 0.39 ± 0.25 0.59 ± 0.28 0.39 ± 0.26 0.60 ± 0.27 0.61 ± 0.81 1.03 ± 1.44 0.43 ± 0.71 0.41 ± 0.62 0.52 ± 0.82 
Iron Profile Measurements 
Serum iron (μg dL-1)^ 105.74 ± 30.91 100.62 ± 33.76 90.01 ± 29.07 82.91 ± 27.77 - - 81.38 ± 31.61 90.21 ± 36.39 80.18 ± 35.62 











130.62 ± 139.86 144.21 ± 163.74 
Serum transferrin (g L-1)^ 2.52 ± 0.39 2.53 ± 0.34 2.62 ± 0.47 2.79 ± 0.57 - - - - - 
TIBC (μmol L-1)^ 63.47 ± 9.99 63.65 ± 8.76 65.82 ± 12.01 70.18 ± 14.40 - - 52.85 ± 8.91 62.70 ± 10.01 62.14 ± 10.54 
TSAT (%)^ 30.22 ± 9.12 28.8 ± 10.06 24.92 ± 8.05 21.56 ± 7.11 - - 28.13 ± 11.05 26.37 ± 11.36 23.72 ± 10.81 
Gout Characteristics 
No of gout flares/year^ - 3.72 ± 7.02 - 7.73 ± 23.71 - 2.02 ± 1.87 - - - 
% Allopurinol treatment 
(% reported) 
- 75 (100) - 75.75 (99) - 97.92 (84.56) - - - 
% Gout tophus (% 
reported) 
- 27 (100) - 66 (100) - NA - - - 
NZ: New Zealand, US: The United States of America, JHS: Jackson Heart Study, NHANES III: US Third National Health and Nutrition Examination Survey, EUR: White Caucasian/European, 
AA: African American, BMI: Body mass index, n (%): total number (percentage), % (% reported): total percentage# of individuals reported yes/no for the particular criteria (percentage who 
reported yes for the particular criteria out of #), CRP: C-reactive protein, TIBC: Total iron binding capacity, TSAT: Transferrin saturation. ^Data are shown as mean ± standard deviation. 
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Table 2.3: Detailed demographic and clinical information for non-gout individuals from the JHS and NHANES III study groups: 
stratified on the basis of gender 
Populations JHS (African American) NHANES III (White Caucasian/European) NHANES III (African American) 
Group Male Female Male Female Male Female 
Baseline Information 
Number (% of total) 567 (45.00) 693 (55.00) 2460 (48.09) 2652 (51.87) 1925 (44.41) 2430 (55.79) 
Age (years)^ 47.57 ± 10.63 47.61 ± 10.98 54.22 ± 19.54 51.77 ± 20.10 42.04 ± 17.67 41.79 ± 17.61 
BMI (kg/m2)^ 29.57 ± 6.03 32.47 ± 7.85 26.34 ± 4.39 25.70 ± 5.57 26.32 ± 5.22 28.71 ± 7.31 
Serum Urate (mmol L-1)^ 0.34 ± 0.07 0.26 ± 0.07 0.35 ± 0.07 0.27 ± 0.06 0.36 ± 0.08 0.28 ± 0.08 
CRP (mg dL-1)^ 0.29 ± 0.49 0.55 ± 0.82 0.39 ± 0.63 0.42 ± 0.61 0.42 ± 0.67 0.60 ± 0.92 
Iron Profile Measurements 
Serum iron (μg dL-1)^ 90.22 ± 30.23 74.14 ± 30.87 94.92 ± 35.14 85.83 ± 36.98 89.89 ± 35.11 72.48 ± 34.13 
Serum ferritin (ng mL-1)^ 224.47 ± 180.17 103.38 ± 107.95 178.81 ± 152.05 85.97 ± 110.121 204.03 ± 175.96 96.77 ± 135.80 
Serum transferrin (g L-1)^ - - - - - - 
TIBC (μmol L-1)^ 51.02 ± 7.01 54.58 ± 9.32 60.91 ± 9.02 64.37 ± 10.58 60.03 ± 9.24 63.81 ± 11.19 
TSAT (%)^ 31.96 ± 10.52 24.99 ± 10.48 28.41 ± 11.17 24.49 ± 11.21 27.18 ± 10.57 20.98 ± 10.19 
JHS: Jackson Heart Study, NHANES III: US Third National Health and Nutrition Examination Survey, EUR: White Caucasian/European, AA: African American, BMI: Body mass index, CRP: 
C-reactive protein, TIBC: Total iron binding capacity, TSAT: Transferrin saturation. ^Data are shown as mean ± standard deviation. 
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2.2.2.1.2 Biochemical measurements 
 The following paragraphs detail the methodologies adopted for the determination 
of biochemical markers (serum urate, total iron, transferrin, ferritin and CRP) for this 
study. 
2.2.2.1.2.1 Plasma/serum urate measurements 
 Serum urate measurement in NZ subjects was carried out following uricase 
oxidation method. The endpoint measurement was done using fully automated Roche 
Cobas 8000 Modular P/D analyser and reagents provided by the manufacturers. The 
median coefficient of variation for this machine is 2.1% and the within-sample 
measurement correlation 99.6%. The test is based on an enzymatic colorimetric principle 
that eliminates interference intrinsic to chemical oxidation. Uricase was added to the 
serum samples as the specific reaction enzyme. This enzyme specifically catalyses the 
oxidation of urate to produce hydrogen peroxide, allantoin, and carbon dioxide. The 
amount of hydrogen peroxide produced in the uricase reaction is then used for the 
coupling of sulphonated dichlorophenol and 4-aminoantipyine to produce a colour. The 
difference in absorbance was measured at 515nm before and after addition of uricase, 
where the difference is directly proportional to the amount of urate present in the sample. 
 For US participants, urate was measured by Liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) in a replicate plasma biomarker sample aliquot; hence urate is 
referred to as PU (plasma urate) in this data set. To measure PU levels, LC-MS/MS 
method was developed at Seventh Wave Laboratories (Missouri, USA). Separation was 
achieved on a Synergi Polar-RP 80A (4.6 x 50 mm, 4 µm) column with mobile phases of 
0.1% formic acid in water and 0.1% formic acid in acetonitrile. Quantification was done 
using a multiple reaction-monitoring mode to monitor the precursor-to-product ion 
transitions of mass to charge ratio or m/z 167.0 to m/z 124.0 for urate and m/z 169 to m/z 
125 for 1,3-(15) N urate in negative ionisation mode. The calibration curve was 
established over the range of 10-250 µg mL-1, and the correlation coefficient was 0.999. 
The accuracy determined at eight concentrations ranged between 92.7 and 107%. 
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2.2.2.1.2.2 Measurement of iron profile markers 
 For NZ participants, serum iron profile markers were measured using Roche 
Cobas® systems (Roche Diagnostics GmbH D-68298 Mannheim, Germany). Standard 
laboratory protocols provided by Cobas® systems e602, c702 and c701/702 were 
followed to measure total iron, ferritin and transferrin, respectively3. 
 The Roche ferritin assay module was based on an in vitro 
electrochemiluminescence immunoassay system. The assay consisted of two rounds of 
incubation followed by aspiration and calibration. A total of 10L of each sample was 
incubated with monoclonal mouse antibodies – M-4.184 and M-3.170 to build up a 
sandwich complex. The plates were incubated for 18 minutes at room temperature. After 
addition of streptavidin-coated micro-particles followed by the second round of 
incubation, the complex became bound to the solid phase via interaction of biotin and 
streptavidin. The reaction mixture was aspirated into the measuring cell where the micro 
particles were magnetically captured onto the surface of the electrode. Unbound 
substances were then removed with ProCell/ProCell M. Chemiluminescent emission was 
then induced through voltage electrode and measured by a photomultiplier. Results were 
determined via a calibration curve (instrument specifically generated by 2-point 
calibration and a master curve provided via the reagent barcode). 
 In vitro tests for the quantitative determination of iron and transferrin in serum 
samples were done using a Roche Cobas c system (c701 and 702). The assay for 
determination of iron was based on colorimetric and photometric analysis and was 
performed by fully automated chemistry analysers (IRON2: ACN 8661). In the first step, 
serum detergent or acids were added to liberate Fe3+ from transferrin-Fe-complex, leaving 
apo-transferrin and Fe3+ as reaction products. Detergent was then used to further clarify 
any lipemic samples. The acid added was ascorbic acid, to provide ascorbate, which 
reduced the released Fe3+ ions to Fe2+ ions to react with FerroZine to form a coloured 
complex. The colour intensity was measured photometrically at 570nm using the Roche 
chemistry analyser. The colour intensity was directly proportional to the iron 
concentration in the serum sample. The measurement of transferrin was done using 
                                                 
3 Vivienne Trethowen (Clinical Trials Assistant at Southern Community Laboratory, Dunedin Hospital, 
New Zealand) carried out the iron profile measurements for the New Zealand sample set. 
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module cobas c701 (TRSF2: ACN 8187). This test employed a 2-point end 
immnoturbidimetric assay i.e., human transferrin formed precipitates with a specific 
antiserum, which was then determined turbidimetrically at 700nm. The assay was 
performed in fully automated Roche/Hitachi chemistry analyser that calculates the 
concentration of the analyte in each sample on a pre-set protocol. 
 Total iron binding capacity (TIBC) and transferrin saturation (TSAT) were 
calculated using the following standardised formulas; 
TIBC (μmol L-1) = 25.1 × Transferrin (g L-1) 
TSAT (%) =  Iron / TIBC × 100 
Where ‘25.1’ is the theoretical ratio of TIBC (in μmol L-1) to transferrin (in g L-1) 
2.2.2.1.2.3 Measurement of C-reactive protein  
 C-reactive protein levels in NZ subjects were measured by me in the Merriman 
Laboratory, using commercially available CRP human enzyme-linked immunosorbent 
assay (ELISA) kits from Abcam (ab99995 from R&D Systems, USA), according to 
manufacturer’s instructions. This assay employs an antibody specific for human CRP 
coated on a 96-well plate. Standards and samples were pipetted into the wells to allow the 
binding of CRP to the immobilised antibody. The wells were then washed and 
biotinylated anti-Human CRP antibody was added. After washing away unbound 
biotinylated antibody, HRP-conjugated streptavidin was pipetted into the wells. The wells 
were again washed, followed by adding a 3,3',5,5'-Tetramethylbenzidine (TMB) substrate 
solution to each well. The intensity of colour developed after adding TMB was directly 
proportional to the bound CRP. Then a stop solution was added that changed the colour 
from blue to yellow. The intensity of the colour was measured at 450nm using a Thermo-
Labsystems multiskan FC absorbance plate reader. 
 The Myriad Rules Based Medicine Human Multi-Analyte Profile system (Myriad 
RBM, Inc., Austin, Texas; https://myriadrbm.com/) was used to measure plasma ferritin 
(assession number P02794 and P02792) and CRP (assession number: P02714) in the US 
subjects. The samples were spun and transferred to a master microtiter plate. Using 
automated pipetting, an aliquot of each sample was added to individual microsphere 
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multiplexes of the selected Multi-Analyte Profile and blocker. This mixture was 
thoroughly mixed and incubated at room temperature for 1 hour. Multiplexed cocktails of 
biotinylated reporter antibodies were added robotically and after thorough mixing 
incubated for an additional hour at room temperature. Multiplexes were labelled using an 
excess of streptavidin-phycoerythrin solution, thoroughly mixed and incubated for one 
hour at room temperature. The volume of each multiplexed reaction was reduced by 
vacuum filtration and washed three times. After the final wash, the volume was increased 
by addition of buffer for analysis using a Luminex instrument and the resulting data 
interpreted using proprietary software developed by Myriad RBM. For each multiplex 
reaction, both calibrators and controls were included on each microtiter plate. Eight-point 
calibrators to form a standard curve were run in the first and last column of each plate and 
controls at three concentration levels were run in duplicate. The standard curve, control, 
and sample QC were performed to ensure proper assay performance. Study sample values 
for each of the analytes were determined using four and five parameter logistics, 
weighted and non-weighted curve fitting algorithms included in the data analysis package. 
 The methodologies followed for urate (Carpenter et al., 2004), iron profile (Li et 
al., 2015) and CRP (Fox et al., 2008) measurements for the JHS are described elsewhere 
while Gunter (1996) provide details for the laboratory measurement protocols in the 
NHANES III cohort. 
2.2.2.2 HFE Genetic association analysis 
 In order to validate the findings from the above observational analyses, two 
variants within haemochromatosis (HFE) gene, rs1799945 and rs1800562, have been 
analysed for their association with urate and gout in New Zealand population. 
2.2.2.2.1 Study participants 
 Participants from the NZ Gout Cohort (Chapter 1: Section 1.2), for whom 
genotype information was available, were included in these analyses. The NZ Gout 
Cohort was categorised into two major ancestral groups, NZ Polynesian (Māori and 
Pacific Islanders: n = 2,017; 941 cases and 1,076 controls) and NZ European (n = 1,421; 
862 cases and 559 controls). In order to keep consistency with above analyses, the NZ 
Polynesian group was not divided further into any sub-groups. Data from the Ngati Porou 
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Hauora (NPH) individuals were also included as a separate Māori sample set (NPH: 144 
cases and 65 controls). Gender-based stratification was done to analyse the associations 
separately in males and females. Data for non-gout or control subjects (from NZ Gout 
Cohort only) were used to test for an association of the two HFE variants (rs1800562 and 
rs1799945) with serum urate. Of these, all subjects who self-reported as taking diuretic 
medication, or had renal failure, gout, or had first-degree relatives with gout were 
excluded from the various analyses. Table 2.4 provide demographic details of the study 
groups. 
2.2.2.2.2 Genotyping 
 Genotype data for the two HFE gene variants, rs1800562 and rs1799945, were 
sourced from the Illumina Chip CoreExome dataset. The genotyping in this dataset was 
done using the Illumina Infinium CoreExome (version 24) bead chip platform. 
Genotyping was performed at the University of Queensland (Centre for Clinical 
Genomics), followed by auto-clustering using GenomeStudio version 2011.1 software 
(Illumina, San Diego). The Illumina GenomeStudio best practice guidelines (Illumina, 
2014) and quality control protocols of Guo et al. (2014) were followed to ensure that final 
genotype calls obtained from the auto-clustered genotypes were of highest possible 
quality. 
2.2.2.2.3 Statistical analysis 
 Multiply-adjusted logistic and linear regression analyses were done using 
statistical software R version 3.3.2 (RCore, 2016) to test for an association of serum iron, 
transferrin, ferritin, TIBC and TSAT (explanatory variables) with gout and 
hyperuricaemia (binary response variables) and urate (continuous response variable), 
respectively. The regression model describes per unit change in response variable via per 
unit change in explanatory variable. Adjusted regression models were also used to assess 
the association of rs1800562 and rs1799945 (explanatory variables) with gout and serum 
urate, where again the regression model describes per unit change in response variables 
via addition of each affected allele (as per unit change in explanatory variables). The 
adjusted odds ratio (OR) and β-estimates were obtained by including age (in years), sex 
and BMI (wherever possible) as baseline covariates in the regression models. Beside 
these, two additional adjustors added in regression models were serum levels of CRP for 
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serum ferritin analysis, and number of self-reported Polynesian grandparents for the 
Polynesian sample set. Adherence to Hardy-Weinberg equilibrium (HWE) was calculated 
using the SHEsis package (Yong and Lin, 2005), with a significant deviation from HWE 
if PHWE ≤ 0.016 (0.05 divided by 3 – the number of data sets tested in Table 2.12). To 
increase the power of analysis, all ORs for logistic and all β-estimates for linear 
regression models were combined together in meta-analysis using meta package in R 
(version 4.3-2). A Q-statistic was calculated to measure the heterogeneity between the 
datasets. If the heterogeneity was significant (P < 0.05), the fixed-effect model was 
replaced with a random-effect model. Differences in the means for inter- and intragroup 
comparisons were calculated using an unpaired t-test in R version 3.3.2. 
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Table 2.4: Demographic and clinical information for study groups used for HFE variant analyses 
Population NZ Polynesian NZ European Ngati Porou Hauora 
Group Gout Non-gout Gout Non-gout Gout Non-gout 
Baseline Information 
Total number (n) 941 1,076 862 559 144 65 
Males, n (%) 804 (85.44) 555 (51.57) 729 (84.57) 416 (74.42) 122 (84.72) 34 (52.31) 
Age (years)^ 52.06 ± 13.14 43.15 ± 15.09 63.86 ± 12.83 54.32 ± 16.71 59.00 ± 11.46 46.30 ± 14.40 
BMI (kg/m2)^ 36.07 ± 7.65 33.04 ± 7.59 30.29 ± 5.33 27.63 ± 5.61 36.54 ± 7.54 29.69 ± 5.69 
Serum Urate (mmol L-1)^ 0.43 ± 0.11 0.37 ± 0.09 0.39 ± 0.11 0.34 ± 0.11 0.41 ± 0.10 0.36 ± 0.08 
Co-morbidities 
Type 2 Diabetes, n (%) 198 (23.77) 138 (14.36) 123 (0.15) 31 (0.07) 42 (0.29) 5 (7.94) 
Dyslipidaemia, n (%) 390 (46.81) 121 (12.59) 382 (0.47) 89 (0.19) 80 (0.56) 19 (30.16) 
Heart problems, n (%) 244 (29.29) 102 (10.61) 300 (0.37) 69 (0.15) 46 (0.32) 6 (9.52) 
Hypertension, n (%) 455 (54.62) 211 (21.95) 439 (0.54) 105 (0.23) 105 (0.73) 11 (17.46) 
Liver problems, n (%) 6 (0.72) 3 (0.13) 17 (0.02) 7 (0.01) 2 (0.013) 0 (0.00) 
Kidney problems, n (%) 173 (20.76) 33 (3.44) 180 (0.22) 23 (0.05) 15 (0.10) 2 (3.17) 
Gout Characteristics 
Age at onset gout (years)^ 38.06 ± 7.66 - 48.81 ± 16.87 - 39.23 ± 14.56 - 
On Allopurinol n (%) 712 (85.47) - 623 (0.769) - 109 (0.762) - 
No of gout flares/year^ 10.65 ± 33.95 - 7.86 ± 34.98 - 3.09 ± 4.67 - 
Gout tophus, n (%) 338 (40.72) - 280 (34.56) - 126 (87.50) - 
NZ: New Zealand, BMI; Body mass index, n (%): total number (percentage), ULT: Urate lowering therapy. ^Data are shown as mean ± standard deviation. Data for the co-morbidities are self-
reported.
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2.2.3 Results 
2.2.3.1 Biochemical analysis 
 Analyses of data from all four groups indicated only ferritin to have consistent 
significant associations with binary and continuous variables under study. The paragraphs 
below mostly provide association results for plasma/serum ferritin, while results for all 
other iron profile markers are provided in Appendix A, Table 2.1 through 2.4. 
 Serum ferritin concentration was positively associated with serum urate 
concentration in non-gout African American individuals from the JHS (Males: ß (mmol 
L-1) = 0.04, Pß = 9.3E-03; Females: ß (mmol L
-1) = 0.08, Pß = 1.7E-03) and NHANES III 
(Males: ß (mmol L-1) = 0.03, Pß = 5.1E-04; Females: ß (mmol L
-1) = 0.09, Pß = 1.76E-15) 
studies as well as Europeans (Males: ß (mmol L-1) = 0.02, Pß = 6.6E-03; Females: ß 
(mmol L-1) = 0.07, Pß = 3.4E-10) from the NHANES III study (Table 2.5). A positive 
association between ferritin and urate was also observed in NZ Polynesian (ß (mmol L-1) 
= 0.09, Pß = 2.5E-04), but not NZ European (ß (mmol L
-1) = 0.05, Pß = 0.31) or US 
individuals (ß (mmol L-1) = 0.24, Pß = 0.15) (Table 2.5). Combining all datasets in meta-
analysis indicated a positive association between serum ferritin and urate (ß (mmol L-1) = 
0.05, PHet = 0.27, Pß = 3.9E-32) (Table 2.5). Among other markers, serum iron, TIBC and 
TSAT were positively associated with urate in NHANES III Europeans (Iron: ß (mmol L-
1) = 0.16, Pß = 3.3E-10; TIBC: ß (mmol L
-1) = 0.31, Pß = 0.001; TSAT: ß (mmol L
-1) = 
0.35, Pß = 1.1E-05). For NHANES III African Americans, positive associations were 
observed between serum iron, TSAT and urate (Iron: ß (mmol L-1) = 0.16, Pß = 1.5E-06; 
TSAT: ß (mmol L-1) = 0.54, Pß = 8.7E-04) (Appendix A, Table 2.1). 
 Analyses comparing normouricaemic with hyperuricaemic individuals also 
indicated association of ferritin with an increased risk of hyperuricaemia in African 
Americans from the JHS (Males: OR (95% CI) =1.012 (1.01 ; 1.02), POR = 1.4E-02; 
Females: OR (95% CI) = 1.040 (1.01 ; 1.07), POR = 3.3E-03) and NHANES III (Males: 
OR (95% CI) = 1.013 (1.01 ; 1.02), POR = 2.4E-06; Females: OR (95% CI) = 1.022 
(1.01 ; 1.03), POR = 7.1E-06) studies (Table 2.6). Odds ratios represent change in serum 
urate per 10 ng mL-1 increase in concentration of serum ferritin. A similar association was 
observed when the normouricaemia and hyperuricaemia comparison was done for 
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NHANES III Europeans (Males: OR (95% CI) = 1.011 (1.01 ; 1.02), POR = 6.8E-04; 
Females: OR (95% CI) = 1.022 (1.01 ; 1.03), POR = 1.7E-08) (Table 2.6). Combining the 
JHS and NHANES III datasets together in meta-analysis showed a significant association 
of serum ferritin with an increased risk of hyperuricaemia (OR (95% CI) = 1.013 (1.01 ; 
1.02), PHet = 0.15, POR = 6.9E-23) (Table 2.6). 
 Average levels of ferritin were significantly elevated in both NZ Polynesian (P = 
2.3E-04) and US (P = 2.4E-17) gout cases compared to controls. The values were not 
significantly different between NZ European gout case-controls (P = 0.21) (Appendix A, 
Table 2.4 and Figure 2.2). Serum ferritin was associated with an increased risk of 
developing gout in NZ Polynesian (OR (95% CI) = 1.032 (1.01 ; 1.05), POR = 1.8E-03) 
and US individuals (OR (95% CI) = 1.112 (1.06 ; 1.17), POR = 7.4E-06) (Table 2.7). An 
increase of 10 ng mL-1  of ferritin was associated with an increased risk of gout of 3% in 
NZ Polynesian and 11% in the US male individuals. Ferritin was not associated with an 
increased risk of gout in European male participants from NZ (OR (95% CI) = 0.99 
(0.97 ; 1.02), POR = 0.83) that possibly introduced heterogeneity in meta-analysis. 
However, meta-analysis still indicated a direction of susceptibility to gout (OR (95% CI) 
= 1.039 (0.99 ; 1.08), PHet = 0.003, POR = 0.09) (Table 2.7). 
Figure 2.2: Distribution of serum ferritin and difference in means between gout case-control groups (males only) 




p = 0.21 p = 2.3E-04 
p = 2.4E-17 
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     Table 2.5: Association of ferritin (ng mL-1) with serum urate (μmol L-1) 
Population n ß [95% CI] P ß [95% CI]* P* 
NZ European 60 0.062 [-0.041 ; 0.165] 0.24 0.055 [-0.054 ; 0.165] 0.31 
NZ Polynesian 60 0.092 [0.045 ; 0.139] 1E-04 0.086 [0.040 ; 0.132] 2.5E-04 
US 60 0.289 [-0.034 ; 0.612] 0.079 0.245 [-0.093 ; 0.584] 0.15 
JHS (Males) 567 0.047 [0.011 ; 0.083] 9.5E-03 0.046 [0.011 ; 0.081] 9.3E-03 
JHS (Females) 693 0.138 [0.087 ; 0.189] 1.6E-07 0.081 [0.030 ; 0.131] 1.7E-03 
JHS (Combined) 1,260 0.163 [0.137 ; 0.196] 1.8E-27 0.059 [0.031 ; 0.087] 3.2E-05 
NHANES III AA (Males) 1,925 0.061 [0.041 ; 0.082] 7.2E-09 0.035 [0.015 ; 0.056] 5.1E-04 
NHANES III AA (Females) 2,430 0.167 [0.143 ; 0.191] 1.3E-42 0.096 [0.072 ; 0.121] 1.8E-15 
NHANES III AA (Combined) 4,355 0.173 [0.158 ; 0.189] 1.9E-97 0.064 [0.049 ; 0.079] 2.1E-16 
NHANES III EUR (Males) 2,460 0.036 [0.018 ; 0.055] 1.0E-04 0.024 [0.006 ; 0.042] 6.6E-03 
NHANES III EUR (Females) 2,652 0.114 [0.091 ; 0.137] 1.3E-22 0.071 [0.048 ; 0.092] 3.4E-10 
NHANES III EUR (Combined) 5,112 0.152 [0.136 ; 0.167] 6.9E-84 0.045 [0.032 ; 0.059] 5.1E-11 
Meta-analysis (All) 10,907 0.149 [0.125 ; 0.173] 9.3E-34 0.056 [0.046 ; 0.065] 3.9E-32 
NZ: New Zealand, US: The United States of America, JHS: Jackson Heart Study, NHANES III: US Third National Health and Nutrition Examination Survey, EUR: 
White Caucasian/European, AA: African American, n; number of non-gout individuals included in serum urate analysis. *Adjusted for age, sex, BMI, C-reactive 
protein and number of self-reported Polynesian grandparents for the NZ Polynesian group. 
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Table 2.6: Association of serum ferritin with hyperuricaemia 
Population OR [95% CI] P OR [95% CI]* P* 
JHS (Males) 1.012 [1.010 ; 1.022] 1.7E-02 1.012 [1.010 ; 1.023] 1.4E-02 
JHS (Females) 1.046 [1.021 ; 1.071] 1.7E-04 1.040 [1.011 ; 1.067] 3.3E-03 
JHS (Combined) 1.031 [1.022 ; 1.041] 8.7E-11 1.021 [1.011 ; 1.026] 1.1E-03 
NHANES III AA  
(Males) 
1.022 [1.017 ; 1.027] 1.5E-17 1.013 [1.007 ; 1.018] 2.4E-06 
NHANES III AA 
(Females) 
1.042 [1.032 ; 1.051] 1.2E-20 1.022 [1.012 ; 1.032] 7.1E-06 
NHANES III AA 
(Combined) 
1.036 [1.032 ; 1.041] 1.3E-58 1.016 [1.011 ; 1.021] 9E-12 
NHANES III EUR 
(Males) 
1.013 [1.010 ; 1.017] 1.8E-13 1.011 [1.002 ; 1.012] 6.8E-04 
NHANES III EUR 
(Females) 
1.036 [1.029 ; 1.043] 3.1E-25 1.022 [1.012 ; 1.025] 1.7E-08 
NHANES III EUR 
(Combined) 
1.030 [1.026 ; 1.032] 1.2E-68 1.011 [1.007 ; 1.014] 4.2E-11 
Meta-analysis (All) 1.032 [1.027 ; 1.037] 4.3E-35 1.013 [1.013 ; 1.016] 6.9E-23 
JHS: Jackson Heart Study, NHANES III: US Third National Health and Nutrition Examination Survey, EUR: White 
Caucasian/European, AA: African American, n: number of non-gout individuals included in serum urate analysis, OR: 
Odds ratio, 95% CI: 95% confidence interval, P; p-values. *Adjusted for age, sex, BMI, C-reactive protein and number 
of self-reported Polynesian grandparents for the NZ Polynesian group. All values represent change in risk for every 10 
ng mL-1 increase in serum ferritin. 
 
 
Table 2.7: Association of serum ferritin with gout 
Population OR [95% CI] P OR [95% CI]* P* 
NZ European 1.011 [0.993 ; 1.031] 0.22 0.997 [0.971 ; 1.023] 0.84 
NZ Polynesian 1.026 [1.011 ; 1.045] 1.7E-03 1.032 [1.013 ; 1.055] 1.8E-03 
US 1.115 [1.072 ; 1.171] 1.3E-06 1.112 [1.066 ; 1.170] 7.4E-06 
Meta-analysis (All) 1.043 [1.014 ; 1.081] 0.02 1.039 [0.993 ; 1.088] 0.09 
NZ: New Zealand, US: The United States of America, OR: Odds ratio, 95% CI: 95% confidence interval, P: p-values. 
*Adjusted for age, sex, BMI, C-reactive protein and number of self-reported Polynesian grandparents for the NZ 
Polynesian group. All values represent change in risk for every 10 ng mL-1 increase in serum ferritin. 
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 As ferritin was positively associated with gout (in NZ Polynesian and US 
datasets), the analysis was extended to assess any possible association of serum ferritin, 
CRP and urate with self-reported data of frequency of gout flares (per year) in the NZ 
Polynesian, NZ European and the US sample sets. It was observed that each 10 ng mL-1 
increase in ferritin was significantly associated with an increased frequency of gout flares 
in the US (ß (flares/year) = 0.02, Pß = 2.0E-03) and NZ European (ß (flares/year) = 0.09, 
Pß = 0.04) but not in NZ Polynesian (ß (flares/year) = -0.11, Pß = 0.14) individuals. C-
reactive protein and urate concentrations were not significantly associated with for the 
self-reported number of gout flares in all three data sets (Table 2.8). 
 The urate-producing enzyme xanthine oxidase also releases iron from ferritin 
(Bolann and Ulvik, 1987). As allopurinol is widely used to treat gout as an inhibitor of 
this enzyme, the average levels of ferritin (and other iron measures) were also compared 
for NZ and US gout cases by stratifying the data sets according to the usage of allopurinol. 
Significantly increased serum ferritin levels were observed in the NZ Polynesian (P = 
0.005) and the US (P = 0.02) participants who reported taking allopurinol for 
management of gout in comparison to those who didn’t report allopurinol usage for gout 
treatment. The average levels of ferritin were not different in NZ European when the 
same stratification was done (P = 0.47) (Table 2.9). Assuming that allopurinol could be a 
possible confounder for an association of ferritin with gout and flare frequency, additional 
analyses were done excluding the individuals not taking allopurinol and adjusting for 
allopurinol usage for gout and flare frequency, respectively. The results obtained, 
however, did not indicate allopurinol as a confounder (Appendix A Table 2.7 and 2.8). 
 A significant difference (P = 0.04) between the mean levels of ferritin was found 
in NZ Polynesian gout participants when participants who self-reported iron-rich food as 
a trigger for gout attacks were compared to those who did not report any trigger. The 
results were however not significant in NZ Europeans (P = 0.78). Also, no significant 
difference was observed in average levels of total iron, transferrin, TIBC and TSAT when 
the same stratification criterion was applied (Table 2.10).  
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Table 2.8: Association of serum ferritin, CRP and urate with gout flares/year 
Population 
Ferritin (ng mL-1)† C-reactive protein (mg dL-1) Serum urate (mg dL-1) 
ß [95% CI] P ß [95% CI]* P* ß [95% CI] P ß [95% CI]* P* ß [95% CI] P ß [95% CI]* P* 
NZ European 
0.08 
[0.001 ; 0.16] 
0.04 
0.09 
[0.003 ; 0.17] 
0.042 
1.55 
[-3.86 ; 6.97] 
0.57 
1.75 
[-3.85 ; 7.37] 
0.54 
-0.61 
[-1.47 ; 0.23] 
0.16 
-0.61 




[-0.24 to 0.03] 
0.13 
-0.11 
[-0.24 ; 0.03] 
0.14 
-11.17 
[-24.47 ; 2.11] 
0.09 
-9.95 
[-23.75 ; 3.84] 
0.16 
-1.79 
[-4.04 ; 0.44] 
0.12 
-1.59 




[0.01 ; 0.041] 
0.003 
0.02 
[0.01 ; 0.04] 
0.002 
0.07 
[-0.17 ; 0.32] 
0.58 
0.01 
[-0.01 ; 0.03] 
0.39 
0.07 
[-0.09 ; 0.23] 
0.39 
0.13 
[-0.03 ; 0.29] 
0.12 
NZ: New Zealand, US: The United States of America, ß: ß-estimates, 95% CI: 95% confidence interval, P: p-values. *Adjusted for age, sex, BMI and number of self-reported Polynesian 
grandparents in the NZ Polynesian group. 
†
Values represent change in the annual frequency of flares for every 10ng mL-1 increase in serum ferritin. Levels of urate are as per recorded at the 
time of subject recruitment. 
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Total number 89 23 66 - - - 
Serum Iron (μmol L-1) - 100.44 98.64 6.35 0.77 [-10.66 ; 14.25] 
Serum Transferrin (g L-1) - 2.53 2.61 0.08 0.40 [-0.22 ; 0.09] 
Serum Ferritin (ng mL-1) - 253.71 284.31 43.46 0.47 [-115.78 ; 54.59] 
TIBC (μmol L-1) - 63.63 65.29 2.01 0.41 [-5.58 ; 2.26] 
TSAT (%) - 28.99 27.57 2.29 0.53 [-3.07 ; 5.91] 
NZ Polynesian 
Total number 96 22 74 - - - 
Serum Iron (μmol L-1) - 91.21 85.08 5.46 0.26 [-4.59 ; 16.82] 
Serum Transferrin (g L-1) - 2.61 2.76 0.09 0.07 [-0.34 ; 0.01] 
Serum Ferritin (ng mL-1) - 373.81 494.32 42.83 0.005 [-204.46 ; -36.54] 
TIBC (μmol L-1) - 65.33 69.51 2.31 0.07 [-8.72 ; 0.35] 
TSAT (%) - 22.9 22.67 1.91 0.90 [-3.50 ; 3.96] 
US 
Total number 189 29 160 - - - 
Serum Ferritin (ng mL-1) - 158.57 248.21 38.36 0.02 [-164.81 ; 14.45] 
NZ: New Zealand, US: The United States of America, n: number of individuals, NoAllop: Not taking allopurinol, 
Allop: taking allopurinol, 95% CI: 95% confidence interval, P: p-values, TIBC: Total iron binding capacity, TSAT: 
Transferrin saturation. 
Table 2.10: Comparison of average values of iron markers in iron-rich food trigger 





(for difference) Trigger No trigger 
NZ European 
Serum Iron (μg dL-1) 92.81 103.29 6.079 0.08 [-1.439 ; 22.392] 
Serum Transferrin (g L-1) 2.52 2.64 0.075 0.11 [-0.027 ; 0.268] 
Serum Ferritin (ng mL-1) 283.45 270.87 39.241 0.78 [-121.21 ; 32.613] 
TIBC (μmol L-1) 66.43 63.41 1.900 0.11 [-0.701 ; 6.748] 
TSAT (%) 29.31 26.68 2.024 0.19 [-1.341 ; 6.593] 
NZ Polynesian 
Serum Iron (μg dL-1) 81.82 90.41 6.446 0.18 [-4.04 ; 21.23] 
Serum Transferrin (g L-1) 2.75 2.81 0.117 0.59 [-0.17 ; 0.29] 
Serum Ferritin (ng mL-1) 528.26 402.27 62.153 0.04 [-247.81 ; -4.17] 
TIBC (μmol L-1) 69.02 70.63 0.819 0.59 [4.31 ; 7.52] 
TSAT (%) 21.99 23.31 1.607 0.41 [-1.83 ; 4.47] 
NZ: New Zealand, US: The United States of America, n: number of individuals, 95% CI: 95% confidence interval, P: 
p-values, TIBC: Total iron binding capacity, TSAT: Transferrin saturation. Trigger: data from the gout subjects 
reporting any iron rich food (seafood, fish, red meat) as a trigger of gout flares, No trigger: data from gout subjects who 
didn’t report any food as a trigger of gouty flares. 
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2.2.3.1.1 Analysis with log transformed ferritin 
 In contrast to the iron and transferrin, the distribution of the data for ferritin were 
not normal (linear) for all study groups (Appendix B Figure 2.1 and Figure 2.2). In order 
to validate the above significant findings with ferritin, the data were log transformed 
(Appendix B Figure 2.3 and Figure 2.4) to obtain a linear distribution and to test if the 
association for urate, hyperuricaemia, gout and frequency of gout flares still persisted. 
Results for the transformed (normalised) data are presented in Appendix A Table 2.5 
through Table 2.8. Analyses of these data followed a similar pattern of associations as for 
the non-transformed data. 
2.2.3.2 HFE Genetic association analysis 
 The two SNPs in the HFE gene were not in LD with each other in the European 
population (Figure 2.3). It was not possible to calculate LD in Chinese Han individuals, 
as the 1000 Genome database (www.browser.1000genomes.org) did not have any 
information available for rs1800562 for this population. The minor allele (A allele) 
frequency for rs1800562 was higher in Europeans (0.079) than Māori and Pacific 
Islanders (NZ Polynesian = 0.015, NPH = 0.021) (Table 2.12). Similarly, the minor allele 
(G allele) frequency for rs1799945 was higher in NZ European (0.152) than Māori and 
Pacific Island (NZ Polynesian = 0.033, NPH = 0.048) individuals (Table 2.12). 
 When tested for an association, the minor allele (A) of rs1800562 did not show 
any association with serum urate in NZ European (Males: ß (mmol L-1) = 0.012, Pß = 
0.40; Females: ß = -0.017, Pß = 0.31), NZ Polynesian (Males: ß = 0.004, Pß = 0.86; 
Females: ß (mmol L-1) = 0.011, Pß = 0.69) or NPH (Males: ß (mmol L
-1) = 0.008, Pß = 
0.91; Females: ß (mmol L-1) = -0.075, Pß = 0.40) individuals (Table 2.11). Analysing 
males and female together also did not show any association of the A allele with serum 
urate in any population dataset (NZ European: ß (mmol L-1) = 0.002, Pß = 0.83; NZ 
Polynesian: ß (mmol L-1) = 0.002, Pß = 0.69; NPH: ß (mmol L
-1) = -0.019, Pß = 0.73) 
(Table 2.11). When combined in meta-analysis, the only difference was the direction of 
association between males and females, with males having positive (ß (mmol L-1) = 0.010 
mmol L-1, Pß = 0.41, PHet = 0.002) and females having negative (ß (mmol L
-1) = -0.012, 
Pß = 0.43, PHet = 0.42) direction without any significant effect (Table 2.11). The meta-
analysis also indicated significant heterogeneity (PHet = 0.002) between male groups from 
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the NZ European, NZ Polynesian and NPH datasets (Table 2.11). Combining male and 
female groups together also did not indicate any association between the A allele of 
rs1800562 and urate (ß (mmol L-1) = 0.003, Pß = 0.75, PHet = 0.89) (Table 2.11). 
 The allele A of rs1800562 did not show any association with gout when tested in 
three data sets i.e., NZ European (Males: OR = 0.95, POR = 0.79; Females: OR = 1.06, 
POR = 0.87), NZ Polynesian (Males: OR = 1.09, POR = 0.80; Females: OR = 1.39, POR = 
0.61) and NPH (Males: OR = 0.63, POR = 0.56; Females: OR = 1.64, POR = 0.82) (Table 
2.13). The non-significant associations remained consistent for all population datasets 
when assessed for all individuals together (NZ European: OR = 1.01, POR = 0.98; NZ 
Polynesian: OR = 1.13, POR = 0.70; NPH: OR = 0.53, POR = 0.49) (Table 2.13). The A 
allele also did not show any association when sex-specific groups were combined 
separately (Males: OR = 0.96, POR = 0.82, PHet = 0.81; Females: OR = 1.17, POR = 0.65, 
PHet = 0.93) and together (Male: OR = 1.09, POR = 0.93, PHet = 0.74) in meta-analysis 
(Table 2.13). 
 The G allele of rs1799945 did not show any association with serum urate in NZ 
European males (ß (mmol L-1) = 0.007, Pß = 0.51), while it indicated a nominal negative 
association in females (ß (mmol L-1) = -0.028, Pß = 0.05) (Table 2.11). The G allele was 
also negatively associated with urate in NZ Polynesian males (ß (mmol L-1) = -0.050, Pß 
= 0.02) with no association in females (ß (mmol L-1) = 0.016, Pß = 0.97) (Table 2.11). 
However, for the NPH data set a positive association was observed between G allele and 
urate for males (ß (mmol L-1) = 0.085, Pß = 0.02) but not females (ß (mmolL
-1) = 0.015, 
Pß = 0.82) (Table 2.11). The G allele, however, did not show any association with urate 
when all individuals were analysed together in different data sets (NZ European: ß (mmol 
L-1) = -0.003, Pß = 0.75; NZ Polynesian: ß (mmol L
-1) = -0.021, Pß = 0.12; NPH: ß (mmol 
L-1) = 0.044, Pß = 0.16) (Table 2.11). Combined meta-analysis did not show any 
significant association of the SNP rs1799945 (G allele) with urate in both males (ß (mmol 
L-1) = 0.008, Pß = 0.78, PHet = 0.96) and females (ß (mmol L
-1) = -0.015, Pß = 0.16, PHet = 
0.52) and all individuals together (ß (mmol L-1) = -0.005, Pß = 0.45, PHet = 0.14) (Table 
2.11). 
 The G allele of rs1799945 indicated a positive association with the risk of gout in 
NZ European females, where addition of each allele (G) was associated with a 28% 
increase in the risk of developing gout (OR = 2.28, POR = 0.03) (Table 2.13). The 
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association was not significant for NZ European males (OR = 0.89, POR = 0.47), NZ 
Polynesian males (OR = 1.03, POR = 0.89) and females (OR = 1.24, POR = 0.61) and NPH 
males (OR = 0.62, POR = 0.62) (Table 2.13). The number of female individuals was not 
enough to test for an association of rs1799945 with gout in the NPH data set (Table 2.13). 
However, the association did not remain when male and female individuals were 
combined together for different population data sets (NZ European: OR = 1.04, POR = 
0.78; NZ Polynesian: OR = 1.07, POR = 0.74; NPH: OR = 0.75, POR = 0.70) (Table 2.13). 
Meta-analysis showed a trend towards susceptible association between the G allele and 
gout in females (OR = 1.71, POR = 0.06, PHet = 0.29) but not males (OR = 0.96, POR = 
0.82, PHet = 0.81) (Table 2.13). However, combining sex-specific groups together in 
meta-analysis did not show any association between the G allele of rs1799945 (OR = 
1.03, POR = 0.73, PHet = 0.90) (Table 2.13). 
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Figure 2.3: Linkage disequilibrium (LD) plot indicating ‘R-squared/r2’ values between the HFE variants (rs1800562 and rs1799945 highlighted in the legend on the right side) in 
European population. Information for variant location, rs ID and LD values are from 1000 Genome database (http://browser.1000genomes.org/). The plot was generated using 
Haploview v4.2. 
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Table 2.11: Association analysis results for the HFE variants for serum urate (mmol 
L-1) 
Population ß [95% CI]† P ß [95% CI]* P* 
rs1800562 
NZ European (Males) -0.008 [-0.041 ; 0.024] 0.59 0.012 [ -0.016 ; 0.041] 0.40 
NZ European (Females) 0.005 [-0.038 ; 0.050] 0.79 -0.017 [-0.051 ; 0.017] 0.31 
NZ European (All) 0.001 [-0.024 ; 0.029] 0.95 0.002 [-0.019 ; 0.024] 0.83 
NZ Polynesian (Males) 0.001 [-0.065 ; 0.064] 0.99 0.004 [ -0.146 ; 0.164] 0.86 
NZ Polynesian (Females) 0.027 [-0.041 ; 0.065] 0.65 0.011 [ -0.043 ; 0.065] 0.69 
NZ Polynesian (All) 0.007 [-0.036 ; 0.051] 0.74 0.007 [-0.013 ; 0.045] 0.69 
NPH (Males) 0.012 [-0.153 ; 0.176] 0.88 0.008 [ -0.146 ; 0.164] 0.91 
NPH (Females) -0.056 [-0.225 ; 0.113] 0.49 -0.075 [ -0.266 ; 0.114] 0.40 
NPH (All) -0.023 [-0.142 ; 0.096] 0.70 -0.019 [-0.132 ; 0.094] 0.73 
Meta-analysis (Males) - - 0.010 [-0.014 ; 0.034] 0.41 
Meta-analysis (Females) - - -0.012 [-0.037; 0.017] 0.43 
Meta-analysis (All) - - 0.003 [-0.016 ; 0.022] 0.75 
rs1799945 
NZ European (Males) 0.013 [-0.012 ; 0.037] 0.30 0.007 [-0.014 ; 0.028] 0.51 
NZ European (Females) -0.015 [-0.048 ; 0.018] 0.36 -0.028 [-0.058 ; 0.001] 0.05 
NZ European (All) 0.011 [-0.010 ; 0.032] 0.30 -0.003 [-0.019 ; 0.014] 0.75 
NZ Polynesian (Males) -0.059 [-0.107 ; -0.011] 0.01 -0.050 [-0.092 ; -0.008] 0.02 
NZ Polynesian (Females) 0.004 [-0.033 ; 0.042] 0.83 0.016 [-0.131 ; 0.162] 0.97 
NZ Polynesian (All) -0.025 [-0.057 ; 0.005] 0.11 -0.021 [-0.047 ; 0.006] 0.12 
NPH (Males) 0.019 [-0.049 ; 0.088] 0.56 0.085 [0.012 ; 0.158] 0.02 
NPH (Females) -0.010 [-0.133 ; 0.113] 0.87 0.015 [-0.131 ; 0.162] 0.82 
NPH (All) 0.018 [-0.042 ; 0.080] 0.54 0.044 [-0.019 ; 0.108] 0.16 
Meta-analysis (Males) - - 0.008 [-0.049 ; 0.065] 0.78 
Meta-analysis (Females) - - -0.015 [-0.037 ; 0.006] 0.16 
Meta-analysis (All) - - -0.005 [-0.019 ; 0.008] 0.45 
NZ: New Zealand, NPH: Ngati Porou Hauora, ß: ß-estimates, 95% CI: 95% confidence interval, P: p-value. * All 
values are adjusted for age, BMI and grand-parental ancestry for Polynesian datasets. 
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Table 2.12: Genotype/allele frequencies of the HFE variants in gout case/control 
groups 
Population Group Genotype/Allele frequency PHWE 
rs1800562 
 GG AG AA A  
NZ European 
Case 731 (0.848) 125 (0.145) 6 (0.070) 137 (0.079) 0.79 
Control 478 (0.855) 78 (0.139) 3 (0.054) 84 (0.075) 0.92 
NZ Polynesian 
Case 912 (0.969) 28 (0.029) 1 (0.001) 30 (0.015) 0.11 
Control 1047 (0.973) 29 (0.027) 0 (0.000) 29 (0.013) 0.65 
NPH 
Case 138 (0.958) 6 (0.042) 0 (0.000) 6 (0.021) 0.79 
Control 62 (0.954) 3 (0.046) 0 (0.000) 3 (0.023) 0.84 
rs1799945 
 CC CG GG G  
NZ European 
Case 613 (0.711) 235 (0.273) 14 (0.016) 263 (0.152) 0.11 
Control 406 (0.727) 142 (0.254) 10 (0.179) 162 (0.145) 0.54 
NZ Polynesian 
Case 879 (0.931) 59 (0.063) 2 (0.002) 63 (0.033) 0.34 
Control 1008 (0.936) 66 (0.061) 2 (0.002) 70 (0.032) 0.40 
NPH 
Case 131 (0.909) 12 (0.083) 1 (0.007) 14 (0.048) 0.23 
Control 60 (0.923) 4 (0.061) 1 (0.015) 6 (0.046) 0.05 
NZ: New Zealand, NPH: Ngati Porou Hauora, PHWE: p-value for Hardy Weinberg Equilibrium. 
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Table 2.13: Association analysis results for the HFE variants for gout 
Population 


































[0.64 ; 1.25] 
0.51 
0.95 
[0.65 ; 1.40] 
0.79 
1.69 
[0.97 ; 2.99] 
0.06 
1.06 
[0.04 ; 2.53] 
0.87 
1.06 
[0.80 ; 1.41] 
0.67 
1.01 




[0.64 ; 2.43] 
0.53 
1.09 
[0.53 ; 2.31] 
0.80 
0.72 
[0.17 ; 2.07] 
0.58 
1.39 
[0.32 ; 4.65] 
0.61 
1.18 
[0.71 ; 1.97] 
0.52 
1.13 




[0.16 ; 5.47] 
0.76 
0.63 
[0.15 ; 3.61] 
0.56 
0.73 
[0.03 ; 8.13] 
0.81 
1.64 
[0.02 ; 1.06] 
0.82 
0.72 
[0.23 ; 4.36] 
0.88 
0.53 
[0.09 ; 3.74] 
0.49 
Meta-analysis - - 
0.96 
[0.69 ; 1.33] 
0.82 - - 
1.17 
[0.58 ; 2.35] 
0.65 - - 
1.09 





[0.72 ; 1.18] 
0.53 
0.89 
[0.67 ; 1.20] 
0.47 
1.36 
[0.86 ; 2.16] 
0.18 
2.28 
[1.04 ; 5.05] 
0.03 
1.11 
[0.85 ; 1.32] 
0.58 
1.04 




[0.62 ; 1.48] 
0.84 
1.03 
[0.63 ; 1.71] 
0.89 
0.99 
[0.47 ; 1.92] 
0.99 
1.24 
[0.51 ; 2.47] 
0.61 
1.03 
[0.73 ; 1.44] 
0.86 
1.07 




[0.17 ; 5.47] 
0.76 
0.62 
[0.10 ; 5.34] 
0.62 - - - - 
1.04 
[0.44 ; 2.85] 
0.92 
0.75 
[0.20 ; 3.73] 
0.7 
 - - 
0.92 
[0.72 ; 1.18] 
0.54 - - 
1.71 
[0.97 ; 3.02] 
0.06 - - 
1.03 
[0.82 ; 1.29] 
0.73 
NZ: New Zealand, NPH: Ngati Porou Hauora, OR: Odds ratio, 95% CI: 95% confidence interval, P: p-values. 
†
Unadjusted analysis, *All values are adjusted for age, BMI and grand-parental 
ancestry for Polynesian datasets. The combined male and female analysis is additionally adjusted for sex. 
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SECTION 2.3 DISCUSSION 
 The study successfully replicated the previously reported association of serum 
ferritin and TSAT with serum urate (Ghio et al., 2005) in two NHANES III sample sets 
(Table 2.5). Additionally, including CRP as an adjustor ensured that the positive 
relationship with ferritin was not the consequence of the association of ferritin with 
inflammatory states (e.g., hyperuricaemia and gout). The association of serum ferritin 
with urate was extended from Europeans and African Americans to Polynesians (Table 
2.5). For the first time, the study associated increased serum ferritin with the risk of gout 
and gout flares, although for both relationships association was observed in only two of 
the three data sets used (Table 2.7 and 2.8). Collectively the data associates ferritin with 
both serum urate levels and the risk of gout, including frequency of flares once gout is 
established. 
 The inconsistent association of ferritin with gout and gout flares between the NZ 
(ß (flares/year) = 0.09, P = 0.04) and US (ß (flares/year) = 0.02, P = 2E-03) European and 
NZ Polynesian (ß (flares/year) = -0.11, P = 0.14) data sets could be due to one of the 
several possible reasons. It is possible that the data represent a false positive association. 
Noting that the sample sets used here are relatively small, analysis of larger well-
phenotyped sample sets to replicate the associations is required. Other factors 
contributing to inconsistent data could be genetic backgrounds of the populations, 
additive or non-additive influence from other environmental factors and population-
specific dietary exposures. As far as usage of allopurinol is concerned, it was not found to 
be a potential confounder for positive association of ferritin with gout or gout flare 
frequency in my analyses (Appendix A Table 2.7 and 2.8). Urate was not found to be 
associated with frequency of gout flares in the literature that agrees with the findings in 
Table 2.8. An increase in ACTH in response to inflammation in gout and its consequent 
effect to increase urate excretion has been described as a possible mechanism behind this 
association (Bădulescu et al., 2013). 
 Serum ferritin concentration has been demonstrated to correlate with body iron 
stores and reflect total metal accumulation in humans (Jacobs et al., 1972; Lipschitz et al., 
1974) and reports of a possible direct relationship of iron and/or ferritin with urate and its 
related arthropathies are not recent (Green and Mazur, 1957; Mazur et al., 1958; Muirden 
and Senator, 1968). It is known that metal ions can potentially cause oxidative stress 
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when bound to storage or transport proteins (Aust et al., 1985) and urate is a well-known 
antioxidant in humans governing its antioxidant abilities by scavenging oxygen radicals, 
singlet oxygen and oxo-haem oxidants (Ames et al., 1981; Howell and Wyngaarden, 
1960; Kellogg and Fridovich, 1977). Thus it has been proposed that urate could reduce 
iron-catalysed oxidative stress by acting as a metal chelator by forming a highly stable 
2:1 complex with Fe3+ ions, which doesn’t support electron transport for iron oxidation 
(Davies et al., 1986). Xanthine oxidase acts as the sole enzymatic source of urate in 
humans and exposure to increased iron may control the oxidation of hypoxanthine or 
xanthine by enhancing the activity of xanthine oxidase (Ghio et al., 2002; Martelin et al., 
2002; Stonehuerner et al., 1998). An increase in urate in both rodents (Muntane et al., 
1993; Ward et al., 1993) and humans (Livrea et al., 1996) in response to acute exposure 
to iron supports a direct link between levels of iron and urate, and elevated serum urate is 
sometimes used as a cue to screen for haemochromatosis (Mainous et al., 2011). 
 Although hyperuricaemia is an essential requirement for gout, there are other 
factors involved in the formation and deposition of MSU crystals in the synovial fluid 
(Chhana et al., 2015). There may be overlap between factors that reduce urate solubility 
(promoting MSU crystal formation) and those that are either associated with elevation of 
iron levels or iron-associated oxidative stress. One such factor is lower levels of albumin 
at a lower temperature (Kippen et al., 1974), with one study demonstrating a negative 
relation between iron-induced acute oxidative stress and serum albumin level in a cohort 
of patients with chronic renal failure (Sezer et al., 2007). The concentration of several 
cations (Füredi-Milhofer et al., 1987; McNabb and McNabb, 1980) and a certain pH (7-8) 
also reduces urate solubility (Wilcox et al., 1972); iron stays as a cation in its free toxic 
state and the presence of significant concentrations of this ionisable iron in the crystals 
from human tophus at physiological pH (Ghio et al., 1994) suggests a connection 
between iron and MSU crystal formation. 
 Another important finding of the study is a positive correlation between the 
number of gout flares and ferritin in both NZ European and US gout subjects (Table 2.8). 
Iron deposits have been reported to be consistently present in the synovial membrane of 
people with rheumatoid arthritis (n = 23) but not those with other joint pathologies 
(Muirden and Senator, 1968). Some rodent-model studies have also demonstrated a 
remarkable improvement in joint-related inflammation following the removal of iron 
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from joints through chelation treatment(s) (Andrews et al., 1987; Blake et al., 1983). A 
28-month follow-up study to maintain a near iron-deficiency by depleting the levels of 
metal via phlebotomy in hyperuricaemic patients (with gout) has been reported to induce 
either complete or marked reduction in incidence and severity of gout flares in humans 
(Facchini, 2003). 
 This study found an increased serum ferritin in NZ Polynesian people (P = 0.04) 
with gout who self-reported the consumption of an iron rich food (seafood, fish & red 
meat) as a trigger for gout (Table 2.10). Another recent study that provides self-reported 
food-trigger data for NZ Māori, Pacific Island and European individuals also indicated 
iron rich foods to be one of the top triggers for gout with 62.54% reporting either seafood 
or fish, and 35.18% reporting red meat as a trigger for gout flares (Flynn et al., 2015). A 
positive correlation between the consumption of red meat and incident gout risk has been 
described previously in a 7.7-year follow-up study of 28,990, ostensibly healthy, men 
(Williams, 2008). Another 12-year prospective study in 47,150 men associated the 
consumption of meat and seafood but not purine-rich vegetables with an increased risk of 
gout (Choi et al., 2004b). A Turkish retrospective study in people with gout indicated that 
higher consumption of total meat (including fish) acts as a precipitating factor for gout 
flares (Öztürk et al., 2013). Also, purines from animal based, but not plant-based, food 
have been associated with increased risk of recurrent gout attacks (Zhang et al., 2012b). 
In line with these findings, a large prospective study in NHANES III data, including 
14,809 participants reported an association of increased consumption of red meat with 
hyperuricaemia (Choi et al., 2005a). It is possible that additional to purines, the iron 
content of such animal-based foods are playing a role in determining the risk of gout and 
gout flares in several populations. 
 The study also indicated a significant elevation of serum ferritin levels in US 
European (P = 0.02) and NZ Polynesian (P = 0.005) gout individuals who were on 
allopurinol treatment (Table 2.9). This is of interest as xanthine oxidase is involved in the 
release of iron from ferritin and facilitating cellular stress through the production of 
hydroxyl radicals (Bolann and Ulvik, 1987). Use of allopurinol as a xanthine oxidase 
inhibitor has been attributed to an increased iron overload in rodent liver cells and 
elevated serum iron in patients with secondary gout (Powell and Emmerson, 1966). 
Although the debate of involvement of allopurinol in affecting iron metabolism in human 
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is controversial (Emmerson, 1966; Powell, 1970), my results suggest higher serum 
ferritin levels in gout patients on allopurinol therapy. Confirming the possible effect of 
allopurinol on iron metabolism in gout patients may be helpful in decision-making 
regarding treatment options for patients with a risk of iron overload. 
 The associations described above are based on observational data and are, 
therefore, prone to biases due to presence of possible confounding (Mann and Wood, 
2012). Whilst its not possible to assign the causality based on my findings, the positive 
association of the G allele of HFE: rs1799945 with gout in European females (OR = 2.28, 
P = 0.03; Table 2.12) and its association with serum urate in New Zealand population 
groups (Table 2.11) provided support to my observational data. Homozygosity of the 
same allele (G/G) has been classically associated with moderate risk of 
haemochromatosis (Hanson et al., 2001). However, a single positive association in the 
NZ European female dataset could also be spurious and cannot be inferred unless 
assessed in the larger population dataset. 
Figure 2.4: Proposed mechanism of involvement of iron in hyperuricaemia and gout pathophysiology. 
 Albeit it seems rather early to evaluate a possible mechanism underpinning the 
particular correlation of increased iron and/or consumption of red meat and seafood/fish 
with increased gout flares, the elevated urate production in the presence of ferritin still 
indicates a biological mechanism between iron availability and urate production in 
healthy humans. Based on my findings and previous data (Dabbagh et al., 1992; Facchini, 
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2003; Ghio et al., 1994), it is suggested that the production of reactive oxygen species 
directly through increased intracellular iron pools or indirectly through modulating the 
activity of XO via elevated ferritin, increased urate production, the formation of MSU 
crystals and hence activation of the NLRP3 inflammasome could lead to gout and gout 
flares (Figure 2.4). 
2.3.1 Strengths and limitations of the study 
 Inclusion of acute-phase inflammatory protein CRP as an adjustor in various 
analyses represents the first strength of this study. While it is not possible to assign 
causality on the basis of the observational data in Section 2.2, the preliminary association 
of ferritin with urate independent of CRP suggests that the relationship is not due to the 
elevation of ferritin in inflammation (Kell and Pretorius, 2014). The consistency of the 
observational findings in this study with previously reported experimental and clinical 
intervention studies supports the argument for a relationship between serum ferritin and 
urate that predicts hyperuricaemia and gout. 
 Although serum urate associations were investigated in larger study cohorts, the 
study groups used for investigating the association of gout were comparatively small. A 
huge overlap between iron and purine rich foods could also be a difficult confounder to 
work with. However, using a larger cohort with richer information for food consumption 
(especially intake of iron rich low purine foods) and gout ascertained may provide a 
clearer picture of the observed relationship. Further investigation of a likelihood of intake 
of iron rich diet as a possible trigger for gout flares in larger cohorts may also help in 
advice for an appropriate diet with low iron content to avoid or decrease the severity of 
gout attacks in patients with gout. 
2.3.2 Conclusion and future directions 
 This study replicates the association of ferritin with serum urate. Increased ferritin 
levels were also associated with gout and self-reported frequency of flares. As the 
associations reported here are derived from cross-sectional observational data, the 
causality of ferritin in control of urate concentration, the risk of gout and gouty flares 
cannot be inferred. Although the genetic association findings for HFE variant rs1799945 
provides some support to these observations, the NZ European female dataset was 
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relatively small and positive results warrant validation. This can either be done 
considering replication in a larger dataset, via randomised clinical trials or the use of 
genetic epidemiological approaches. One such approach is Mendelian randomisation that 
could shed light on any causal relationship (Robinson et al., 2016). This approach is 
increasingly used as it can exploit existing data sets and is, therefore, a considerably 
cheaper alternative to a randomised clinical trial. The next chapter of my thesis is based 
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SECTION 3.1 MENDELIAN RANDOMISATION: AN 
INTRODUCTION 
3.1.1 Background 
 Interventional and observational studies that apparently represent robust 
associations between environmental and physiological measures and disease risk are 
subject to a variety of biases or confounding (Hayden et al., 2013; Shrank et al., 2011). 
This means that statistical associations observed in the observational studies are not 
enough to draw a causal relationship between an exposure and an outcome. The biases in 
such studies sustain unless potential association confounders are appropriately adjusted 
for following their identification and perfect measurements (Bowden et al., 2017). 
Unaccounted confounding along with misclassification and selection bias are the reasons 
why such studies may fail to replicate the reported associations or prove any causality 
when tested in randomised controlled trials (RCTs) (Kovesdy and Kalantar-Zadeh, 2012; 
Smith and Ebrahim, 2001, 2008). Detecting association in an observational study could 
be the result of influence of a confounder rather than the direct effect of the biomarker on 
a disease itself. As it is hard to separate the causal associations from confounding and/or 
reverse causation (Lipsitch et al., 2016), incorrect causal inferences have been reported in 
such studies even after careful statistical adjustments for possible measured confounders 
and careful study design (Fewell et al., 2007; Smith and Ebrahim, 2001). In addition, 
effect estimates from interventional studies may be prone to errors e.g., regression 
dilution bias and/or incorrect measurement of biomarkers for technical (or biological) 
reasons (Smith and Ebrahim, 2005). After the identification of these problematic aspects 
of epidemiological investigation, a number of methods, aimed at improving causal 
inference, were developed (Lipsitch et al., 2012; Smith, 2008). One such successful 
approach, analogous to RCT (Iturrieta-Zuazo and Walter, 2015; Smith and Hemani, 
2014), is Mendelian randomisation or MR (Smith and Ebrahim, 2003). 
3.1.2 Basic principle of Mendelian randomisation 
 Presented for the first time by Smith and Ebrahim (2003), the Mendelian 
randomisation approach is based on ‘Mendel’s law of independent assortment’ that states 
that ‘during gamete-formation, individual hereditary factors (alleles) are assorted 
independent of each other and thus their associated traits get equal opportunity to occur 
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by chance (or together)’. Also known as nature’s randomised trial, this statistical 
approach exploits random assignment of alleles at conception to disentangle cause and 
effect in the presence of confounding. Genetic variants robustly associated with exposure 
phenotype (usually a physiological biomarker also known as the risk factor) can be used 
to identify the predictive (causal or non-causal) effect of the variant on the outcome 
(usually a disease) (Didelez and Sheehan, 2007). The promising applicability of MR is 
made possible via two unique characteristics of the genotype. First, the random allocation 
of alleles at conception independent of the environmental exposures lowers the chances 
of potential confounding to occur in genetic association studies in the same way as 
randomised treatment allocation in RCT (Hingorani and Humphries, 2005). Second, the 
invariable nature of DNA sequence and unidirectional flow of the information from DNA 
to complex phenotype or disease make reverse causation impossible (Swerdlow et al., 
2016). Thus MR can also provide valid cause-effect information that is not prone to 
variability via environmental influences. 
3.1.3 Mendelian randomisation model and instrumental variable 
 The first step of any MR study is to select a valid instrumental variable (IV), 
which is usually a genetic variant (G) robustly associated with the exposure/risk factor 
(X) that can be used as a proxy indicator for ‘X’. The number of instrumental variables is 
solely dependent on their validity, which is in turn determined by three major 
assumptions (Smith and Ebrahim, 2003). Illustrated in the MR model in Figure 3.1, these 
assumptions are detailed below; 
1. IV1: The instrument (G) is associated with the exposure/risk factor (X). 
2. IV2: The instrument (G) is not associated with any known and unknown 
confounders (U) of the exposure (X)-outcome (Y) association. 
3. IV3: The instrument (G) is independent of the outcome (Y) conditional on the 
exposure (X) and confounders (U) i.e., no horizontal pleiotropy (Burgess et al., 
2013; Hemani et al., 2016). 
 In addition to finding causality, the selection of a valid IV can provide a clear 
picture of two attributes of the relationship between exposure and outcome i.e., the 
‘direction of association’ and ‘horizontal pleiotropy’ (Smith and Hemani, 2014). As the 
whole point of MR is to indicate a cause and effect relationship between ‘X’ and ‘Y’ 
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independent of ‘U’, provided the direction of association (either positive or negative) 
between ‘G’ and ‘X’ is known, the direction of causal association between ‘X’ and ‘Y’ 
can be inferred. Also, interpretation of results from MR analyses must be done carefully 
if the genetic variant (G) chosen as the IV exhibits horizontal pleiotropy i.e., ‘G’ is 
associated with ‘X’ but also influences ‘Y’ through a pathway that does not include ‘X’. 
If any horizontal pleiotropy is found, the IV3 assumption in the MR model is violated 
(Haycock et al., 2016; Smith and Ebrahim, 2003). Unlike the IV1 assumption in the MR 
model, the chances of selecting an instrument that completely fulfils IV2 and IV3 are low 
(Bowden et al., 2016), the IV3 assumption being reported to be nearly impossible to 










Figure 3.1: The Mendelian randomisation model detailing selection of exposure (X) instrument variable (IV or 
G) and the assumptions (solid blue arrows) it should fulfil with regard to its association with potential 
confounders (U) and the outcome (Y). Dotted arrows indicate potential violation of the MR model. Adapted from 
Burgess et al. (2013) and Hemani et al. (2016). 
3.1.4 Extensions to basic MR in the wake of time 
 Given that the use of MR as a genetic epidemiological approach could shed light 
on a causal relationship (Robinson et al., 2016), there have been a number of 
developments and extensions to the basic MR study design since its first proposal by 
Smith and Ebrahim (2003). Like conventional MR, each extension has its own 
advantages and limitations. More broadly and in the milieu of this chapter, MR study 
designs can be categorised on the basis of the number of variants and samples (datasets) 
used. 
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3.1.4.1 Multiple-instrument MR 
 Mendelian randomisation is conventionally performed using a single genetic 
variant as IV, whose biological aspects for an association with exposure are well 
understood. If a single variant is used as a proxy indicator (or IV) for an exposure 
phenotype, it should have a strong association with the exposure i.e., it must explain 
sufficiently large variance in the exposure (trait) in the said population and must be 
exclusively associated with the exposure independent of other traits (Smith and Ebrahim, 
2008; Taylor et al., 2014). Using as an instrument a variant that is known for its 
association(s) with traits other than exposure would increase the chances of pleiotropy. 
This means that the same genetic variant may be a proxy for more than one 
environmentally modifiable exposure or may be in linkage disequilibrium (LD) with 
another variant that is known to be affecting the outcome (Smith and Ebrahim, 2008; 
Solovieff et al., 2013). Both of these scenarios would make the selected variant a weak 
instrument and could increase the degree of biases in MR analyses. 
 The limitation to the MR approach arising from usage of a single weak IV can be 
partially alleviated by increasing the number of selected instruments (genetic variants). 
For example, using multiple instruments instead of one would increase the proportion of 
explained variance for an exposure and thereby improve the accuracy in two-stage least 
squares (2SLS) regression (Smith and Hemani, 2014). In this situation, the variance 
explained by all of the selected instruments is combined into a weighted allele score as an 
optimal approach (Burgess and Thompson, 2013). When using a multiple-instrument MR 
approach, the selection of variants should be done carefully as the presence of a complete 
LD between the selected instruments can cause drastic biases in the MR outcomes. 
Similar predicted causal effects of low-density lipoprotein cholesterol (LDL-C) on 
coronary heart disease (CHD) through 9 genetic variants from 6 genes provides a 
convincing example of pleiotropy via intra-instrument LD (Ference et al., 2012). 
3.1.4.2 Two-sample MR 
 Another advantageous extension to the basic MR model is to utilise data from two 
independent samples rather than one, an approach known as two-sample MR (Inoue and 
Solon, 2010; Pierce and Burgess, 2013). The idea behind two-sample MR is to obtain the 
estimates of instrument-exposure association and instrument-outcome association from 
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two different sets of participants. The phenomenon of underestimation of true causal 
effects or having ‘winners curse’ in one-sample MR (Taylor et al., 2014) is unlikely to 
happen when the two-sample approach is applied. Also, unlike one-sample MR using 
multiple instruments, the impact of weak instrument bias (biased due to confounding in 
multivariable regression) is towards the null in the two-sample model (Smith and Hemani, 
2014). This approach can also successfully reduce the finite (small) sample biases, 
especially in the cases where the instruments are weak and individual-level data are tested 
through 2SLS regression (Burgess et al., 2016). 
 Two-sample MR holds best when no information about the intermediate 
phenotype (individual-level data) is available and the data to be tested only provide 
values of estimates and effect sizes e.g., the summary data from GWA studies’ or large 
consortia (Smith and Hemani, 2014). Use of multiple instruments from two large studies 
not only increase the statistical power (Burgess and Thompson, 2015) but also provide 
the opportunity to use proxy variants for the instruments whose information is not 
available in the outcome study data (Gao et al., 2016). While considering large samples, 
however, a huge overlap of the participants between the two studies should be avoided as 
it could lead to potential biases, especially if the outcome is a continuous variable 
(Burgess et al., 2016). 
3.1.5 Use of summary-level data in MR and possible statistical 
approach 
 As the field of biological research develops, more and more data becomes 
publicly-available on a larger number of participants e.g., GWA studies that often provide 
genetic association results over tens of thousands of samples (Benyamin et al., 2014; 
Köttgen et al., 2013). For most GWAS, however, it may not be possible for the authors to 
provide public access to the individual-level data due to ethical reasons. The availability 
of limited data, in turn, makes it challenging to carry out MR analysis especially via using 
the 2SLS regression approach in the absence of intermediate phenotype information. A 
number of statistical models (explained further in the next paragraph) have been 
introduced that could exploit the summarised data from GWAS in MR analyses, each 
having its own advantages and limitations. 
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 In order to obtain MR estimates for each variant in summary data, the Wald ratio 
method (Lawlor et al., 2008) can be applied. This approach employs the ratio method to 
calculate the estimate (Wald estimate: equivalent to regression coefficient) wherein the 
regression coefficient of ‘Y’ on ‘G’ is divided by the regression coefficient of ‘X’ on ‘G’. 
The estimates from individual variants can be combined using the inverse-variance 
weighted (IVW) method using summary data. The IVW method averages the estimates 
(ß) of causality of ‘X’ on ‘Y’ across the sample(s) and does not require information of 
intermediate phenotype (Burgess et al., 2013). Another method that can combine 
estimates across the sample is the likelihood-based method, constructed assuming a linear 
relationship between ‘X’ and ‘Y’ and normal distribution of ‘ß’ (Burgess et al., 2013). 
 Although, the IVW and likelihood methods provide equivalent statistics to 2SLS, 
yet both methods are unable to cope with possible horizontal pleiotropy that usually arises 
in the presence of multiple weak variants (violation of IV3 assumption). A more robust 
approach that can address this problem is sensitivity analysis e.g., Egger-regression 
(termed as MR-Egger for MR analysis) (Bowden et al., 2015). A recent study indicating a 
causal association of adiposity-related traits with breast cancer provides a convincing 
example of the applied use of IVW and MR-Egger on the summary data from GWA 
studies (Gao et al., 2016). 
3.1.6 Mendelian randomisation studies for iron biomarkers 
 In the context of rheumatology, the MR approach has predominantly been applied 
to explain the cause-effect relationship between urate levels and cardio-metabolic traits 
e.g., hypertension (Kleber et al., 2015), coronary heart disease/CHD (Palmer et al., 2013; 
White et al., 2016), diabetes (Pfister et al., 2011; Sluijs et al., 2015), BMI (Palmer et al., 
2013; White et al., 2016), obesity (Chen et al., 2017; Lyngdoh et al., 2012) and renal 
function (Hughes et al., 2014). However, there are only a couple of studies using MR 
analyses to explain a causal relationship between iron metabolism and other traits, 
including an MR study that provided evidence supporting a causal association between 
blood iron and decreased risk of Parkinson disease using iron-related variants as 
instruments from GWAS data (from European and Australian individuals) (Pichler et al., 
2013), and another more recent study that indicated a protective effect of iron and ferritin 
on kidney function via MR analysis (del Greco et al., 2016). The latter is the only MR 
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study available until now (to my knowledge) that has reported that exposure to iron is 
causal in decreasing the risk of kidney disease. 
 Since it is impossible to exclude pleiotropy due to the presence of potential 
confounders in observational studies, an RCT should be done to determine if the 
association is causal. Whilst it was not possible to carry out an RCT, I chose Mendelian 
randomisation (MR) as an alternative approach to investigate the causal relationship of 
the associations between iron profile markers and urate found in the biochemical analysis 
in Chapter 2. The specific aim of my study was ‘to use Mendelian randomisation as an 
alternative to RCT to test for a causal role of total serum iron, serum ferritin, serum 
transferrin and TSAT (the exposures) in raising or lowering urate levels (the outcome) 
using multiple variants as instruments by exploiting summarised data from recent GWAS. 
In addition, the causal role of urate in increasing/decreasing the levels of total serum iron, 
serum ferritin, serum transferrin and TSAT was also assessed by selecting urate-related 
variants as instruments for iron profile biomarkers as outcome using summary statistics 
from same GWAS datasets. 
 The results are expected to provide additional information to address the broader 
question of whether or not iron homeostasis is causally involved in affecting urate 
concentrations and its associated aetiologies. 
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SECTION 3.2 MENDELIAN RANDOMISATION ANALYSES 
USING SUMMARY DATA FROM GENOME-WIDE 
ASSOCIATION STUDIES 
3.2.1 Background 
 As described in Section 3.1, whilst searching for a causal effect of a risk factor on 
a disease outcome, it is mandatory to carefully adjust error due to confounding to increase 
the reliability of results in observational studies. This section was aimed to make use of 
large summary-level data from GWA studies to run MR analysis through a valid 
statistical approach that is equivalent or even more robust than 2SLS (used when 
individual-level data are available). 
3.2.2 Methods 
 The two-sample bidirectional (iron as a cause for urate as an effect and urate as a 
cause for iron as an effect) MR approach was adopted in this study using multiple 
instruments. This approach allows the selection of variant-exposure associations 
(instruments) from one GWAS, and variant-outcome associations from a different GWAS 
(Burgess et al., 2015a). Two-sample MR increases the sample size, which in turn 
provides MR analysis with adequate statistical power to identify small-sized causal 
effects of common variants (Gage et al., 2016). The MR model was built on the basis of a 
hypothesis that states that “an increase in exposure (iron profile biomarkers or urate) is 
causal for an increase in the outcome (urate or iron profile biomarkers)”. 
3.2.2.1 Selection of GWAS datasets 
 Mendelian randomisation analysis in this study was based on publicly-available 
summary-level data from two large previously reported GWAS for iron (Benyamin et al., 
2014) and urate (Köttgen et al., 2013). 
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3.2.2.1.1 Iron as exposure for urate as outcome 
3.2.2.1.1.1 Exposure instrument data 
 Summary statistics from a recent GWAS of iron-related phenotypes (Benyamin et 
al., 2014) were used to select the exposure-associated instruments. Overall, this GWA 
study reported genetic association data for a sample set of over 48,900 European male 
and female individuals from 18 study cohorts (Discovery and Replication cohorts; see 
Appendix A Table 3.1) within ‘Genetics of Iron Status Consortium’ (GIS). Publicly-
available meta-analysis effect estimates (in standard deviation/SD units) for serum iron 
(2,096,457 SNPs), serum ferritin (2,036,124 SNPs), serum transferrin (2,104,242 SNPs) 
and transferrin saturation/TSAT (2,102,226 SNPs) were sourced from ‘GeneEpi platform’ 
(Genetic Epidemiology, Psychiatric Genetics, Asthma Genetics and Statistical Genetics 
Laboratories Brisbane, Australia; Link: www.genepi.qimr.edu.au). 
 As it was not possible to calculate F-statistics (F-statistics is calculated as a 
measure of strength of association of IV to exposure in MR studies) for variants based on 
the summary information in the available data, the threshold of p < 5 x 10-8 was set for a 
SNP to be a valid instrument for exposure. The GWAS-level (p < 5 x 10-8) threshold is 
known to correspond to an F-statistic of 30 (Burgess et al., 2013), and as most variants 
were well below the above threshold, their F-statistics would be even greater than 30. 
Following this criteria, all SNPs that were significantly associated (p < 5 x 10-8) with 
serum iron, transferrin, ferritin or TSAT, were selected as MR instruments (Table 3.1) for 
the study. A number of these SNPs were in high LD with each other. For each iron-
related trait, where r2 > 0.6, one SNP was randomly designated as a potential instrument 
for the MR analysis and all other highly correlated SNPs were omitted. Any variant that 
was in LD with a known urate-related variant or was in high eQTL (i.e., coexpressed with 
another gene) with any known urate loci, was also excluded. Two different gene-
expression platforms, GTEx portal (www.gtexportal.org) and HaploReg v4.1 
(www.archive.broadinstitute.org) were used to determine the degree of coexpression of 
the instrument SNPs with other genes to check if any of the instrument carries a 
pleiotropic effect by up/down-regulating expression of other genes. Using these criteria 
resulted in a list of three instruments for serum iron (rs1525892, rs1800562, rs855791), 
eight for serum transferrin (rs1495741, rs174577, rs1800562, rs744653, rs7646473, 
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rs8177240, rs9268633, rs9990333), five for serum ferritin (rs12693541, rs1800562, 
rs2413450, rs651007, rs411988) and three for TSAT (rs1800562, rs8177272, rs855791). 
Table 3.2 provides complete detail for all selected exposure-instruments. Any instrument 
showing possible pleiotropy due to high LD with another instrument (rs1525892, 
rs1495741, rs411988), high co-expression with urate-related genes (rs1799945), and 
possible pleiotropic effect reported in the literature (rs7385804) has been removed from 
the various MR analyses. 
3.2.2.1.1.2 Outcome data 
 Summary statistics data from the largest urate GWAS (Köttgen et al., 2013) were 
used for outcome-instrument association estimates in the MR model. This GWA study 
provided the meta-analysis data for urate-associated loci in > 110,000 European male and 
female individuals from 48 study cohorts (Appendix A Table 3.1) within Global Urate 
Genetics Consortium (GUGC). Publicly-available effect estimates (for urate) of 
2,450,547 SNPs were used as outcome-association variables 
(www.metabolomics.helmholtz-muenchen.de/gugc/). 
3.2.2.1.2 Urate as exposure for iron as outcome 
3.2.2.1.2.1 Exposure instrument and outcome data 
 To assess the exposure-outcome relationship between urate and iron, a reverse 
MR analysis was also carried out via instrumenting the urate-related variants from 
Köttgen et al. (2013) GWAS summary statistic data while summary GWAS statistics 
from Benyamin et al. (2014) were used as outcome data. 
 Using the above-described criteria for selection of IVs, four variants from known 
urate transporter genes were selected as potential urate instruments from the exposure 
GWAS (Köttgen et al., 2013); SLC2A9: rs12498742, SLAC16A9: rs1171614, SLC22A11: 
rs2078267 and SLC22A12: rs478607 (Table 3.1). Although the effect estimate at SLC2A9 
locus was strong enough (ß (mg dL-1) = 0.373, P = 1E-700) to be selected as a single IV 
in the MR model, additional loci were required to be selected to fulfil the IV selection 
requirements of the statistical approach applied in this study (explained in Section 3.2.2.2 
below). 
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3.2.2.1.3 Assessment of GWAS sample overlap 
 As mentioned earlier, the use of two datasets in the two-sample MR model can 
lead to false positive results and can create bias due to large sample overlap between the 
exposure and outcome datasets (Burgess et al., 2016). The GWA studies used in this 
chapter provide the meta-analysis results from several study cohorts of European ancestry. 
Due to the same ancestral background of the participants within two selected GWA 
studies (Benyamin et al., 2014; Köttgen et al., 2013), it was highly likely to expect a large 
sample overlap between them making the two-sample MR prone to biases. Before 
running the MR analysis, the percentage of the sample overlap was also measured 
between the two studies. 
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Iron profile-related instruments 
Iron/Urate 
rs1525892 A G 3 TF 0.074 0.0104 1.65E-12 0.096 - - 
rs1800562 A G 6 HFE 0.372 0.02 3.96E-77 0.001 - - 
rs855791 A G 22 TMPRSS6 -0.186 0.0101 4.31E-77 0.979 - - 
rs1799945 C G 6 HFE -0.189 0.01 1.10E-81 2.94E-06 - SLC17A3 (8.5E-06) 
rs7385804 A C 7 TFR2 0.064 0.007 1.36E-18 0.396 - Pleiotropic 
rs8177240 T G 3 TF -0.089 0.011 2.37E-12 0.091 1 (rs1525892) - 
Trf/Urate 
rs1495741 A G 8 NAT2 0.082 0.0122 1.57E-11 0.309 - - 
rs174577 A C 11 FADS1 0.068 0.0107 1.90E-10 0.002 - - 
rs1800562 A G 6 HFE -0.549 0.0208 1.26E-153 0.001 - - 
rs744653 T C 2 SLC40A1 0.092 0.0144 2.00E-10 0.558 - - 
rs7646473 A G 3 SLC20A1 -0.062 0.0107 6.84E-09 0.457 - - 
rs8177240 T G 3 TF -0.423 0.0107 3.82E-340 0.091 - - 
rs9268633 A G 6 HLA-DRA -0.072 0.0128 2.31E-08 0.522 - - 
rs9990333 T C 3 TFRC -0.067 0.0101 3.01E-11 0.381 - - 
rs4921915 A G 8 NAT2 0.082 0.012 1.74E-11 0.289 1 (rs1495741) - 
rs1799945 C G 6 HFE 0.114 0.01 9.36E-30 2.94E-06 - SLC17A3 (8.5E-06) 
Ferritin/Urate 
rs12693541 T C 2 SLC40A1 -0.106 0.014 4.18E-14 0.375 - - 
rs1800562 A G 6 HFE 0.211 0.0187 1.43E-29 0.001 - - 
rs2413450 T C 22 TMPRSS6 -0.056 0.0095 3.57E-09 0.913 - - 
rs368243 T C 17 TEX14 0.051 0.0093 3.80E-08 0.620 0.9 (rs411988) - 
rs651007 T C 9 ABO -0.05 0.009 1.31E-08 0.021 - - 
rs411988 A G 17 TEX14 -0.044 0.007 1.59E-10 0.692 - - 




rs1800562 A G 6 HFE 0.577 0.0203 1.52E-178 0.001 - - 
rs8177272 A G 3 TF -0.097 0.0106 5.52E-20 0.107 - - 
rs855791 A G 22 TMPRSS6 -0.192 0.0101 3.50E-80 0.979 - - 
rs1799945 C G 6 HFE -0.231 0.01 5.13E-109 2.94E-06 - SLC17A3 (8.5E-06) 




rs12498742 A G 4 SLC2A9 0.373 0.006 1E-700 0.312 - - 
rs1171614 T C 10 SLC16A9 -0.079 0.007 2.3E-28 0.940 - - 
rs2078267 T C 11 SLC22A11 -0.073 0.006 9.4E-38 - - Not in outcome data 
rs478607 A G 11 SLC22A12 -0.047 0.007 4.4E-11 0.871 - - 
Urate/Trf 
rs12498742 A G 4 SLC2A9 0.373 0.006 1E-700 0.929 - - 
rs1171614 T C 10 SLC16A9 -0.079 0.007 2.3E-28 0.333 - - 
rs2078267 T C 11 SLC22A11 -0.073 0.006 9.4E-38 - - Not in outcome data 
rs478607 A G 11 SLC22A12 -0.047 0.007 4.4E-11 0.546 - - 
Urate/Ferritin 
rs12498742 A G 4 SLC2A9 0.373 0.006 1E-700 0.460 - - 
rs1171614 T C 10 SLC16A9 -0.079 0.007 2.3E-28 0.551 - - 
rs2078267 T C 11 SLC22A11 -0.073 0.006 9.4E-38 - - Not in outcome data 
rs478607 A G 11 SLC22A12 -0.047 0.007 4.4E-11 0.059 - - 
Urate/TSAT 
rs12498742 A G 4 SLC2A9 0.373 0.006 1E-700 0.108 - - 
rs1171614 T C 10 SLC16A9 -0.079 0.007 2.3E-28 0.857 - - 
rs2078267 T C 11 SLC22A11 -0.073 0.006 9.4E-38 - - Not in outcome data 
rs478607 A G 11 SLC22A12 -0.047 0.007 4.4E-11 0.523 - - 
Trf: Transferrin, Ferritin: Log ferritin, TSAT: Transferrin saturation, Exp/Outc: Exposure and outcome traits, rs ID: SNP reference number, Eff: effect allele, Ref: reference allele, Chr: 
chromosome, SE: standard error, Exp-GWAS_ß: Effect estimate for association with exposure trait in Exposure GWAS, Exp-GWAS_p: p-value from exposure association GWAS, OutC-
GWAS_p: p-value from outcome association GWAS, r2: R-squared value for the LD (linkage disequilibrium) with another SNP in the list, eQTL-gene: gene with which the said SNP is 
coexpressed, eQTL: expression quantitative trait loci, Status: Absence of selected IV in the outcome data. 
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3.2.2.2 Statistical analysis 
 Two-sample MR analysis was performed using the MR-Base (Mendelian 
Randomisation-Base) platform (www.mrbase.org) (Hemani et al., 2016). The files for 
exposure instruments were manually uploaded in the MR-Base. In order to assure no LD 
between the instruments, the ‘LD clumping’ command was used that excluded one out of 
any two instruments that were in LD with each other at the threshold of 60% or above (r2 
> 0.6) for each exposure trait. For any instrument (SNP) that was absent in the outcome 
data, a proxy instrument was used (if it was available in the outcome data) at LD 60% or 
above (r2 > 0.6) to assure that the power of using multiple instruments was not lost (Table 
3.1). The proxy variants were obtained within MR-Base from outcome data in the 
European population using the 1000 Genomes database (www.internationalgenome.org), 
with a limit of +/- 250kb or +/- 1000 SNPs for each variant. In order to make sure that the 
effect estimate of exposure-instrument corresponds to the same allele as their effects on 
the outcome, the ‘allele harmonisation’ command was used that attempts to align strands 
for palindromic sequences (at MAF > 0.3) before the MR model is run. 
 The following four statistical approaches were used to assure robust analysis and 
to attain reliable causal outcomes in the MR model. All of these methodologies are 
considered valid while dealing with summarised data from GWA studies in presence of a 
continuous exposure and a continuous outcome (Section 3.1.5). 
1. Wald ratio method (single SNP MR estimate analysis) 
2. Inverse-variance weighted (IVW) method (combined MR estimate analysis) 
3. Leave-one out method (sensitivity analysis for an outlier IV) 
4. Egger-regression method (sensitivity analysis for horizontal pleiotropy) 
3.2.2.2.1 Wald ratio method 
 First, the MR estimates (Wald estimate) were calculated and obtained within MR-
Base using the ratio of coefficients or Wald ratio method (Wald, 1940). The Wald ratio is 
the simplest method that estimates the causal effect of the exposure (X) on the outcome 
(Y) using each IV as a separate entity. If the IV is indexed as ‘k’, the Wald estimate 
represents the ratio between estimates of two linear regressions i.e., a regression of 
outcome/Y on ‘k’ and the regression of exposure/X on ‘k’ (Burgess et al., 2015b; Lawlor 
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et al., 2008). For the continuous outcome under study i.e., urate, the Wald ratio for each 
variant ‘k’ was calculated as; 
 
 Where, Yk is the coefficient of ‘k’ (IV) in the regression of ‘Y’ on ‘k’ and Xk is the 
coefficient of ‘k’ in the regression of ‘X’ on ‘k’. 
3.2.2.2.2 Inverse-variance weighted (IVW) method 
 As the Wald ratio method is more efficient for single IV MR, and the data 
employed in this study included multiple-variants, the combined cause-effect relationship 
was analysed via the inverse-variance weighted (IVW) method that requires at least two 
IVs to provide accurate MR measurements (Burgess et al., 2013; Burgess et al., 2015b). 
Under the IVW model, the combined ratio estimate (βIVW) of the effect of the exposure ‘X’ 
on the outcome ‘Y’ using genetic variants k = 1, …, K was calculated as; 
 
 
 Where Xk is the per-allele addition effect of SNP k (IV) with exposure (e.g., iron 
biomarkers in SD units), Yk is the per-allele addition change in the outcome (e.g., urate in 
mg dL-1 units), σYk-2 indicates inverse-variance of the gene-outcome associations. The 
IVW analysis assumes all genetic variants used in the MR model to be valid instruments. 
 Further to these, two sensitivity analyses were done to provide robustness to the 
MR outputs. The details as to why these methods were adopted are described in the 
paragraphs below. 
3.2.2.2.3 Leave-one-out method 
 Leave-one-out analysis (Corbin et al., 2016) was applied as an extension to the 
IVW analyses above. The basic calculations in the leave-one-out method are same as 
IVW, except that it provides the MR estimates between exposure and outcome by 
excluding each IV, one at a time, from the IVW model. The test checks if one particular 
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SNP (IV) disproportionately influences the summary causal estimates or is an outlier. 
Briefly, the method sequentially removes each SNP from the MR model as ‘leave-one-out 
permutation analysis’. 
3.2.2.2.4 Egger-regression method 
 Given that MR analysis is prone to horizontal pleiotropy that violates IV3 in the 
MR model (Section 3.1), the MR-Egger test (Egger-regression) was applied as a 
sensitivity analysis to detect directional (horizontal pleiotropy) within MR-Base (Bowden 
et al., 2015). The MR-Egger test is a regression of the Yk (gene-outcome) on the Xk (gene-
exposure) associations where the intercept is not constrained to pass through zero and 
requires at least three IVs to provide accurate assessment of the pleiotropy. In detail, the 
MR-Egger intercept allows the information on the directional pleiotropy to be detected 
i.e., if the Xk is zero, the Yk should also be zero and represent average pleiotropic effect 
across the genetic variants. Any contrary result indicates the presence of a ‘direct effect’, 
that is a pathway between the gene (G or IV or k) and the outcome (Y) independent of the 
exposure (X). In practice, the bias detected via MR-Egger is equivalent to the detection of 
finite-study or weak instrument bias (Burgess et al., 2015b). In contrast to IVW, MR-
Egger assumes all instruments to be violating the IV assumptions in the MR-model. 
 Both IVW and MR-Egger are efficient enough to calculate small causal effects or 
information on the gene-outcome relationship independent of the exposure under variable 
number (at least two for IVW and three for MR-Egger) and strength of instruments 
(Bowden et al., 2017; Bowden et al., 2015; Burgess et al., 2015b). Heterogeneity of 
estimates across the variants was also calculated using the Cochran Q test via IVW and 
MR-Egger methods, with a threshold of p ≤ 0.05 indicating the presence of heterogeneity. 
3.2.3 Results 
3.2.3.1 Selection of iron exposure instruments 
 Of the variants associated with iron-related phenotypes in the combined discovery 
and replication data from the GIS consortium (Benyamin et al., 2014), the HFE variant 
rs1799945 was excluded from the list because of the possible pleiotropic effect with a 
known urate locus. The SNP rs1799945 has been reported to be in a cis-eQTL in the 
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adrenal gland and is associated with the expression of solute carrier family 17 member 3 
gene (SLC17A3: P = 8.5E-06) that encodes a urate transporter (www.gtexportal.org). 
Also, the SNP was observed to be significantly associated with urate (P = 2.9E-06) in the 
outcome data (Köttgen et al., 2013), which might be indicative of this SNP to be a urate-
association signal independent of iron and its related serum biomarkers. Another iron-
associated SNP within the TFR2 gene, rs7385804, has been reported as a cis-eQTL in 
whole blood (Westra et al., 2013) and is associated with the expression of solute carrier 
family 12 member 9 gene (SLC12A9: P = 1.29E-05) and Ephrin type-B receptor 4 gene 
(EPHB4: P = 2.7E-34) (www.archive.broadinstitute.org). The SLC12A9 gene encodes a 
protein that acts as the inhibitor of member 2 gene within same family (SLC12A2) (Caron 
et al., 2000). Expressed ubiquitously in the body, SLC12A2 is a Na+-K+-Cl- cotransporter, 
which is inhibited by diuretics (Markadieu and Delpire, 2014) and its increased activity is 
associated with increased blood pressure in animals (Orlov et al., 2015). As blood 
pressure could influence glomerular filteration rate independent of iron metabolism, a 
pleiotropic effect could not be ruled out. The EPHB4 gene is known to upregulate 
podocyte activity in glomerulonephritis (Wnuk et al., 2012), and thereby suggested to 
have an additional pleiotropic effect via the iron-independent influence on renal function. 
Two SNPs, NAT2: rs4921915 and TEX14: rs368243 were excluded from the list of 
potential instruments due to their high LD with NAT2: rs1495741 (r2 = 1.0) and TEX14: 
rs411988 (r2 = 0.93), respectively. For other selected instruments, no evidence of a 
pleiotropic effect was found based on literature and gene-expression search on 
bioinformatics platforms. 
3.2.3.2 Selection of urate exposure instruments 
 The variants selected as instruments for urate exposure were exclusively selected 
from urate-transporter genes and have not been reported in the literature to possess 
pleiotropic effect for iron metabolism (to my knowledge). The SLC2A9 (solute carrier 
family 2 member 9) is a member of the SLC2A facilitative glucose transporter family that 
encodes for a protein GLUT9/human glucose transporter 9 (www.genecards.org). 
Members of the SLC2A family play a significant role in maintaining glucose homeostasis 
with SLC2A9 specifically being recognised as major urate transporter gene (Vitart et al., 
2008). The SLC2A9: rs12498742 was the top urate-associated locus in Köttgen et al. 
(2013) GWAS. No cis-eQTL has been reported for the SNP rs12498742 in two gene-
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expression platforms used in this study (HaploRegv4: www.archive.broadinstitute.org 
and GTEx portal: www.gtexportal.org) except SLC2A9 in the whole blood (P = 6.42E-
09). A number of other variants have been reported to be in complete LD with 
rs12498742, all within or near the SLC2A9 locus (www.archive.broadinstitute.org and 
www.gtexportal.org). The second IV (rs1171614) was selected from a urate-transport 
gene called solute carrier family 16 member 9 (SLC16A9), which encodes for MCT9 
(monocarboxylate transporter 9) protein. The SNP rs1171614 has been reported to be 
mainly associated with expression of only SLC16A9 in several tissues in cis-eQTL data 
(Westra et al., 2013) i.e., artery aorta (P = 1.92E-06), esophagous mucosa: (P = 2.31E-
08) and thyroid gland (P = 1.77E-06) (www.archive.broadinstitute.org and 
www.gtexportal.org). The variant rs1171614 was not reported to alter the expression of 
another gene that could have suggested its possible pleiotropic effect on iron metabolism. 
The third IV (rs478607) was selected from the gene SLC22A12/URAT1 (solute carrier 
family 22 member 12). The protein encoded by this gene is a member of the organic 
anion transporter (OAT) family, and acts as a urate transporter to regulate urate levels in 
the blood (www.genecards.org). The SNP rs478607 has been reported to be a cis-eQTL 
for expression of SLC22A12 in several tissues and expression of splicing factor 1 (SF1) 
gene in the whole blood (P = 3.15E-08) (www.archive.broadinstitute.org and 
www.gtexportal.org), which is not suggestive for possible pleiotropy. No data were found 
for the SLC22A11: rs2078267 variant in the outcome GWAS (Benyamin et al., 2014), 
which is why this variant was not included as an IV in the MR model. 
3.2.3.3 Sample overlap in selected GWAS datasets 
 The two GWA studies selected for two-sample MR (Benyamin et al., 2014; 
Köttgen et al., 2013) were found to have only 14% participant overlap (Appendix B 
Figure 3.1) when their corresponding European cohorts (Appendix A Table 3.1) were 
observed. As the overlap was sufficiently low, it was considered to not drastically affect 
the MR model with sample biases. 
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3.2.3.4 Iron biomarkers as exposure for urate as outcome 
3.2.3.4.1 Iron as exposure for urate as outcome 
 Single variant two-sample MR using the Wald ratio method indicated a positive 
causal association between iron and urate via one instrument only i.e., rs1800562 (ß = 
0.107, P = 0.0008) (Table 3.2, Figure 3.2: A). No causal iron-urate relationship was 
observed in primary combined MR analysis using IVW (ß = 0.05, P = 0.16) (Table 3.2, 
Figure 3.2: A). Heterogeneity between the effects across the variants was not significant 
for IVW (Q-P = 0.11), but significant when MR-Egger (Q-P = 0.02) was done (Table 3.2, 
Figure 3.3: A). However, a sensitivity MR-Egger indicated little evidence of pleiotropy 
(intercept: ß = -0.006, OR = 0.99, P = 0.63) for an association between iron and urate 
using all 3 SNPs (Table 3.3, Figure 3.3: B). The MR-Egger combined causal estimate was 
also not significant and similar to the primary (IVW) analysis (ß = 0.083, P = 0.37) 
(Table 3.2, Figure 3.2: A). Leave-one-out IVW meta-analysis showed a significant causal 
iron-urate relationship (ß = 0.110, P = 1.96E-04) after removing rs855791 from the iron-
instrument list (Table 3.4). The result also indicated that the non-causal association in the 
IVW meta-analysis was driven by rs855791 (Table 3.4, Figure 3.2: B). All MR ß-
estimates are presented as an effect of an SD unit increase in iron on urate (mg dL-1). This 
analysis provided evidence that iron plays a causal role in increasing urate concentrations. 
3.2.3.4.2 Transferrin as exposure for urate as outcome 
 Two independent instruments showed a causal transferrin-urate association when 
assessed via the Wald ratio method i.e., rs174577 (ß = 0.263, P = 0.002) and rs1800562 
(ß = -0.073, P = 0.0008) (Table 3.2, Figure 3.4: A). Transferrin was not causally 
associated with urate in combined IVW meta-analysis (ß = 0.001, P = 0.97) (Table 3.2, 
Figure 3.4: A). Significant heterogeneity (IVW: Q-P = 0.002, MR-Egger: Q-P = 0.001) 
was found for effect estimates across the instruments (Table 3.2, Figure 3.5: A). A 
sensitivity MR-Egger, however, did not indicate evidence of pleiotropy for an association 
between transferrin and urate using the full list of 8 SNPs (intercept: ß = 0.005, OR = 
1.00, P = 0.45) (Table 3.3, Figure 3.5: B). The combined causal estimate via MR-Egger 
did not show a significant association (ß = -0.016, P = 0.61) (Table 3.2, Figure 3.4: A). 
Leave-one-out permutation analysis also did not indicate any variant to be 
unproportionately altering the non-significant association in IVW (Table 3.4, Figure 3.4: 
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B). All MR ß-estimates are presented as an effect of an SD unit increase in transferrin on 
urate (mg dL-1). Overall, this analysis did not provide any evidence of a causal role of 
serum transferrin in changing serum urate concentrations. 
3.2.3.4.3 Ferritin as exposure for urate as outcome 
 The Wald ratio method showed two instruments indicating a positive causal 
association between ferritin and urate i.e., rs1800562 (ß = 0.190, P = 0.0002) and 
rs651007 (ß = 0.320, P = 0.022) (Table 3.2, Figure 3.6: A). However, when combined in 
standard IVW analysis, no significant ferritin-urate association was observed (ß = 0.089, 
P = 0.17) (Table 3.2, Figure 3.6: A). Heterogeneity between the effects across the 
variants was not significant for IVW (Q-P = 0.06), but significant when assessed through 
MR-Egger regression (Q-P = 0.01) (Table 3.2, Figure 3.7: A). A sensitivity MR-Egger 
indicated very little pleiotropy (intercept: ß = -0.007, OR = 0.99, P = 0.57) in association 
between ferritin and urate using the full list of 5 SNPs (Table 3.3, Figure 3.7: B). The 
combined causal estimate obtained using MR-Egger was not significant similar to 
standard MR analysis (ß = 0.160, P = 0.32) (Table 3.2, Figure 3.6: A). The secondary 
sensitivity approach using leave-one-out analysis did not indicate any variant to be 
considerably changing the non-significant association in IVW, except rs12693541, 
removal of which showed a positive causal association between ferritin and urate (ß = 
0.14, P = 0.02) (Table 3.4, Figure 3.6: B). All MR ß-estimates are presented as an effect 
of an SD unit increase in ferritin (log10) on urate (mg dL
-1). The analysis provided 
evidence of a causal relationship of ferritin with urate. 
3.2.3.4.4 Transferrin saturation as exposure for urate as outcome 
 None of the 3 instruments indicated a causal TSAT-urate association when 
assessed via the Wald ratio method, except rs1800562 (ß = 0.069, P = 0.001) (Table 3.2, 
Figure 3.8: A). Transferrin saturation was also not causal for urate in combined IVW 
meta-analysis (ß = 0.035, P = 0.31) (Table 3.2, Figure 3.8: A). No significant 
heterogeneity (IVW: Q-P = 0.106, MR-Egger: Q-P = 0.924) was found for effect 
estimates across the instruments (Table 3.2, Figure 3.9: A). A sensitivity MR-Egger, 
however, did not indicate evidence of pleiotropy for an association between TSAT and 
urate using full list of 3 SNPs (intercept: ß = -0.019, OR = 0.98, P = 0.20) (Table 3.3, 
Figure 3.9: B). The combined causal estimate via MR-Egger did not show a significant 
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association (ß = 0.102, P = 0.17) (Table 3.2, Figure 3.8: A). Leave-one-out permutation 
analysis also did not indicate any variant to be unproportionately altering the non-
significant association in IVW (Table 3.4, Figure 3.8: B). All MR ß-estimates are 
presented as an effect of an SD unit increase in TSAT on urate (mg dL-1). This analysis 
did not provide any evidence of a causal role of transferrin saturation in changing serum 
urate concentrations. 
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Table 3.2 Association between iron-related traits and urate using two-sample Mendelian randomisation 
MR-analysis Method 




SE [95% CI] p-causal Q-p 
Exposure Outcome  
Wald ratio Iron Urate TF rs1525892 0.127 0.076 [-0.02 ; 0.28] 0.093 - 
- Iron Urate HFE rs1800562 0.107 0.032 [0.04 ; 0.17] 0.0008 - 
- Iron Urate TMPRSS6 rs855791 -0.001 0.031 [-0.06 ; 0.06] 0.986 - 
All - IVW Iron Urate - All 0.056 0.039 [-0.02 ; 0.13] 0.151 0.179 
All - MR Egger Iron Urate - All 0.064 0.109 [-0.15 ; 0.28] 0.661 0.011 
Wald ratio Transferrin Urate NAT2 rs1495741 -0.079 0.077 [-0.23 ; 0.07] 0.310 - 
- Transferrin Urate FADS1 rs174577 0.263 0.083 [0.10 ; 0.43] 0.001 - 
- Transferrin Urate HFE rs1800562 -0.073 0.022 [-0.12 ; -0.03] 0.0008 - 
- Transferrin Urate SLC40A1 rs744653 0.049 0.084 [-0.12 ; 0.21] 0.559 - 
- Transferrin Urate SLC20A1 rs7646473 0.071 0.101 [-0.13 ; 0.27] 0.485 - 
- Transferrin Urate TF rs8177240 0.023 0.013 [0.01 ; 0.05] 0.092 - 
- Transferrin Urate HLA-DRA rs9268633 0.064 0.100 [-0.13 ; 0.26] 0.523 - 
- Transferrin Urate TFRC rs9990333 -0.070 0.081 [-0.23 ; 0.09] 0.384 - 
All - IVW Transferrin Urate - All 0.001 0.021 [-0.04 ; 0.04] 0.970 0.002 
All - MR Egger Transferrin Urate - All -0.016 0.031 [-0.08 ; 0.04] 0.611 0.0004 
Wald ratio Log Ferritin Urate SLC40A1 rs12693541 -0.068 0.076 [-0.22 ; 0.08] 0.374 - 
- Log Ferritin Urate HFE rs1800562 0.190 0.057 [0.08 ; 0.30] 0.0002 - 
- Log Ferritin Urate TMPRSS6 rs2413450 0.011 0.106 [-0.20 ; 0.22] 0.919 - 
- Log Ferritin Urate TEX14 rs411988 -0.048 0.123 [-0.29 ; 0.19] 0.697 - 
- Log Ferritin Urate ABO rs651007 0.320 0.140 [0.05 ; 0.59] 0.022 - 
All - IVW Log Ferritin Urate - All 0.089 0.066 [-0.04 ; 0.22] 0.176 0.063 
All - MR Egger Log Ferritin Urate - All 0.160 0.134 [-0.10 ; 0.42] 0.320 0.014 
Wald ratio TSAT Urate HFE rs1800562 0.069 0.021 [0.03 ; 0.11] 0.0001 - 
- TSAT Urate TF rs8177272 -0.094 0.059 [-0.21 ; 0.02] 0.110 - 
- TSAT Urate TMPRSS6 rs855791 -0.001 0.030 [-0.06 ; 0.06] 0.986 - 
All - IVW TSAT Urate - All 0.035 0.034 [-0.03 ; 0.10] 0.306 0.106 
All - MR Egger TSAT Urate - All 0.102 0.027 [0.05 ; 0.16] 0.168 0.924 
TSAT: Transferrin saturation, All - IVW: Meta-analysis using inverse-variance method, All - MR Egger: Mendelian randomisation using Egger regression, ß: beta estimates, SE: standard error, 
95% CI: 95% confidence interval, p-causal: p-value using MR analysis, Q-p: Cochran’s heterogeneity test p-value for heterogeneity. 
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Table 3.3: Results of horizontal pleiotropy for two-sample MR-Egger test 





Iron Urate -0.0016 (0.99) 0.019 0.946 
     
Transferrin Urate 0.0052 (1.00) 0.006 0.451 
     
Log Ferritin Urate -0.0067 (0.99) 0.011 0.577 
     
TSAT Urate -0.0193 (0.98) 0.006 0.205 
TSAT: Transferrin saturation, MR Egger: Mendelian randomisation using Egger regression, ß (OR): beta estimates 
(odds ratio for ß), SE: standard error, p-value: p-value for directional pleiotropy. 
 
Table 3.4: Results of leave-one-out sensitivity analysis for association between iron-
related traits and urate using two-sample Mendelian randomisation 





[95% CI] p-causal 
Exposure Outcome 
Iron Urate rs1525892 0.050 [-0.06 ; 0.16] 0.348 
Iron Urate rs1800562 0.017 [-0.07 ; 0.10] 0.697 
Iron Urate rs855791 0.110 [0.05 ; 0.17] 1.96E-04 
Iron Urate All 0.050 [-0.02 ; 0.13] 0.151 
Transferrin Urate rs1495741 0.002 [-0.04 ; 0.05] 0.917 
Transferrin Urate rs174577 -0.004 [-0.04 ; 0.03] 0.838 
Transferrin Urate rs1800562 0.025 [-0.01 ; 0.06 0.153 
Transferrin Urate rs744653 0.0001 [-0.05 ; 0.05] 0.999 
Transferrin Urate rs7646473 0.0001 [-0.05 ; 0.05] 0.999 
Transferrin Urate rs8177240 -0.041 [-0.11 ; 0.02] 0.220 
Transferrin Urate rs9268633 0.0001 [-0.05 ; 0.05] 0.999 
Transferrin Urate rs9990333 0.002 [-0.04 ; 0.05] 0.927 
Transferrin Urate All 0.001 [-0.04 ; 0.04] 0.970 
Log Ferritin Urate rs12693541 0.141 [0.02 ; 0.27] 0.027 
Log Ferritin Urate rs1800562 0.007 [-0.14 ; 0.15] 0.929 
Log Ferritin Urate rs2413450 0.101 [-0.05 ; 0.26] 0.204 
Log Ferritin Urate rs411988 0.103 [-0.04 ; 0.25] 0.168 
Log Ferritin Urate rs651007 0.070 [-0.06 ; 0.20] 0.303 
Log Ferritin Urate All 0.089 [-0.04 ; 0.22] 0.176 
TSAT Urate rs1800562 -0.019 [-0.09 ; 0.05] 0.604 
TSAT Urate rs8177272 0.046 [-0.02 ; 0.11] 0.158 
TSAT Urate rs855791 0.051 [-0.05 ; 0.15] 0.319 
TSAT Urate All 0.035 [-0.03 ; 0.10] 0.306 
IVW: meta-analysis using inverse-variance method, ß: beta estimate, 95% CI: 95% confidence interval, p-causal: p-
value using IVW meta-analysis. 
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Figure 3.2: Forest graphs showing results of MR-analysis for three variants (SNPs) instrumented for serum iron as exposure (and serum urate as outcome) with their effect sizes on 
the x-axis and IDs on the y-axis (A) Graph showing results from the Wald ratio, ‘Inverse-variance weighted (IVW)’ and ‘MR-Egger’ methods; black dots indicate Wald ratio 
estimate for each SNP with black horizontal lines across the dots representing 95% confidence intervals (CI) corresponding to each estimate. ‘All-IVW’ red dot at the bottom 
indicates regression estimate from IVW meta-analysis with the red line across the dot representing 95% CI, while the ‘All-Egger’ red dot indicates regression estimate from MR-
Egger sensitivity meta-analysis with the red line across the dot representing the 95% CI (B) Graph showing results from ‘Leave-one-out’ sensitivity analysis; each black dot indicates 
IVW estimate for all instrument SNPs excluding the one indicated on y-axis, while the black horizontal lines across the dots represents the 95% CI corresponding to each estimate. 
The ‘All’ red dot at the bottom indicates estimate from IVW analysis including all SNPs that are the same as ‘All-IVW’ in graph (A) for a comparison. The vertical dashed line in (A) 
and (B) represents effect size = zero (null). 
A B 
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Figure 3.3: Graphs showing results of MR-analysis for three variants (SNPs) instrumented for serum iron as exposure on serum urate as an outcome via ‘Inverse-variance weighted 
(IVW)’ (indicated with light blue lines) and ‘MR-Egger’ (indicated with dark blue lines) methods (A) Funnel graph plotted to compare heterogeneity assessed via IVW and MR-
Egger methods. Values on the x and y-axis represent effect estimates (ßIV) and reciprocal standard errors (1/SEIV) for the instrument variables (IVs indicated by black dots). Less 
precise estimates (lower values on y-axis) 'funnel' in as they increase in precision, while asymmetry in the funnel plot indicates directional heterogeneity between the estimates (B) 
Scatter plot to compare IVW and Egger-regression MR results: SNP effects (black dots with their 95% CI as vertical grey lines through the dots) on the outcome [urate (mg dL-1) on 
y-axis] are plotted against SNP effects (black dots with their 95% CI as horizontal grey lines through the dots) on the exposure [iron (SD) on x-axis]. All SNPs with negative effects on 
the exposure are shown to be positive, with the sign of the effect on the outcome flipped. The slope of the line represents the causal association. 
A B 
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Figure 3.4: Forest graphs showing results of MR-analysis for eight variants (SNPs) instrumented for serum transferrin as exposure (and serum urate as outcome) with their effect 
sizes on the x-axis and IDs on the y-axis (A) Graph showing results from the Wald ratio, ‘Inverse-variance weighted (IVW)’ and ‘MR-Egger’ methods; black dots indicate Wald ratio 
estimate for each SNP with black horizontal lines across the dots representing 95% confidence intervals (CI) corresponding to each estimate. ‘All-IVW’ red dot at the bottom 
indicates regression estimate from IVW meta-analysis with the red line across the dot representing 95% CI, while the ‘All-Egger’ red dot indicates regression estimate from MR-
Egger sensitivity meta-analysis with the red line across the dot representing the 95% CI (B) Graph showing results from ‘Leave-one-out’ sensitivity analysis; each black dot indicates 
IVW estimate for all instrument SNPs excluding the one indicated on y-axis, while the black horizontal lines across the dots represents the 95% CI corresponding to each estimate. 
The ‘All’ red dot at the bottom indicates estimate from IVW analysis including all SNPs that are the same as ‘All-IVW’ in graph (A) for a comparison. The vertical dashed line in (A) 
and (B) represents effect size = zero (null). 
A B 
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Figure 3.5: Graphs showing results of MR-analysis for eight variants (SNPs) instrumented for serum transferrin as exposure on serum urate as an outcome via ‘Inverse-variance 
weighted (IVW)’ (indicated with light blue lines) and ‘MR-Egger’ (indicated with dark blue lines) methods (A) Funnel graph plotted to compare heterogeneity assessed via IVW and 
MR-Egger methods. Values on the x and y-axis represent effect estimates (ßIV) and reciprocal standard errors (1/SEIV) for the instrument variables (IVs indicated by black dots). 
Less precise estimates (lower values on y-axis) 'funnel' in as they increase in precision, while asymmetry in the funnel plot indicates directional heterogeneity between the estimates 
(B) Scatter plot to compare IVW and Egger-regression MR results: SNP effects (black dots with their 95% CI as vertical grey lines through the dots) on the outcome [urate (mg dL-1) 
on y-axis] are plotted against SNP effects (black dots with their 95% CI as horizontal grey lines through the dots) on the exposure [transferrin (SD) on x-axis]. All SNPs with negative 
effects on the exposure are shown to be positive, with the sign of the effect on the outcome flipped. The slope of the line represents the causal association. 
A B 
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Figure 3.6: Forest graphs showing results of MR-analysis for five variants (SNPs) instrumented for serum ferritin (log) as exposure (and serum urate as outcome) with their effect 
sizes on the x-axis and IDs on the y-axis (A) Graph showing results from the Wald ratio, ‘Inverse-variance weighted (IVW)’ and ‘MR-Egger’ methods; black dots indicate Wald ratio 
estimate for each SNP with black horizontal lines across the dots representing 95% confidence intervals (CI) corresponding to each estimate. ‘All-IVW’ red dot at the bottom 
indicates regression estimate from IVW meta-analysis with the red line across the dot representing 95% CI, while the ‘All-Egger’ red dot indicates regression estimate from MR-
Egger sensitivity meta-analysis with the red line across the dot representing the 95% CI (B) Graph showing results from ‘Leave-one-out’ sensitivity analysis; each black dot indicates 
IVW estimate for all instrument SNPs excluding the one indicated on y-axis, while the black horizontal lines across the dots represents the 95% CI corresponding to each estimate. 
The ‘All’ red dot at the bottom indicates estimate from IVW analysis including all SNPs that are the same as ‘All-IVW’ in graph (A) for a comparison. The vertical dashed line in (A) 
and (B) represents effect size = zero (null). 
A B A 
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Figure 3.7: Graphs showing results of MR-analysis for five variants (SNPs) instrumented for serum ferritin (log) as exposure on serum urate as an outcome via ‘Inverse-variance 
weighted (IVW)’ (indicated with light blue lines) and ‘MR-Egger’ (indicated with dark blue lines) methods (A) Funnel graph plotted to compare heterogeneity assessed via IVW and 
MR-Egger methods. Values on the x and y-axis represent effect estimates (ßIV) and reciprocal standard errors (1/SEIV) for the instrument variables (IVs indicated by black dots). 
Less precise estimates (lower values on y-axis) 'funnel' in as they increase in precision, while asymmetry in the funnel plot indicates directional heterogeneity between the estimates 
(B) Scatter plot to compare IVW and Egger-regression MR results: SNP effects (black dots with their 95% CI as vertical grey lines through the dots) on the outcome [urate (mg dL-1) 
on y-axis] are plotted against SNP effects (black dots with their 95% CI as horizontal grey lines through the dots) on the exposure [ferritin (log) (SD) on x-axis]. All SNPs with 
negative effects on the exposure are shown to be positive, with the sign of the effect on the outcome flipped. The slope of the line represents the causal association. 
A B 
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Figure 3.8: Forest graphs showing results of MR-analysis for three variants (SNPs) instrumented for serum transferrin saturation (TSAT) as exposure (and serum urate as outcome) 
with their effect sizes on the x-axis and IDs on the y-axis (A) Graph showing results from the Wald ratio, ‘Inverse-variance weighted (IVW)’ and ‘MR-Egger’ methods; black dots 
indicate Wald ratio estimate for each SNP with black horizontal lines across the dots representing 95% confidence intervals (CI) corresponding to each estimate. ‘All-IVW’ red dot at 
the bottom indicates regression estimate from IVW meta-analysis with the red line across the dot representing 95% CI, while the ‘All-Egger’ red dot indicates regression estimate 
from MR-Egger sensitivity meta-analysis with the red line across the dot representing the 95% CI (B) Graph showing results from ‘Leave-one-out’ sensitivity analysis; each black dot 
indicates IVW estimate for all instrument SNPs excluding the one indicated on y-axis, while the black horizontal lines across the dots represents the 95% CI corresponding to each 
estimate. The ‘All’ red dot at the bottom indicates estimate from IVW analysis including all SNPs that are the same as ‘All-IVW’ in graph (A) for a comparison. The vertical dashed 
line in (A) and (B) represents effect size = zero (null). 
B A 
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Figure 3.9: Graphs showing results of MR-analysis for three variants (SNPs) instrumented for serum transferrin saturation/TSAT as exposure on serum urate as an outcome via 
‘Inverse-variance weighted (IVW)’ (indicated with light blue lines) and ‘MR-Egger’ (indicated with dark blue lines) methods (A) Funnel graph plotted to compare heterogeneity 
assessed via IVW and MR-Egger methods. Values on the x and y-axis represent effect estimates (ßIV) and reciprocal standard errors (1/SEIV) for the instrument variables (IVs 
indicated by black dots). Less precise estimates (lower values on y-axis) 'funnel' in as they increase in precision, while asymmetry in the funnel plot indicates directional heterogeneity 
between the estimates (B) Scatter plot to compare IVW and Egger-regression MR results: SNP effects (black dots with their 95% CI as vertical grey lines through the dots) on the 
outcome [urate (mg dL-1) on y-axis] are plotted against SNP effects (black dots with their 95% CI as horizontal grey lines through the dots) on the exposure [TSAT (SD) on x-axis]. 
All SNPs with negative effects on the exposure are shown to be positive, with the sign of the effect on the outcome flipped. The slope of the line represents the causal association. 
A B 
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3.2.3.5 Urate as exposure for iron profile biomarkers as outcome 
3.2.3.5.1 Urate as exposure for iron as outcome 
 Single variant two-sample MR using the Wald ratio method did not indicate a 
causal association between urate and iron for any instrument (rs12498742: ß = -0.032, P 
= 0.31; rs1171614: ß = 0.011, P = 0.943; rs478607: ß = 0.047, P = 0.872) (Table 3.5, 
Figure 3.10: A). No causal urate-iron relationship was observed in primary combined MR 
analysis using IVW (ß = -0.029, P = 0.33) or MR-Egger (ß = -0.043, P = 0.53) (Table 3.5, 
Figure 3.10: A). Heterogeneity between the effects across the variants was not significant 
for IVW (Q-P = 0.96) or MR-Egger (Q-P = 0.99) (Table 3.5, Figure 3.11: A). However, 
a sensitivity MR-Egger indicated an evidence of little pleiotropy (intercept: ß = 0.004, OR 
= 1.01, P = 0.77) for an association between urate and iron using all 3 SNPs (Table 3.6, 
Figure 3.11: B). Removing any variant in leave-one-out IVW meta-analysis also did not 
indicate any significant causal urate-iron relationship (Table 3.7, Figure 3.10: B). All MR 
ß-estimates are presented as an effect of a mg dL-1 increase in urate on iron (per SD unit). 
This analysis did not provide any evidence of a causal role of urate in changing blood 
iron levels. 
3.2.3.5.2 Urate as exposure for transferrin as outcome 
 None of the 3 instruments indicated a causal urate-transferrin association when 
assessed via the Wald ratio method, except rs478607 that showed only nominal 
significance (ß = -0.519, P = 0.058) (Table 3.5, Figure 3.12: A). Urate was also not 
causal for transferrin in combined IVW meta-analysis (ß = 0.106, P = 0.74) (Table 3.5, 
Figure 3.12: A). No significant heterogeneity (IVW: Q-P = 0.743, MR-Egger: Q-P = 
0.803) was found for effect estimates across the instruments (Table 3.5, Figure 3.13: A). 
A sensitivity MR-Egger only indicated an evidence of little pleiotropy for an association 
between urate and transferrin using full list of 3 SNPs (intercept: ß = 0.0124, OR = 1.02, 
P = 0.48) (Table 3.6, Figure 3.13: B). The combined causal estimate via MR-Egger did 
not show a significant urate-transferrin association (ß = -0.030, P = 0.65) (Table 3.5, 
Figure 3.12: A). Leave-one-out permutation analysis also did not indicate any variant to 
be unproportionately altering the non-significant association in IVW meta-analysis (Table 
3.7, Figure 3.12: B). All MR ß-estimates are presented as an effect of a mg dL-1 increase 
3 | Iron Metabolism – Mendelian Randomisation 
 121 
in urate on transferrin (per SD unit). This analysis did not provide any evidence of a 
causal role of urate in changing blood transferrin levels. 
3.2.3.5.3 Urate as exposure for ferritin as outcome 
 The Wald ratio method did not indicate a positive urate-ferritin relationship via 
any of the 3 instruments (rs12498742: ß = 0.003, P = 0.97; rs1171614: ß = 0.156, P = 
0.33; rs478607: ß = 0.183, P = 0.302) (Table 3.5, Figure 3.14: A). The primary combined 
MR analysis using IVW (ß = 0.018, P = 0.65) or MR-Egger (ß = 0.056, P = 0.59) 
regression also did not indicate any causal urate-ferritin relationship (Table 3.5, Figure 
3.14: A). Heterogeneity between the effects across the variants was not significant for 
IVW (Q-P = 0.361) or MR-Egger regression (Q-P = 0.089) (Table 3.5, Figure 3.15: A). 
A sensitivity MR-Egger indicated very little pleiotropy (intercept: ß = -0.007, OR = 0.99, 
P = 0.57) in association between urate and ferritin using the full list of 3 SNPs (Table 3.6, 
Figure 3.15: B). The sensitivity analysis using leave-one-out approach did not indicate 
any variant to be considerably changing the non-significant association in IVW meta-
analysis (Table 3.7, Figure 3.14: B). All MR ß-estimates are presented as an effect of a 
mg dL-1 increase in urate on ferritin (log10) (per SD unit). This analysis did not provide 
any evidence of a causal role of urate in changing ferritin levels. 
3.2.3.5.4 Urate as exposure for transferrin saturation as outcome 
 No instrument showed a causal urate-TSAT association when assessed 
individually via the Wald ratio method (rs12498742: ß = -0.0501, P = 0.11; rs1171614: ß 
= 0.027, P = 0.86; rs478607: ß = -0.187, P = 0.52) (Table 3.5, Figure 3.16: A). Urate was 
also not causally associated with TSAT in combined IVW meta-analysis (ß = -0.051, P = 
0.096) or MR-Egger sensitivity regression analysis (ß = -0.042, P = 0.542) (Table 3.5, 
Figure 3.16: A). No heterogeneity (IVW: Q-P = 0.94, MR-Egger: Q-P = 0.66) was found 
for effect estimates across the instruments (Table 3.5, Figure 3.17: A). A sensitivity MR-
Egger, however, did indicate an evidence of little pleiotropy for an association between 
urate and TSAT using the full list of 3 SNPs (intercept: ß = -0.005, OR = 0.99, P = 0.85) 
(Table 3.6, Figure 3.17: B). Leave-one-out permutation analysis also did not indicate any 
variant to be unproportionately altering the non-significant association in IVW meta-
analysis (Table 3.7, Figure 3.16: B). All MR ß-estimates are presented as an effect of a 
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mg dL-1 increase in urate on TSAT (per SD unit). This analysis did not provide any 
evidence of a causal role of urate in changing transferrin saturation levels. 
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Table 3.5 Association between urate and iron-related traits using two-sample Mendelian randomisation 
MR-analysis Method 




SE [95% CI] p-causal Q-p 
Exposure Outcome  
Wald ratio Urate Iron SLC2A9 rs12498742 -0.032 0.031 [-0.09 ; 0.03] 0.309 - 
- Urate Iron SLC16A9 rs1171614 0.011 0.158 [-0.30 ; 0.32] 0.943 - 
- Urate Iron SLC22A12 rs478607 0.046 0.291 [-0.52 ; 0.62] 0.872 - 
All - IVW Urate Iron - All -0.029 0.031 [-0.09 ; 0.03] 0.335 0.965 
All - MR Egger Urate Iron - All -0.043 0.047 [-0.14 ; 0.05] 0.534 0.996 
Wald ratio Urate Transferrin SLC2A9 rs12498742 0.022 0.029 [-0.04 ; 0.08] 0.461 - 
- Urate Transferrin SLC16A9 rs1171614 0.091 0.152 [-0.21 ; 0.39] 0.548 - 
- Urate Transferrin SLC22A12 rs478607 -0.519 0.274 [-1.06 ; 0.02] 0.058 - 
All - IVW Urate Transferrin - All 0.011 0.031 [-0.05 ; 0.07] 0.736 0.743 
All - MR Egger Urate Transferrin - All -0.030 0.049 [-0.13 ; 0.07] 0.653 0.803 
Wald ratio Urate Log Ferritin SLC2A9 rs12498742 0.003 0.032 [-0.06 ; 0.07] 0.926 - 
- Urate Log Ferritin SLC16A9 rs1171614 0.156 0.163 [-0.16 ; 0.48] 0.336 - 
- Urate Log Ferritin SLC22A12 rs478607 0.183 0.302 [-0.41 ; 0.77] 0.544 - 
All - IVW Urate Log Ferritin - All 0.018 0.041 [-0.06 ; 0.10] 0.656 0.361 
All - MR Egger Urate Log Ferritin - All 0.057 0.077 [-0.09 ; 0.21] 0.595 0.089 
Wald ratio Urate TSAT SLC2A9 rs12498742 -0.050 0.031 [-0.11 ; 0.01] 0.109 - 
- Urate TSAT SLC16A9 rs1171614 -0.028 0.158 [-0.34 ; 0.28] 0.860 - 
- Urate TSAT SLC22A12 rs478607 -0.187 0.293 [-0.76 ; 0.39] 0.523 - 
All - IVW Urate TSAT - All -0.051 0.031 [-0.11 ; 0.01] 0.096 0.942 
All - MR Egger Urate TSAT - All -0.042 0.048 [-0.14 ; 0.05] 0.542 0.668 
TSAT: Transferrin saturation, All - IVW: Meta-analysis using inverse-variance method, All - MR Egger: Mendelian randomisation using Egger regression, ß: Beta estimates, SE: Standard error, 
95% CI: 95% confidence interval, p-causal: p-value using MR analysis, Q-p: Cochran’s heterogeneity test p-value for heterogeneity. 
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Table 3.6: Results of horizontal pleiotropy for two-sample MR-Egger test 





Urate Iron  0.0042 (1.004) 0.0114 0.772 
     
Urate Transferrin 0.0124 (1.012) 0.0117 0.481 
     
Urate Log Ferritin -0.0118 (0.988) 0.0183 0.634 
     
Urate TSAT -0.0026 (0.997) 0.0114 0.855 
TSAT: Transferrin saturation, MR Egger: Mendelian randomisation using Egger regression, ß (OR): beta estimates 
(odds ratio for ß), SE: standard error, p-value: p-value for directional pleiotropy. 
 
Table 3.7: Results of leave-one-out sensitivity analysis for association between urate 
and iron-related traits using two-sample Mendelian randomisation 
Phenotype Instrument variant 




[95% CI] p-causal 
Exposure Outcome 
Urate Iron rs12498742 0.094 [-0.25 ; 0.29] 0.888 
Urate Iron rs1171614 -0.031 [-0.09 ; 0.03] 0.319 
Urate Iron rs478607 -0.030 [-0.09 ; 0.03] 0.324 
Urate Iron All -0.029 [-0.09 ; 0.03] 0.335 
Urate Transferrin rs12498742 0.162 [-0.12 ; 0.44] 0.256 
Urate Transferrin rs1171614 0.004 [-0.06 ; 0.07] 0.876 
Urate Transferrin rs478607 0.008 [-0.05 ; 0.07] 0.782 
Urate Transferrin All 0.010 [-0.05 ; 0.07] 0.735 
Urate Log Ferritin rs12498742 -0.052 [-0.56 ; 0.45] 0.841 
Urate Log Ferritin rs1171614 0.015 [-0.10 ; 0.13] 0.786 
Urate Log Ferritin rs478607 0.024 [-0.03 ; 0.08] 0.402 
Urate Log Ferritin All 0.018 [-0.06 ; 0.10] 0.656 
Urate TSAT rs12498742 -0.064 [-0.34 ; 0.21] 0.647 
Urate TSAT rs1171614 -0.052 [-0.11 ; 0.01] 0.097 
Urate TSAT rs478607 -0.049 [-0.11 ; 0.01] 0.109 
Urate TSAT All -0.051 [-0.11 ; 0.01] 0.096 
TSAT: Transferrin saturation, IVW: meta-analysis using inverse-variance method, ß: beta estimate, 95% CI: 95% 
confidence interval, p-causal: p-value using IVW meta-analysis. 
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Figure 3.10: Forest graphs showing results of MR-analysis for three variants (SNPs) instrumented for serum urate as exposure (and serum iron as outcome) with their effect sizes on 
the x-axis and IDs on the y-axis (A) Graph showing results from the Wald ratio, ‘Inverse-variance weighted (IVW)’ and ‘MR-Egger’ methods; black dots indicate Wald ratio 
estimate for each SNP with black horizontal lines across the dots representing 95% confidence intervals (CI) corresponding to each estimate. ‘All-IVW’ red dot at the bottom 
indicates regression estimate from IVW meta-analysis with the red line across the dot representing 95% CI, while the ‘All-Egger’ red dot indicates regression estimate from MR-
Egger sensitivity meta-analysis with the red line across the dot representing the 95% CI (B) Graph showing results from ‘Leave-one-out’ sensitivity analysis; each black dot indicates 
IVW estimate for all instrument SNPs excluding the one indicated on y-axis, while the black horizontal lines across the dots represents the 95% CI corresponding to each estimate. 
The ‘All’ red dot at the bottom indicates estimate from IVW analysis including all SNPs that are the same as ‘All-IVW’ in graph (A) for a comparison. The vertical dashed line in (A) 
and (B) represents effect size = zero (null). 
A B 
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Figure 3.11: Graphs showing results of MR-analysis for three variants (SNPs) instrumented for serum urate as exposure on serum iron as an outcome via ‘Inverse-variance weighted 
(IVW)’ (indicated with light blue lines) and ‘MR-Egger’ (indicated with dark blue lines) methods (A) Funnel graph plotted to compare heterogeneity assessed via the IVW and MR-
Egger methods. Values on the x and the y-axis represent effect estimates (ßIV) and reciprocal standard errors (1/SEIV) for the instrument variables (IVs indicated by black dots). Less 
precise estimates (lower values on y-axis) 'funnel' in as they increase in precision, while asymmetry in the funnel plot indicates directional heterogeneity between the estimates (B) 
Scatter plot to compare the IVW and Egger-regression MR results: SNP effects (black dots with their 95% CI as vertical grey lines through the dots) on the outcome [iron (SD) on 
the y-axis] are plotted against SNP effects (black dots with their 95% CI as horizontal grey lines through the dots) on the exposure [urate (mg dL-1) on the x-axis]. All SNPs with 
negative effects on the exposure are shown to be positive, with the sign of the effect on the outcome flipped. The slope of the line represents the causal association. 
A 
B 
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Figure 3.12: Forest graphs showing results of MR-analysis for three variants (SNPs) instrumented for serum urate as exposure (and serum transferrin as outcome) with their effect 
sizes on the x-axis and IDs on the y-axis (A) Graph showing results from the Wald ratio, ‘Inverse-variance weighted (IVW)’ and ‘MR-Egger’ methods; black dots indicate Wald ratio 
estimate for each SNP with black horizontal lines across the dots representing 95% confidence intervals (CI) corresponding to each estimate. ‘All-IVW’ red dot at the bottom 
indicates regression estimate from IVW meta-analysis with the red line across the dot representing 95% CI, while the ‘All-Egger’ red dot indicates regression estimate from MR-
Egger sensitivity meta-analysis with the red line across the dot representing the 95% CI (B) Graph showing results from ‘Leave-one-out’ sensitivity analysis; each black dot indicates 
IVW estimate for all instrument SNPs excluding the one indicated on y-axis, while the black horizontal lines across the dots represents the 95% CI corresponding to each estimate. 
The ‘All’ red dot at the bottom indicates estimate from IVW analysis including all SNPs that are the same as ‘All-IVW’ in graph (A) for a comparison. The vertical dashed line in (A) 
and (B) represents effect size = zero (null). 
A B 
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Figure 3.13: Graphs showing results of MR-analysis for three variants (SNPs) instrumented for serum urate as exposure on serum transferrin as an outcome via ‘Inverse-variance 
weighted (IVW)’ (indicated with light blue lines) and ‘MR-Egger’ (indicated with dark blue lines) methods (A) Funnel graph plotted to compare heterogeneity assessed via IVW and 
MR-Egger methods. Values on the x and the y-axis represent effect estimates (ßIV) and reciprocal standard errors (1/SEIV) for the instrument variables (IVs indicated by black dots). 
Less precise estimates (lower values on y-axis) 'funnel' in as they increase in precision, while asymmetry in the funnel plot indicates directional heterogeneity between the estimates 
(B) Scatter plot to compare IVW and Egger-regression MR results: SNP effects (black dots with their 95% CI as vertical grey lines through the dots) on the outcome [transferrin 
(SD) on the y-axis] are plotted against SNP effects (black dots with their 95% CI as horizontal grey lines through the dots) on the exposure [urate (mg dL-1) on the x-axis]. All SNPs 
with negative effects on the exposure are shown to be positive, with the sign of the effect on the outcome flipped. The slope of the line represents the causal association. 
A B 
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Figure 3.14: Forest graphs showing results of MR-analysis for three variants (SNPs) instrumented for serum urate as exposure (and serum ferritin (log) as outcome) with their effect 
sizes on the x-axis and IDs on the y-axis (A) Graph showing results from the Wald ratio, ‘Inverse-variance weighted (IVW)’ and ‘MR-Egger’ methods; black dots indicate Wald ratio 
estimate for each SNP with black horizontal lines across the dots representing 95% confidence intervals (CI) corresponding to each estimate. ‘All-IVW’ red dot at the bottom 
indicates regression estimate from IVW meta-analysis with the red line across the dot representing 95% CI, while the ‘All-Egger’ red dot indicates regression estimate from MR-
Egger sensitivity meta-analysis with the red line across the dot representing the 95% CI (B) Graph showing results from ‘Leave-one-out’ sensitivity analysis; each black dot indicates 
IVW estimate for all instrument SNPs excluding the one indicated on y-axis, while the black horizontal lines across the dots represents the 95% CI corresponding to each estimate. 
The ‘All’ red dot at the bottom indicates estimate from IVW analysis including all SNPs that are the same as ‘All-IVW’ in graph (A) for a comparison. The vertical dashed line in (A) 
and (B) represents effect size = zero (null). 
A B 
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Figure 3.15: Graphs showing results of MR-analysis for three variants (SNPs) instrumented for serum urate as exposure on serum ferritin (log) as an outcome via ‘Inverse-variance 
weighted (IVW)’ (indicated with light blue lines) and ‘MR-Egger’ (indicated with dark blue lines) methods (A) Funnel graph plotted to compare heterogeneity assessed via IVW and 
MR-Egger methods. Values on the x and the y-axis represent effect estimates (ßIV) and reciprocal standard errors (1/SEIV) for the instrument variables (IVs indicated by black dots). 
Less precise estimates (lower values on y-axis) 'funnel' in as they increase in precision, while asymmetry in the funnel plot indicates directional heterogeneity between the estimates 
(B) Scatter plot to compare IVW and Egger-regression MR results: SNP effects (black dots with their 95% CI as vertical grey lines through the dots) on the outcome [Ferritin (log) 
(SD) on the y-axis] are plotted against SNP effects (black dots with their 95% CI as horizontal grey lines through the dots) on the exposure [urate (mg dL-1) on the x-axis]. All SNPs 
with negative effects on the exposure are shown to be positive, with the sign of the effect on the outcome flipped. The slope of the line represents the causal association. 
A B 
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Figure 3.16: Forest graphs showing results of MR-analysis for three variants (SNPs) instrumented for serum urate as exposure (and serum transferrin saturation (TSAT) as 
outcome) with their effect sizes on the x-axis and IDs on the y-axis (A) Graph showing results from the Wald ratio, ‘Inverse-variance weighted (IVW)’ and ‘MR-Egger’ methods; 
black dots indicate Wald ratio estimate for each SNP with black horizontal lines across the dots representing 95% confidence intervals (CI) corresponding to each estimate. ‘All-IVW’ 
red dot at the bottom indicates regression estimate from IVW meta-analysis with the red line across the dot representing 95% CI, while the ‘All-Egger’ red dot indicates regression 
estimate from MR-Egger sensitivity meta-analysis with the red line across the dot representing the 95% CI (B) Graph showing results from ‘Leave-one-out’ sensitivity analysis; each 
black dot indicates IVW estimate for all instrument SNPs excluding the one indicated on y-axis, while the black horizontal lines across the dots represents the 95% CI corresponding 
to each estimate. The ‘All’ red dot at the bottom indicates estimate from IVW analysis including all SNPs that are the same as ‘All-IVW’ in graph (A) for a comparison. The vertical 
dashed line in (A) and (B) represents effect size = zero (null). 
A B 
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Figure 3.17: Graphs showing results of MR-analysis for three variants (SNPs) instrumented for serum urate as exposure on serum transferrin saturation as an outcome via ‘Inverse-
variance weighted (IVW)’ (indicated with light blue lines) and ‘MR-Egger’ (indicated with dark blue lines) methods (A) Funnel graph plotted to compare heterogeneity assessed via 
IVW and MR-Egger methods. Values on the x and the y-axis represent effect estimates (ßIV) and reciprocal standard errors (1/SEIV) for the instrument variables (IVs indicated by 
black dots). Less precise estimates (lower values on y-axis) 'funnel' in as they increase in precision, while asymmetry in the funnel plot indicates directional heterogeneity between the 
estimates (B) Scatter plot to compare IVW and Egger-regression MR results: SNP effects (black dots with their 95% CI as vertical grey lines through the dots) on the outcome 
[transferrin saturation (SD) on the y-axis] are plotted against SNP effects (black dots with their 95% CI as horizontal grey lines through the dots) on the exposure [urate (mg dL-1) on 
the x-axis]. All SNPs with negative effects on the exposure are shown to be positive, with the sign of the effect on the outcome flipped. The slope of the line represents the causal 
association. 
A B 
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SECTION 3.3 DISCUSSION 
 Two-sample single-instrument Mendelian randomisation using GWAS summary-
level data indicated a causal effect of exposure to iron or its biomarkers in increasing 
urate concentration. Combined meta-analyses, using the selective set of iron-related 
instruments, also indicated a causal association of an exposure of iron and ferritin in 
increasing serum urate concentrations. 
3.3.1 Single-instrument MR and pleiotropy 
 Instrumenting iron biomarkers as exposure for urate as outcome in single-
instrument MR via the Wald ratio method showed a significant causal relationship 
between all four iron profile biomarkers (iron, transferrin, ferritin and TSAT) and urate 
using a missense SNP, HFE: rs1800562, as the instrument (Table 3.2). This variant has 
been described as a cis-eQTL for tripartite motif-containing protein 8 (TRIM38), histone 
gene cluster 1 (HIST1H-2AC, 2BD, 4A and 4H) and mostly for lincRNA of unknown 
function (U91328.19 and 22) (www.archive.broadinstitute.org and www.gtexportal.org). 
On the basis of evidence available in the literature, TRIM38 was found to be involved in 
production of E3 ubiquitin-protein, which negatively regulates the immune response via 
toll-like receptors (TLRs) (Zhao et al., 2012), although the protein doesn’t seem to be 
involved in urate metabolism (Jeong et al., 2009). Overexpression of histone cluster 1 
family genes has been reported in human meningioma (Pérez-Magán et al., 2010), while 
no evidence has been found for a direct involvement in any renal function or urate 
metabolism. The variant rs1800562 is present within the HFE gene on chromosome 6 in 
close proximity to known urate loci SLC17A1-3 and therefore its causality may be 
questionable. Although, the variant rs1800562 was shown to have a low LD (r2 < 0.6) 
with only one variant within the SLC17A1 gene in Köttgen et al. (2013) data (Appendix B 
Figure 3.2), the causal signal at rs1800562 in my study was still not considered to be 
ambiguous. 
 In addition, two non-coding variants showed a significant causality of transferrin 
for urate via rs174577 and ferritin for urate via rs651007 (Table 3.2). Since these variants 
are found in intronic regions, no functionality has been described in the literature (to my 
knowledge). The SNP rs174577 is located in the intronic region of the fatty acid 
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desaturase2 (FADS2) gene and has been reported to be co-expressed with multiple loci at 
gene-expression (eQTL: expression quantitative trait loci) platforms 
(www.archive.broadinstitute.org and www.gtexportal.org), while no association with 
urate has been reported for rs174577 so far except Köttgen et al. (2013) that reported a 
positive association between the A allele of rs174577 and serum urate concentration (ß = 
0.018, P = 0.002) in European individuals. However, no pleiotropic effect has been 
reported yet for this variant in the context of iron metabolism. The second SNP, rs651007, 
is located in the non-coding region of the ABO gene and is known to be associated with a 
number of traits including red blood cell count (Van Der Harst et al., 2012). The ABO 
gene encodes the glycosyltransferase responsible for the A-B-O blood groups. This 
variant has been reported to have high coexpression with only two other genes, Surfeit 6 
(SURF6) and Globoside alpha-1,3-N-acetyl-galactossaminyl-transferase (GBGT1) in the 
cis-eQTL database (www.gtexportal.org and www.archive.broadinstitute.org). Based on 
the evidence available in the literature, SURF6 is a member of the family of genes that 
codes for RNA-binding proteins in the nucleolus (Magoulas and Fried, 2000), while 
GBGT1 not only encodes for the ABO-related glycosyltransferase but also participates in 
the biosynthesis of a glycolipid heterophil protein called ‘the Forssman antigen’ (Haslam 
and Baenziger, 1996). These findings are suggestive for ‘no pleiotropy’ between the 
exposure and outcome and provide the evidence of involvement of a change in iron 
homeostasis (as exposure) to be causal for a change in urate metabolism (as outcome) 
only if certain variants are selected as potential IVs in the Mendelian randomisation 
model. 
 Instrumenting urate as exposure for iron (and its biomarkers) as outcome did not 
indicate any urate-iron positive causal relationship for any of the variant (Table 3.5). As 
detailed in Section 3.2.3.2, none of the 3 variants selected as instruments for urate 
exposure suggested a possible pleiotropy with iron metabolism. Leave-one-out sensitivity 
analysis also did not provide any evidence for any of these three variants to be outliers in 
combined meta-analysis (Table 3.7). Therefore, my study does not indicate that an 
increase in urate concentration can increase blood levels of iron or its related biomarkers. 
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3.3.2 Combined multiple-instrument MR 
 The findings from the combined multiple-instrument MR did not show any 
causality in standard IVW MR analyses for iron biomarkers on urate (Table 3.2). 
Although, these results do not support the observational findings presented in Chapter 2, 
they do not oppose them either. A possible explanation that can address these differences 
is the presence of unmeasured confounding factors in the observational results that were 
responsible for overexpression of large significant values. On the other side of the picture, 
there seems to exist a high degree of pleiotropy between iron and urate metabolism that 
makes it difficult to separate these two mechanisms on the basis of available summarised 
GWAS data. For example, rs1799945 has been reported as one of the top iron-related 
SNPs within the HFE gene in European and African American individuals (Benyamin et 
al., 2014; Li et al., 2015). Not only was this variant found to have high co-expression (P 
= 8.5E-06) with SLC17A3 (a known urate-locus), but also was significantly associated 
with urate in Köttgen et al. (2013) data (P = 2.94E-06), and having an LD (r2 < 0.6) with 
variants within SLC17A1, SLC17A2 and SLC17A3 (Appendix B Figure 5.2). This 
pleiotropy made it impossible to include this strong exposure-associated SNP as an IV in 
MR analysis, especially for serum iron and TSAT. As described earlier, the second 
variant within the HFE gene, rs1800562, provided nearly equally significant causal 
signals for all four iron-related traits (Table 3.2). Although, there is no proof available to 
support pleiotropy for rs1800562 with urate and its risk factors, the highly significant MR 
findings still require validation and may be considered less reliable than causal signals 
from rs174577 and rs651007 (Table 3.2). 
 Besides, when a sensitivity analysis was carried out using the leave-one-out 
approach, a significant causal effect of iron and ferritin was observed in increasing urate 
concentration via combined IVW meta-analysis (Table 3.4). For iron, keeping TMPRSS6: 
rs855791 out of the meta-analysis showed a highly significant cause-effect relationship 
between iron and urate (ß = 0.110, P = 1.96E-04), which in turn indicated rs855791 to be 
the variant driving non-significant association in the standard IVW analysis (Table 3.4). 
Excluding another SNP, SLC40A1: rs12693541, out of the meta-analysis also showed 
significant casual association of ferritin exposure in increasing urate concentration (ß = 
0.141, P = 0.027) (Table 3.4). The gene TMPRSS6 (transmembrane protease serine 6) 
encodes a transmembrane enzyme called ‘serine 6’, and is reported to be involved in 
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extracellular matrix remodelling within the liver (www.ncbi.nlm.nih.gov), sensing iron 
deficiency and promoting its absorption via blocking the gene encoding for hepcidin (Du 
et al., 2008). The SNP rs855791 is a missense variant that increases the enzyme 
efficiency for inhibiting hepcidin (Nai et al., 2011) and has been reported to be protective 
against iron deficiency anaemia in aged women (Pei et al., 2014). The SNP rs12693541 is 
a non-coding variant within SLC40A1 (solute carrier family 40 member 1) gene. The 
SLC40A1 gene (also known as ferroportin gene) encodes ‘ferroportin’ protein. As 
described in Chapter 2, ferroportin is so far the only known mammalian iron exporter in 
duodenal and other epithelial cells. Defects in the SLC40A1 gene can cause 
haemochromatosis type 1 and 4 (Altès et al., 2009; Camaschella, 2006) and reduced iron 
export (Moreno‐ Carralero et al., 2014). The SNP rs12693541 has been reported as a cis-
eQTL for two other genes ‘asparagine synthetase domain containing 1 (ASNSD1) and 
ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3). These genes encode for 
proteins involved in the synthesis of aspartate and sphingolipids, respectively (Siow et al., 
2015). Although, excluding the variants within these genes gave significant causal 
associations for iron and ferritin in MR analysis (Table 3.4), the roles of these two genes 
in iron homeostasis cannot be denied. These facts may not only explain how the non-
significant associations in MR analysis were driven by these two variants (rs855791 and 
rs12693541) alone, but are also suggestive of an underpinning unmeasured correlation 
between pathways involved in iron and urate metabolism. In a nutshell, excluding 
rs855791 and rs12693541 from meta-analysis provides evidence for a causal relationship 
between iron exposure and a change in urate concentration (Table 3.4). Considering 
together that urate is a natural chelator for the metal ‘iron’, studies explaining the 
upregulation and increased production of urate following exposure of iron (explained in 
Section 2.1) and causal signals in my study via rs174577 and rs651007 (detailed in 
Section 3.3.1), the presence of a possible iron to urate pathway linking these two 
metabolites cannot be ruled out. An MR analysis from del Greco et al. (2016) explained 
the protective causality between iron and ferritin as exposure and eGFR (estimated 
glomerular filtration rate) as outcome. Given that a decrease in eGFR has been associated 
with an increase in urate concentration (Johnson et al., 2013a; Mohandas and Johnson, 
2008; Suliman et al., 2006), the positive causal association in my study can be compared 
with del Greco et al. (2016) results as the set of genetic loci explaining renal function and 
serum urate concentration have 20% overlap (Köttgen et al., 2013; Pattaro et al., 2016). 
On the basis these findings, a possible role of iron in increasing urate concentration via 
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renal dysfunction can be speculated. However, there is no literature explaining a genetic 
correlation between iron and urate till date. 
3.3.3 Strengths and limitations of the study 
 This study provides the first-ever two-sample MR analysis using summary data 
from large GWAS datasets to investigate a cause-effect relationship between iron and 
urate metabolism. The prime strength of my study is the use of large-sized datasets from 
two GWAS with minimal sample overlap, which provided strength to the MR analysis by 
excluding finite sample study bias and biases created by sample overlap. The removal of 
possible pleiotropy on the basis of an a priori search of literature and gene coexpression 
information available on the bioinformatics platforms (GTEx, HaploReg 4.1, ENCODE) 
and intra-instrument LD made the MR analysis more valid. Another attribute of the study 
is the use of a robust and updated statistical approach available to analyse the summarised 
data in the context of two-sample MR and a posteriori adjustment for horizontal 
pleiotropy in various analyses after detection of intra-instrument heterogeneity. While the 
results presented from various approaches used in the MR model may seem inconsistent, 
it should be considered that each approach has its own limitations and differ in terms of 
how the validity of an instrument and possible pleiotropy is determined in each model. 
Single MR clearly provides causal signals for iron and ferritin, specifically for the top loci 
in the iron GWAS. In this study, the causality of iron and ferritin for a change in urate has 
been described via multiple-instrument analysis for a selected set of instruments using the 
leave-one-out approach. The results from IVW and MR-Egger approaches are considered 
to be robust; however, carrying out a sensitivity analysis may totally end up changing the 
status of causality. A recent study has depicted this post-test to be valid enough to 
describe a causal effect while using summary data in any MR analysis (Burgess et al., 
2017). 
 A possible limitation of the study could be the presence of unmeasured pleiotropic 
confounders that were impossible to remove, especially those other than intra-instrument 
heterogeneity e.g., gene-environment interaction (Smith and Ebrahim, 2003). Also, the 
effect estimates described by single variant or sensitivity analyses were of limited 
magnitude. A possible solution to this limitation is the availability of larger GWAS data 
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encompassing wide ranges of iron biomarkers and urate and carrying out similar MR 
analyses using such datasets. 
3.3.4 Conclusion and future directions 
 In conclusion, this study provides causal association signals for iron-urate 
correlation using single or selective instruments only. This is the first study explaining a 
cause-effect relationship between iron biomarkers and urate using a two-sample MR 
approach while incorporating GWAS summary data. A follow-up of this study using in 
vitro functional model experiments can provide evidence of any intermediate 
pathway/phenotype involved in controlling both iron and urate metabolism 
simultaneously. Several established human/animal cell lines, primary tissues or disease 
model animals (mice, zebrafish) are now available for such in vitro analyses. 
Programmable nucleases can be used to successfully introduce mutations in these cell 
lines followed by determining changes in gene regulatory function(s) and their possible 
effect on other gene expression and functionality. The gene expression study could be an 
appropriate follow-up to MR studies where any change in expression of exposure 
associated genes and their possible effect on the functionality of outcome-associated 
gene/phenotype can be recorded. This would be useful especially since urate is a natural 
chelator of iron and has been proposed to be elevated in response to the metal exposure. 
Such an experimental approach would also be helpful to explain the cause and effect 
relationship between iron and urate elevation on the basis of the ‘which is driving which’ 
principle. The significant causal effects from single variant and leave-one-out sensitivity 
analyses should be replicated in large-sized datasets where individual-level data are 
available. Due to the involvement of iron in increasing oxidative stress and enhancing 
inflammation, similar MR analysis using GWAS data for gout (no such data was 
available to carry out similar MR analysis in my thesis) will be helpful in analysing if 
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SECTION 4.1 URATE, GOUT AND METABOLIC SYNDROME: 
AN INTRODUCTION 
4.1.1 Background 
 Metabolic syndrome (MetS) is a combination of physiological and anthropometric 
anomalies that act as risk factors for the development of cardiovascular disease and 
diabetes (Sookoian and Pirola, 2011; Wilson et al., 2005). The components that constitute 
MetS typically include abdominal obesity, hypertension, dyslipidaemia and insulin 
resistance (Alberti et al., 2005; Grundy et al., 2004). These risk factors are highly 
interrelated and, when clustered together, can increase the risk of developing 
atherosclerosis and type-2 diabetes mellitus (T2DM) by 3 and 5-fold, respectively (AHA, 
2005; Grundy et al., 2005; Sookoian and Pirola, 2011). Metabolic syndrome has also 
been associated with a 1.6-fold increase in the rate of mortality worldwide (Harris, 2013). 
Whilst MetS has classically been categorised as a combination of various 
pathophysiological conditions, several studies have described MetS as a binary factor 
including some GWA studies (Kraja et al., 2011; Kristiansson et al., 2012; Zabaneh and 
Balding, 2010). More recent studies in comparative physiology indicate that the 
syndrome and many of its associated factors can arise simply as a consequence of 
excessive fat storage (Johnson et al., 2013c). Since not all of these factors sufficiently 
explain all cardiovascular events, several other factors have been considered to be 
included in the definition of MetS. These factors broadly include increased inflammatory 
biomarkers, microalbuminuria and coagulation-related anomalies (Fu et al., 2009; Guo et 
al., 2012; Meigs et al., 2000; Ramakrishna and Jailkhani, 2008). In addition, elevated 
urate concentration (Kanbay et al., 2016) and gout (Billiet et al., 2014) have been 
described to be associated with single or multiple components of the syndrome. 
4.1.2 Prevalence of metabolic syndrome 
 The worldwide prevalence of MetS is increasing, specifically in accordance with 
age and increased BMI (Ervin, 2009). Despite the ambiguity in accurately defining the 
term ‘MetS’, a large number of studies (refer to subsequent paragraphs) have been 
undertaken to determine its prevalence in different parts of the world. Subject to attributes 
such as ethnic background, age and gender, the recent worldwide prevalence of MetS 
ranges between 10 to 84% (Kaur, 2014). A population-based study by Pal and Ellis 
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(2010) suggests that MetS affects nearly 20% of adults in the Western world. Table 4.1 
indicates some of the recent studies and their reported MetS prevalence averaged between 
males and females. 
Table 4.1 Prevalence of metabolic syndrome in the different geographical regions 
Region MetS prevalence (%) Reference 
Asia Pacific 11.9 to 37.1 (Ranasinghe et al., 2017) 
South Asia 8.6 to 46.1 (Aryal and Wasti, 2016) 
Europe 11.6 to 26.3 (van Vliet-Ostaptchouk et al., 2014) 
USA (overall) 22.9 to 34.2 
(Beltrán-Sánchez et al., 2013; Mozumdar and 
Liguori, 2011) 
USA (Central) 23.0 to 35.1 (Wong-McClure et al., 2015) 
USA (South) 18.8 to 43.3 (Márquez-Sandoval et al., 2011) 
Africa 12.5 to 62.5 (Okafor, 2012) 
Middle East 13.6 to 36.3 (Sliem et al., 2012) 
MetS: metabolic syndrome, USA: United States of America. 
 A comparative study using data from NHANES III (6,423 US individuals) and 
NHANES 1999-2006 (6,962 US individuals) showed an increase in the prevalence of 
MetS in the US population between the two survey periods (Mozumdar and Liguori, 
2011). The study also reported nearly 68 million adult US individuals (32.4 million males 
and 35.3 million females) as having MetS, with an overall prevalence ranging between 
29.2 to 34.2%. However, another more recent study using data from NHANES 2009-
2010 (> 1,800 US individuals) showed a decrease in MetS prevalence with an average of 
22.9% (Beltrán-Sánchez et al., 2013). A meta-analysis including data of adult South 
American individuals from 12 different studies also revealed the prevalence of MetS to be 
23.2% in men and 25.3% in women (Márquez-Sandoval et al., 2011). A study in the 
Australian population reported 34.4% males and 27.4% females as having MetS, with 
males having greater prevalence than females with a progression of age (Cameron et al., 
2007). Two studies, including data of European individuals from Ireland (Waterhouse et 
al., 2009) and Denmark (Jeppesen et al., 2007), showed an overall prevalence of MetS to 
be 21.4 and 23.4%, respectively. A more recent study combining data from 51 countries 
in the Asia-Pacific region reported an overall prevalence of MetS in between the range of 
11.9 to 37.1% (Ranasinghe et al., 2017). 
 Like other regions, a higher prevalence of MetS, or some of its components, have 
been reported among multicultural populations residing within New Zealand (Simmons 
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and Thompson, 2004). An initial survey in the Auckland region reported an average MetS 
prevalence of 32% for Māori, 39% for Pacific Island and 16% for European individuals 
(Gentles et al., 2007). Moreover, a number of studies showed a higher prevalence of 
MetS components in the New Zealand population, especially in Polynesian individuals. 
Some of the examples also include reports on increased obesity (Ng et al., 2014), insulin 
resistance (IR) (Simmons and Thompson, 2004), diabetes (Chan et al., 2014), 
cardiovascular disease (CVD) (Linhart et al., 2016) and CHD (Winnard et al., 2013). 
Having the highest prevalence of gout in the world (explained in Chapter 1), the New 
Zealand Polynesian population also has a considerably higher rate on occurrence of 
T2DM and CVD as comorbidities of gout (Winnard et al., 2013; Winnard et al., 2012). 
4.1.3 Urate and components of metabolic syndrome 
 While a number of studies have argued that hyperuricaemia is one of the 
components of MetS, the debate of inclusion of increased urate concentrations in the 
definition of the metabolic syndrome is still controversial (Nejatinamini et al., 2015; Wei 
et al., 2015). The simultaneous occurrence of hyperuricaemia and conditions contributing 
to MetS has been excessively observed (Billiet et al., 2014), with a number of 
epidemiological studies confirming the association between the two (Chen et al., 2007; 
Liu et al., 2015; Yamasaki and Tomita, 2008). Although a number of studies have 
suggested hyperuricaemia to be a condition occurring secondary to hyperinsulinaemia 
(Muscelli et al., 1996; Soltani et al., 2013), data suggesting its association with insulin 
resistance, diabetes (Li et al., 2013; Lippi et al., 2008), obesity (Han et al., 2014; Tang et 
al., 2010), cardiovascular disorders, hypertension (Borghi et al., 2014; Nakanishi et al., 
2003) and interlinking complex correlation of all of these conditions (Desai et al., 2010; 
Soltani et al., 2013) are still growing. 
 A recent study by Johnson et al. (2013c) redefined MetS and several of its 
associated conditions as consequences of excessive fat storage. The study also indicated 
that in most mammals and birds, excess fat is not only stored in adipose tissues but also in 
the liver and serum (as triglycerides/TG). This storage, in turn, has been shown to 
correlate with the development of decreased insulin sensitivity and hypertension in the 
form of increased blood pressure (Johnson et al., 2013c). In addition to other biological 
aspects, nucleic acid metabolism plays an important role in controlling the process of fat 
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storage in our bodies. This metabolism regulates fat storage and insulin resistance via the 
stimulation of adenosine monophosphate (AMP) deaminase, fat degradation and reduced 
gluconeogenesis through activation of AMP-activated protein kinase (Cicerchi et al., 
2014; Lanaspa et al., 2012a; Lanaspa et al., 2015). As urate is a key product of AMP 
deaminase (details in Chapter 1), a high likeliness of its major role in promoting fat 
storage have been proposed (Choi et al., 2014; Cicerchi et al., 2014; Lanaspa et al., 
2012a; Lanaspa et al., 2012b). Another recent study by Nejatinamini et al. (2015) 
reported an association of urate with factors involved in developing MetS. The major 
components of MetS included in this study are detailed in the subsequent paragraphs, 
while Figure 4.1 below illustrates the possible link between these components and 
increased urate concentration. 
Figure 4.1: Schematic diagram illustrating the interaction of urate with components of the metabolic syndrome 
(MetS), the risk of developing diabetes and cardiovascular disease. Double-headed dark-blue arrows indicate a 
two-sided interaction between urate and MetS components. The light blue arrows indicate all possible routes 
that could contribute to the development of either cardiovascular disease or diabetes, while the red arrow 
indicates interrelationship of these two anomalies with increased urate. 
4.1.3.1 Urate, insulin resistance and diabetes 
 Without question, insulin resistance (IR) contributes to the development of 
diabetes. The involvement of IR in the epidemiology of MetS was first proposed in 1988 
(Reaven, 1988). The study, for the first time, attributed insensitivity to insulin or IR as a 
major cause of MetS. Determined as being the major factor linking to gout and its 
associated co-morbidities, hyperuricaemia was first described as a contributory factor to 
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diabetes in the late 1800s (Duckworth, 1889). Johnson et al. (2013b) provided a detailed 
review of an overwhelming epidemiological literature explaining the coexistence and role 
of hyperuricaemia in the development of IR and T2DM. A study by Meshkani et al. 
(2011) found a higher prevalence of IR, hyperinsulinaemia, hypertension, dyslipidaemia 
and obesity in subjects with higher urate levels. 
 Historically, hyperuricaemia has been considered as a condition secondary to IR 
(Facchini et al., 1991; Muscelli et al., 1996). However, more recent evidence brings to 
light a plausible causal role of hyperuricaemia in the development of IR (Johnson et al., 
2013b), especially since a decrease in insulin sensitivity is preceded by an increase in 
urate concentration (Krishnan et al., 2012). In fact, a decrease in urate concentration has 
been proposed to increase insulin sensitivity in MetS murine models (Baldwin et al., 
2011). A 15-year follow-up study by Krishnan et al. (2012) investigated an increase in 
baseline urate levels in 5,012 US young adults and found a significant hazard of onset of 
both, diabetes (HR = 1.87) and IR (HR = 1.36). However, no association was reported 
between the elevated baseline urate and plasma insulin concentrations, suggesting urate 
as being a risk factor for the development of IR and, thus, diabetes. A 10-year population-
based follow-up study in the Netherland also reported urate as an independent risk factor 
for diabetes (Dehghan et al., 2008b). In a rat-model experiment, Scott et al. (1981) found 
a 26% decrease in serum insulin and 38% increase in serum glucose 4 weeks following 
inhibition of uricase. A study on sugar-induced diabetes in rats showed that elevated 
levels of urate increased oxidative stress and up-regulated the activity of urate 
transporters in pancreatic islet cells (Roncal-Jimenez et al., 2011). Although not many 
examples are available to explain the effect of reduced urate level on IR in humans, two 
small randomised controlled trials reported a reduction in IR following the administration 
of the urate lowering drugs allopurinol (Facchini et al., 2016) and benzbromarone (Ogino 
et al., 2009). In contrast to these observational studies, findings from the MR studies 
failed to report a causal association between serum urate and risk of T2DM (Keenan et al., 
2016; Pfister et al., 2011; Sluijs et al., 2015). Sluijs et al. (2015) further suggested that 
use of urate lowering therapy may not be beneficial in reducing diabetes risk. These MR 
findings make a possible role of urate levels in increasing the risk of diabetes 
controversial (Johnson et al., 2015). However, as almost all of these MR studies used 
selected variants from urate transport genes (especially SLC2A9) as MR instruments, it 
may point towards the role of these genes in improved kidney functions as described by 
4 | Metabolic Syndrome 
 146 
Hughes et al. (2014). Hughes et al. (2014) found that the individual genetic variants of 
the genetic risk score with the strongest effect on serum urate did not have the strongest 
beneficial effect on renal function and suggested the possibility of pathways distinct from 
serum urate levels to be involved in enhanced renal function. The authors further 
described that an increase in urate levels could possibly influence tubule biochemistry by 
exchanging uric acid for other metabolites and cofactors. For example, two well-known 
urate transporters, SLC2A9 and ABCG2 play a vital role in exchanging hexose sugars for 
uric acid and an adenosine triphosphate-dependent secretion of uric acid, respectively 
(reviewed in Anzai and Endou (2011)). While most of the observational studies showed a 
positive correlation between high urate levels and increased risk of developing diabetes 
and insulin resistance, these detrimental effects have not yet been proved via the role of 
best choice urate transport genes in MR studies. 
4.1.3.2 Urate and obesity 
 Obesity, especially abdominal obesity, is considered as a major manifestation of 
MetS (Després and Lemieux, 2006). Urate has been described as a potential predictor of 
fatty liver (Sirota et al., 2013) and obesity (Masuo et al., 2003). The simultaneous 
occurrence of hyperuricaemia and obesity has been reported to co-exist with other 
components of the syndrome e.g., diabetes and IR (Johnson et al., 2013b). An in vitro 
experiment using cultured liver cells, showed that an increase in urate concentration 
increased triglyceride levels in cells (Lanaspa et al., 2012b). Another in vitro study model 
demonstrated that urate induced fat accumulation in hepatocytes (Choi et al., 2014). 
Further to these, hyperuricaemia was also found to increase the triglyceride levels in 
hepatic cells using animal model (rat) in vitro experiments (Tapia et al., 2013). The fact 
that an increase in hepatic triglyceride levels is a known risk factor for increased 
adiposity irrespective of alcohol consumption (Fabbrini et al., 2010; Jung and Choi, 
2014), abnormally high urate concentrations could, therefore, be directly related to 
inducing this increase. Contrary to these, reports of genetically determined higher urate 
levels being causal for increased triglycerides via the MR studies provide different 
findings, with studies describing elevated serum urate as a consequence rather than a 
cause of an increased BMI, adiposity and/or its risk factors (Lyngdoh et al., 2012; Palmer 
et al., 2013; Rasheed et al., 2014). The possible factor playing a role in contradictory 
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findings between observational and MR studies has been described in the preceding 
paragraph. 
 When it comes to weight gain and adiposity, without a doubt, diet plays a central 
role. Most of the purine-rich foods that increase body concentrations of urate have been 
shown to act as risk factors for the development of MetS or its components (Choi et al., 
2004a). Historically, foods high in fat are also known to increase serum urate levels 
(Ogryzlo, 1965). A fructose-rich diet plays an interlinking role between elevated serum 
urate and increased risk of obesity and other components of MetS (Nakagawa et al., 
2006), especially the amount of fructose in ‘added sugars’ (Johnson et al., 2007). In fact, 
the use of sugar-sweetened beverages has been found to have a link with the epidemic of 
obesity as well as MetS (Basu et al., 2013; Malik et al., 2013; Malik et al., 2010). 
Additionally, several lines of experimental evidence suggest that the primary fructose-
related mechanism involved in increasing urate levels and inducing hyperuricaemia is in 
fact one of the master pathways that can lead to the development of obesity, insulin 
resistance and cardiovascular disorders (collectively called MetS) (Baldwin et al., 2011; 
Lanaspa et al., 2012b; Lanaspa et al., 2012c; Sánchez-Lozada et al., 2008; Tapia et al., 
2013). 
 A number of studies have reported that considerable weight loss can reduce serum 
urate levels in a clinically significant way (Dalbeth et al., 2014). In a dataset of 4,047 
individuals from the Swedish Obese Subjects Study, bariatric surgery was found to 
decrease urate levels by 14% at 2 years and 8% in 10 years in 1,845 and 641 Swedish 
individuals in comparison to their controls (Sjöström et al., 2004). Decreasing urate 
concentrations have also been shown to reduce the fructose sensitised fatty liver 
development in human hepatocytes. In addition, reports on reduction in liver fat 
following a urate-lowering treatment are available in both animal models with 
components of MetS (Lanaspa et al., 2012c) and in those with alcohol-induced fatty liver 
(Kono et al., 2000). 
4.1.3.3 Urate and cardiovascular disease 
 In addition to an association with IR, diabetes and obesity, hyperuricaemia has 
been associated with CVD for decades (Gertler et al., 1951). Since the first suggestion of 
a urate-CVD relationship back in the 19th century (Haig, 1889), a number of studies 
4 | Metabolic Syndrome 
 148 
reported urate to be a risk factor for cardiovascular events (Bos et al., 2006; Moriarity et 
al., 2000; Okura et al., 2009). Albeit the direct independent role of urate in causing heart 
disease in the general population is still controversial (Soltani et al., 2013), many 
examples report its indirect role in occurrence of CVD via IR, hypertension, and renal 
disease or a combination of these conditions (Johnson et al., 1999; Johnson and Tuttle, 
2000). A number of studies have also shown an association of hyperuricaemia with 
surrogate markers of arterial plaque build-up (atherosclerosis) e.g., coronary artery 
calcification (Krishnan et al., 2011), carotid artery thickness (Zhang et al., 2012c) and 
brachial pulse velocity (Ishizaka et al., 2007). 
 In a large study including participants with hypertension and T2DM, a higher 
serum urate concentration (> 7 mg dL-1) was found to be associated with increased 
cardiovascular mortality (Chen et al., 2009b). Another similar study suggested increased 
mortality in patients with coronary syndrome to be associated with a serum urate 
concentration of 7.5 mg dL-1 or higher (Ndrepepa et al., 2012). The occurrence of 
hyperuricaemia in patients with congestive heart failure was also reported to be 
associated with a higher rate of mortality (Kim et al., 2010). A large meta-analysis study 
including data from 15 prospective cohorts suggested a link between high serum urate 
and greater incidence of heart stroke and associated mortality (Li et al., 2014). More 
recent MR studies have reported a causal relationship between the genetically predicted 
serum urate and adverse cardiovascular outcomes including sudden cardiac death (Kleber 
et al., 2015), especially cardiometabolic disease in T2DM patients (Yan et al., 2016). 
Other similar studies, however, were unable to find any causal association of genetically 
determined elevated urate concentration with an increased risk of cardiometabolic 
anomalies including CHD, hypertension, heart failure and/or ischemic stroke (Keenan et 
al., 2016; Palmer et al., 2013). 
 Since the direct causal effect of hyperuricaemia in the context of heart disease is 
still unclear, the possible relationship between them has been a topic of interest for a 
number of clinical randomised trial studies. One such study showed that the 
administration of allopurinol to reduce urate levels improved hypertension and carotid 
intimal thickness in CHD patients with and without renal disease (Higgins et al., 2014). 
Other such examples include studies reporting benefits of urate-lowering therapy in 
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improving arterial stiffness (Grimaldi-Bensouda et al., 2014), angina (Noman et al., 
2010) and ventricular hypertrophy (Kao et al., 2011). 
4.1.4 Gout and components of metabolic syndrome 
 The five components of MetS described above (insulin resistance, T2DM, obesity, 
hypertension and CVD) are well-known comorbidities for gout and have long been 
speculated for a link with gout (Chen et al., 2012; Choi et al., 2005b; Fam, 2002). Given 
that hyperuricaemia is the main risk factor for gout aetiology and MetS being potentially 
associated with urate, it is highly unlikely that MetS would not simultaneously co-exist 
with gout. Gout, being a complex disease, has been reported to be associated with all-
cause mortality in a number of studies. However, most of the studies have reported the 
rate of mortality in gout patients to be higher for two major factors of MetS i.e., 
cardiovascular or renal disease (Choi and Curhan, 2007a; Stamp and Chapman, 2013). 
 A quantitative study by Rho et al. (2005) was the first report that combined the 
prevalence of MetS and gout in the Korean population. Their data showed that gout cases 
were more likely to develop components of MetS (43.6%) in comparison to healthy 
controls (5.2%). The data also found increased BMI and HDL to be the variables most 
significantly associated with the development of MetS in individuals with gout when 
compared to otherwise healthy controls in the same population (Rho et al., 2005). A 
similar study including US population data from NHANES III also reported the 
prevalence of MetS in gout cases to be as high as 62.8% in comparison to the individuals 
without gout (25.4%) (Choi et al., 2007). The study further reported that 3.5 million US 
adults who had ever suffered from gout also simultaneously suffered from metabolic 
conditions included in the definition of MetS. Another more recent example comes from 
the study by Kuo et al. (2014a) that assessed data from more than 75,000 European 
individuals (from the United Kingdom) for gout and its associated comorbidities prior to 
and following the diagnosis. Kuo et al. (2014a) found that participants in the gout cohort 
were more likely to have at least one or more MetS components unlike the participants in 
the non-gout cohort. The gout individuals were also on the higher hazard of developing 
cardiovascular disease, obesity, diabetes and other endocrine disorders within an average 
timeframe of ~3.5 years unlike their ancestrally-matched controls who had an average 
time period of ~9.2 years to develop any of the aforementioned comorbidities (Kuo et al., 
4 | Metabolic Syndrome 
 150 
2014a). Given the higher prevalence of the coexistence of MetS (or its individual 
components) and gout in several populations, the components should be appropriately 
recognised and taken into account while suggesting any long-term treatment to 
individuals with gout. 
4.1.5 Genetics of metabolic syndrome 
 Running a large GWA study in order to identify the genetic components of MetS 
is particularly complicated owing to its complexity at both genetic and clinical levels. 
This is the reason as to why, until now, most of the genetic association studies have been 
done on individual components of MetS or a combination of a few rather than the 
syndrome per se as a binary phenotype (O'Neill and O'Driscoll, 2015). 
  Family and twin studies have provided a large amount of evidence with regard to 
the heritability of MetS. A genetic familial study by Lin et al. (2005) analysed the data of 
803 participants from 89 Hispanic families in Northern Manhattan Family Study (NMFS) 
and reported an overall heritability of 24% for MetS. The heritability for individual 
components of MetS was shown to be 46%, 24%, 47% and 60% for waist circumference, 
higher glucose, TG and HDL cholesterol levels, respectively (Lin et al., 2005). The 
heritability of MetS was reported to be 29.9% when the data of 293 Italian individuals (51 
families) within the Linosa Study were analysed (Bellia et al., 2009). Moreover, the 
results from twin studies showed a concordance in clustering of hypertension, diabetes 
and obesity to be higher (31.6%) in monozygotic twins than dizygotic (6.3%) twins 
(Carmelli et al., 1994). 
 A number of research groups also have performed MetS-related GWAS. The 
classic example comes from an intronic SNP within the fat mass obesity-associated gene 
(FTO) that was found to be associated with T2DM in a UK-based cohort (Frayling et al., 
2007). The study further explained that the FTO gene increases the risk for developing 
T2DM via its effect on BMI (Frayling et al., 2007). Similar results were also reported in 
other populations including individuals of European (Loos et al., 2008; Polašek et al., 
2009; Speliotes et al., 2010; Willer et al., 2009) and Asian decent (Wen et al., 2012). 
These GWA studies also reported some other genes to be associated with increased BMI 
and risk of obesity i.e., genes coding for transmembrane protein 13 (TMEM13), 
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potassium channel tetramerisation domain containing 15 (KCTD15) and melanocortin 
receptor 4 (MC4R). 
 To date, only three GWA studies have reported the data for MetS as a binary trait. 
A genetic association study in an Indian-Asian male population (n = 2,300) reported a 
number of loci to be associated with discrete MetS components, but was unable to find 
any loci associated with MetS as a binary trait (Zabaneh and Balding, 2010). Another 
GWA study conducted in European population of ~22,000 male and female individuals 
reported five SNPs within three loci (LPL: Lipoprotein lipase, APOA5: Apolipoprotein 
A5 and CETP: Cholesteryl ester transfer protein) to be associated with MetS at a genome-
wide threshold (Kraja et al., 2011). This and another study showed a total of 17 loci to be 
associated with either MetS as a whole or a combination of some of its components 
(Kristiansson et al., 2012). 
 While the genetic association data for MetS are limited, a bulk of literature 
presents the GWA results for its individual components reporting dozens of loci, with 
most loci including genes implicated in IR, obesity or lipid metabolism (O'Neill and 
O'Driscoll, 2015). However, the data describing a possible genetic association of 
components of MetS with urate and gout are still scarce. This chapter was structured to 
investigate this substantial gap in the literature by studying selected variants that have 
been reported to be robustly associated with major MetS components and analysing them 
for their association with urate and gout within the NZ Polynesian and European 
populations. While the particular details of each MetS-related genetic variant selected for 
this study from the ADRB3, MC3R, MC4R and ADTRP genes and their possible 
association with urate and gout are provided in the next section (Section 4.2), the specific 
aims of the study were; 
1. To genotype and test the IR and BMI associated variant, ADRB3: rs4994, for its 
association with urate and gout in the European and NZ Polynesian populations. 
2. To genotype and test the obesity and BMI associated variants, MC3R: rs3827103, 
MC4R: rs17700633 and MC4R: rs17782313 for their association with urate and 
gout in the European and NZ Polynesian populations. 
3. To genotype and test the CHD associated variant, ADTRP: rs6903956, for its 
association with urate and gout in the European and NZ Polynesian populations.  
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SECTION 4.2 GENETIC ASSOCIATION OF COMPONENTS 
OF METABOLIC SYNDROME WITH URATE AND GOUT 
4.2.1 Background 
 Hyperuricaemia and gout are closely related to most of the components of MetS, 
especially, dyslipidaemia, obesity, hypertension and glucose intolerance (Choi and Ford, 
2007; Choi et al., 2007). These, and other similar reports (Facchini et al., 1991) has led to 
construction of the basic hypothesis of this chapter. According to this hypothesis ‘if urate 
is associated with the components of MetS in observational studies, the genetic variants 
contributing to these components should also contribute to hyperuricaemia and gout’. 
This section was designed to do genetic association analyses of the selected MetS-related 
variants with serum urate and gout in European and NZ Māori and Pacific Island 
(Polynesian) individuals. Although the basic hypothesis of this study is the same as 
Mendelian randomisation, a different approach (explained in the next section) was used to 
assess the causal association due to the unavailability of genetic association data for 
selected genes/variants for the New Zealand population. 
4.2.2 Methods 
4.2.2.1 Selection of variants 
 Five MetS-related variants (SNPs) were selected based on their association with 
urate and gout in the literature. Table 4.2 provides a list of these variants, while a 
summary of each of these variants is provided in the subsequent paragraphs. 
Table 4.2: List of the MetS-associated variants selected in this study 
Variant (SNP) Chromosome 
Gene/nearest 
gene 
Consequence Gene-related trait 
rs4994 8 ADRB3 Missense BMI, IR 
rs3827103 20 MC3R Missense 
LM, Obesity, Anti-
inflam 
rs17700633 18 MC4R Intergenic BMI, LM, Obesity 
rs17782313 18 MC4R Intergenic 
BMI, LM, T2DM, 
IR, Obesity 
rs6903956 6 ADTRP Intronic CHD 
SNP: Single nucleotide polymorphism, BMI: body mass index, LM: lipid metabolism, Anti-inflam: anti-inflammatory 
response, T2DM: Type 2 diabetes mellitus, CHD: Coronary heart disease. 
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4.2.2.1.1 Insulin resistance & BMI associated variant 
 The first variant that was selected for this study is a missense variant, rs4994, 
within the beta-3 adrenergic receptor gene (ADRB3) on chromosome 8 (Table 4.1). The 
SNP causes a substitution of tryptophan (Trp) to arginine (Arg) at codon 64 (Trp64Arg) 
within the first transmembrane domain of the ADRB3 protein. The ADRB3 gene in 
humans encodes the beta-3 adrenergic receptor or β3 adrenoreceptor protein (Blocker, 
2013). This protein is a part of the adrenergic nervous system, which releases adrenaline 
and/or norepinephrine as neurotransmitters. The adrenergic system acts as one of the 
main neurohormonal regulatory centres to maintain normal smooth muscle tone within 
the heart and overall cardiac action-response. The ADRB3 gene is classically known for 
its role in the regulation of lipid metabolism and glucose homeostasis through its 
expression in adipose tissues (Krief et al., 1993). However, more recently, ADRB3 was 
reported to be abundantly expressed in the acetylcholine-releasing nerve fibres in the 
bladder, which was suggestive of its role in the regulation of metabolic functions in the 
bladder (Coelho et al., 2017). The presence of the Trp64Arg polymorphism has been 
extensively reported for its association with early onset diabetes (Gjesing et al., 2008; 
Nagase et al., 1997), obesity, BMI (Gjesing et al., 2008; Valve et al., 1998), and insulin 
resistance (Allison et al., 1998; De Luis et al., 2009; Widén et al., 1995). In a meta-
analysis of 97 cohorts (n = 44,833 individuals), Kurokawa et al. (2008) found Arg64 to 
be significantly associated with BMI having a stronger effect in East Asian sample sets. 
Consistent reports of association of the Arg64 allele with increased adiposity measures, 
high blood pressure and elevated serum urate was provided in a longitudinal study that 
analysed data of elderly male individuals in Olivetti Prospective Heart Study (OPHS) 
(Strazzullo et al., 2001). 
 The variant rs4994 was selected based on the above hypothesis (reported 
association with urate and gout) and the rationality of the MetS-related evidence in 
previous literature. A combination of increased BMI and the presence of Arg64 was 
reported to be associated with a 4-fold increase in the risk of developing hyperuricaemia 
in a postprandial diabetic group from Chinese population (Wang et al., 2002). Similar 
association of the Arg64 allele and hyperuricaemia were also reported in data sets of 
Korean (Rho et al., 2007) and Chinese (Huang et al., 2013) male individuals. The Arg64 
allele was also indicated to be significantly associated with high risk of hyperuricaemia in 
4 | Metabolic Syndrome 
 154 
a 6-year follow-up study including male and female individuals from Southern Spain 
(Morcillo et al., 2010). In addition to hyperuricaemia, Arg64 (rs4994: G allele) also has 
been reported to be associated with gout susceptibility in Chinese Han population (Wang 
et al., 2011a). 
4.2.2.1.2 Obesity & BMI associated variants 
 Three variants, associated with obesity and BMI, were selected from the genes 
within the melanocortin receptor (MCR) family. The selected variants included a 
missense variant, rs3827103, within the MC3R gene on chromosome 20 and two intronic 
variants, rs17700633 and rs17782313, within the MC4R gene on chromosome 18 (Table 
4.1). 
 The MCR family includes five members of the melanocortin system, expressed in 
the central nervous system (CNS) and several peripheral tissues, each holding distinctive 
specification for different melanocortins (Dores, 2009; Hadley and Dorr, 2006; Voisey et 
al., 2003). The melanocortins are members of a class of naturally occurring peptide 
hormones derived from a larger precursor molecule named pro-opiomelanocortin 
(POMC) (Hadley and Haskell, 1999; Raffin-Sanson et al., 2003). During post-
translational modification, the POMC molecule cleaves to form smaller melanocortins 
that, in turn, act as potential substrates for MCRs. Two melanocortin molecules, 
adrenocorticotropic hormone (ACTH) and melanocyte-stimulating hormones (MSH; α- 
and β-forms), are known to be involved in the regulation of anti-inflammatory response 
and hunger cycle via binding to MC3R and MC4R, respectively. The gene encoding 
MC3R has also been observed to be expressed in a range of peripheral cells including 
placenta, heart, gut, pancreas and macrophages (found within gout inflamed knee joint) 
(Getting et al., 2002). Getting et al. (2002) further explained that ACTH and other 
smaller fragments of α- and β-MSH can inhibit monosodium urate crystal-induced 
neutrophil migration and release of proinflammatory cytokines and chemokines in gouty 
arthritis. Development of severe IR and higher levels of adipose tissue inflammation have 
also been reported in experiments using MC4R and MC3R knockout mice, respectively 
(Trevaskis et al., 2007). 
 The MC3R gene has been classically known for its role in weight regulation, 
energy metabolism, and regulation of the cardiovascular system (Getting et al., 2002; 
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Rediger et al., 2012; Tao and Segaloff, 2004). Polymorphisms in this gene can cause the 
potential loss of receptor function and expression or defective receptor activation (Lee et 
al., 2007; Savastano et al., 2009). The selected SNP, rs3827103, is a missense variant 
within the MC3R gene that causes a substitution of valine (Val) to isoleucine (Ile) at 
codon 81, denoted as Val81Ile. Ile81 allele homozygosity has been reported to be 
associated with an increased risk of obesity and higher IR in children (Feng et al., 2005; 
Savastano et al., 2009). A familial study including data from T2DM patients also showed 
a marginal association between the Ile81 allele and increased IR in adult French 
Caucasians (Hani et al., 2001). More recent studies have also indicated the association of 
the Ile81 allele with significantly higher risk of developing MetS (Suazo et al., 2013). 
Alsmadi et al. (2014) also suggested a possible role of the Ile81 allele in elevated blood 
pressure and thus increased hypertension. 
 The MC4R gene is known for its role in regulating appetite, food intake and its 
associated behaviours and energy metabolism via signalling for α-MSH and agouti-
related peptide (AgRP). Common variants within/near the MC4R gene (including the 
MC4R variants selected for this study) have been associated with increased adiposity, 
reduced insulin sensitivity and higher BMI in GWA studies (Chambers et al., 2008; Loos 
et al., 2008). The variant rs17700633 is located 188 kb and rs17782313 is located 109 kb 
downstream of the MC4R gene. The literature has reported these variants to be involved 
in increasing the risk of obesity and its related phenotypes (explained hereafter). Large 
case-control studies have confirmed the association of the A allele of rs17700633 and the 
C allele of rs17782313 with obesity and increased BMI in several populations (Beckers et 
al., 2011; Srivastava et al., 2014; Zobel et al., 2009). Additionally, the same alleles have 
been reported to be significantly associated with higher intakes of total energy and dietary 
fat (Kring et al., 2010; Qi et al., 2008) and increased risk of diabetes in adults 
(Marcadenti et al., 2013; Mutombo et al., 2014). As both of these variants are located 
within non-coding regions, their direct influence on gene function is unclear. However, 
the presence of these variants is considered to alter the function of the gene as the pattern 
of phenotypic associations provided in the literature for these variants are similar to those 
mediated via altering the function of the MC4R gene (Zobel et al., 2009). 
 Although, the selected variants from the MCR genes have not been reported for 
their direct potential association with urate or gout, higher adiposity, weight gain and 
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diabetes are still strong risk factors/common comorbidities for gout (detailed in Chapter 
1). The pieces of evidence described above are supportive for strong role of MC4R and 
MC3R polymorphisms in the onset of obesity, decreased inflammatory response and 
increased insulin resistance. These facts, if incorporated into the hypothesis of this study, 
support the idea of a possible role of MetS-related variants in the aetiology of gout. 
4.2.2.1.3 Coronary heart disease associated variant 
 A CHD-associated variant, rs6903956, was also selected for this study. The SNP 
rs6903956 is an intronic variant located on chromosome 6, at position 24.1, within the 
ADTRP gene encoding the androgen-dependent tissue factor pathway inhibitor (TFPI) 
regulating protein (ADTRP). The ADTRP: rs6903956 variant is a comparatively nascent 
locus known to be associated with increased CHD susceptibility at GWAS level (Nikpay 
et al., 2015; Wang et al., 2011c). The ADTRP protein functions to up-regulate TFPI 
expression and maintain the anticoagulant protection of the endothelium to avoid 
endothelial dysfunction in response to androgen stimulus (Lupu et al., 2011). More 
recently, ADTRP gene expression has been shown to regulate the expression of other 
genes involved in the sustenance of cell cycle progression via proliferation and apoptosis 
(Luo et al., 2016). A study in the Han Chinese population reported that the A allele of 
rs6903956 can increase the risk of developing asymptomatic hyperuricaemia (aHU) in 
adults (Meng et al., 2015). 
4.2.2.2 Study participants 
 Four different data sets were used to assess the association of selected variants 
with gout. The first dataset was a sub-set of the New Zealand Gout Cohort (Section 1.2), 
including 1,872 European and 2,464 Polynesian case-control individuals from New 
Zealand. The NZ Gout Cohort was stratified into four ancestral groups as detailed in 
Section 1.2.1: NZ European (NZ EUR; 910 cases and 962 controls), Eastern Polynesian 
(EP; 510 cases and 698 controls), Western Polynesian (WP; 365 cases and 320 controls) 
and mixed Eastern and Western Polynesian (EPWP; 33 cases and 76 controls). The Māori 
dataset from NPH consisted of 270 gout cases and 192 controls. Data for the EP group 
were separately analysed in EPN (334 cases and 392 controls) and EPZ (157 cases and 
311 controls) sub-groups (details provided in Section 1.2.1). Two additional datasets of 
European gout case individuals were selected from the European Crystal Network Cohort 
4 | Metabolic Syndrome 
 157 
(EUROGOUT; n = 818) and the Arthritis Genomics Recruitment Initiative in Australia 
Cohort (AGRIA; n = 198) (details in Section 1.2). The gout cases from EUROGOUT and 
AGRIA Cohorts were combined with the NZ European dataset to increase the power of 
the study, hereafter referred to as ‘EUR (Combined European)’ dataset. The fourth 
dataset for gout association analysis was selected from the UK Biobank Gout Cohort 
(please refer to details in Section 1.2). This dataset included 2,432 gout cases and 102,989 
controls. Table 4.3 represents a summary of demographic details for these datasets. 
 Data for non-gout (control) individuals were sourced from four publicly-available 
datasets (detailed in Section 1.2.6 through 1.2.9). The information for individuals in these 
cohorts was only used for serum urate association analyses. The data were sourced for a 
total of 5,367 individuals in ARIC, 5,109 in FHS (Offspring and Generation 3), 1,432 in 
CARDIA and 2,421 individuals in CHS Cohort. Table 4.4 provides demographic and 
clinical details of these datasets. Analyses for serum urate association were also 
performed in NZ European and Polynesian non-gout individuals. For this purpose, any 
individuals who self-reported as taking diuretic medication or were on any other urate 
lowering therapy (ULT), had renal failure, gout or had first-degree relatives with gout 
were excluded from the various analyses. 
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Table 4.3: Demographic details of the datasets included in the study for serum urate (non-gout individuals only) and gout association 
analyses 
Population NZ Polynesian  European 
Sub-population EP WP EPWP 
 


















Gout Non-gout Gout Gout 
Baseline Information 
Total Participants 510 698 365 320 33 76 270 192  910 962 2432 102989 818 198 
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- - - 33.45 (77.61) 
43.13 
(76.11) 
NZ; New Zealand, EP; East Polynesian, WP; West Polynesian, EPWP; Mixture of East and West Polynesian, NPH; Māori cohort from Ngati Porou Hauora, NZ EUR; NZ European, UK; United 
Kingdom, EUROGOUT; European Crystal Network Gout Cohort, AGRIA; Arthritis Genomics Recruitment Initiative in Australia Gout Cohort, BMI; Body mass index, n (%); total number 
(percentage). ^Data are shown as mean ± standard deviation. †Data are shown as percentage reported with comorbidities (total percentage who answered the question of having comorbidities as 
‘yes’ or ‘no’), Data for the comorbidities are self-reported. Data presented as an average for five MetS-related variants genotyped through TaqMan PCR. The genotype success rate was 99.37% 
for rs4994, 98.99% for rs3827103, 98.89% for rs17700633, 98.93% for rs17782313 and 99.01% for rs6903956. 
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Table 4.4: Demographic details of publicly-available datasets used only for serum urate analysis in non-gout individuals 
Population ARIC FHS CARDIA CHS 
Baseline Information 
Total Participants 5367 5109 1432 2421 
Male, n (%) 2459 (45.81) 2360 (46.19) 671 (46.85) 987 (40.76) 
Age (years)^ 53.48 ± 5.58 36.99 ± 9.41 25.54 ± 3.33 72.13 ± 5.35 
BMI (kg/m2)^ 25.98 ± 4.32 25.81 ± 4.91 23.65 ± 3.94 25.87 ± 4.18 
Serum Urate (mmol L-1)^ 0.33 ± 0.07 0.30 ± 0.08 0.31 ± 0.07 0.31 ± 0.07 
Comorbidities 
Type II Diabetes† 2.92 (99.96) 0.72 (94.78) 0.49 (99.44) 6.21(99.71) 
Dyslipidaemia† - - 2.73 (97.28) - 
Heart problems† 1.76 (99.96) 0.48 (66.14) 5.83 (99.25) 7.98 (98.31) 
Hypertension† 6.12 (99.49) 0.99 (93.87) 7.41 (99.19) 17.71 (99.09) 
Kidney problems† - - 3.09 (100) 0 (99.46) 
ARIC; Atherosclerosis Risk in Community Study Cohort, FHS; Framingham Heart Study Cohort (Offspring and Generation 3), CARDIA; Coronary Artery Risk Development in (Young) 
Adults Study Cohort, CHS; Cardiovascular Health Study Cohort, BMI; Body mass index, n (%); total number (percentage). ^Data are shown as mean ± standard deviation. †Data are shown as 
percentage reported with comorbidities (total percentage who answered the question of having comorbidities as ‘yes’ or ‘no’), Data for the comorbidities are self-reported. 
4 | Metabolic Syndrome 
 160 
4.2.2.3 Genotyping 
 All five variants, rs4994, rs3827103, rs17700633, rs17782313 and rs6903956 
were genotyped over all European (NZ European, EUROGOUT and AGRIA) and NZ 
Polynesian serum samples. Genotyping was performed by an allelic discrimination assay 
i.e., TaqMan® SNP Genotyping assay (C_2215549_20; Applied Biosystems, Foster City, 
USA) following the instruction provided in the manufacturer’s protocol. The TaqMan 
SNP genotyping were auto-called via reporter dye signal plots on Lightcycler® 480 Real-
Time Polymerase Chain Reaction (RT-PCR) System (Roche Applied Science, 
Indianapolis, IN, USA). The details about the sources for genotype data for UK Biobank, 
ARIC, FHS, CARDIA and CHS cohorts are already described in Section 1.2. 
4.2.2.3.1 Genotype data imputation 
 Publicly-available European data sets used for serum urate analyses were missing 
the genotype data for a number of variants. In such groups, genotype data were imputed 
using 1000 Genomes haplotype data [phase 1; 2013, NCBI (National Center for 
Biotechnology Information) build 37] as a reference panel for all populations. A platform 
‘IMPUTE2’ was used for the purpose of imputation as described by Howie and Marchini 
(2011). Table 4.4 below provides the details of variants and populations for which the 
genotype data were imputed. 
Table 4.5: Details of variants and study cohorts for which the genotype data were 
imputed 
Variant Study Cohort Reference panel 
Imputation 
platform 
rs4994 ARIC, FHS, CHS, CARDIA 
1000 Genomes haplotype data 
(phase 1; 2013) 
IMPUTE2 
rs3827103 - 
1000 Genomes haplotype data 
(phase 1; 2013) 
IMPUTE2 
rs17700633 CHS 
1000 Genomes haplotype data 
(phase 1; 2013) 
IMPUTE2 
rs17782313 CHS 
1000 Genomes haplotype data 
(phase 1; 2013) 
IMPUTE2 
rs6903956 CHS 
1000 Genomes haplotype data 
(phase 1; 2013) 
IMPUTE2 
ARIC; Atherosclerosis Risk in Community Study Cohort, FHS; Framingham Heart Study Cohort (Offspring and 
Generation 3), CARDIA; Coronary Artery Risk Development in (Young) Adults Study Cohort, CHS; Cardiovascular 
Health Study Cohort. 
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4.2.2.4 Statistical analysis 
 A multiply-adjusted regression analysis approach was used to measure the 
association of the five MetS-related variants (explanatory variables) with gout (binary 
response variables) and serum urate (continuous response variable). All logistic and linear 
regression analyses were done using statistical software R version 3.3.2 (RCore, 2016). 
Any participant with missing data for any variable was excluded from the various 
analyses. Allelic ORs and β-estimates were calculated for each variant including age, sex 
and BMI as primary adjustors in the regression model. For Polynesian individuals, self-
reported grandparental ancestry was included as an additional adjustor in the various 
analyses. To increase the power of analysis, all NZ Polynesian subgroups were combined 
separately and with the European data sets in meta-analysis using the Meta package 
within R (http://CRAN.R-project.org/package=meta, 2014) using a fixed-effect model. 
For a meta-analysis showing heterogeneity (PHet < 0.05), the fixed-effect model was 
replaced with a random-effect model. A P ≤ 0.05 was used to indicate the threshold for 
nominal statistical significance between response and explanatory variables in regression 
and meta models. 
 Linkage disequilibrium was calculated between two MC4R variants using the 
information from 1000 Genome database (http://browser.1000genomes.org/) for both 
European and Chinese datasets. Haploview v4.2 was used to generate LD plots where r2 
≥ 60 was set as the threshold for significant LD. Power to detect a POR < 0.05 was 
calculated in the NZ Polynesian, European and UK Biobank data sets following Johnson 
et al. (2001) methodology. Additionally, power to detect an effect size (ß) of 0.02 was 
calculated for non-gout datasets using the methodology described by Cohen (1988) and 
Selya et al. (2012). 
4.2.3 Results 
 The two selected variants from the MC4R gene, rs17700633 and rs17782313, 
were not in LD with each other, both in the European and Chinese sample sets in the 
1000 Genomes database (Figure 4.2). 
 








Figure 4.2: Linkage disequilibrium (LD) plot indicating ‘R-squared/r2’ values between the 2 MC4R variants in 
(A) European and (B) Chinese populations. An r2 ≥ 60 in the above plot indicates LD between the particular 
variants. Information for variant location, rs ID and LD values are from 1000 Genome database 
(http://browser.1000genomes.org/). The plots were generated using Haploview v4.2. 
 Both NZ Polynesian and combined European data sets were highly powered (> 
90%) to detect a moderate effect (OR = 1.5) at an altered allele frequency > 0.1 (Figure 
4.3). The UK Biobank data set was highly powered (100%) to detect a weaker effect (OR 
= 1.2) at an altered allele frequency > 0.1 (Figure 4.4). 
 All non-gout European sample sets used for serum urate association analysis were 
adequately powered (> 80%) to detect an effect size (ß) of > 0.02 (Figure 4.5). 
Figure 4.3: Association detection power in New Zealand European (A) and Polynesian (B) sample sets across a 
range of odds ratio (effect sizes) and altered allele frequencies. The broken red line indicates an adequate 
detection power ≥ 80%. 
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Figure 4.4: Association detection power in the UK Biobank dataset across a range of odds ratio (effect sizes) and 









Figure 4.5: Detection power in the European datasets used for serum urate association analyses across a range of 
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4.2.3.1 Association analysis results for the ADRB3 variant 
 The G allele (Arg64 allele) of rs4994 was significantly associated with reduced 
risk of gout in the UK Biobank data (OR = 0.88, P = 0.04) after including age, sex and 
BMI as potential confounders. For the NZ Polynesian datasets, similar association was 
observed only in the WP sample set (OR = 0.62, PUnadjusted = 0.04). However, the 
association became insignificant when adjusted for potential confounders (OR = 0.61, P = 
0.08) (Table 4.6). The G allele did not show any association with gout in any other 
Polynesian and European data set (Table 4.6). The protective effect of the G allele was 
still observed in WP sample set when adjusted for T2DM (OR = 0.57, P = 0.05), 
hypertension (OR = 0.56, P = 0.05) and renal dysfunction (OR = 0.53, P = 0.03) (Table 
4.7). Including renal dysfunction as a potential adjustor also showed that the addition of 
each G allele was significantly associated with increasing susceptibility to gout by 86% in 
the EPZ data set (OR = 1.86, P = 0.05) (Table 4.7). In order to increase the power of 
analysis, all European and NZ Polynesian case-control groups were combined together 
and separately with the UK Biobank group. No significant association of the G allele of 
rs4994 with gout was observed for the combined NZ Polynesian data set (OR = 0.98, P = 
0.88, PHet = 0.10) (Table 4.9, Appendix B Figure 4.1). However, on combining the 
European and UK Biobank data sets together, the G allele showed a significant protective 
association with gout (OR = 0.89, P = 0.03, PHet = 0.22) (Table 4.9, Appendix B Figure 
4.1). The protective association was sustained when all Polynesian and European data 
sets were combined together in single meta-analysis (OR = 0.91, P = 0.04, PHet = 0.14) 
(Table 4.9, Appendix B Figure 4.1). 
 When tested for an association with serum urate in non-gout sample sets, the 
Arg64 (G) allele of rs4994 showed a strong positive association with serum urate only in 
WP individuals (β (mmol L-1) = 0.036, P = 0.004) (Table 4.8). The G allele did not show 
any association with serum urate in any other sample set (Table 4.8). Combining all NZ 
Polynesian data sets together by a meta-analysis did not show any association of the G 
allele of rs4994 with urate (β (mmol L-1) = 0.008, P = 0.16, PHet = 0.08) (Table 4.9, 
Appendix B Figure 4.2). Also, no association of the G allele of rs4994 with urate was 
found when all European sample sets were combined together (β (mmol L-1) = 0.0003, P 
= 0.84, PHet = 0.62) (Table 4.9, Appendix B Figure 4.2) and with Polynesian sample sets 
(β (mmol L-1) = 0.0007, P = 0.61, PHet = 0.19) (Table 4.9, Appendix B Figure 4.2). 
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4.2.3.2 Association analysis results for the MC3/4R variants 
4.2.3.2.1 MC3R: rs3827103 
 The A allele (Ile81 allele) of rs3827103 was significantly associated with a 
decreased risk of gout in the EPWP data set (OR = 0.43, PUnadjusted = 0.02) (Table 4.6). 
However, including age, sex, BMI and grand-parental ancestry estimates as potential 
adjustors weakened the association (OR = 0.44, P = 0.07) (Table 4.6). A similar but 
weaker trend of protective association between the Ile81 allele and gout risk was 
observed in the EPZ data set (OR = 0.64, P = 0.06) in multiply-adjusted regression (Table 
4.6). No such association was observed in any other NZ Polynesian and/or European data 
sets (Table 4.6). Including various comorbidities in the analyses showed a nominal 
protective association between the A allele of rs3827103 and gout in the EPZ, EPWP and 
EUR sample sets when adjusted for hypertension (OR = 0.60, P = 0.05), renal 
dysfunction (OR = 0.41, P = 0.05) and dyslipidaemia (OR = 0.75, P = 0.05), respectively 
(Table 4.7). The NZ Polynesian sample showed a trend towards protective association of 
the Ile81 allele with gout when combined in meta-analysis (OR = 0.85, P = 0.07, PHet = 
0.22) (Table 4.9, Appendix B Figure 4.3). Increasing the sample size in meta-analysis 
(combining all NZ Polynesian and European datasets) indicated a positive, yet no 
difference in effect size, association between the A allele and gout (OR = 0.92, P = 0.03, 
PHet = 0.27) (Table 4.9, Appendix B Figure 4.3) in comparison to when all European 
samples were combined together (OR = 0.92, P = 0.14, PHet = 0.27) (Table 4.9, Appendix 
B Figure 4.3). 
 Linear regression analysis was performed to test for association of the Ile81 allele 
of rs3827103 with urate in non-gout data sets. A weak trend of both negative and positive 
association of the A allele with urate was observed in the EPN (β (mmol L-1) = -0.01, P = 
0.06) and EPZ (β (mmol L-1) = 0.02, P = 0.06) sample sets, which did not retain after 
adjustment for potential confounders (EPN: β (mmol L-1) = -0.001, P = 0.10; EPZ: (β 
(mmol L-1) = 0.004, P = 0.66) (Table 4.8). Meta-analysing NZ Polynesian ( (mmol L-1) 
= -0.001, P = 0.88, PHet = 0.25) (Table 4.9, Appendix B Figure 4.4) and European ( 
(mmol L-1) = 0.0001, P = 0.95, PHet = 0.62) (Table 4.9, Appendix B Figure 4.4) 
populations separately and together ( (mmol L-1) = 0.0001, P = 0.99, PHet = 0.53) also 
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did not show any association of the A allele with serum urate (Table 4.9, Appendix B 
Figure 4.4). 
4.2.3.2.2 MC4R: rs17700633 
 The A allele of rs17700633 did not show any association with gout in any of the 
Polynesian and European data sets (Table 4.6). There was only a weak trend of protective 
association of the A allele with gout in the WP sample set in adjusted analysis (OR = 0.19, 
P = 0.08) (Table 4.6). The association followed a similar pattern when adjusted for 
comorbid conditions, T2DM (OR = 0.73, P = 0.06) and renal dysfunction (OR = 0.76, P 
= 0.09) (Table 4.7). Combining the Polynesian and European study groups together (OR 
= 1.03, P = 0.31, PHet = 0.48) (Table 4.9, Appendix B Figure 4.5) and separately 
(Polynesian: OR = 0.97, P = 0.76, PHet = 0.29; European: OR = 1.03, P = 0.24, PHet = 
0.76) (Table 4.9, Appendix B Figure 4.5) in meta-analyses did not show any association 
of the A allele with gout (Table 4.9). 
 No association of the A allele of rs17700633 with serum urate was found in both 
unadjusted and adjusted regression analyses in any of the study groups (Table 4.8). 
However, combining the Polynesian and European data sets together in meta-analysis 
indicated a positive but weak association of the A allele with serum urate ( (mmol L-1) = 
0.001, P = 0.07, PHet = 0.96) (Table 4.9, Appendix B Figure 4.6). No such trend was 
observed when the Polynesian ( (mmol L-1) = 0.005, P = 0.18, PHet = 0.97) and 
European ( (mmol L-1) = 0.001, P = 0.12, PHet = 0.79) data sets were combined 
separately (Table 4.9, Appendix B Figure 4.6). 
4.2.3.2.3 MC4R: rs17782313 
 The C allele of rs17782313 was significantly associated with an increased risk of 
gout in the EPZ sample set (OR = 1.51, PUnadjusted = 0.03). The association was, however, 
not significant when potential confounders were added as adjustors in the analysis (OR = 
1.56, P = 0.11) (Table 4.6). In the EUR group, each additional C allele was found to be 
associated with a 23% increase in gout risk (OR = 1.23, P = 0.02) (Table 4.6). No such 
association was observed for any other population group (Table 4.6). The association 
followed a consistent, but stronger, pattern after including renal dysfunction as an 
adjustor in the analysis (OR = 1.23, P = 0.01) (Table 4.7). Combining European datasets 
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in meta-analysis showed a 7% increase in the risk of developing gout with each additional 
C allele (OR = 1.07, P = 0.02, PHet = 0.11) (Table 4.9, Appendix B Figure 4.7). The 
association retained a similar pattern in Polynesian and European combined meta-analysis 
(OR = 1.06, P = 0.03, PHet = 0.23) that was not observed when only Polynesian data sets 
were combined (OR = 0.96, P = 0.77, PHet = 0.23) (Table 4.9, Appendix B Figure 4.7). 
 The C allele of rs17782313 was found to be positively associated with serum 
urate concentrations in non-gout individuals from the FHS data set (β (mmol L-1) = 0.004, 
P = 0.01) (Table 4.8). A strong association of the C allele was also observed in the CHS 
data set (β (mmol L-1) = 0.006, PUnadjusted = 0.008), which became weaker when adjusted 
for covariates (β (mmol L-1) = 0.004, P = 0.07) (Table 4.8). Meta-analysis indicated a 
positive association of the C allele of rs17782313 with serum urate in non-gout European 
individuals ( (mmol L-1) = 0.002, P = 0.007, PHet = 0.47) (Table 4.9, Appendix B Figure 
4.8). No such association was observed in the combined Polynesian data set ( (mmol L-
1) = 0.004, P = 0.52, PHet = 0.57) (Table 4.9, Appendix B Figure 4.8). However, when the 
Polynesian and European data sets were combined together, the C allele showed a 
positive association with serum urate ( (mmol L-1) = 0.002, P = 0.006, PHet = 0.69) 
(Table 4.9, Appendix B Figure 4.8). 
4.2.3.3 Association analysis results for the ADTRP variant 
 No association was observed with the A allele of rs6903956 and gout in any of the 
NZ Polynesian or European data sets (Table 4.6). The association remained insignificant 
even after including comorbidities, T2DM, hypertension, renal dysfunction and 
dyslipidaemia as potential confounders (Table 4.7). Moreover, the A allele was not 
associated with gout when Polynesian and European data sets were combined together 
(OR = 0.99, P = 0.71, PHet = 0.74) and separately (Polynesian: OR = 1.02, P = 0.83, PHet 
= 0.49; European: OR = 0.98, P = 0.66, PHet = 0.95) in meta-analyses (Table 4.9, 
Appendix B Figure 4.9). 
 The A allele was found to be negatively associated with serum urate in the NPH 
data set (β (mmol L-1) = -0.035, P = 0.004) (Table 4.8). However, the same allele 
indicated a positive association with serum urate concentrations in the ARIC European 
data set (β (mmol L-1) = 0.002, P = 0.05) (Table 4.8). Combining all NZ Polynesian data 
sets together in a meta-analysis showed significant negative association of the A allele 
4 | Metabolic Syndrome 
 168 
with serum urate ( (mmol L-1) = -0.011, P = 0.02, PHet = 0.08) (Table 4.9, Appendix B 
Figure 4.10). No such association was observed when all European datasets were 
combined ( (mmol L-1) = 0.001, P = 0.11, PHet = 0.61) and when European and 
Polynesian data sets were combined together in meta-analyses ( (mmol L-1) = 0.001, P = 
0.22, PHet = 0.05) (Table 4.9, Appendix B Figure 4.10). 
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Table 4.6: Genotype/allele frequencies and association analysis of MetS-related variants with gout 
Population Group Genotype/Altered Allele Frequency 
Unadjusted Adjusted* HWE 




AA AG GG G 
     
EPN 
Case 266 (0.796) 66 (0.197) 2 (0.006) 70 (0.10) 
0.89 [0.64 ; 1.25] 0.53 1.08 [0.69 ; 1.68] 0.72 
0.33 
Control 306 (0.780) 82 (0.209) 4 (0.011) 90 (0.114) 0.56 
EPZ 
Case 122 (0.777) 33 (0.210) 2 (0.012) 37 (0.117) 
1.49 [0.95 ; 2.35] 0.07 1.66 [0.91 ; 3.08] 0.09 
0.89 
Control 262 (0.842) 47 (0.151) 2 (0.006) 51 (0.081) 0.94 
WP 
Case 336 (0.915) 31 (0.084) 0 (0.000) 31 (0.042) 
0.62 [0.38 ; 0.99] 0.04 0.61 [0.34 ; 1.06] 0.08 
0.39 
Control 272 (0.877) 34 (0.109) 4 (0.012) 42 (0.067) 0.02 
EPWP 
Case 27 (0.931) 2 (0.069) 0 (0.000) 2 (0.034) 
0.31 [0.04 ; 1.21] 0.13 0.31 [0.04 ; 1.44] 0.17 
0.84 
Control 57 (0.814) 13 (0.185) 0 (0.000) 13 (0.092) 0.39 
NPH 
Case 213 (0.803) 52 (0.196) 0 (0.000) 52 (0.098) 
1.07 [0.66 ; 1.73] 0.77 0.95 [0.47 ; 1.90] 0.89 
0.07 
Control 160 (0.833) 28 (0.144) 4 (0.020) 36 (0.093) 0.05 
EUR 
Case 1397 (0.838) 262 (0.157) 7 (0.004) 276 (0.083) 
1.00 [0.76 ; 1.30] 0.99 1.11 [0.77 ; 1.61] 0.57 
0.15 
Control 801 (0.834) 151 (0.157) 4 (0.004) 159 (0.083) 0.27 
UK Biobank 
Case 2099 (0.863) 321 (0.132) 12 (0.004) 345 (0.071) 
0.85 [0.78 ; 0.97] 0.02 0.88 [0.79 ; 0.99] 0.04 
0.94 
Control 87102 (0.845) 15252 (0.148) 635 (0.006) 16522 (0.080) 0.24 
MC3R: rs3827103 
 
GG AG AA A 
     
EPN 
Case 128 (0.389) 147 (0.446) 54 (0.164) 255 (0.387) 
0.95 [0.77 ; 1.18] 0.69 1.04 [0.78 ; 1.38] 0.77 
0.28 
Control 133 (0.341) 204 (0.523) 53 (0.135) 310 (0.397) 0.06 
EPZ 
Case 88 (0.560) 61 (0.388) 8 (0.051) 77 (0.245) 
1.05 [0.76 ; 1.45] 0.73 0.64 [0.39 ; 1.02] 0.06 
0.53 
Control 179 (0.581) 113 (0.366) 16 (0.051) 145 (0.235) 0.73 
WP 
Case 239 (0.654) 108 (0.295) 18 (0.049) 144 (0.197) 
0.97 [0.74 ; 1.26] 0.82 0.79 [0.57 ; 1.09] 0.15 
0.21 
Control 203 (0.636) 103 (0.322) 13 (0.041) 129 (0.202) 0.98 
EPWP 
Case 20 (0.606) 13 (0.393) 0  (0.000) 13 (0.196) 
0.43 [0.21 ; 0.88] 0.02 0.44 [0.17 ; 1.04] 0.07 
0.15 
Control 32 (0.421) 36 (0.473) 8 (0.105) 52 (0.342) 0.64 
NPH Case 84 (0.381) 104 (0.472) 32 (0.145) 168 (0.381) 0.90 [0.67 ; 1.21] 0.49 0.91 [0.61 ; 1.39] 0.68 0.98 
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Control 58 (0.308) 108 (0.574) 22 (0.117) 152 (0.404) 0.01 
EUR 
Case 1427 (0.857) 229 (0.137) 9 (0.005) 247 (0.074) 
0.89 [0.72 ; 1.09] 0.27 0.81 [0.61 ; 1.06] 0.12 
0.95 
Control 812 (0.844) 141 (0.146) 9 (0.009) 159 (0.082) 0.31 
UK Biobank 
Case 2057 (0.845) 366 (0.150) 9 (0.004) 384 (0.078) 
0.94 [0.85 ; 1.05] 0.34 0.96 [0.86 ; 1.06] 0.46 
0.08 
Control 86619 (0.841) 15689 (0.152) 681 (0.006) 17051 (0.082) 0.31 
MC4R: rs17700633 
  
GG AG AA A 
     
EPN 
Case 128 (0.455) 125 (0.444) 28 (0.099) 181 (0.322) 
1.14 [0.89 ; 1.45] 0.28 1.14 [0.85 ; 1.54] 0.36 
0.75 
Control 188 (0.484) 171 (0.441) 29 (0.074) 229 (0.295) 0.24 
EPZ 
Case 67 (0.527) 50 (0.393) 10 (0.078) 70 (0.275) 
1.10 [0.79 ; 1.52] 0.56 1.21 [0.78 ; 1.91] 0.38 
0.87 
Control 169 (0.555) 114 (0.375) 21 (0.069) 156 (0.256) 0.76 
WP 
Case 246 (0.677) 102 (0.281) 15 (0.041) 132 (0.181) 
0.84 [0.65 ; 1.09] 0.19 0.75 [0.55 ; 1.03] 0.08 
0.28 
Control 205 (0.641) 95 (0.296) 20 (0.062) 135 (0.211) 0.05 
EPWP 
Case 19 (0.575) 14 (0.424) 0  (0.000) 14 (0.212) 
0.68 [0.34 ; 1.29] 0.26 0.77 [0.35 ; 1.64] 0.52 
0.12 
Control 42 (0.552) 24 (0.315) 10 (0.131) 44 (0.289) 0.04 
NPH 
Case 114 (0.518) 94 (0.427) 12 (0.545) 118 (0.268) 
0.91 [0.66 ; 1.26] 0.6 0.95 [0.61 ; 1.51] 0.84 
0.18 
Control 92 (0.473) 81 (0.437) 12 (0.064) 105 (0.283) 0.29 
EUR 
Case 770 (0.464) 726 (0.437) 162 (0.097) 1050 (0.316) 
1.07 [0.95 ; 1.21] 0.23 1.01 [0.85 ; 1.19] 0.91 
0.63 
Control 475 (0.494) 394 (0.410) 92 (0.095) 578 (0.300) 0.43 
UK Biobank 
Case 1150 (0.482) 1016 (0.426) 217 (0.091) 1450 (0.304) 
1.03 [0.97 ; 1.11] 0.23 1.04 [0.97 ; 1.11] 0.27 
0.72 
Control 49892 (0.495) 42032 (0.417) 8829 (0.087) 59690 (0.296) 0.86 
MC4R: rs17782313 
  
TT CT CC C 
     
EPN 
Case 241 (0.899) 21 (0.078) 6 (0.022) 33 (0.061) 
1.11 [0.71 ; 1.71] 0.65 1.12 [0.64 ; 1.96] 0.68 
1.40E-07 
Control 347 (0.892) 41 (0.105) 1 (0.002) 43 (0.055) 0.85 
EPZ 
Case 78 (0.634) 40 (0.325) 5 (0.040) 50 (0.203) 
1.51 [1.02 ; 2.22] 0.03 1.56 [0.91 ; 2.76] 0.11 
0.96 
Control 222 (0.730) 76 (0.250) 6 (0.019) 88 (0.144) 0.86 
WP 
Case 220 (0.700) 79 (0.251) 15 (0.047) 109 (0.173) 
0.88 [0.67 ; 1.16] 0.39 0.83 [0.60 ; 1.16] 0.29 
0.02 
Control 209 (0.655) 97 (0.304) 13 (0.041) 123 (0.192) 0.68 
EPWP 
Case 21 (0.700) 9 (0.300) 0  (0.000) 9 (0.15) 
0.66 [0.28 ; 1.38] 0.29 0.61 [0.22 ; 1.44] 0.27 
0.33 
Control 49 (0.644) 21 (0.276) 6 (0.078) 33 (0.217) 0.11 
NPH Case 192 (0.868) 27 (0.1222) 2 (0.009) 31 (0.070) 1.18 [0.69 ; 2.07] 0.53 0.86 [0.41 ; 1.84] 0.70 0.34 
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Control 167 (0.893) 18 (0.096) 2 (0.012) 22 (0.058) 0.07 
EUR 
Case 925 (0.554) 629 (0.376) 115 (0.068) 859 (0.257) 
1.12 [0.99 ; 1.25] 0.06 1.23 [1.03 ; 1.49] 0.02 
0.56 
Control 566 (0.589) 339 (0.352) 56 (0.058) 451 (0.234) 0.57 
UK Biobank 
Case 1394 (0.573) 893 (0.367) 145 (0.059) 1183 (0.243) 
1.05 [0.98 ; 1.13] 0.12 1.05 [0.98 ; 1.12] 0.13 
0.91 
Control 60408 (0.586) 
37009 
(0.359) 
5572 (0.054) 48153 (0.233) 0.32 
ADTRP: rs6903956 
  
GG AG AA A 
     
EPN 
Case 254 (0.765) 73 (0.219) 5 (0.015) 83 (0.125) 
0.83 [0.61 ; 1.14] 0.26 0.95 [0.64 ; 1.44] 0.83 
0.92 
Control 282 (0.723) 103 (0.264) 5 (0.012) 113 (0.144) 0.19 
EPZ 
Case 88 (0.567) 58 (0.374) 9 (0.058) 76 (0.245) 
0.89 [0.64 ; 1.22] 0.48 1.04 [0.66 ; 1.63] 0.85 
0.89 
Control 164 (0.539) 118 (0.388) 22 (0.072) 162 (0.266) 0.90 
WP 
Case 313 (0.778) 85 (0.211) 4 (0.010) 93 (0.115) 
0.83 [0.61 ; 1.15] 0.27 0.83 [0.57 ; 1.24] 0.37 
0.51 
Control 239 (0.749) 74 (0.232) 6 (0.018) 86 (0.134) 0.92 
EPWP 
Case 22 (0.666) 11 (0.333) 0 (0.000) 11 (0.166) 
1.33 [0.59 ; 2.90] 0.47 1.81 [0.65 ; 4.95] 0.24 
0.25 
Control 58 (0.783) 13 (0.175) 3 (0.040) 19 (0.128) 0.06 
NPH 
Case 182 (0.674) 81 (0.300) 7 (0.025) 95 (0.176) 
1.22 [0.85 ; 1.77] 0.27 1.33 [0.80 ; 2.24] 0.26 
0.56 
Control 138 (0.722) 49 (0.256) 4 (0.021) 57 (0.149) 0.88 
EUR 
Case 604 (0.372) 791 (0.487) 227 (0.140) 1345 (0.414) 
0.99 [0.88 ; 1.12] 0.91 0.99 [0.84 ; 1.17] 0.93 
0.21 
Control 361 (0.377) 453 (0.473) 142 (0.148) 737 (0.385) 0.99 
UK Biobank 
Case 940 (0.386) 1137 (0.467) 355 (0.145) 1847 (0.379) 
0.98 [0.93 ; 1.05] 0.66 0.99 [0.93 ; 1.04] 0.67 
0.71 
Control 39294 (0.381) 48551 (0.471) 15144 (147) 78839 (0.383) 0.46 
*All values are adjusted for age, sex and body mass index, plus, for grand-parental ancestry estimates for Polynesian datasets. EPN: East Polynesian subjects with high EP ancestry, EPZ: East 
Polynesian subjects with low EP ancestry, WP: West Polynesian, EPWP; Mixture of East and West Polynesian, NPH; Māori cohort from Ngati Porou Hauora, EUR; NZ European, EUROGT 
(European Crystal Network Gout Cohort) and AGRIA (Arthritis Genomics Recruitment Initiative in Australia Gout Cohort) combined, UK Biobank; United Kingdom Biobank Cohort. OR 
[95% CI]; Odds ratio [95% confidence interval], P = p-value for ORs, HWE; Values for Hardy Weinberg Equilibrium. 
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OR [95% CI] P OR [95% CI] P OR [95% CI] P OR [95% CI] P OR [95% CI] P 
ADRB3: rs4994 
EPN 1.08 [0.69 ; 1.68] 0.72 1.03 [0.66 ; 1.62] 0.86 1.08 [0.69 ; 1.70] 0.72 0.93 [0.58 ; 1.49] 0.77 0.92 [0.14 ; 1.10] 0.72 
EPZ 1.66 [0.91 ; 3.08] 0.09 1.78 [0.96 ; 3.34] 0.06 1.56 [0.80 ; 3.05] 0.18 1.86 [0.98 ; 3.60] 0.05 1.72 [0.90 ; 3.13] 0.09 
WP 0.61 [0.34 ; 1.06] 0.08 0.57 [0.32 ; 1.01] 0.05 0.56 [0.31 ; 1.01] 0.05 0.53 [0.29 ; 0.95] 0.03 0.62 [0.33 ; 1.13] 0.12 
EPWP 0.31 [0.04 ; 1.44] 0.17 0.31 [0.04 ; 1.45] 0.17 0.35 [0.04 ; 1.76] 0.24 0.41 [0.05 ; 2.02] 0.31 0.61 [0.07 ; 3.30] 0.58 
NPH 0.95 [0.47 ; 1.90] 0.89 0.93 [0.46 ; 1.89] 0.85 0.92 [0.45 ; 1.90] 0.83 0.98 [0.48 ; 1.98] 0.96 0.96 [0.47 ; 1.94] 0.91 
EUR 1.11 [0.77 ; 1.61] 0.57 1.12 [0.77 ; 1.63] 0.55 1.12 [0.76 ; 1.65] 0.56 1.11 [0.76 ; 1.63] 0.58 1.13 [0.11 ; 0.63] 0.52 
MC3R: rs3827103 
EPN 1.04 [0.78 ; 1.38] 0.77 1.03 [0.77 ; 1.37] 0.81 1.06 [0.79 ; 1.43] 0.65 1.05 [0.78 ; 1.42] 0.66 1.01 [0.73 ; 1.37] 0.96 
EPZ 0.64 [0.39 ; 1.02] 0.06 0.65 [0.40 ; 1.04] 0.08 0.60 [0.36 ; 1.00] 0.05 0.68 [0.41 ; 1.11] 0.12 0.74 [0.45 ; 1.21] 0.24 
WP 0.79 [0.57 ; 1.09] 0.15 0.77 [0.56 ; 1.07] 0.13 0.79 [0.57 ; 1.10] 0.16 0.78 [0.56 ; 1.08] 0.14 0.87 [0.62 ; 1.22] 0.42 
EPWP 0.44 [0.17 ; 1.04] 0.07 0.43 [0.17 ; 1.01] 0.06 0.44 [0.16 ; 1.08] 0.08 0.41 [0.14 ; 0.98] 0.05 0.56 [0.19 ; 1.45] 0.25 
NPH 0.91 [0.61 ; 1.39] 0.68 0.87 [0.56 ; 1.34] 0.53 0.84 [0.55 ; 1.29] 0.45 0.90 [0.58 ; 1.39] 0.64 0.91 [0.59 ; 1.38] 0.65 
EUR 0.81 [0.61 ; 1.06] 0.12 0.77 [0.58 ; 1.03] 0.08 0.77 [0.58 ; 1.04] 0.08 0.81 [0.61 ; 1.08] 0.15 0.75 [0.56 ; 1.01] 0.05 
MC4R: rs17700633 
EPN 1.14 [0.85 ; 1.54] 0.36 1.18 [0.87 ; 1.59] 0.27 1.17 [0.86 ; 1.59] 0.29 1.16 [0.86 ; 1.58] 0.31 1.27 [0.91 ; 1.78] 0.14 
EPZ 1.21 [0.78 ; 1.91] 0.38 1.24 [0.79 ; 1.96] 0.33 1.21 [0.75 ; 1.95] 0.42 1.27 [0.79 ; 2.04] 0.32 1.28 [0.81 ; 2.06] 0.28 
WP 0.75 [0.55 ; 1.03] 0.08 0.73 [0.53 ; 1.01] 0.06 0.79 [0.57 ; 1.09] 0.15 0.76 [0.55 ; 1.04] 0.09 0.77 [0.55 ; 1.07] 0.12 
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EPWP 0.77 [0.35 ; 1.64] 0.52 0.76 [0.33 ; 1.64] 0.50 0.82 [0.36 ; 1.81] 0.63 0.92 [0.41 ; 2.06] 0.85 0.85 [0.36 ; 1.94] 0.71 
NPH 0.95 [0.61 ; 1.51] 0.84 0.98 [0.61 ; 1.57] 0.95 0.97 [0.62 ; 1.55] 0.92 0.98 [0.61 ; 1.58] 0.95 1.02 [0.63 ; 1.63] 0.94 
EUR 1.01 [0.85 ; 1.19] 0.91 1.01 [0.84 ; 1.21] 0.91 1.02 [0.81 ; 1.15] 0.70 1.00 [0.84 ; 1.20] 0.94 1.01 [0.83 ; 1.21] 0.97 
MC4R: rs17782313 
EPN 1.12 [0.64 ; 1.96] 0.68 1.11 [0.63 ; 1.99] 0.7 0.13 [0.65 ; 2.01] 0.66 1.24 [0.71 ; 2.22] 0.45 0.85 [0.45 ; 1.59] 0.61 
EPZ 1.56  [0.91 ; 2.76] 0.11 1.55 [0.89 ; 2.74] 0.12 1.50 [0.84 ; 2.69] 0.16 1.71 [0.95 ; 3.11] 0.07 1.60 [0.91 ; 2.91] 0.11 
WP 0.83 [0.60 ; 1.16] 0.29 0.84 [0.61 ; 1.17] 0.32 0.92 [0.65 ; 1.31] 0.65 0.86 [0.62 ; 1.21] 0.41 0.86 [0.61 ; 1.22] 0.41 
EPWP 0.61 [0.22 ; 1.44] 0.27 0.59 [0.22 ; 1.42] 0.27 0.54 [0.18 ; 1.38] 0.22 0.57 [0.19 ; 1.44] 0.26 0.49 [0.16 ; 1.29] 0.17 
NPH 0.86 [0.41 ; 1.84] 0.70 0.83 [0.38 ; 1.81] 0.64 0.83 [0.38 ; 1.81] 0.63 0.85 [0.39 ; 1.89] 0.69 0.91 [0.42 ; 2.01] 0.81 
EUR 1.23 [1.03 ; 1.49] 0.02 1.19 [0.98 ; 1.44] 0.06 1.17 [0.97 ; 1.43] 0.09 1.23 [1.02 ; 1.51] 0.01 1.19 [0.97 ; 1.45] 0.08 
ADTRP: rs6903956 
EPN 0.95 [0.63 ; 1.44] 0.83 0.95 [0.62 ; 1.44] 0.81 0.93 [0.61 ; 1.44] 0.75 0.84 [0.54 ; 1.29] 0.43 0.81 [0.51 ; 1.28] 0.37 
EPZ 1.04 [0.66 ; 1.63] 0.85 1.03 [0.65 ; 1.62] 0.88 1.15 [0.72 ; 1.85] 0.55 1.08 [0.67 ; 1.74] 0.72 1.09 [0.68 ; 1.75] 0.71 
WP 0.83 [0.56 ; 2.24] 0.37 0.78 [0.52 ; 1.16] 0.22 0.85 [0.56 ; 1.27] 0.42 0.84 [0.57 ; 1.26] 0.40 0.94 [0.62 ; 1.44] 0.79 
EPWP 1.81 [0.65 ; 4.95] 0.24 1.81 [0.65 ; 4.92] 0.24 1.82 [0.62 ; 5.17] 0.25 1.81 [0.61 ; 5.21] 0.27 1.36 [0.41 ; 4.24] 0.59 
NPH 1.33 [0.81 ; 2.24] 0.26 1.24 [0.75 ; 2.11] 0.39 1.21 [0.72 ; 2.08] 0.47 1.22 [0.73 ; 2.08] 0.43 0.98 [0.82 ; 1.17] 0.86 
EUR 0.99 [0.84 ; 1.17] 0.93 0.97 [0.82 ; 1.17] 0.77 0.98 [0.83 ; 1.17] 0.9 0.98 [0.82 ; 1.17] 0.86 1.25 [0.75 ; 2.11] 0.39 
*All values are adjusted for age, sex and body mass index, plus, for grand-parental ancestry estimates for Polynesian datasets. EPN: East Polynesian subjects with high EP ancestry, EPZ: East 
Polynesian subjects with low EP ancestry, WP: West Polynesian, EPWP; Mixture of East and West Polynesian, NPH; Māori cohort from Ngati Porou Hauora, EUR; NZ European, EUROGT 
(European Crystal Network Gout Cohort) and AGRIA (Arthritis Genomics Recruitment Initiative in Australia Gout Cohort) combined. OR [95% CI]; Odds ratio [95% confidence interval], P = 
p-value for ORs. 
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Unadjusted Adjusted * 
ß [95% CI] P ß [95% CI] P 
ADRB3: 
rs4994 
EPN 0.004 [-0.016 ; 0.026] 0.66 0.003 [-0.015 ; 0.023] 0.7 
EPZ 0.017 [-0.018 ; 0.054] 0.33 0.011 [-0.018 ; 0.040] 0.45 
WP 0.036 [0.009 ; 0.063] 0.01 0.036 [0.011 ; 0.062] 0.004 
EPWP -0.021 [-0.088 ; 0.044] 0.51 -0.018 [-0.076 ; 0.039] 0.53 
NPH -0.006 [-0.041 ; 0.026] 0.68 -0.008 [-0.051 ; 0.008] 0.16 
NZ EUR -0.025 [-0.054 ; 0.004] 0.09 -0.012 [-0.037 ; 0.012] 0.29 
ARIC EUR 0.001 [-0.003 ; 0.006] 0.56 0.001 [-0.002 ; 0.005] 0.49 
FHS EUR 0.001 [-0.005 ; 0.006] 0.9 -0.001 [-0.005 ; 0.003] 0.61 
CARDIA EUR -0.048 [-0.026 ; 0.0314] 0.87 0.011 [-0.013 ; 0.035] 0.37 
CHS EUR 0.002 [-0.006 ; 0.011] 0.55 0.001 [-0.006 ; 0.008] 0.82 
MC3R: 
rs3827103 
EPN -0.014 [-0.029 ; 0.001] 0.06 -0.001 [-0.025 ; 0.002] 0.1 
EPZ 0.021 [-0.002 ; 0.045] 0.06 0.004 [-0.014 ; 0.022] 0.66 
WP -0.001 [-0.020 ; 0.019] 0.95 0.0001 [-0.017 ; 0.018] 0.98 
EPWP 0.012  [-0.032 ; 0.057] 0.57 -0.001 [-0.042 ; 0.041] 0.95 
NPH 0.028 [0.006 ; 0.049] 0.01 0.016 [-0.004 ; 0.036] 0.11 
NZ EUR 0.012 [-0.009 ; 0.034] 0.27 0.009 [-0.0001 ; 0.027] 0.29 
ARIC EUR -0.00004 [-0.005 ; 0.005] 0.98 -0.001 [-0.005 ; 0.003] 0.6 
FHS EUR -0.003 [-0.009 ; 0.002] 0.28 -0.001 [-0.004 ; 0.003] 0.86 
CARDIA EUR -0.006 [-0.037 ; 0.024] 0.67 -0.004 [-0.030 ; 0.021] 0.72 
CHS EUR 0.006 [-0.002 ; 0.015] 0.16 0.004 [-0.003 ; 0.011] 0.29 
MC4R: 
rs17700633 
EPN 0.008 [-0.006 ; 0.023] 0.26 0.0063 [-0.006 ; 0.019] 0.34 
EPZ -0.017 [-0.041 ; 0.006] 0.14 0.000[-0.018 ; 0.019] 0.93 
WP 0.008 [-0.010 ; 0.027] 0.36 0.004 [-0.012 ; 0.021] 0.58 
EPWP 0.008 [-0.030 ; 0.048] 0.65 0.011 [-0.023 ; 0.046] 0.5 
NPH 0.006 [-0.016 ; 0.029] 0.58 0.008 [-0.013 ; 0.029] 0.46 
NZ EUR 0.001 [-0.012 ; 0.015] 0.84 -0.002 [0.001 ; 0.009] 0.67 
ARIC EUR 0.0002 [-0.002 ; 0.003] 0.86 0.001 [-0.002 ; 0.002] 0.77 
FHS EUR 0.001 [-0.002 ; 0.005] 0.41 0.002 [-0.001 ; 0.004] 0.09 
CARDIA EUR 0.006 [-0.011 ; 0.023] 0.47 0.004 [-0.009 ; 0.018] 0.52 
CHS EUR 0.003 [-0.001 ; 0.008] 0.15 0.002 [-0.002 ; 0.006] 0.41 
MC4R: 
rs17782313 
EPN 0.001 [-0.028 ; 0.031] 0.92 0.006 [-0.021 ; 0.033] 0.65 
EPZ -0.01 [-0.042 ; 0.022] 0.53 0.001 [-0.024 ; 0.026] 0.93 
WP 0.002 [-0.018 ; 0.022] 0.84 0.008 [-0.009 ; 0.026] 0.35 
EPWP 0.02 [-0.022 ; 0.064] 0.34 0.013 [-0.024 ; 0.052] 0.47 
4 | Metabolic Syndrome 
 175 
NPH -0.00005 [-0.044 ; 0.043] 0.99 -0.002 [-0.06 ; 0.017] 0.18 
NZ EUR -0.0001 [-0.016 ; 0.016] 0.99 0.001 [-0.002 ; 0.014] 0.87 
ARIC EUR 0.001 [-0.001 ; 0.005] 0.3 0.001 [-0.001 ; 0.003] 0.47 
FHS EUR 0.005 [0.001 ; 0.009] 0.01 0.0037 [0.0008 ; 0.006] 0.01 
CARDIA EUR -0.006 [-0.024 ; 0.012] 0.52 -0.006 [-0.021 ; 0.009] 0.42 
CHS EUR 0.006 [0.002 ; 0.012] 0.008 0.004 [-0.001 ; 0.008] 0.07 
ADTRP: 
rs6903956 
EPN 0.007 [-0.014 ; 0.029] 0.48 0.0085 [-0.010 ; 0.028] 0.38 
EPZ -0.017 [-0.042 ; 0.006] 0.15 -0.015 [-0.034 ; 0.002] 0.09 
WP -0.011 [-0.035 ; 0.012] 0.36 -0.012 [-0.034 ; 0.009] 0.27 
EPWP -0.035 [-0.086 ; 0.015] 0.16 -0.005 [-0.055 ; 0.045] 0.83 
NPH -0.036 [-0.062 ; -0.011] 0.004 -0.035 [-0.059 ; -0.011] 0.004 
NZ EUR 0.006 [-0.007 ; 0.020] 0.35 0.006 [-0.004 ; 0.018] 0.24 
ARIC EUR 0.002 [-0.001 ; 0.005] 0.15 0.002 [-0.00003; 0.005] 0.05 
FHS EUR 0.001 [-0.002 ; 0.004] 0.45 0.0004 [-0.002 ; 0.002] 0.75 
CARDIA EUR 0.0003 [-0.014 ; 0.015] 0.96 -0.00005 [-0.0127 ; 0.011] 0.92 
CHS EUR 0.0006 [-0.004 ; 0.005] 0.78 0.0001 [-0.004 ; 0.004] 0.94 
*All values are adjusted for age, sex and BMI for NZ European plus with the estimates of grand-parental ancestry for 
NZ Polynesian datasets. EP; East Polynesian, WP; West Polynesian, EPWP; Mixture of East and West Polynesian, 
NPH; Ngati Porou Hauora, NZ EUR; NZ Europeans, ARIC EUR; Europeans from Atherosclerosis risk in community 
study cohort, FHS; Europeans from Framingham Heart study Cohort (Offspring and Generation 3), CARDIA EUR; 
Europeans from Coronary Artery Risk Development in (Young) Adults Study Cohort, CHS EUR; Europeans from 
Cardiovascular Health Study Cohort, rs ID; Reference SNP cluster ID, ß; Beta/effect estimates for the alternate allele, 
95% CI; 95% confidence interval, P; p-values for effect estimates. 
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Table 4.9: Meta-analysis results of MetS-related variants for association with gout and serum urate 
rs ID Population 
Gout (case/control) Serum urate (mmol L-1) 
OR [95% CI] POR PHet ß [95% CI] Pß PHet 
rs4994 
POLY 0.98 [0.74 ; 1.28] 0.88 0.1 0.008 [-0.003 ; 0.019] 0.16 0.08 
EUR 0.89 [0.80 ; 0.99] 0.03 0.22 0.0003 [-0.0002 ; 0.003] 0.84 0.62 
POLY & EUR 0.91 [0.82 ; 0.99] 0.04 0.14 0.0007 [-0.002 ; 0.003] 0.61 0.19 
rs3827103 
POLY 0.85 [0.72 ; 1.02] 0.07 0.22 -0.001 [-0.009 ; 0.007] 0.88 0.25 
EUR 0.92 [0.84 ; 1.02] 0.14 0.27 0.0001 [-0.003 ; 0.002] 0.95 0.62 
POLY & EUR 0.92 [0.83 ; 0.99] 0.03 0.27 0.0001 [-0.003 ; 0.002] 0.99 0.53 
rs17700633 
POLY 0.97 [0.82 ; 1.15] 0.76 0.29 0.005 [-0.003 ; 0.013] 0.18 0.97 
EUR 1.03 [0.97 ; 1.09] 0.24 0.76 0.001 [-0.0003 ; 0.003] 0.12 0.79 
POLY & EUR 1.03 [0.97 ; 1.09] 0.31 0.48 0.001 [-0.0001 ; 0.003] 0.07 0.96 
rs17782313 
POLY 0.96 [0.76 ; 1.21] 0.77 0.23 0.004 [-0.008 ; 0.015] 0.52 0.57 
EUR 1.07 [1.08 ; 1.14] 0.02 0.11 0.002 [0.001 ; 0.004] 0.007 0.47 
POLY & EUR 1.06 [1.01 ; 1.13] 0.03 0.23 0.002 [0.001 ; 0.003] 0.006 0.69 
rs6903956 
POLY 1.02 [0.83 ; 1.26] 0.83 0.49 -0.011 [-0.021 ; -0.002] 0.02 0.08 
EUR 0.98 [0.93 ; 1.04] 0.66 0.95 0.001 [-0.0003 ; 0.002] 0.11 0.61 
POLY & EUR 0.99 [0.94 ; 1.04] 0.71 0.74 0.001 [-0.001 ; 0.002] 0.22 0.05 
POLY; NZ Polynesian, EUR; NZ and UK Biobank Cohort Europeans for gout analysis and NZ, ARIC, FHS, CHS and CARDIA Cohort Europeans for serum urate analysis, rs ID; Reference 
SNP cluster ID, OR/ß; Odds ratio/beta or effect estimates for the alternate allele, 95% CI; 95% confidence interval, P; p-values, POR/ß; p-value for odds ratio/beta estimates, Het; Heterogeneity. 
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SECTION 4.3: DISCUSSION 
4.3.1 ADRB3 
 Note: The below findings have recently been published in the Rheumatology 
International Journal (Fatima et al., 2016) (Appendix C). 
 This study reports association of the Arg64 (G) allele with increased serum urate 
in WP individuals ( (mmol L-1) = 0.036, P = 0.004). This finding is consistent with the 
Morcillo et al. (2010) study in Spanish individuals that associated Arg64 allele with 
development of hyperuricaemia. The finding is also in line with the studies that 
demonstrated an association of the Arg64 allele with increased serum urate and risk of 
gout in Asian subjects (Huang et al., 2013; Rho et al., 2007; Wang et al., 2011a). The 
consistent positive association observed in these findings collectively increases the 
support for a causal role of ADRB3 and adrenergic system in urate control. However, it 
was not possible to meta-analyse serum urate findings in the NZ data set with previously 
published studies as they were either described as secondary findings in conjunction with 
other metabolic conditions, from a population subgroup or as a binary outcome (Rho et 
al., 2007; Strazzullo et al., 2001; Wang et al., 2002). My study also reports a protective 
association of the Arg64 (G) allele of rs4994 polymorphism with gout in European 
individuals (OR = 0.89, P = 0.03). The G allele was also found to show a protective 
association in the WP sample set (OR = 0.62, PUnadjusted = 0.04) (Table 4.6), which did not 
change when adjusted for comorbidities, T2DM, hypertension and renal dysfunction 
(Table 4.7). The direction of association with gout in European and WP individuals 
conflicted with Wang et al. (2011a), who reported the G allele to be associated with 
increased susceptibility to gout in Han Chinese individuals. The same allele was found to 
increase the risk of gout by 86% in the EPZ sample set when adjusted for renal 
dysfunction (OR = 1.86, P = 0.05) (Table 4.6), which is consistent with the Wang et al. 
(2011a) findings in Han Chinese. However, for the WP sample set, the direction of 
association of the Arg64 allele with gout was opposite to what was observed earlier for 
serum urate. A possible explanation for the opposite effect of Agr64 allele with gout and 
hyperuricaemia could be its pleiotropic effect in the WP population, perhaps having a role 
both in determining hyperuricaemia and in the inflammatory processes leading to gout. 
The opposing effect of the Arg64 allele in the EPZ population may reflect different 
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ancestral haplotypes, which is consistent with ABCG2 having differential effects between 
EP and WP sample sets (Phipps-Green et al., 2010). 
 The ADRB3 gene encodes for beta-3 adrenergic receptor, primarily via its 
expression in adipose tissue (human visceral fat). The receptor activation, in turn, induces 
lipolysis in adipose tissue and thermogenesis in skeletal muscles. The receptor is also 
responsible for delivery of free fatty acids into the portal vein (Emorine et al., 1994), 
which can disrupt the insulin receptor signaling pathway, thereby leading to increased 
insulin resistance (Savage et al., 2005). The Arg64 allele has been reported to be 
associated with increased BMI, obesity and higher IR (Kurokawa et al., 2008; Park et al., 
2008; Zhan and Ho, 2005). A decrease in the activity of the receptor due to the Arg64 
polymorphism (Ahles and Engelhardt, 2014) could lead to a decrease in lipolysis as well 
as an increase in fat deposition in adipose tissue. The beta-3 adrenergic receptor is 
proposed to be a part of ‘leptin-sympathetic-leptin-feedback loop’; decrease in the 
activity of this receptor causes an increase in leptin secretion from the adipose tissue 
(Mark et al., 2003). Leptin is secreted in the body as an appetite suppressor, thereby 
opposing the effect of the hormone ghrelin that increases hunger (Chen et al., 2015c). The 
increase in leptin level has been positively associated with obesity (Pan et al., 2014), 
while a decrease in leptin has been associated with an improved insulin sensitivity (Wang 
et al., 2013). An increase in the levels of leptin has also been observed in hyperuricaemic 
patients (Bedir et al., 2003), which is consistent with association of Arg64 with 
hyperuricaemia. Obesity and hyperuricaemia can be possibly linked via IR (Li et al., 
2013; Modan et al., 1987). My findings for ADRB3 in relation to the Arg64 allele, 
supports the study hypothesis that the IR and BMI associated variant (rs4994) is involved 
in determining hyperuricaemia and gout. 
4.3.2 MC3R 
 This study also reports a protective association of the Ile81 (A) allele of the 
rs3827103 polymorphism of the MC3R gene with gout in combined Māori, Pacific Island 
and European data set (OR = 0.92, P = 0.03) (Table 4.9). Melanocortin 3 receptor 
(MC3R) is a major receptor for ACTH and α and ß-MSH and is thereby involved in anti-
inflammatory response (Daoussis et al., 2014; Getting et al., 2006), weight regulation, 
energy metabolism and regulation of the cardiovascular system (Feng et al., 2005; 
4 | Metabolic Syndrome 
 179 
Getting et al., 2006; Tao and Segaloff, 2004). This receptor is located on chromosome 
20q13 and Val81Ile or rs3827103 is a missense variant in the first transmembrane helix 
of the MC3R protein, involved in the binding of melanocortin peptides. Variations in this 
domain are predicted to affect melanocortin receptor functions (Schiöth et al., 1998). This 
variant has been related with in vitro diminished functionality and expression of the 
receptor, showing a significant association with childhood obesity in a case-control study 
(Feng et al., 2005). However, more recent genetic epidemiological studies have reported 
that the predisposing effect of the Ile81 allele to common forms of obesity in adults is 
unlikely (Cieslak et al., 2013; Wannaiampikul et al., 2015). This variant has been 
reported to be positively associated with developing insulin and leptin resistance in obese 
Greek Caucasians (Yiannakouris et al., 2004) and increased BMI in Belgian individuals 
(Zegers et al., 2010) while a number of studies including relatively larger data sets from 
different populations were unable to find any association between the Ile81 allele (or ‘AA’ 
homozygosity) and childhood/adolescent obesity (Cieslak et al., 2013; Obregón et al., 
2010) or increased leptin levels (Alsmadi et al., 2014). One possible explanation for these 
inconsistencies could be the more pronounced damaging effects of the MC3R 
polymorphisms during childhood. The variant, Ile81Val, is a conservative substitution 
and has been found in homologous regions of MC3/4/5 receptors of normally functioning 
mammalian models (mice, rat). No association of this variant has been reported for the 
obesity phenotype in extremely obese African American and Caucasian females (Li et al., 
2000), which suggests that Ile81Val polymorphism may not be involved in altering the 
functionality of human MC3R. In addition to these, a study in Māori kindred failed to 
report a role of the MC3R coding region variations in the development of T2D but 
suggested that other variations in regulatory regions of this gene may possibly be 
involved in insulin secretion and T2D development (Wong et al., 2002). These 
inconsistencies are also supportive for non-significant findings of the Ile81 allele with 
serum urate in my study, especially in context of the hypothesis that obesity-related 
variants should also be associated with increased serum urate (Table 4.8 and Table 4.9). 
My findings are also in line with the largest urate GWA study to now, which failed to 
report an association between the Ile81 allele with serum urate (P = 0.61) in data from 
~110,000 European individuals (Köttgen et al., 2013). Differential epistatic interactions 
between the MC3R alleles and other loci between the populations also could be a possible 
cause for the discrepancy between previous studies and my findings. 
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 While admitting the fact that the role of this variant in disrupting receptor 
functionality is controversial, it is suggested that the presence of this variant may play a 
role in increasing the binding between MC3R and ACTH in gout patients through 
modifying the overall receptor structure or it’s binding site(s). This may in turn be 
involved in enhanced anti-inflammatory effects of ACTH through modulating 
proinflammatory cytokines, attenuation of the effect(s) of inflammatory response genes 
and subsequent leukocyte extravasation in gouty arthritis. 
4.3.3 MC4R 
 Another important finding of this study is the association of the C allele of the 
variant rs17782313 with increased risk of gout in European participants (OR = 1.03, P = 
0.02) (Table 4.9). A similar association of the C allele of rs17782313 was also found in 
EPZ (OR = 1.51, PUnadjusted = 0.03), which was not retained when age, sex, BMI and 
Polynesian grandparental ancestry were added as potential confounders (OR = 1.56, P = 
0.11) (Table 4.9). A consistent direction of association of the C allele with increased risk 
of gout was also observed in most of the Polynesian data sets (EPN, EPZ and NPH) 
(Table 4.6), which became significant when all Polynesian and European data sets were 
analysed together (OR = 1.06, P = 0.03) (Table 6.9). However, my study found no 
association of the A allele of rs17700633 with gout or serum urate (Table 4.6, 4.8 and 
4.9). 
 These findings point towards an unknown underpinning pathway that depicts 
obesity as a possible risk factor for gout, especially in Europeans. Melanocortin 4 
receptor (MC4R) is the fourth member of the MCR family. It is located on chromosome 
18q21 and essentially acts as a receptor for α- and ß-MSH. The expression of MC4R is 
restricted to food regulating centres in brain (specifically within arcuate nuclei of 
hypothalamus) where it controls food intake and energy expenditure by integrating an 
agonist (satiety) signal from α-MSH and antagonist (orexigenic) signal from AgRP 
(Huszar et al., 1997; Lu et al., 1994). A large GWAS study including 16,876 individuals 
of European descent has reported two intergenic variants near MC4R, rs17782313 and 
rs17700633, to be associated with the onset of obesity (Loos et al., 2008). Other GWAS 
and replication studies also reported MC4R variants to be significantly associated with 
early onset of obesity and increased BMI (Beckers et al., 2011; Chambers et al., 2008; 
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Zobel et al., 2009). Moreover, using MC4R and TMEM18 variants (rs17782313, 
rs6548238) as instruments for BMI in an MR study, Palmer et al. (2013) reported 
increased BMI to be causal for hyperuricaemia. Similarly, another MR study reported fat 
mass explained by genetic variants of the FTO, MC4R and TMEM18 genes to be 
positively associated with hyperuricaemia (Lyngdoh et al., 2012). The findings from 
previous studies being in line with my study is supportive of the idea that rs17782313 (C 
allele) is a genuine signal for obesity and, could in turn contribute to the aetiology of gout. 
A positive association of the C allele of rs17782313 with serum urate in the combined 
European ( (mmol L-1) = 0.002, P = 0.007) data set is also consistent with the Köttgen et 
al. (2013) urate GWAS findings that found a significant association (P = 2.6E-05) of the 
same allele with urate in a large population including ~110,000 European adults. A 
positive association of the C allele with serum urate in combined European plus 
Polynesian meta-analysis ( (mmol L-1) = 0.002, P = 0.006) (Table 4.9) was also 
consistent with these findings and suggested the contribution of this variant (rs17782313: 
C allele) in gout pathophysiology through hyperuricaemia. 
 As two selected MC4R variants, rs17782313 and rs17700633 are intergenic, it is 
not possible to describe any functionality for these two. However, their association with 
obesity-related phenotypes in large GWAS datasets from several populations may 
indicate their involvement in regulating/manipulating the expression and/or response of 
other obesity-associated genes. The minor alleles of these two variants have been shown 
to possess differential, and sometimes opposite, correlation with the same obesity-related 
phenotype(s) (explained with references hereafter) in one population. The contradictory 
non-significant association results for the A allele of rs17700633 in both NZ Polynesian 
and European populations can be explained in light of these findings. In a population of 
2,265 from the Nurse’s Health Study (NHS) cohort, Qi et al. (2008) found the C allele of 
rs17782313 to be associated with a higher intake of total dietary fat and other adiposity 
measures but was unable to find any association for the A allele of rs17700633 with the 
same phenotypic traits. Another more recent analysis, including data from men and 
women, identified a relationship between rs17782313 (C allele) and morbid obesity in 
North Indian individuals, but could not find similar associations for rs17700633 (A allele) 
(Srivastava et al., 2014). These findings are supportive of the differential association 
patterns observed for the two MC4R variants (rs17782313 and rs17700633) among 
different populations in my study. 
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 It is possible that the presence of the obesity-associated C allele of rs17782313 in 
gout patients leads to an impaired signal transduction in food regulating nuclei in central 
nervous system (CNS). Peripheral enhanced food intake and reduced energy expenditure 
appear as effective responses to these abnormal signals. A recent study indicated that 
increased food craving and emotional over-eating in a set of adult European individuals 
may account for an association between rs17782313 (C allele) and increased BMI 
(Yilmaz et al., 2015). Evidences of abnormal regulation of the satiety responsiveness and 
hyperphagia (excessive eating) add to this explanation (Valette et al., 2013). Tschritter et 
al. (2011) provided evidence of leptin and insulin resistance in the presence of the minor 
C allele of rs17782313. Leptin and insulin resistance are strong risk factors for T2DM, 
renal dysfunction and hyperuricaemia (Vuorinen-Markkola and Yki-Järvinen, 1994). 
Given that hyperuricaemia, gout, obesity (McAdams DeMarco et al., 2011) and the above 
mentioned comorbidities often coexist, a consistent trend of positive association after 
including these comorbidities in the regression model (Table 4.7) strongly suggests a role 
of the C allele (rs17782313) as a possible etiologic link between obesity, elevated serum 
urate and gout. 
4.3.4 ADTRP 
 The study reports no association of the A allele of rs6903956 with gout in either 
the European (OR = 0.98, P = 0.66) and NZ Polynesian populations (OR = 1.02, P = 
0.83) (Table 4.9). However, the A allele was found to be negatively associated with 
serum urate concentrations in the combined Polynesian population ( (mmol L-1) = -0.011, 
P = 0.02), especially in Māori individuals in the NPH dataset ( (mmol L-1) = -0.035, P = 
0.004) (Table 6.8 and 6.9). In addition, the A allele of rs6903956 indicated a nominally 
positive association with serum urate in the ARIC European data set ( (mmol L-1) = 
0.002, P = 0.05) (Table 4.8). 
 Rs6903956 is located in intron 1 of the ADTRP gene (classically known as the 
C6orf105 gene). The variant was first identified as a CHD-associated signal in a GWAS 
in the Han Chinese population (Wang et al., 2011c). Following this, a number of studies 
confirmed this association with CHD in other population data sets (Nikpay et al., 2015; 
Tayebi et al., 2013). Although, a large scale study by Schunkert et al. (2011) was not able 
to find an association between the A allele and the risk of CHD in Europeans. The A 
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allele of rs6903956 was recently found to be associated with asymptomatic 
hyperuricaemia in Han Chinese individuals (Meng et al., 2015). Although, functionally 
uncharacterised, the expression of the C6orf105 (ADTRP) gene has largely been reported 
in heart, skin, stomach and kidney, and to a lesser extent in leukocytes (Wang et al., 
2011c). The A allele of rs6903956 has been suggested to decrease the expression of TFPI 
(Tissue factor pathway inhibitor: a natural inhibitor of coagulation), which in turn causes 
increased coagulation and thrombosis leading to atherosclerosis (Lupu et al., 2011; Wang 
et al., 2011c), indicating the predictable role of rs6903956 in CAD. However, a recent 
study by Chang et al. (2017) reported the A allele not to be associated with plasma 
coagulation factors in Singaporean Chinese adults and neonates, which contradicts to the 
idea of the A allele being involved in thrombosis. Additionally, the mechanism(s) 
involved in the negative association of rs6903956 (A allele) and serum urate in my study 
remains unclear. 
 A possible explanation for association of the A allele with decreased urate 
concentration could be given by considering a study by Chen et al. (2016), who found 
better prognosis of acute coronary heart stroke in men with higher urate levels. There are 
a number of recent clinical studies indicating a beneficial role of using urate as a potential 
therapy agent for patients with acute ischemic heart stroke (Amaro et al., 2016; Llull et 
al., 2016). It is suggested that the presence of the A allele may be involved in decreasing 
serum urate concentration in NZ Polynesian individuals and, thereby, increasing the risk 
of developing CHD via increased TFPI production. The contradictory findings in my 
study to Meng et al. (2015) can be explained by a couple of reasons. First, the 
associations described by Meng et al. (2015) could be false positive due to a small sample 
size being used. Second, the negative association may be present exclusively in the 
Polynesian population due to different haplotypic background and may not be comparable 
with the positive association findings of Meng et al. (2015) in the Han Chinese 
population. 
4.3.5 Strengths and limitations of the study 
 This is the first study to provide evidence for a direct genetic association of 
variants in the melanocortin system involved in obesity and anti-inflammatory response 
with serum urate and gout. The study also represents the first example describing the 
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involvement of adrenergic system TFP inhibitor (ADTRP) in reducing the serum urate 
concentration in NZ Polynesian individuals. It is also important to note that two MetS-
related variants within ADRB3 and ADTRP analysed in my study were not present in the 
largest serum urate GWAS (Köttgen et al., 2013). The reason could be the absence of any 
data for these two variants in the HapMap2 platform (www.hapmap.ncbi.nlm.nih.gov) 
that was used for imputing genotypes in Köttgen et al. (2013) GWAS. The findings in my 
study, therefore, would be a valuable addition to the knowledge through associations of 
these loci with serum urate and gout in European as well as Polynesian populations. 
Moreover, this study is one of the few studies reporting associations of more than one 
MetS-related variant in the European population as well as variants exclusive for NZ-
based Polynesian subgroups. Although all data sets used in my study had adequate power 
to determine an intermediate effect at a low allele frequency (> 0.2), still the small size of 
individual Polynesian datasets to detect a lower effect represents a study limitation. In 
addition, it is hard to comment on functional roles of the variant rs17782313 (and 
rs17700633) in context of MC4R due to the absence of any data reporting its association 
with expression of MC4R gene in currently available gene-tissue expression platforms 
(GTEx portal: www.gtexportal.org and Haploreg4: www.archive.broadinstitute.org). 
4.3.6 Conclusion and future directions 
 The study reports effects at four different MetS-related loci, ADRB3, MC3R, 
MC4R and ADTRP, predictable for increase/decrease in serum urate in European and NZ 
Polynesian individuals. It is not abnormal to find differences in direction of associations 
for the same genetic variant while dealing with two or more populations with an 
ancestrally different background. Even within the same population set, an allele could be 
expected to be positively associated with increased risk of gout while showing a negative 
association with urate levels. In addition to the difference between the genetic history of 
two populations, the involvement of different pathways controlling increased urate and 
establishment of gout (via inflammation) can help explain intra-group association 
inconsistencies. In my study, two of the loci, ADRB3 and MC4R, also indicated 
population-specific associations with gout, while negative effects of the minor allele of 
ADTRP with serum urate were exclusive to Polynesian individuals only. Results that were 
contradictory to the previous literature still warrant testing in larger data sets from diverse 
populations to eliminate the chances of any false positive/negative findings this study 
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may have found. Overall, my study reports a positive association of components of MetS 
in determining the risk of hyperuricaemia and gout in European and NZ Polynesian 
individuals. If replicated successfully, the proposed mechanism(s) may also have a 
significant impact on increasing our understanding of hyperuricaemia and gout 
pathophysiology that coexist with metabolic syndrome or some of its components. Use of 
in vitro techniques to study gene expression and function in early childhood, adulthood 
and elderly may also provide a better idea of the roles these MetS-related variants play in 
these age groups. The in vitro gene functional studies exploring the role of these loci in 
up- and down-regulating the expression of other genes would also help to better 
understand the involvement of these genes in gout pathophysiology via urate production, 
its transport and renal impairment or other conditions associated with renal impairment 
e.g., insulin resistance. Availability of customary human/animal cell lines, tissue cultures 
and mammalian model animals (for gene expression studies in intact animals) have made 
these functional studies relatively easy to follow. Studying individual sequence variant’s 
functionality and expression may require a panel of genetically matched ‘normal cells’ 
alongside the ‘mutated cells’. This isogenic system can be obtained via engineered 
nucleases (e.g., zinc finger or transcription-activator-like effector nucleases) to generate 
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SECTION 5.1 RARE VARIANTS IN COMPLEX DISEASE: AN 
INTRODUCTION 
5.1.1 Background 
 Understanding the genetic basis of complex diseases has been the subject of 
interest for many decades. A number of genetic factors have been recognised that 
contribute to the risk of common diseases, with an open question of ‘how many more 
genetic factors to be found?’ Genome-wide association studies (GWAS) in humans have 
successfully identified thousands of common genetic variants contributing to quite a large 
number of more common phenotypes/traits. Despite these successes, the genetic makeup 
of complex traits has not been fully elucidated. As most of the genome-wide significant 
variants in GWAS exist in intronic or non-coding regions of the genome with weaker 
effect, it is hard to predict any functionality or to explain a link between disease and the 
variant through a biological mechanism. The robust associations explained by common 
genetic variants in GWAS usually explain a relatively small proportion of the disease 
heritability, with a large proportion of the heritability still ‘missing’ or unexplained 
(Goldstein, 2009; Pritchard, 2001). It is possible that some of this so-called ‘missing 
heritability’ is accounted by the genetic variants that are either rare or occur in low-
frequency (Manolio et al., 2009; McClellan and King, 2010). A second possibility is from 
studies that have suggested replacing the term ‘missing’ with ‘hidden’ by taking into 
account all SNPs being genotyped in a GWAS to explain variance in disease heritability 
(Morris et al., 2012; Yang et al., 2010a). For example, Yang et al. (2010a) reported that a 
large proportion (45%) of the heritability for human height can be explained by 
considering all common SNPs in the genome-wide data simultaneously rather than 
considering significant signals only. Consistently, the most recent urate GWAS provided 
evidence to support the possibility of ~27-41% of this ‘hidden’ heritability to be 
explainable when all common variants in the GWAS are considered together (Köttgen et 
al., 2013). Still, that a substantial proportion of variance remains unexplained by common 
variants requires looking into other possible culprits i.e., rare variants. The idea that these 
less common variants could possess considerably larger effect on disease phenotype(s) 
led researchers to discover high-throughput methodologies that precisely capture these 
variants in the genome to analyse their association with phenotypes, although the key 
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challenge in the analyses of such variants is strictly their ‘rarity’. High-tech advances in 
molecular biology using high-throughput sequencing (HTS) and exome arrays have 
provided detailed insights into the entire genome of individuals in contrast to focusing on 
some predefined loci. This not only opens up new opportunities for the genetic research 
on common diseases but also raises some new challenges e.g., how to exploit these data 
in the most efficient way. These human genome resequencing methodologies have 
explored many different types of study designs and analytical techniques (as explained in 
section 5.1.5) that can be applied for rare variant association studies with greater accuracy 
(Auer and Lettre, 2015). 
5.1.2 Common and rare variants and common disease 
 Simple (or Mendelian) diseases are the results of mutation(s) in single genes, 
which are causal and may have a variable degree of penetrance and expressivity (Auer 
and Lettre, 2015). In contrast, complex (or common) human diseases result from a 
combined effect of multiple genetic modifications and environmental factors (Craig, 
2008). These genetic variants may or may not be causal, which means that they might be 
involved in increasing the risk of developing the disease rather than individually causing 
the disease itself. Explaining the genetic architecture of common disease susceptibility 
relies on two model patterns i.e., common disease-common variant/CDCV and common 
disease-rare variant (Schork et al., 2009). The CDCV explains that more frequent, low 
penetrance variants are the major contributors in increasing the risk to common disease in 
a general population. This model is the underlying rationale to most of the GWA studies. 
The common disease-rare variant model argues for the presence of multiple, rather rare, 
high penetrance variants that increase the genetic susceptibility for a complex trait in 
specific individuals (Reich and Lander, 2001). 
5.1.3 Defining a rare variant 
 Given that the idea of studying rare variants is nascent, there is little consensus to 
separate rare from common variants on the basis of their allele frequency in any 
population. Assigning the rarity is rather reliant on their insufficient frequency and failure 
of GWAS genotyping assays to capture these variants (Pritchard, 2001). It is also not 
possible to detect such variants by classical linkage analysis in family studies, as they 
usually don’t carry sufficiently large effect sizes (McCarthy and Hirschhorn, 2008). 
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Though the meaning differs from one study to the other, ‘rarity’ is usually differentiated 
from ‘commonality’ based on the frequency of a minor allele in a said population. For 
example, a MAF of < 1% has been described as rare by Frazer et al. (2009), whereas 
Gorlov et al. (2011) set a threshold of 5% for rare variants. Bodmer and Bonilla (2008) 
described an upper limit of 1% and a lower limit of ~0.1% to differentiate the rare 
variants from their third category of ‘clearly deleterious’ mutations. The authors also 
described the possibility of an overlap between ‘low-frequency’ and ‘rare’ variants. A 
classical categorisation assigned the terms very common, less common and rare for any 
variant with MAF of 5-50%, 1-5% and < 1%, respectively (Cirulli and Goldstein, 2010). 
McCarthy et al. (2008) and Manolio et al. (2009), however, provided a more precise 
classification for assigning the rarity to any variant on the basis of allele frequency and 
disease susceptibility or penetrance (Figure 5.1). Common variants, on the contrary, are 
those that are employed in most GWAS. Zuk et al. (2014) have recently defined common 
variants as those occurring with a count that is frequent enough to allow their testing in 
affected and healthy subjects. 
Figure 5.1: Feasibility of identifying genetic variants by risk allele frequency and effect size. Modified and 
redrawn from McCarthy et al. (2008) and Manolio et al. (2009). 
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5.1.4 Types of rare genetic variants 
 Genetic variants are broadly categorised as single nucleotide polymorphisms and 
structural variants (Frazer et al., 2009). A change at a single nucleotide position on the 
DNA sequence is referred to as single nucleotide variant. Although most SNPs are 
biallelic, the presence of more than one allele or multiallelic SNPs have also been 
observed (Hüebner et al., 2007). Structural variants primarily include indel (insertion-
deletion) polymorphisms, where an addition or removal of one to a few nucleotides in the 
DNA sequence occurs. Other variants are block substitutions and inversions, which lead 
to a change in numerous adjacent nucleotides or their order. Copy number variants 
(CNVs) are DNA sequences of ≥ 1kb found in variable number in contrast to the 
reference genome (Feuk et al., 2006). Feuk et al. (2006) differentiated CNV from copy-
number polymorphism (CNP) by defining CNP as “CNV that ensues in more than 1% of 
the population”. 
5.1.5 Evaluation of rare variants for a complex trait 
 As rare variants are hard to identify because of their extremely low frequency, 
assessing these variants is a major challenge. One of the current approaches used to 
investigate the role of a rare variant in a complex disease is direct genotyping. The 
Exome chip (www.genome.sph.umich.edu/wiki/Exome_Chip_Design), metabochip 
(Voight et al., 2012) and the Immunochip (Cortes and Brown, 2011) are a few examples 
of targeted and custom designed arrays used for direct genotyping of such variants. 
Genotyping on such arrays usually requires a GWAS as a supportive platform for 
imputation of low-frequency variants and a sequenced reference panel (e.g., 1000 
Genomes Project) to provide a base to imputing genotypes (Abecasis et al., 2012). 
Another method efficiently used to assess rare variants is sequencing – either sequencing 
of whole genome (or exome) or targeted sequencing of specific regions or candidate 
genes within the genome, using again a reference panel genome to align and arrange the 
small reads obtained in re-sequencing. Figure 5.2 illustrates a schematic overview of the 
steps involved in rare-variants’ association studies for a complex trait. 
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5.1.5.1 Association analysis approach 
 Development and implementation of an efficient method to analyse rare-variant 
associations is vital. An underpowered single-point based association analysis is 
becoming obsolete. It is suggested that combining information across multiple variants 
(or burden) within a gene should be used as a viable alternative to isolated rare-variant 
association analyses. A number of statistical models are now available to carry out such 
locus-based analyses (explained hereafter). An example of widely used method is the 
Kernel Based Associations Test and Sequence Kernel Association Test/SKAT that 
analyse data for the contribution of both rare and common genetic variants to risk of 
complex diseases (Mukhopadhyay et al., 2010; Wu et al., 2011). Other methods broadly 
involve allele-collapsing approaches based on summary statistics [such as Cohort Allelic 
Sum Test (Morgenthaler and Thilly, 2007), Weighted Sum Test (Madsen and Browning, 
2009) and Combined Multivariate and Collapsing Test (Li and Leal, 2008)] and 
regression models (Han and Pan, 2010; Morris and Zeggini, 2010; Zhou et al., 2010). The 











Figure 5.2: An overview of the steps involved in low-frequency and rare-variant association studies. Modified 
and redrawn from Panoutsopoulou et al. (2013) and Lee et al. (2014). 
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5.1.5.2 Functional annotation 
 In addition to choosing a suitable statistical approach to test for rare variant 
association, it is also crucial to decide if all of the discovered rare variants are to be 
included for a combined analysis. For instance, the sequencing of a particular gene might 
generate a range of variants in both coding (exonic) as well as non-coding (intronic, 
regulatory and un-translated) regions. It is ideal to pick those variants in coding regions 
that more likely result in structural and functional change of the protein (Auer and Lettre, 
2015). Table 5.1 presents a list of some of the many resources available to interpret 
functional consequences of genetic variants. These annotations are exceedingly helpful in 
prioritising the variants to be included and/or excluded from group-based analysis (e.g., 
burden analysis) or replication analysis. Usually, high-signal, non-synonymous variants 
with large effect sizes are chosen or prioritised from the discovery-phase to follow-up in 
replication (Lee et al., 2014). 
Table 5.1: List of tools and resources for functional annotation 
Tool/Resource Brief description URL (Reference) 
CADD 
CADD (Combined Annotation Dependent 
Depletion) is a framework that integrates 
multiple annotations into one metric by 
contrasting variants that survived natural 
selection with simulated mutations. 
http://cadd.gs.washington.edu/ 
(Kircher et al., 2014) 
ENCODE 
ENCODE (The Encyclopedia of DNA 
Elements) is a platform to build a 
comprehensive parts list of functional 





PolyPhen-2 (Polymorphism Phenotyping version 
2) is a tool that predicts the possible impact of an 
amino acid substitution on the structure and 
function of a human protein using 




(Adzhubei et al., 2010) 
SIFT 
SIFT (Scale-Invariant Feature Transform) 
predicts whether an amino acid substitution 
affects protein function. SIFT prediction is based 
on the degree of conservation of amino acid 
residues in sequence alignments derived from 
closely related sequences. 
http://sift.jcvi.org/ 
(Kumar et al., 2009) 
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HaploReg v1-4 
HaploReg is a tool for exploring annotations of 
the noncoding genome at variants on haplotype 
blocks, such as candidate regulatory SNPs at 




(Ward and Kellis, 2012) 
VEP 
VEP (Variant Effect Predictor) determines the 
effect of given variants (SNPs, insertions, 
deletions, CNVs or structural variants) on genes, 





(McLaren et al., 2010) 
PROVEAN 
PROVEAN (Protein Variation Effect Analyser) 
is a software tool, which predicts whether an 
amino acid substitution or indel has an impact on 
the biological function of a protein. 
http://provean.jcvi.org/index.php 
(Choi, 2015) 
5.1.5.3 Replication of genetic signals 
5.1.5.3.1 Foreword 
 It is essential to prioritise and replicate any signals of interest identified in the 
discovery-phase of a rare variant analysis/project in another large and independent cohort 
of individuals (replication cohort). The criteria of prioritisation may vary according to the 
study, population genetics, functional consequences, direction of association, rarity and 
novelty of the variants. The replication, however, totally relies on the allelic architecture 
of the associated locus and may require either genotyping or resequencing in the 
replication cohort (Lee et al., 2014). For example, for a single rare-variant signal, 
genotyping of the said variant in an independent sample set would suffice (Beaudoin et 
al., 2012). For multiple variants with high signals, a variant-based (genotyping of 
discovery-phase variants) and locus-based (resequencing of whole region) follow-up 
replication would be ideal (Figure 5.2). 
5.1.5.3.2 Why we need replication? 
 As described briefly above, it is important to validate any association found in 
sequencing analysis by replicating it in an independent set of individuals called a 
replication cohort. Replication of the genome-wide level (P < 5 × 10-8) signals from 
GWAS is now considered mandatory to accept, standardise and publish a variant as a 
novel phenotype/disease associated variant (Barsh et al., 2012). For sequencing studies, 
however, replication of the rare or low-frequency variants is more challenging than for 
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the variants identified by GWAS. The main factor that makes replication difficult for rare 
variants is indeed their extremely low frequency and population-specificity. A rare 
variant in the LDLR (low-density lipoprotein receptor; MAF = 0.5%) gene, associated 
with LDL-cholesterol, is an example of one such variant found to be polymorphic only in 
the Sardinian population (Sanna et al., 2011). Discovering other variants in the same gene 
associated with the same trait and evaluating their functionality to describe possible 
metabolic pathways could be the only approach to replicate such association in other 
populations. 
 In addition to the rare and low-frequency signals, it is also crucial to confirm any 
common and population-specific associations in the discovery-phase of the sequencing 
study by replicating them in an independent cohort. The first step in the replication-phase 
is to set a criterion (which may vary from study to study) and prioritise a few variants 
accordingly. While there are no definite criteria described in the literature, the 
prioritisation could be based on the direction and significance of association, frequency or 
population statistics of the alternate allele, estimated effect size, apparent biological 
relevance and functionality and novelty of the variant (Lee et al., 2014). 
 Once prioritised, the replication of the associated locus may require either 
genotyping or resequencing in the replication cohort (Lee et al., 2014). For a few or 
single variant signals, genotyping of the prioritised variants in an independent sample set 
would suffice (Beaudoin et al., 2012). This could be performed in a multitude of ways 
using a different population or an independent set of individuals within the same 
population, particularly for the population-specific variants. The strategies could be 
genotyping of the selected (prioritised) variants, selected genotyping of a perfect tag SNP 
or in silico genotyping (imputation; considered as a suboptimal approach for replication) 
of the variants of interest (Auer and Lettre, 2015). For multiple variants with high signals, 
a locus-based follow-up replication or resequencing is recommended as ideal. Adapting 
both, genotyping and resequencing, has been successful to replicate a discovery 
association in practice. Replication of a DCTN4 (Dynactin subunit 4) gene rare variant by 
Sanger sequencing (Emond et al., 2012) and of four loss-of-function variants in APOC3 
(Apolipoprotein C-III) by Illumi-Exome Chip genotyping (Crosby et al., 2014) are two 
such successful examples. A statistically significant (P ≤ 0.05) association signal in the 
replication cohort indicates that the discovery has been replicated and validated. 
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 Sample size in the replication-phase is the most important determinant of power. 
While designing a replication study, it is important to select a large group of individuals 
to gain adequate power, especially if it involves a rare or low-frequency variant. Liu and 
Leal (2010) indicated that in comparison to single variant genotyping, sequencing of a 
region could be a better and more powerful approach to validate the discovery for rare 
variants. They described that sequencing could also increase the power of the study by 
recognising additional variants that might have been missed in discovery-phase. 
Whichever strategy (sequencing or genotyping) results in the largest sample size and the 
higher rare variant frequency should be the preferred approach (Auer and Lettre, 2015). 
5.1.6 Rare variants contributing to complex traits 
 The number of rare variant association studies is growing continuously with 
advancement in the technology and analytical tools. Success stories like PCSK9 
(proprotein convertase subtilisin kexin type 9) in hypercholesterolemia are further 
motivating researchers to characterise the role of rare variants in other complex 
phenotypes. Rare variants have been associated with increased risk of major diseases in 
large GWAS and resequencing data sets. Targeted resequencing studies found multiple 
rare variants independently associated with type 1 (T1D) (Nejentsev et al., 2009) and type 
2 diabetes (T2D) (Bonnefond et al., 2012; Lohmueller et al., 2013). A large resequencing 
study of 25 GWAS including genes for autoimmune diseases identified a total of 2,990 
protein coding variants with 97.1% having frequency of < 0.5%, along with a large 
proportion of variants (68.9%) only reported in one or two individuals (Hunt et al., 2013). 
The study, however, did not formally test variants for association with autoimmune 
diseases (Hunt et al., 2013). Five discrete rare variants in the NOD2 gene have been 
reported to be associated with Crohn’s disease (Hugot et al., 2001; Ogura et al., 2001; 
Rivas et al., 2011). There are also examples of several rare variants associated with 
complex diseases with large effect sizes. A rare missense variant in the MYH6 gene was 
found to increase the risk of sick sinus syndrome by 12-fold (Holm et al., 2011). Huyghe 
et al. (2013) identified five independent low-frequency variants associated with fasting 
insulin levels in a study based on exome array genotyping. 
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5.1.7 Rare genetics of serum urate and gout 
 Genome-wide association studies have identified a number of loci explaining the 
genetic architecture of urate and gout (reviewed in Dalbeth (2016)). Still, it is challenging 
to describe the functional consequences of a number of high-signal variants in non-coding 
regions. Like many other complex phenotypes, the rare genetics’ studies are new for 
serum urate and gout and not much has been described in the literature. Li et al. (2007) 
used the term ‘rare allele’ to describe the association of a variant (rs6855911) in the 
GLUT9 gene for an allele frequency as high as 0.26 (Allele G). However, a whole-
genome sequencing study of 16 million SNPs from 457 Icelanders identified a low-
frequency missense variant (risk-allele (G) frequency = 0.019) in the ALDH16A1 
(aldehyde dehydrogenase 16 family member A1) gene to be associated with gout (OR = 
3.12, P = 1.5 x 10-16) and serum urate (effect = 0.36, P = 4.5 x 10-21) at genome-wide 
threshold levels (Sulem et al., 2011). They further confirmed the association through 
Sanger sequencing on 6,017 Icelanders and reported it to be consistent with a stronger 
effect in males than females. A recent report in 622 Han Chinese males described two 
intronic variants as ‘rare’ for their population. One of the two variants in SLC2A9 
(rs734553) was associated with gout (case-control allele (C) frequency = 0.008, 0.018, P 
= 0.028, OR = 0.45), while the association for other rare variant in SLC16A9 
(rs12356193) was neutral (case-control allele (G) frequency = 0.002, P = 0.659, OR = 
1.43) (Zhou et al., 2015). Given that no data are available to explain the possible ‘missing 
heritability’ of gout until now, the next section of this chapter was designed to carry out a 
rare-variant association analysis of exon sequencing data of two lipid-related genes, LRP2 
and A1CF, for serum urate and gout. The specific aims of this study were; 
1. To characterise the variants obtained from exon sequencing of LRP2 and A1CF 
genes in NZ Polynesian and European individuals. 
2. To identify common, low-frequency and rare variants and test for an association 
with hyperuricaemia and gout. 
3. To identify all non-synonymous and rare variants and test for their burden for 
hyperuricaemia in Europeans NZ Polynesians. 
4. To replicate any interesting findings in larger NZ ancestry based population 
cohorts (Polynesian and European). 
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SECTION 5.2 EXON SEQUENCING OF LRP2 AND A1CF 
GENES: ASSOCIATION ANALYSES 
5.2.1 Background 
 Quantitative traits underlying common diseases including urate control have a 
significant degree of heritability. The most recent genome-wide association study from 
Köttgen et al. (2013), that combined data from > 110,000 European-ancestry individuals, 
provided evidence for association of 28 loci that collectively explain 7.0% of the variance 
in urate. Besides the loci involved in urate transport, an understanding of non-urate 
transporting loci (those controlling formation of MSU crystals and the immune reaction) 
is important to characterise the shared genetic basis of gout or urate with other metabolic 
conditions. 
 As described in detail in Chapter 1 (Section 1.1.7.3), lipoprotein receptor-related 
protein 2 (LRP2/megalin) is a non-urate transport locus that has been identified for its 
major role in lipid metabolism (Cabezas et al., 2011; Christensen and Birn, 2002). The 
megalin (LRP2) protein is principally located on the apical surface of the proximal renal 
tubule (Cue et al, 1996, Nielsen 1998) and known for its role in reabsorption and 
metabolism of glomerular-filtered substances (Hosaka et al., 2009). Clusters of rare 
variants have been identified within LRP2 to be associated with pathologic conditions 
like ASD (Autism spectrum disorders) (Ionita-Laza et al., 2012) and renal injury 
(McMahon et al., 2014). Apolipoprotein B mRNA-editing enzyme 1 (APOBEC1) 
complementation factor  (A1CF) is another emerging candidate in the list of non-urate 
transport genes. This gene is known for its role in the production of two different protein 
isomers, apo B-48 and apo B-100 from one nuclear gene (Chen et al., 1987; Powell et al., 
1987). In the recent GWAS, the A1CF variant (rs10821905) was associated with serum 
urate levels in Europeans (Köttgen et al., 2013), along with significant association with 
gout risk in New Zealand Europeans although not in Māori and Pacific Islanders (Phipps-
Green et al., 2014). In terms of data from fine mapping and whole genome or exonic 
sequencing, no study has yet reported any disease-based association for other variants 
within A1CF. Both LRP2 and A1CF have been reported to be associated with increased 
eGFR (a marker for kidney function) in a recent GWAS based on European population 
(Appendix B Figure 5.2) (Pattaro et al., 2016). 
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 Despite evidence for involvement of LRP2 and A1CF in a number of 
physiological processes, little is known about the effect of their possible causal variants 
on biological pathways, particularly those leading to gout. It was, therefore, hypothesised 
that other population-specific variants within LRP2 and A1CF coding regions could 
contribute to gout risk in New Zealand (NZ) Māori and Pacific Islanders and Europeans, 
which may prove helpful in explaining some part of the ‘unexplained heritability’ for 
gout in these populations. This particular section of my thesis was aimed towards 
carrying out association analyses to determine if other common and rare variants that 
reside in exonic regions of LRP2 and A1CF are associated with gout and hyperuricaemia 
(HU). 
5.2.2 Methods 
 A replication based rare-variant analysis approach was adopted to analyse the 
association of variants within exonic regions of LRP2 and A1CF genes with 
hyperuricaemia and gout. Genotype information for these two genes was extracted from 
the ReSequencing Cohort followed by discovery and replication analyses. Below are the 
major steps that were sequentially followed for the completion of rare-variant-analysis in 
this chapter: 
1. Sequencing protocol: This section describes the overall selection of gene regions 
and the methods that were used to carry out sequencing in European and NZ 
Polynesian subjects (The ReSequencing Cohort). 
2. Association analyses – Discovery phase: This section details the extraction of the 
LRP2 and A1CF exonic regions from the ReSequencing Cohort followed by; 
i. Single variant analysis (individual association analysis of each variant 
within two genes for hyperuricaemia (European and NZ Polynesian) and 
gout (NZ Polynesian only). 
ii. Burden analysis (combined analysis for rare and non-synonymous variants 
to test for a burden of risk/protection for hyperuricaemia and gout 
(European and NZ Polynesian). 
iii. Functional annotation of variants (to check the functional status of each 
exonic variant within LRP2 and A1CF genes). 
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3. Association analyses – Replication phase: This section provides details for a list of 
variants that were prioritised from the Discovery-phase analysis to replicate (via 
TaqMan genotyping) in an independent cohort (NZ Polynesian and European 
subjects) and their subsequent association analyses. 
5.2.2.1 Sequencing protocol 
5.2.2.1.1 Study participants 
 The ReSequencing Cohort consisted of 819 individuals from three different data 
sets selected according to urate level. The first set included 526 European and Polynesian 
individuals from New Zealand. This data set was a sub-set of New Zealand Gout Cohort 
(Section 1.2). Two additional sets of European individuals were selected from Health 
Professional Follow-up Study (HPFS: n = 169) and Nurses’ Health Study (NHS: n = 
125)4. The ReSequencing Cohort was then stratified on the basis of serum urate levels 
with a cut-off value of ≥ 0.41mmol L-1 between hyperuricaemic cases (n = 427: serum 
urate ≥ 0.41 mmol L-1) and normouricaemic controls (n = 392: serum urate ≤ 0.37mmol 
L-1). Hyperuricaemic cases were selected irrespective of their gout status and urate-
lowering therapy while controls self-reported no history of gout. Self-reported ancestry 
was used to further split this cohort into European (n = 376) and Polynesian (n = 443) 
sub-sets. As it is not ideal to perform rare-variant analyses in smaller groups due to a 
drastic reduction in the power of analysis, the Polynesian sub-set was not further split into 
Eastern and Western Polynesian subgroups. Table 5.2 represents a summary of 
demographic details for the ReSequencing Cohort. 
                                                 
4 Samples from the HPFS and NHS were kindly provided by Professor Hyon K Choi (Gout and Crystal 
Arthropathy Center, Massachusetts General Hospital, Boston, MA). 
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 Table 5.2: Demographic details of the individuals in the ReSequencing Cohort 
Population NZ Polynesian European* 
Group Hyperuricaemic Normouricaemic Hyperuricaemic Normouricaemic 
Baseline Information 
Total number (n) 229 214 198 178 
Males, n (%) 192 (83.84) 92 (42.99) 165 (83.33) 73 (41.01) 
Age (years)^ 45 ± 14 45 ± 14 60 ± 15 - 
BMI (kg/m2)^ 36.97 ± 7.80 31.56 ± 6.69 30.16 ± 3.83 - 
Serum Urate (mmol L-1)^ 0.53 ± 0.64 0.30 ± 0.40 0.52 ± 0.55 0.22 ± 0.33 
Co-morbidities 
Type II Diabetes, n (%) 33 (14.40) 42 (19.63) 15 (7.57) - 
Dyslipidaemia, n (%) 26 (11.35) 75 (35.04) 31 (15.65) - 
Heart problems, n (%) 20 (8.73) 18 (8.41) 19 (23.17) - 
Hypertension, n (%) 83 (36.24) 39 (18.22) 44 (53.66) - 
Kidney problems, n (%) 22 (9.60) 5 (2.34) 13 (15.85) - 
Gout Characteristics 
Gout cases, n (%) 170 (74.24) - 76 (92.68) - 
Age at onset gout (years)^ 34 ± 12 - 47 ± 18 - 
On Diuretics/ULT, n (%) 120 (52.41) - 38 (46.34) - 
Gout attacks (per year)^ 11.56 ± 37.05 - 4.33 ± 7.56 - 
Gout tophus, n (%) 57 (24.89) - 20 (24.39) - 
 NZ: New Zealand, BMI: Body mass index, n (%): total number (percentage), ULT: Urate lowering therapy. ^Data are shown as mean ± standard deviation. Data for the co- 
 morbidities are self-reported. *Demographic data for the European cohort is based only on the NZ samples (excluding sex and serum urate levels). 
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5.2.2.1.2 Selection of the genome regions for sequencing 
 The project was based on ‘targeted resequencing’ of candidate genes and the 
genomic regions of interest. The idea behind this specific project was to sequence the 
genetic loci that have been associated with hyperuricaemia and/or gout in the earlier 
literature, and to further analyse these associations through fine mapping of these loci in 
European and Polynesian populations. For this purpose, several criteria as described 
below were followed while selecting the genomic regions with prior evidence for an 
association with gout or serum urate concentrations.5 
1. Gene/gene regions identified in Köttgen et al. (2013) in the largest serum urate 
GWAS including more than 110,000 Europeans. 
2. Sixty-seven biallelic genomic control markers genotyped in Hollis-Moffatt et al. 
(2012b) to calculate estimates of Eastern Polynesian ancestry (Appendix A Table 
5.1). 
3. Gene/gene regions coding for those proteins that contribute to allopurinol 
metabolism. 
4. Urate-transport genes that had not previously been associated with urate or gout. 
5. Gene/gene regions influencing renal function, body mass index or weight. 
6. Candidate gout risk genes known to determine the risk of gout through other 
metabolic pathways e.g., inflammation, lipid metabolism, or some unknown 
mechanisms. 
7. Deoxyribonuclease (DNAse) hypersensitivity regions were idenetified from their 
expression data in 19 renal cell samples (Appendix A Table 5.2). The expression 
data was accessed through Gene Expression Omnibus website 
(www.ncbi.nlm.nih.gov/geo). 
8. The genes/regions within or around the above chosen genic regions were also 
selected for sequencing. 
                                                 
5 Professor Tony R Merriman (PhD supervisor), Assistant Professor Eli Stahl (Icahn School of Medicine, 
Mount Sinai, New York), Professor Hyon K Choi (Gout and Crystal Arthropathy Center, Massachusetts 
General Hospital, Boston, MA) and Assisstant Professor David B Mount (Brigham and Women's Hospital, 
Boston) selected the regions for targeted sequencing. Two staff members of the Merriman Laboratory 
identified the specific genome positions to be sequenced: Murray Cadzow (Assistant Research Fellow) and 
Ruth Topless (Assistant Research Fellow). 
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Figure 5.3: An overview of the detail of region selection for sequencing 
 Using the above selection criteria ended up in a list of 790 different genes. This 
selection essentially included both, genic and regulatory genes/regions. In detail, this list 
comprised 182 gout and urate associated genes encompassing 28 loci from the Köttgen et 
al. (2013) GWAS study, all Polynesian ancestry informative genes from Hollis-Moffatt et 
al. (2012b), 14 BMI and renal function genes, 45 genes involved in allopurinol 
metabolism, 12 candidate gout risk genes and 6 urate transporters not previously known 
for an association with gout. Selected regulatory regions included SLC22A7/ABCC10 and 
30 other regions that indicated association in Köttgen et al. (2013) at GWAS level (with 
P < 5x10-8). The regulatory regions also included 865 DNAse hypersensitivity peaks 
(H3K9ac and H4K4me3) from kidney cell lines. Overlapping data from these peaks were 
combined with association regions to reduce the sequencing primer design. For each gene 
on this list, exon sequence was extracted for +/- 10 bp (base pairs) and 3' and 5' un-
translated regions (UTRs). Moreover, regions of 800 bp upstream of the transcription 
start site(s) were also sequenced for each of these genes. Markers of Polynesian ancestry 
information were sequenced +/- 50 bp upstream/downstream and entire peaks were 
sequenced for DNAse hypersensitivity regions. Merging these regions ended up in 
sequencing of nearly 2.6 Mb of the whole genome (Figure 5.3). 
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5.2.2.1.3 Library preparation and sequencing6 
 For library preparation and sequencing, 250 ng of the genomic DNA was sent to 
McDonnell Genome Institute (Washington University, St. Louis) for each participant 
included in the Sequencing Cohort. Construction of Ilmumina indexed libraries was done 
following a modified version of the manufacturer’s protocol and Nextera DNA Sample 
Prep kit (Illumina Inc., San Diego). The protocol includes fragmentation of DNA in 100 
to 400 bp strands using a Covaris E220 DNA Sonicator (Covaris Inc., Woburn) followed 
by an addition of a sequence adapter to either end of the fragmented DNA. The 
amplification was done in eight cycles adding sequencing primers and indices to the 
adapter ligated DNA fragments. Library purification and size selection was carried out 
via the Solid Phase Reversible Immobilisation (SPRI) technique that uses AMPure XP 
beads specified for targeting 300 to 500 bp DNA fragments. Next, fragment hybridisation 
and amplification was completed using custom Roche NimbleGen SeqCap kit (Roche 
NimbleGen Inc., Madison). All instructions were followed as provided in the 
manufacturer’s protocol. Sequencing was done on Illumina HiSeq 2500 (Illumina, San 
Diego) with 90 dual-indexed samples combined and captured as a pool to run in a single 
sequence lane. The sequencing was completed with an average of 51.2x coverage across 
2.6 Mb of the targeted sequenced genome. 
5.2.2.1.4 Variant calling7 
 The Genome Analysis Tool Kit (GATK) best practice pipeline (Auwera et al., 
2013) was followed for alignment of the raw sequence data and variant calling. All 
procedures for sequence alignment and variant calling were carried out in the Merriman 
Laboratory. As a first step of variant calling, Sequence Alignment/Map (SAM) tools 1.1.2 
was used to extract FastQ files from the raw sequence data files. These files were then 
aligned to human reference genome (build GRCh37) using the ‘mem’ (memory) 
command of the Burrows-Wheeler Aligner (BWA 0.7.12) to create binary alignment/map 
(BAM) files (Li and Durbin, 2009; Li et al., 2009). To mark the reads from PCR 
duplication, the above BAM files were processed using Picard 1.114 
                                                 
6  A staff member of the Merriman Laboratory, Amanda Phipps Green (Assistant Research Fellow), 
managed the sample shipping. 
7  All sequence alignment, variant calling and library preparation was performed by James Boocock 
(Research Assistant) at the Merriman Laboratory. 
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(www.github.com/broadinstitute/picard), followed by insertion/deletion (indel) alignment 
and base recalibration in GATK 3.3.0 (McKenna et al., 2010). Genomic variant call 
format (gVCF) files were created using GNU Parallel command line and the GATK 
HaplotypeCaller (DePristo et al., 2011; Tange, 2011). Prior to variant calling, these gVCF 
files were merged in batches (100 files per batch) using GATK. The SNPs in the resulting 
variant call format (VCF) file were processed using the GATK variant quality score 
recalibration utility. This utility calculated the quality of the SNPs by depth, Fisher score, 
mapping quality rank sum and read position rank sum. Next, any SNP with a truth 
sensitivity of less than 99.00 was removed during recalibration of the VCF file. Ensembl 
variant effect predictor or Ve!P (www.grch37.ensembl.org/Tools/VEP) and GEMINI 
0.17.0 (www.gemini.readthedocs.org) platforms were used to annotate the resultant SNPs. 
The annotations mainly included assigning the reference SNP cluster ID (rs number), type 
of the variant (exonic, intronic or intergenic), genes and transcripts (with length of the 
transcript) possibly affected by each variant and location of each variant. 
5.2.2.2 Association analyses – Discovery-phase 
 For the purpose of analysis in this study, the detailed exon (coding) region data of 
LRP2 and A1CF genes were extracted from the targeted sequencing of 2.6 Mb of the 
genome (Figure 5.3). A systematic flow was followed to analyse for an association of 
variants within the LRP2 and A1CF genes with hyperuricaemia (NZ Polynesian and 
European) and gout (NZ Polynesian). It was not possible to assess the European data set 
for an association with gout due to the unavailability of gout diagnosis status in HPFS and 
NHS datasets. After extracting out all coding (exon) region variants (SNPs) for both 
genes, each of these variants was analysed separately to assess an association with 
hyperuricaemia and gout. Non-synonymous (missense), low-frequency and rare variants 
were then selected and analysed for a burden for hyperuricaemia and gout in respective 
populations. 
5.2.2.2.1 Single variant association analysis 
 The study focused only on variants that fell within the LRP2 (2:169,983,619 to 
170,219,195) and A1CF (10:52,559,169 to 52,645,435) transcribed gene regions 
(ENST00000263816 and ENST00000374001 coordinates). Those variants that passed the 
quality control criteria were selected within these regions. Any variant for which an rs ID 
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was not available was annotated by its location on the chromosome with a prefix ‘var’ 
(var = variant). A logistic regression based loop model was created in R version 3.3.2 
(RCore, 2016) to calculate the effect estimates and allelic odds ratio (OR) for each variant 
(explanatory variable) in the NZ Polynesian and European data sets. The regression was 
applied to test for association with hyperuricaemia and gout (binary response variables) 
and estimated glomerular filtration rate (eGFR: continuous response variable). The 
regression model was adjusted for sex, age and BMI (wherever possible) to obtain the 
odds ratios for both populations. Estimates for grand-parental ancestry and collection 
study were added as additional adjustors for NZ Polynesian and European data sets, 
respectively. In order to calculate the combined effect of variants, meta-analysis was done 
using the ‘meta package’ (www.CRAN.R-project.org/package=meta) within R (version 
3.3.2) using a fixed-effect model. For analyses showing heterogeneity (PHet < 0.05), the 
fixed-effect model was replaced with a random-effect model. All allelic odds ratio 
calculated for the ReSequencing Cohort were relevant to the minor allele. Any individual 
with missing or incomplete data was excluded from the various analyses. Power to detect 
a POR < 0.05 was calculated in NZ Polynesian and European data sets following the 
Johnson et al. (2001) methodology. 
5.2.2.2.2 Burden analysis 
 Burden analysis is designed to calculate the effect of all variants in a gene 
together in contrast to analysing each variant separately. This type of analysis considers 
the gene or region of interest a single unit rather than taking the effect of each variant 
alone. The analysis could, therefore, mitigate the inherent lack of power in single variant 
association analyses (Lee et al., 2014). 
 Allele frequencies obtained from single variant analyses were combined 
separately for each variant, in each sample set, for both LRP2 and A1CF genes. A 
combined allele frequency of < 0.05 (5%) was set as cut-off to determine the rare (< 0.05 
- 0.01) and very rare (< 0.01) variants in the genes regardless of their functional 
cosequences. The allele collapsing methodology of Li and Leal (2008) was used to 
classify the individuals as carriers or non-carriers of the rare allele. Following this 
methodology, the individuals were classified as having or not having a rare allele at any 
site, i.e., 




 The number of individuals carrying a rare allele, it’s frequency and the difference 
between allele-frequency was then calculated for hyperuricaemic (cases) and 
normouricaemic (controls) via Pearson Chi-square test (Li and Leal, 2008). 
 A weighted sum statistic was used to calculate the burden of rare variants for 
hyperuricaemia in the NZ Polynesian and European sample sets. The specific 
methodology followed to calculate the weighted sum (adaptive burden test) of variants 
was first proposed by Ionita-Laza et al. (2011). This test is less sensitive to the presence 
of both risk and protective variants in a genetic region of interest and calculates the 
burden according to the frequency of variants in cases and controls. The test was 
performed by following these basic steps; 
1. Variants in question were classified into those that have a higher observed 
frequency in cases (k') and those that have a higher observed frequency in controls 
(k). 
2. A two-sided weighted (SNP effect-weighted) summary statistic (S+ and S-) was 
calculated that represents the possible burden of risk and protective variants in the 
gene or region. 
3. A one-sided p-value was calculated for risk and protective variants through 
standard permutation. The permutation involves random permuting (shuffling) of 
case/control label followed by recalculating S statistic. 
4. A two-sided p-value was calculated to assess combined burden of risk and 
protective variants (Sc = S+ + S-) via the same permutation. 
 The source code/C++ for the analysis was downloaded from www.columbia.edu. 
The code was separately run for both study populations, each tested for 1,000; 10,000; 
50,000 and 100,000 turns of permutations. The above strategy was applied to calculate 
the burden of low-frequency and rare (< 5% MAF), only rare (≤ 1% MAF) and non-
synonymous variants in both genes. 
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5.2.2.2.3 Functional annotation of variants 
 Functional attributes for each variant were identified and added to the VCF during 
the ‘variant calling’ phase via GEMINI and Ve!P. This phase added synonymous and 
non-synonymous annotations to all variants in the VCF along with the indication of the 
codon and the amino acid these variants could change. The functional annotations were 
assessed using four of the several tools specified in the Table 5.1. These tools are 
designed to provide a prediction score with a cut-off value that indicates if a variant is 
deleterious or neutral for a change in protein. For this study, the impact of each exonic 
variant within LRP2 and A1CF was evaluated online by applying corresponding binary 
classification criteria (deleterious or damaging and neutral). The online platforms used to 
assess the scores were; CADD (www.cadd.gs.washington.edu: score ≥ 10 indicates 
deleteriousness), SIFT (www.sift.jcvi.org: score ≤ 0.05 indicates damaging affect), 
PolyPhen-2 (www.genetics.bwh.harvard.edu: score ≥ 0.43 indicates damaging affect) and 
PROVEAN (www.provean.jcvi.org: score ≤ -2.5 is deleterious). 
5.2.2.3 Association analyses – Replication-phase 
 The distinct association signals in the discovery-phase analysis were replicated in 
NZ European and Polynesian datasets. The replication was carried out to 1) confirm and 
validate the putative associations found in the ‘discovery-phase’, and 2) to describe the 
possible biological significance of the validated associations for hyperuricaemia and gout. 
5.2.2.3.1 Prioritisation of variants 
 Prioritisation of the discovery-phase variants within LRP2 and A1CF was done 
based on several criteria. The same selection criteria were applied for NZ Polynesian and 
European populations. These criteria were: 
1. Level of significance – All variants having a nominally significant (P < 0.05) 
association for hyperuricaemia for at least one population were included. 
2. Direction of association – The prioritisation was done independent of direction of 
association i.e., rare variants showing either risk or protective association were 
selected from both populations. 
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3. Population-specificity – Any variant found in only one of the two populations (NZ 
Polynesian and European) was included. 
4. Novelty – Any significant variant with no earlier record in 1000 Genome database 
was also included. 
 In order to rule out the possibility of complete linkage disequilibrium, an LD (R-
squared limit = 0.60) was calculated between all prioritised variants using information 
available in the 1000 Genome database (www.browser.1000genomes.org). 
5.2.2.3.2 Study participants 
 A sub-set of individuals was included from New Zealand Gout Cohort (Section 
1.2.1) to create the Replication Cohort. All subjects who were part of the ReSequencing 
Cohort (Discovery-phase) were excluded from the Replication Cohort. The Replication 
Cohort was categorised into two major ancestral groups, NZ Polynesian and European 
(728 cases and 446 controls). The New Zealand Polynesian group (1001 cases and 1134 
controls) was further divided into three sub-groups, East Polynesian (EP: 396 cases and 
613 controls), West Polynesian (WP: 310 cases and 270 controls) and a mixture of East 
and West Polynesian (EPWP: 26 cases and 59 controls). The categorisation was done as 
described by Hollis-Moffatt et al. (2012b). Data from the Ngati Porou Hauora (NPH) 
individuals were also included as a separate Māori sample set (NPH: 269 cases and 192 
controls) (See details of each Polynesian sub-group in Chapter 1, Section 1.2.1). Table 
5.3 provides demographic details of the Replication Cohort. 
 Of the above, control (non-gout) subjects were included to test for an association 
with serum urate in NZ Polynesian and NZ European individuals in the Replication 
Cohort. All subjects who self-reported as taking diuretic medication, or had renal failure 
or gout, or who were first-degree relatives with gout patients, were removed from serum 
urate association analysis. 
5.2.2.3.3 Genotyping 
 Two Polynesian specific variants, rs111360923 and var170115626, were 
genotyped over the NZ Polynesian samples only. Genotyping was performed by an allelic 
discrimination assay i.e., TaqMan® SNP Genotyping assay (C_2215549_20; Applied 
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Biosystems, Foster City, USA) following the instruction provided in their protocol. The 
TaqMan SNP genotyping were auto-called via reporter dye signal plots on Lightcycler® 
480 Real-Time Polymerase Chain Reaction (RT-PCR) System (Roche Applied Science, 
Indianapolis, IN, USA). These plots were then used to analyse and export correct 
genotype clustering. Genotyping data for rs2302694, rs4667596, rs2075252, rs4667591 
and rs41268685 were sourced from the Illumina Chip CoreExome dataset. The 
genotyping details for this dataset are already described in Chapter 2 (Section 2.2.2.2). 
5.2.2.3.4 Statistical analysis 
 A multiply adjusted regression analysis approach was used to measure an 
association of the seven prioritised variants (explanatory variables) with hyperuricaemia, 
gout (binary response variables) and serum urate (continuous response variable). All 
logistic and linear regression analyses were done using statistical software R version 3.3.2 
(RCore, 2016). Any participant with missing data for any variable was excluded from the 
various analyses. Allelic ORs and β-estimates were calculated for each variant including 
age, sex and BMI as primary adjustors in the regression model. For Polynesian 
individuals, self-reported grandparental ancestry was included as an additional adjustor in 
the various analyses. To increase the power of analysis, all NZ Polynesian subgroups 
were combined separately and with the European data set in meta-analysis using the Meta 
package within R (http://CRAN.R-project.org/package=meta, 2014) using a fixed-effect 
model. For a meta analysis showing heterogeneity (PHet < 0.05), the fixed-effect model 
was replaced with a random-effect model. A P ≤ 0.05 was used to indicate the threshold 
for nominal statistical significance between response and explanatory variables in 
regression and meta models. Power to detect a POR < 0.05 was calculated in NZ 
Polynesian and European data sets following the Johnson et al. (2001) methodology. For 
any variants with Polynesian-specific outcomes, an intra-variant LD (R-squared limit = 
0.60) was calculated in order to rule out the possibility of complete linkage 
disequilibrium, using genotype information in NZ Polynesian population. 
5| Lipid Metabolism - Rare Variant Analysis 
 210 
Table 5.3: Demographic details of the Replication Cohort 
Population NZ Polynesian 
NZ European 
Sub-population East Polynesian/EP West Polynesian/WP EPWP Ngati Porou Hauora/NPH 
Group Gout Non-gout Gout Non-gout Gout Non-gout Gout Non-gout Gout Non-gout 
Baseline Information 
Total number (n) 396 613 310 270 26 59 269 192 728 446 
Males, n (%) 334 (84.34) 250 (40.78) 308 (99.35) 154 (57.03) 25 (96.15) 24 (40.67) 224 (83.27) 99 (51.56) 654 (89.83) 308 (69.05) 
Age (years)^ 57.02 ± 12.36 43.19 ± 15.43 49.92 ± 11.86 37.37 ± 14.98 45.25 ± 11.78 35.29 ± 17.11 58.41 ± 12.66 42.15 ± 14.64 63.88 ± 12.87 54.40 ± 16.68 
BMI (kg/m2)^ 35.06 ± 7.68 32.11 ± 8.20 36.80 ± 8.33 33.90 ± 6.56 36.76 ± 8.14 33.52 ± 7.57 36.49 ± 8.01 30.71 ± 5.89 30.29 ± 5.30 27.65 ± 5.63 
Serum Urate (mmol L-1)^ 0.38 ± 0.10 0.36 ± 0.08 0.41 ± 0.11 0.40 ± 0.08 0.43 ± 0.07 0.40 ± 0.10 0.43 ± 0.11 0.36 ± 0.08 0.39 ± 0.11 0.34 ± 0.11 
Co-morbidities 
Type II Diabetes, n (%) 122 (28.57) 68 (11.48) 83 (24.85) 35 (13.31) 9 (32.14) 4 (6.77) 82 (31.41) 12 (6.41) 118 (15.14) 30 (6.83) 
Dyslipidaemia, n (%) 202 (50.88) 77 (13.65) 166 (51.55) 32 (12.40) 14 (51.85) 5 (8.92) 137 (52.69) 37 (20.11) 370 (48.23) 86 (20.57) 
Heart problems, n (%) 192 (44.44) 71 (11.79) 80 (23.52) 18 (6.69) 9 (33.33) 4 (6.66) 92 (35.38) 19 (10.05) 288 (37.02) 65 (14.61) 
Hypertension, n (%) 277 (64.58) 152 (25.81) 173 (52.26) 40 (14.92) 15 (53.57) 8 (13.79) 177 (67.30) 35 (18.61) 424 (54.85) 104 (23.63) 
Kidney problems, n (%) 114 (26.76) 19 (3.59) 72 (21.95) 8 (3.18) 8 (29.62) 2 (4.00) 32 (12.40) 5 (3.04) 176 (22.76) 22 (5.21) 
Gout Characteristics 
Age at onset gout (years)^ 41.57 ± 15.35 - 37.11 ± 13.05 - 29.39 ± 10.84 - 40.49 ± 15.24 - 48.82 ± 16.93 - 
On Diuretics/ULT, n (%) 143 (45.11) - 80 (27.02) - 12 (48.00) - 15 (19.23) - 199 (71.84) - 
Gout attacks (per year)^ 9.53 ± 34.66 - 11.30 ± 28.35 - 7.53 ± 10.34 - 2.89 ± 4.85 - 7.97 ± 35.36 - 
Gout tophus, n (%) 164 (38.95) - 155 (46.68) - 12 (46.15) - 25 (9.54) - 271 (65.38) - 
NZ: New Zealand, BMI: Body mass index, n (%): total number (percentage: calculated for the number of individuals who reported for any category), ULT: Urate lowering therapy. ^Data 
are shown as mean ± standard deviation (for the number of individuals who reported for any category). Data for the co-morbidities are self-reported. Data for NZ Polynesian are represented 
as an average for individuals genotyped through TaqMan PCR and Illumina Core Exome Chip genotyping (EP: 370 cases and 463 controls, WP: 282 cases and 192 controls, EPWP: 24 
cases and 45 controls, NPH: 144 cases and 65 controls), while demographic data for NZ European represents demographic of indiviuals genotyped through Illumina Core Exome Chip 
genotyping only.  
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5.2.3 Results – Discovery-phase 
 Power calculations inidcated European and NZ Polynesian data sets to be only 
adequately powered (> 80%) to detect a significant association (OR = 2.0) in the variants 
with a minor allele frequency > 0.2 (Figure 5.4). A formal multiple-testing correction was 
avoided due to the low power of the study and due to replication being included in the 
study design. 
Figure 5.4: Association detection power in the (A) European and (B) Polynesian ReSequencing Cohorts across a 
range of odds ratio effect sizes and minor allele frequencies. The broken red line indicates an adequate detection 
power ≥ 80%. 
 Extracting the data of coding regions ended up in a list of 134 variants for LRP2 
and 69 for A1CF (Appendix A Table 5.3 and Appendix B Figure 5.1). Within LRP2, 81 
variants were identified to be non-synonymous (missense), while only 4 non-synonymous 
(missense) variants were found in A1CF. Table 5.4 provides a summary of variable 
nucleotide sites for both genes.  
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Table 5.4: Summary of coding region variants of LRP2 and A1CF 
Ex Len Ts Tv Ts/Tv Sn NS Ex Len Ts Tv Ts/Tv Sn NS 
A1CF 
5' UTR - 3 0 - - - 8 274 1 0 - 1 0 
1 95 0 0 - 0 0 9 182 1 0 - 0 1 
2 144 1 0 - 1 0 10 137 0 0 - 0 0 
3 135 2 0 - 2 0 11 149 0 0 - 0 0 
4 131 1 0 - 1 0 12 7,472 1 1 1 2 0 
5 239 3 0 - 1 2 3' UTR - 31 20 1.55 - - 
6 165 2 0 - 1 1 Total 9,221 48 21 2.28 11 4 
7 98 2 0 - 2 0        
LRP2 
1 365 0 0 - 0 0 41 159 0 1 - 1 0 
2 108 1 1 1.00 0 2 42 290 5 0 - 4 1 
3 123 1 0 - 0 1 43 204 0 0 - 0 0 
4 117 1 2 0.50 2 1 44 243 0 1 - 0 1 
5 111 0 0 - 0 0 45 126 1 0 - 0 1 
6 114 1 0 - 1 0 46 120 1 0 - 0 1 
7 117 1 0 - 0 1 47 132 1 0 - 0 1 
8 153 2 1 2.00 2 1 48 202 1 0 - 1 0 
9 120 0 0 - 0 0 49 296 1 0 - 0 1 
10 129 0 0 - 0 0 50 517 4 0 - 2 2 
11 170 2 0 - 2 0 51 153 2 1 2.00 1 2 
12 224 2 0 - 0 2 52 171 1 0 - 1 0 
13 207 4 0 - 1 3 53 224 1 0 - 0 1 
14 203 4 0 - 2 2 54 178 1 0 - 1 0 
15 141 5 0 - 2 3 55 197 3 0 - 1 2 
16 204 2 3 0.67 1 4 56 246 2 1 2.00 1 2 
17 193 0 0 - 0 0 57 129 2 0 - 1 1 
18 126 0 1 - 0 1 58 120 1 0 - 1 0 
19 131 5 2 2.50 5 2 59 117 1 1 1.00 1 1 
20 138 2 0 - 1 1 60 117 1 0 - 0 1 
21 282 1 0 - 0 1 61 138 1 0 - 1 0 
22 240 2 0 - 1 1 62 123 1 0 - 0 1 
23 120 2 1 2.00 2 1 63 129 0 0 - 0 0 
24 117 0 0 - 0 0 64 132 1 1 1.00 0 2 
25 378 0 0 - 0 0 65 132 1 0 - 0 1 
26 249 1 1 1.00 1 1 66 144 1 0 - 1 0 
27 212 0 1 - 0 1 67 166 1 1 1.00 0 2 
28 185 0 1 - 1 0 68 129 0 0 - 0 0 
29 229 4 0 - 2 2 69 221 1 1 1.00 0 2 
30 178 2 0 - 1 1 70 177 1 1 1.00 1 1 
31 129 1 3 0.33 1 3 71 120 0 0 - 0 0 
32 167 1 0 - 0 1 72 91 1 0 - 0 1 
33 144 0 0 - 0 0 73 68 2 0 - 0 2 
34 110 0 0 - 0 0 74 121 1 1 1.00 1 1 
35 178 0 0 - 0 0 75 130 0 1 - 1 0 
36 214 2 0 - 1 1 76 102 0 0 - 0 0 
37 240 2 1 2.00 0 3 77 108 1 0 - 0 1 
38 189 1 0 - 0 1 78 72 0 0 - 0 0 
39 921 7 3 2.33 2 8 79 1,722 1 0 - 1 0 
40 166 0 0 - 0 0 Total 15,808 102 32 3.19 53 81 
Ex: Exon number, Len: Length of the exon in base pairs (bps) according to the longest transcript reported in Genome 
Reference consortium human genome build 37 (GRCh37) on Ensembl (http://grch37.ensembl.org/), Ts: Transitions, 
Tv: Transversions, Ts/Tv: Ratio of transitions to transversions, Sn: Total synonymous variants, NS: Total non-
synonymous (missense) variants, UTR: Untranslated region. 
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5.2.3.1 Single variant association analyses 
 Single variant association analysis for each variant within LRP2 and A1CF exonic 
regions indicated population-specific variants for both genes. Only 31.86% of the variants 
were present in one out of two populations with 18 European-specific (12 for LRP2; 6 for 
A1CF) and 11 Polynesian-specific variants (8 for LRP2; 3 for A1CF). A total of 25 (19 
for LRP2; 6 for A1CF) variants were found to be common (combined altered allele 
frequency > 5%) for both genes. 
 For LRP2, overall, 10 variants (i.e., the altered allele of each variant) were 
significantly associated with hyperuricaemia in European (rs34693334, rs41268685, 
rs2075252, rs4667591) and NZ Polynesian (rs111360923, rs13397109, rs2302694, 
rs4667596, rs830994, var170115626) (Table 5.5). Out of these, two non-synonymous 
(missense) variants were found only in the Polynesian population with almost equal allele 
frequencies (rs111360923: C-allele frequency = 0.071; var170115626: C-allele frequency 
= 0.074) (Table 5.5). The C allele of rs111360923 and the C allele of var170115626 were 
protectively associated with hyperuricaemia (rs111360923: OR = 0.55, POR = 0.02; 
var170115626: OR = 0.57, POR = 0.03) (Table 5.5). It was also not possible to calculate 
linkage disequilibrium (LD) between these two variants in any population due to 
unavailability of the information in 1000 Genome database 
(www.browser.1000genomes.org). The altered alleles of all other variants indicated a 
protective association with hyperuricaemia, except two missense variants, rs34693334 
and rs34693334. The G allele of rs34693334 and T allele of rs41268685 were found to 
be associated with an increased risk of hyperuricaemia in Europeans only (rs34693334: 
OR = 2.33, POR = 0.02; rs41268685: OR = 3.85, POR = 0.04) (Table 5.5). However, 
similar effects were not observed for NZ Polynesians for these two variants (Table 5.5). 
Another variant of interest was rs4667591 (missense), where the G allele was found to be 
protectively associated with hyperuricaemia in Europeans (OR = 0.61, POR = 0.05) and 
indicated a similar trend of association in NZ Polynesians (OR = 0.75, POR = 0.08) (Table 
5.5). Of the above 10 significant variants (except 2 Polynesian-specific SNPs), none was 
in LD with any other in the Caucasian or Han Chinese populations (Figure 5.5). Two 
exceptions were rs2075252 and rs4667591 having 82% LD and rs4667596 and 
rs2302694 having 100% LD only in Han Chinese population (Figure 5.5). No association 
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was found for any of the A1CF variants with hyperuricaemia in either population (Table 
5.5). 
 When the European and NZ Polynesian data sets were combined together in meta-
analysis, only few variants within LRP2 indicated some interesting results (Appendix A 
Table 5.3). The A allele of rs2302694 (OR = 0.54, POR = 0.001, PHet = 0.29), the T allele 
of rs4667596 (OR = 0.36, POR = 0.03, PHet = 0.31), the C allele of rs2075252 (OR = 0.75, 
POR = 0.03, PHet =0.41) and the G allele of rs4667591 (OR = 0.72, POR = 0.01, PHet = 
0.43) all indicated a protective association with hyperuricaemia (Appendix A Table 5.3). 
The C allele of rs2229265 was associated with 32% increase in risk of developing 
hyperuricaemia (OR = 1.32, POR = 0.03, PHet = 0.81) (Appendix A Table 5.3). 
 Single variant regression analysis was also carried out with gout and eGFR 
(estimated glomerular filtration rate) to assess an association with gout and kidney 
function. However, these two analyses were limited to NZ Polynesians only due to 
unavailability of information for both traits, gout status and eGFR, in HPFS and NHS 
data sets. Owing to the significance of outcomes, the results for association analysis for 
gout are provided below, while those for eGFR are provided in Appendix A Table 5.4. 
 The C alleles of two Polynesian-specific non-synonymous variants within LRP2 
were also protectively associated with gout (rs111360923: OR = 0.44, POR = 0.004; 
var170115626: OR = 0.46, POR = 0.006) (Table 5.6). The consistent pattern of protective 
association with gout was observed for the G allele of rs4667591 (OR = 0.72, POR = 0.04), 
the G allele of rs830994 (OR = 0.55, POR = 0.003), the A allele of rs2302694 (OR = 0.44, 
POR = 0.001) and the C allele of rs13397109 (OR = 0.45, POR = 0.0009) (Table 5.6). In 
addition, the T allele of rs2075249 (OR = 1.42, POR = 0.05) and the C allele of rs2229265 
(OR = 1.55, POR = 0.019) indicated a susceptible association with gout in NZ Polynesians 
(Table 5.6). Neither of these two variants were in LD with each other in European or 
Hans Chinese populations on 1000 Genomes database (Figure 5.5). In addition, only the 
A allele of rs149367019 (within LRP2) indicated a negative association with eGFR (ß 
(mL/min/1.73m2) = -44.15, Pß = 0.044) (Appendix A Table 5.4). 
 Two variants within A1CF indicated interesting results (Table 5.6). The G allele 
of rs16751 was found to be associated with an increased risk of gout (OR = 1.38, POR = 
0.01), while the A allele of rs184644838 showed an association with decreased risk of 
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gout (OR = 0.59, POR = 0.006) in the NZ Polynesian population (Table 5.6). It was not 
possible to calculate the LD for these variants in European and Han Chinese populations 
as no information was available for rs16751 on any selected array on 1000 Genome 
database. 
Figure 5.5: Linkage disequilibrium (LD) plot indicating ‘R-squared/r2’ values between the 12 LRP2 variants in 
(A) Europeans and (B) Chinese populations. An r2 ≥ 60 in the above plot indicates LD between the particular 
variants. Information for variant location, rs ID and LD values are from 1000 Genome database 
(http://browser.1000genomes.org/). The plots were generated using Haploview v4.2. 
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UTR: Un-translated region, rs ID: Reference SNP cluster ID, Chr: Chromosome, var: Variant, Ref: Reference, Alt: Alternate. Normo: Normouricaemic, Hyper: Hyperuricaemic, OR: Odds 
ratio for the alternate allele, 95% CI: 95% confidence interval, POR: p-value for odds ratio. *Odds ratios are adjusted for sex, age, BMI and estimates of grand-parental ancestry. ^Odds 
ratios are adjusted for sex and collection study. Exon numbers and variant positions are sourced from the Genome Reference Consortium human genome build 37 (GRCh37) on Ensembl 
(http://grch37.ensembl.org/). 
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Allele Codon Allele Frequency 
*OR [95% CI] *POR 
Ref Alt Ref|Alt Control Case 
     LRP2     
2 2:170177382 rs144829356 G A gGg|gAg 93 (0.171) 73 (0.221) 1.27 [0.88 ; 1.82] 0.20 
3 2:170175334 rs2229263 T C aTc|aCc 86 (0.158) 44 (0.133) 0.78 [0.51 ; 1.20] 0.26 
4 2:170163816 rs34104660 G T ccG|ccT 3 (0.006) 0 (0.000) - 0.98 
4 2:170163808 var170163808 G T gGt|gTt 0 (0.000) 1 (0.003) - 0.98 
6 2:170150671 rs2229266 G A gaG|gaA 190 (0.349) 125 (0.379) 1.19 [0.87 ; 1.65] 0.28 
7 2:170148871 var170148871 T C Tcc|Ccc 0 (0.000) 1 (0.003) - 0.98 
8 2:170147502 rs34693334 C G Cgt|Ggt 5 (0.009) 3 (0.009) 0.62 [0.14 ; 2.75] 0.53 
8 2:170147408 var170147408 A G tAa|tGa 0 (0.000) 1 (0.003) - 0.98 
14 2:170131548 rs111360923 T C tTt|tCt 60 (0.110) 20 (0.061) 0.44 [0.25 ; 0.78] 0.004 
14 2:170129547 rs34291900 C T gCc|gTc 2 (0.004) 1 (0.003) 0.77 [0.06 ; 9.86] 0.84 
14 2:170129528 rs830994 A G gtA|gtG 121 (0.222) 49 (0.148) 0.55 [0.37 ; 0.82] 0.003 
15 2:170115588 rs2241190 T C acT|acC 219 (0.403) 123 (0.373) 0.91 [0.67 ; 1.24] 0.56 
15 2:170115672 rs33954745 A G gaA|gaG 8 (0.015) 4 (0.012) 0.76 [0.19 ; 2.96] 0.69 
16 2:170127559 rs141180155 G A acG|acA 0 (0.000) 1 (0.003) - 0.98 
16 2:170113671 rs147621120 T A Tct|Act 1 (0.002) 0 (0.000) - 0.98 
16 2:170127497 var170127497 A G aAt|aGt 0 (0.000) 1 (0.003) - 0.98 
17 2:170115626 var170115626 T C Ttc|Ctc 59 (0.108) 20 (0.061) 0.46 [0.26 ; 0.81] 0.006 
18 2:170104017 var170104017 A C Att|Ctt 2 (0.004) 0 (0.000) - 0.98 
19 2:170103471 rs17848143 C T acC|acT 6 (0.011) 3 (0.009) 0.81 [0.18 ; 3.67] 0.79 
19 2:170103351 rs2075249 G T acG|acT 126 (0.232) 93 (0.282) 1.42 [1.00 ; 2.01] 0.05 
19 2:170103336 rs831043 T C acT|acC 218 (0.401) 123 (0.373) 0.92 [0.68 ; 1.26] 0.61 
19 2:170103219 var170103219 T A acT|acA 1 (0.002) 0 (0.000) - 0.98 
22 2:170099474 rs144723964 G A gGa|gAa 1 (0.002) 0 (0.000) - 0.98 
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22 2:170099473 rs831042 T C gcT|gcC 218 (0.401) 123 (0.373) 0.92 [0.68 ; 1.26] 0.61 
23 2:170097655 rs138030034 G A tgG|tgA 1 (0.002) 0 (0.000) - 0.98 
23 2:170097707 rs17848149 T G gTc|gGc 35 (0.064) 183 (0.555) 1.12 [0.61 ; 2.06] 0.72 
26 2:170096095 rs34915742 C G cgC|cgG 1 (0.002) 0 (0.000) - 0.98 
28 2:170093726 var170093726 T G acT|acG 5 (0.009) 2 (0.006) 0.60 [0.10 ; 3.74] 0.59 
29 2:170092395 rs2229267 A G tgA|tgG 164 (0.301) 90 (0.273) 0.90 [0.64 ; 1.27] 0.56 
29 2:170092504 var170092504 C T cCc|cTc 6 (0.011) 9 (0.027) 2.59 [0.81 ; 8.33] 0.11 
30 2:170089934 rs145384264 C T tcC|tcT 2 (0.004) 1 (0.003) 0.79 [0.06 ; 10.35] 0.86 
31 2:170088296 rs144054579 C G Cgg|Ggg 1 (0.002) 0 (0.000) - 0.98 
31 2:170088242 rs149469954 G A Gtc|Atc 0 (0.000) 1 (0.003) - 0.98 
31 2:170088351 rs2302694 G A tcG|tcA 78 (0.143) 28 (0.085) 0.44 [0.27 ; 0.72] 0.001 
36 2:170070348 rs11886219 T C cgT|cgC 8 (0.015) 4 (0.012) 0.93 [0.23 ; 3.74] 0.92 
36 2:170070172 rs4667596 C T aCa|aTa 10 (0.018) 4 (0.012) 0.43 [0.12 ; 1.46] 0.17 
39 2:170063263 rs149367019 G A Gta|Ata 1 (0.002) 0 (0.000) - 0.98 
39 2:170063471 rs35114151 A G gaA|gaG 35 (0.064) 17 (0.052) 1.07 [0.57 ; 1.98] 0.84 
39 2:170063380 rs35413340 T C Tct|Cct 1 (0.002) 0 (0.000) - 0.98 
39 2:170062977 rs61995915 T C gTa|gCa 0 (0.000) 1 (0.003) - 0.98 
41 2:170062078 rs13397109 G C cgG|cgC 95 (0.175) 31 (0.094) 0.45 [0.28 ; 0.72] 0.0009 
42 2:170060603 rs17848169 T C Tat|Cat 2 (0.004) 1 (0.003) 0.77 [0.06 ; 9.86] 0.84 
42 2:170060619 rs199593393 C T caC|caT 0 (0.000) 1 (0.003) - 0.98 
44 2:170058345 var170058345 C A Ccc|Acc 5 (0.009) 3 (0.009) 0.75 [0.16 ; 3.46] 0.71 
45 2:170055385 var170055385 T C cTt|cCt 1 (0.002) 0 (0.000) - 0.98 
46 2:170053505 rs2228171 T C Tca|Cca 234 (0.430) 132 (0.400) 0.88 [0.65 ; 1.19] 0.40 
48 2:170048482 var170038806 C T cCc|cTc 0 (0.000) 1 (0.003) - 0.98 
54 2:170032989 rs2229265 T C caT|caC 409 (0.752) 268 (0.812) 1.55 [1.07 ; 2.23] 0.019 
55 2:170031824 rs17848184 C T ccC|ccT 107 (0.197) 76 (0.230) 1.31 [0.90 ; 1.92] 0.16 
56 2:170030506 rs142549310 C T cCc|cTc 1 (0.002) 0 (0.000) - 0.98 
56 2:170030556 var170030556 G A caG|caA 0 (0.000) 3 (0.009) - 0.98 
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58 2:170028529 rs199528723 G A aaG|aaA 5 (0.009) 5 (0.015) 1.08 [0.29 ; 3.99] 0.91 
61 2:170025083 rs2229268 A G tgA|tgG 34 (0.063) 33 (0.100) 1.72 [0.96 ; 3.09] 0.06 
62 2:170022511 var170022511 T C Ttt|Ctt 1 (0.002) 0 (0.000) - 0.98 
64 2:170013904 rs79723119 A C gAt|gCt 1 (0.002) 0 (0.000) - 0.98 
64 2:170013979 var170013979 A G aAa|aGa 1 (0.002) 0 (0.000) - 0.98 
66 2:170010985 rs2075252 T C Tag|Cag 173 (0.318) 96 (0.291) 0.81 [0.58 ; 1.13] 0.21 
69 2:170003432 rs4667591 T G Ttc|Gtc 214 (0.393) 110 (0.333) 0.72 [0.53 ; 0.99] 0.04 
70 2:170002412 var170002412 T C gTc|gCc 1 (0.002) 1 (0.003) 0.90 [0.06 ; 14.56] 0.94 
72 2:169997051 rs990626 G A atG|atA 231 (0.425) 127 (0.385) 0.81 [0.60 ; 1.11] 0.19 
73 2:169996070 rs41268685 C T gCc|gTc 1 (0.002) 0 (0.000) - 0.98 
74 2:169995880 rs370978040 G A acG|acA 0 (0.000) 1 (0.003) - 0.98 
A1CF 
5' UTR 10:52645424 rs10994860 C T - 67 (0.124) 38 (0.113) 1.03 [0.63 ; 1.67] 0.91 
5' UTR 10:52619722 var52619722 A G - 1 (0.002) 0 (0.000) - 0.98 
2 10:52623804 var52623804 A G - 11 (0.020) 5 (0.015) 0.64 [0.22 ; 1.88] 0.42 
3 10:52603874 rs142969066 T C ggT|ggC 1 (0.002) 0 (0.000) - 0.98 
3 10:52603754 rs35967725 A G tgA|tgG 1 (0.002) 1 (0.003) 2.40 [0.11 ; 51.57] 0.58 
5 10:52595864 var52595864 C T Cct|Tct 1 (0.002) 0 (0.000) - 0.98 
6 10:52588045 rs146662131 C T caC|caT 1 (0.002) 0 (0.000) - 0.98 
7 10:52576068 rs4245008 A G - 100 (0.185) 57 (0.170) 0.94 [0.63 ; 1.39] 0.74 
9 10:52573772 rs41274050 C T Cgc|Tgc 1 (0.002) 0 (0.000) - 0.98 
12 10:52566594 rs34190540 G C ctG|ctC 3 (0.006) 2 (0.006) 1.32 [0.18 ; 9.81] 0.78 
3' UTR 10:52559291 rs61856570 A G - 1 (0.002) 3 (0.009) 1.84 [0.18 ; 18.82] 0.61 
3' UTR 10:52559634 rs10994507 A G - 27 (0.050) 13 (0.039) 0.85 [0.41 ; 1.76] 0.20 
3' UTR 10:52559843 rs7084132 G T - 100 (0.185) 57 (0.170) 0.94 [0.63 ; 1.39] 0.74 
3' UTR 10:52559853 var52559853 T G - 1 (0.002) 0 (0.000) - 0.98 
3' UTR 10:52560181 var52560181 T C - 1 (0.002) 0 (0.000) - 0.98 
3' UTR 10:52560476 rs75907017 G A - 124 (0.229) 85 (0.253) 1.26 [0.89 ; 1.81] 0.20 
5| Lipid Metabolism - Rare Variant Analysis 
 225 
3' UTR 10:52560557 rs6479731 A G - 100 (0.185) 57 (0.170) 0.94 [0.63 ; 1.39] 0.74 
3' UTR 10:52561178 var52561178 G C - 0 (0.000) 1 (0.003) - 0.98 
3' UTR 10:52561680 var52561680 T G - 4 (0.007) 5 (0.015) 2.30 [0.50 ; 10.55] 0.28 
3' UTR 10:52561803 rs74352101 A G - 27 (0.050) 13 (0.039) 0.85 [0.41 ; 1.76] 0.65 
3' UTR 10:52561829 rs7072584 A C - 100 (0.185) 57 (0.170) 0.94 [0.63 ; 1.39] 0.74 
3' UTR 10:52561919 rs12571156 C T - 124 (0.229) 85 (0.253) 1.26 [0.89 ; 1.81] 0.98 
3' UTR 10:52562339 var52562339 C T - 1 (0.002) 0 (0.000) - 0.98 
3' UTR 10:52563051 rs4282939 C T - 250 (0.473) 125 (0.391) 0.76 [0.57 ; 1.02] 0.07 
3' UTR 10:52563196 rs16751 A G - 136 (0.251) 115 (0.342) 1.38 [1.00 ; 1.90] 0.01 
3' UTR 10:52563707 rs184644838 G A - 133 (0.245) 55 (0.164) 0.59 [0.40 ; 0.86] 0.006 
3' UTR 10:52563725 var52563845 A C - 0 (0.000) 1 (0.003) - 0.98 
3' UTR 10:52563904 var52563981 G C - 5 (0.009) 0 (0.000) - 0.98 
3' UTR 10:52563981 rs150545950 C T - 1 (0.002) 0 (0.000) - 0.05 
3' UTR 10:52564065 rs4619096 A G - 100 (0.185) 57 (0.170) 0.94 [0.63 ; 1.39] 0.74 
3' UTR 10:52564524 var52564700 A T - 0 (0.000) 1 (0.003) - 0.98 
3' UTR 10:52564700 rs74874346 G A - 27 (0.050) 13 (0.039) 0.85 [0.41 ; 1.76] 0.65 
3' UTR 10:52564768 var52565100 G A - 0 (0.000) 1 (0.003) - 0.98 
3' UTR 10:52565903 rs4078160 C A - 100 (0.185) 57 (0.170) 0.94 [0.63 ; 1.39] 0.74 
3' UTR 10:52565940 var52565951 T C - 30 (0.055) 14 (0.042) 0.72 [0.35 ; 1.47] 0.36 
3' UTR 10:52566049 rs10821846 A G - 136 (0.251) 115 (0.342) 1.38 [1.00 ; 1.90] 0.65 
3' UTR 10:52566333 var52566417 G A - 0 (0.000) 1 (0.003) - 0.98 
UTR: Un-translated region, rs ID: Reference SNP cluster ID, Chr: Chromosome, var: Variant, Ref: Reference, Alt: Alternate. Normo: Normouricaemic, Hyper: Hyperuricaemic, OR: Odds 
ratio for the alternate allele, 95% CI: 95% confidence interval, POR: p-value for odds ratio. *Odds ratios are adjusted for sex, age, BMI and estimates of grand-parental ancestry. ^Odds 
ratios are adjusted for sex and collection study. Exon numbers and variant positions are sourced from the Genome Reference Consortium human genome build 37 (GRCh37) on Ensembl 
(http://grch37.ensembl.org/).
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5.2.3.2 Burden analysis 
 Combining the allele frequencies obtained from single variant analyses with a cut-
off combined allele frequency of < 0.05 (5%) to determine the rarity resulted in a list of 
111 variants (11 rare and 100 very rare variants) within LRP2 and 53 variants (1 rare 52 
very rare variants) within A1CF (Appendix A Table 5.4). Non-synonymous variants were 
also identified for both genes regardless of their allele frequency. This ended up in a list 
of 81 missense variants in LRP2 and 4 missense variants in A1CF. Out of 81 missense 
variants in LRP2, 74 were still very rare (< 0.01), while only 7 variants had a combined 
allele frequency < 0.05 to 0.01. One out of 4 missense variants in A1CF was rare and 3 
were very rare (Appendix A Table 5.4). Non-synonymous deleterious variants were 
identified on the basis of information gained via functional annotations for the variants in 
all four annotation platforms being used (see details in Sections 5.2.2.2.3 and 5.2.3.3). 
 Analysing the burden of rare exonic variants of LRP2 and A1CF did not signify an 
effect associated with hyperuricaemia in both NZ Polynesian and European individuals 
(Table 5.7). The rare variants within A1CF indicated a slight trend for protection against 
hyperuricaemia only in European individuals (PBurden (Protection) = 0.06) but not Polynesians 
(PBurden (Protection) = 0.51) (Table 5.7). The frequency of individuals carrying a rare allele 
was almost equal when compared between hyperuricaemic cases and normouricaemic 
controls for both genes. All results from allele-collapsing and adaptive weighted sum tests 
were insignificant for a rare variant burden in LRP2 and A1CF (Table 5.7). Changing the 
number of permutations also did not indicate a considerable change for burden 
associations at any gene (Table 5.7). 
 Non-synonymous variants within LRP2 and A1CF with combined allele-
frequency of < 0.05 were also tested for having a burden for hyperuricaemia in NZ 
Polynesian and Europeans. The analysis indicated a significant burden of risk variants 
within LRP2 only in the European population (PBurden (Risk) = 0.009) (Table 5.8), which 
retained when burden for risk and protective variants was collectively calculated (PBurden 
(Combined) = 0.023) (Table 5.8). The number of rare allele carriers for non-synonymous 
variants was significantly higher in hyperuricaemic than normouricaemic European 
individuals (P = 0.04) (Table 5.8). The rare non-synonymous variants did not indicate a 
burden for hyperuricaemia in NZ Polynesian (PBurden (Risk) = 0.14 and PBurden (Protection) = 
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0.37) with almost equal frequency of rare non-synonymous variants between the 
hyperuricaemic cases and nonrmouricaemic controls (P = 0.98) (Table 5.8). No notable 
burden effects or difference in frequency were observed in A1CF for both Europeans and 
Polynesians (Table 5.8).  
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Table 5.7: Rare variant burden analysis of LRP2 and A1CF for hyperuricaemia 
Permut NZ Polynesian European 
 
Frequency PBurden Frequency PBurden 
 













0.997 - - 
1,000 - - 0.543 0.649 0.375 - - 0.565 0.183 0.843 
10,000 - - 0.519 0.666 0.349 - - 0.555 0.171 0.859 
50,000 - - 0.521 0.664 0.349 - - 0.565 0.168 0.861 













0.999 - - 
1,000 - - 0.811 0.778 0.528 - - 0.077 0.407 0.077 
10,000 - - 0.828 0.796 0.503 - - 0.066 0.396 0.066 
50,000 - - 0.819 0.789 0.508 - - 0.068 0.401 0.068 
100,000 - - 0.817 0.787 0.510 - - 0.066 0.401 0.066 
Frequency: number and frequency of individulas carrying a rare allele. Permut: Permutations, Normo: Normouricaemic 
controls, Hyper: Hyperuricaemic cases, Comb: Combined, Protect: Protective. 
 
Table 5.8: Rare and non-synonymous variant burden analysis of LRP2 and A1CF 
for hyperuricaemia 
Permut NZ Polynesian European 
 
Frequency PBurden Frequency PBurden 
 













0.045 - - 
1,000 - - 0.255 0.141 0.372 - - 0.024 0.008 0.150 
10,000 - - 0.270 0.151 0.365 - - 0.023 0.009 0.151 
50,000 - - 0.259 0.144 0.373 - - 0.023 0.009 0.151 













0.529 - - 
1,000 - - 1 0.546 1 - - 0.432 0.432 1 
10,000 - - 1 0.550 1 - - 0.458 0.458 1 
50,000 - - 1 0.537 1 - - 0.444 0.444 1 
100,000 - - 1 0.543 1 - - 0.444 0.444 1 
All values are calculated at combined allel-frequency threshold of < 0.05. Frequency; number and frequency of 
individulas carrying a rare allele. Permut: Permutations, Normo: Normouricaemic controls, Hyper: Hyperuricaemic 
cases, Com: Combined, Protect: Protective. 
5| Lipid Metabolism - Rare Variant Analysis 
 229 
5.2.3.3 Functional annotation of variants 
 All non-synonymous (missense) variants within LRP2 and A1CF were classified 
on the basis of having deleterious (damaging) and neutral effects at the protein level. The 
binary prediction scores indicated some consistency in all four ‘functional annotation 
platforms’ namely, CADD, SIFT, PolyPhen-2 and PROVEAN (Table 5.1). The four 
scores were consistent for a damaging effect on protein function in 52.63% of the cases 
(Figure 5.6). 
 Overall, the prediction score was calculated for 72 (84.70%) missense variants for 
either a deleterious or neutral effect on protein function. Ten variants (LRP2: 9; A1CF: 1) 
were identified to have damaging effect in all prediction programs, while 21 variants 
were identified to be deleterious in at least two out of the four prediction programs. There 
were 27 (37.5%) missense variants that were found to have a neutral effect on protein 
function when all four scores were obtained. Both genes had 64 (LRP2: 53; A1CF: 11) 
synonymous variants, with 54 untranslated region/UTR variants (5'UTR: 3; 3'UTR: 51) in 
A1CF. A detail of significant non-synonymous annotations is provided in Table 5.9 
below (full details provided in Appendix A, Table 5.6). A CADD score of ≥ 10 indicates 
deleteriousness of the particular variant at protein level. Likewise, a score of ≤ 0.05, ≥ 








Figure 5.6: Consistency between four methods predicting the deleterious functional consequences of non-
synonymous variants in LRP2 and A1CF. 
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Table 5.9: Predicted consequences of ten LRP2 and A1CF non-synonymous variants on protein function 
Exon Chr: location rs ID/var position 
CADD PolyPhen-2 SIFT PROVEAN 
Score Score Prediction Score Prediction Score Prediction 
73 2:169996058 var169996058 29.7 2.1 Deleterious 0.03 Deleterious -3.15 Deleterious 
59 2:170027153 rs200475391 32 2.19 Deleterious 0 Deleterious -6.94 Deleterious 
56 2:170030458 var170030458 28.1 2.02 Deleterious 0 Deleterious -7.67 Deleterious 
51 2:170038795 var170038795 25 2.19 Deleterious 0.01 Deleterious -3.22 Deleterious 
50 2:170042245 rs35734447 27.8 1.63 Deleterious 0.01 Deleterious -4.96 Deleterious 
37 2:170068592 var170068592 34 3.62 Deleterious 0.02 Deleterious -3.34 Deleterious 
15 2:170115652 var170115652 28.7 3.46 Deleterious 0 Deleterious -8.28 Deleterious 
14 2:170129529 rs116332504 24 1.42 Deleterious 0 Deleterious -3.8 Deleterious 
13 2:170134385 rs201490492 31 3.58 Deleterious 0.02 Deleterious -4.29 Deleterious 
5 10:52595978 rs143123872 10.7 1.54 Deleterious 0.03 Deleterious -2.58 Deleterious 
Chr: Chromosome, rs ID: Reference SNP cluster ID, var: variant, CADD: Combined annotation dependent depletion, PolyPhen-2: Polymorphism phenotyping verision 2, SIFT: Scale-
invariant feature transform, PROVEAN: Protein variantion effect analyser.  
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5.2.4 Results – Replication-phase 
 Power calculations inidcated the NZ Polynesian dataset to be highly powered (> 
90%) to detect a moderate effect (OR = 1.5) at an altered allele frequency > 0.1 (Figure 
5.7). The European dataset was only adequately powered (> 80%) to detect a moderate 
effect (OR = 1.5) at an altered allele frequency > 0.1 (Figure 5.7). 
 Applying the criteria for prioritisation described in Section 5.2.2.3.1 ended up in a 
list of seven common variants within exonic regions of LRP2 only. Table 5.10 provides a 
detailed summary of these variants while Figure 5.8 illustrates an overview of exonic 
regions (n (exons) = 79) of the gene LRP2 with positions of all 7 variants indicated within 
their respective exons. Calculation of LD showed no in between variant LD in Europeans, 
while there was a complete LD between rs2302694 and rs4667596 and between 
rs4667591 and rs2075252 only in the Han Chinese population. However, all four variants 
were selected for replication in NZ datasets. (Table 5.11). Only one variant, rs41268685, 
was found to be monomorphic for European and South Asian populations when 
population-genetic data were used from the Genome Reference consortium human 
genome build 37 (GRCh37) on Ensembl (www.grch37.ensembl.org), while all other six 
variants were polymorphic.   

















Figure 5.7: Association detection power in the (A) NZ Polynesian and (B) NZ European subsets in the 
Replication Cohorts across a range of odds ratio effect sizes and minor allele frequencies. The broken red line 
indicates an adequate detection power ≥ 80%. 
A 
B 
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31 2:170088351 rs2302694 Synonymous 0.46 (0.01) 0.71 (0.31) 0.44 (0.001) Protective Both 0.095 0.082 Not novel 
36 2:170070172 rs4667596 Missense 0.22 (0.02) 0.65 (0.56) 0.43 (0.17) Protective Both 0.009 0.013 Not novel 
66 2:170010985 rs2075252 
Stop-lost 
(nonsense) 
0.78 (0.19) 0.65 (0.05) 0.18 (0.21) Protective Both 0.289 0.714 Not novel 
69 2:170003432 rs4667591 Missense 0.75 (0.08) 0.61 (0.05) 0.72 (0.05) Protective Both 0.341 0.768 Not novel 
73 2:169996070 rs41268685 Missense - 3.85 (0.04) - Risk Both 0.002 0.028 Not novel 
rs ID: Reference SNP cluster ID, var: Variant, Poly: NZ Polynesian, Eur: European, OR: Odds ratio, POR: p-value of odds ratio. 








Figure 5.8: An overview of LRP2 showing 79 exons (dark red blocks) and the position of each prioritised variant on the respective exons. Labels on the x-axis 
indicates location of variants in each exon, while values on y-axis are only presenting graphics in the plot. Plot was created using exon sequencing data in European 
and NZ Polynesian individuals in R (v3.3.2). Exons numbers and variant positions are sourced from the Genome Reference Consortium human genome build 37 
(GRCh37) on Ensembl (http://grch37.ensembl.org/). 
Exon    79                   1 
 
Location 
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Query Proxy Caucasian Han Chinese 
rs111360923 No record on any array - - - 
var170115626 No record on any array - - - 
rs4667591 
rs2075252 7553 0.39 0.829 
rs4667596 66740 0.087 0.001 
rs2302694 84919 0.009 0.001 
rs2302694 
rs4667596 18179 0.174 1 
rs2075252 77366 0.007 0.003 
rs4667591 84919 0.009 0.001 
rs2075252 
rs4667591 7553 0.39 0.829 
rs4667596 59187 0.064 0.003 
rs2302694 77366 0.007 0.003 
rs4667596 
rs2302694 18179 0.174 1 
rs4667591 66740 0.087 0.001 
rs2075252 59187 0.39 0.003 
rs41268685 
rs4667591 7362 0.004 - 
rs2302694 92281 0.156 - 
rs2075252 14915 0.004 - 
rs4667596 74102 0 - 
SNP: Single nucleotide polymorphism, Query: SNP for which the LD was calculated, Proxy: SNP with which the LD 
was calculated. R-squared ≥ 0.60 indicates an LD. All values are as provided in 1000 Genome database 
(http://browser.1000genomes.org/). 
 The association results in resequencing for rs111360923 were successfully 
replicated for gout in a larger NZ Polynesian dataset (Table 5.12). The altered allele (C) 
of the Polynesian-specific missense variant rs111360923 was significantly associated 
with gout in both EP (OR  = 0.59, P = 0.01) and WP (OR  = 0.57, P = 0.02) individuals 
(Table 5.12). The association was not significant for both EPWP (OR = 1.15, P = 0.80) 
and NPH (OR = 0.89, P = 0.76) individuals (Table 5.12). When all Polynesian subgroups 
were combined together in a meta-analysis, the C allele of rs111360923 indicated a 
strong protective association for gout with no heterogeneity between the subgroups (OR  
= 0.64, POR = 0.002, PHet = 0.52) (Table 5.14). The Replication-phase failed to follow 
similar trend of association between rs111360923 and hyperuricaemia (Table 5.12 and 
Table 5.14). Also, no association was observed between the C allele of rs111360923 and 
serum urate concentrations in NZ Polynesian controls (ß (mmol L-1) = -0.01, Pß = 0.12, 
PHet = 0.61) (Table 5.14). 
 The association for the C allele of another Polynesian-specific variant, 
var170115626, was also successfully replicated and was found to be nominally associated 
with a decreased risk of gout in WP individuals (OR  = 0.73, P = 0.05) (Table 5.12). No 
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significant association was found for any other population subgroup, although the 
direction of effect was consistent in EP, WP and NH subgoups (Table 5.12). Combining 
the Polynesian subgroups in meta-analysis indicated a significant protective association 
between the C allele of var170115625 and gout with no heterogeneity intra populations 
(OR  = 0.73, POR = 0.02, PHet = 0.65) (Table 5.14). The C allele also indicated a trend of 
negative association with serum urate concentrations (ß (mmol L-1) = -0.012, Pß = 0.06, 
PHet = 0.59) (Table 5.14). However, the association results from the Discovery-phase 
were not replicated for hyperuricaemia in any Polynesian subgroups (Table 5.12 and 
Table 5.14). 
 Given the data for above two variants indicated Polynesian-specific effects and 
the evidence of previously reported variant within LRP2 (rs2544390) that also indicated 
to have Polynesian-specific effects (Rasheed et al., 2013a), an LD between all three 
variants was calculated using the genotype data in NZ Polynesian population using 
Haploview (v4.2) platform. While the results from the LD calculation showed a strong 
(83%) LD between rs111360923 and var170115626, both of the variants were found to 
be independent of the signals at rs2544390 with only 5% in between LD (Figure 5.9). 
 The A allele of the synonymous variant rs2302694 was not associated with either 
hyperuricaemia or gout when tested in the NZ Polynesian subgroups and NZ Europeans 
separately (Table 5.12), although meta-analysis successfully replicated the protective 
association against hyperuricaemia (OR = 0.79, POR = 0.04, PHet = 0.35) (Table 5.14). 
The A allele also indicated a trend of protective association with gout (OR = 0.80, POR = 
0.06, PHet = 0.89) in NZ Polynesians only (Table 5.14). The allele A was also found to be 
associated with decreasing the serum urate concentrations in EP (ß (mmol L-1) = -0.014, 
P = 0.04) (Table 5.13) and combined Polynesian healthy controls (ß (mmol L-1) = -0.015, 
Pß = 0.01, PHet = 0.63) (Table 5.14). 
 The association results for another synonymous variant, rs2075252, were 
successfully replicated for hyperuricaemia. The C allele of rs2075252 was associated 
with hyperuricaemia with a protective effect in EP (OR = 0.81, P = 0.05), while it showed 
an opposite susceptible association in EPWP (OR = 2.54, P = 0.05) individuals (Table 
5.12). Meta-analysis of all Polynesian group together indicated a protective association of 
the C allele against hyperuricaemia (OR = 0.83, POR = 0.01, PHet = 0.11) (Table 5.12), 
which followed the similar trend of association when NZ Polynesian and European 
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populations were combined together (OR = 0.87, POR = 0.03, PHet = 0.12) (Table 5.14). 
However, the C allele was not associated with serum urate in either NZ Polynesian (ß 
(mmol L-1) = -0.005, Pß = 0.23, PHet = 0.24) or NZ European (ß (mmol L
-1) = -0.007, P = 
0.30) individuals (Table 5.13 and Table 5.14). 
 The missense variant rs4667591 represents another example of successful 
replication of Discovery-phase associations in this study. The G allele of rs4667591 
showed a significant protective association with hyperuricaemia in both EP (OR = 0.74, P 
= 0.006) and NPH (OR = 0.67, P = 0.04) sample sets (Table 5.12). The same G allele was 
also found to be associated with increased risk of developing gout in NZ Europeans (OR 
= 1.26, P = 0.02) (Table 5.12). Combining the NZ Polynesian sample sets together 
indicated association of the G allele with hyperuricaemia (OR = 0.79, POR = 0.002, PHet = 
0.38). Meta-analysis also showed association with hyperuricaemia when NZ Polynesian 
and European populations were combined together (OR = 0.82, POR = 0.002, PHet = 0.39) 
(Table 5.14). The G allele was not associated with serum urate concentrations in any 
population group (Table 5.13 and Table 5.14). 
 The Replication-phase failed to replicate the association for two missense 
variants, rs4667596 and rs41268685, in NZ Polynesian and European populations (Table 
5.12). However, the T allele of rs4667596 (ß (mmol L-1) = 0.136, Pß = 0.03) and the G 
allele of rs41268685 (ß (mmol L-1) = 0.192, Pß = 0.01) were found to be associated with 
















Figure 5.8: Linkage disequilibrium (LD) plot indicating ‘R-squared/r2’ values between the 3 Polynesian-specific 
LRP2 variants. An r2 ≥ 60 in the above plot indicates LD between the particular variants. Information for 
variant location, rs ID and LD values are from NZ Polynesian data. The plot was generated using Haploview 
v4.2. 
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0.08 
0.57 
[0.35 ; 0.93] 
0.02 
0.84 
[0.56 ; 1.28] 
0.42 
0.79 





















[0.53 ; 3.45] 
0.49 
1.15 
[0.37 ; 3.49] 
0.80 
1.55 
[0.60 ; 4.36] 
0.38 
1.32 





















[0.72 ; 2.01] 
0.50 
0.89 
[4.34 ; 1.92] 
0.76 
0.98 
[0.61 ; 1.55] 
0.92 
0.77 













TT CT CC C 
   











[0.68 ; 1.24] 
0.60 
0.72 
[0.49 ; 1.07] 
0.11 
0.87 
[0.61 ; 1.21] 
0.41 
0.79 





















[0.53 ; 1.16] 
0.22 
0.73 
[0.39 ; 1.02] 
0.05 
0.79 
[0.52 ; 1.19] 
0.27 
0.71 





















[0.50 ; 3.64] 
0.50 
0.63 
[0.41 ; 4.28] 
0.63 
1.47 
[0.54 ; 4.44] 
0.46 
1.40 
























[0.66 ; 1.95] 
0.66 
1.33 
[4.15 ; 1.97] 
0.76 
1.18 
[0.72 ; 1.91] 
0.51 
0.95 













GG AG AA A 
   











[0.69 ; 1.15] 
0.40 
0.85 
[0.62 ; 1.16] 
0.30 
0.83 
[0.62 ; 1.09] 
0.19 
0.79 





















[0.59 ; 1.23] 
0.39 
0.71 
[0.47 ; 1.10] 
0.12 
0.80 
[0.55 ; 1.16] 
0.24 
0.71 





















[0.44 ; 2.69] 
0.82 
0.99 
[0.33 ; 2.82] 
0.98 
1.61 
[0.67 ; 4.12] 
0.30 
2.13 





















[0.54 ; 1.94] 
0.99 
0.70 
[2.76 ; 1.83] 
0.46 
0.93 
[0.54 ; 1.56] 
0.77 
0.84 





















[0.75 ; 1.29] 
0.89 
0.96 
[0.71 ; 1.31] 
0.81 
1.03 
[0.77 ; 1.38] 
0.82 
0.98 













CC CT TT T 
   











[0.93 ; 3.25] 
0.08 
1.76 
[0.82 ; 3.92] 
0.15 
0.85 
[0.41 ; 1.68] 
0.65 
0.79 





















[0.68 ; 3.41] 
0.35 
0.98 
[0.42 ; 2.47] 
0.97 
0.86 
[0.36 ; 2.04] 
0.72 
0.69 





















[0.40 ; 95.09] 
0.24 
3.77 
[0.28 ; 94.81] 
0.33 
0.38 
[0.02 ; 4.07] 
0.43 
0.51 











NPH Case 139 5 0 5 0.55 0.38 0.68 0.69 1.27 0.70 1.51 0.58 
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[0.56 ; 1.60] 
0.81 
0.82 
[0.46 ; 1.50] 
0.51 
1.25 
[0.71 ; 2.17] 
0.43 
1.14 














TT CT CC C 
   











[0.75 ; 1.07] 
0.24 
0.86 
[0.69 ; 1.07] 
0.17 
0.79 
[0.66 ; 0.97] 
0.02 
0.81 





















[0.86 ; 1.38] 
0.46 
1.27 
[0.95 ; 1.70] 
0.11 
0.85 
[0.66 ; 1.09] 
0.19 
0.85 





















[0.33 ; 1.38] 
0.30 
0.57 
[0.21 ; 1.45] 
0.25 
1.56 
[0.79 ; 3.22] 
0.21 
2.54 





















[0.76 ; 1.71] 
0.55 
1.07 
[5.76 ; 1.99] 
0.84 
0.76 
[0.54 ; 1.06] 
0.11 
0.75 





















[0.94 ; 1.36] 
0.20 
1.12 
[0.92 ; 1.38] 
0.26 
0.99 
[0.81 ; 1.20] 
0.89 
0.97 













TT GT GG G 
   











[0.79 ; 1.10] 
0.41 
0.87 
[0.70 ; 1.07] 
0.19 
0.77 
[0.64 ; 0.93] 
0.006 
0.74 





















[0.62 ; 0.98] 
0.03 
0.94 
[0.71 ; 1.24] 
0.66 
0.83 
[0.65 ; 1.05] 
0.13 
0.89 





















[0.28 ; 1.09] 
0.10 
0.76 
[0.34 ; 1.66] 
0.49 
1.04 
[0.56 ; 1.94] 
0.91 
1.21 
[0.56 ; 2.70] 
0.62 





















[0.69 ; 1.57] 
0.86 
0.79 
[4.16 ; 1.48] 
0.46 
0.73 
[0.52 ; 1.02] 
0.07 
0.67 





















[1.06 ; 1.57] 
0.01 
1.26 
[1.02 ; 1.56] 
0.02 
0.94 
[0.76 ; 1.16] 
0.57 
0.91 













AA AG GG G 
   











[0.21 ; 4.78] 
0.95 
0.50 
[0.09 ; 2.84] 
0.42 
1.52 
[0.28 ; 8.25] 
0.61 
1.78 





















[0.03 ; 19.8] 
0.86 
0.50 
[0.02 ; 16.01] 




























































[0.86 ; 2.71] 
0.17 
1.64 
[0.88 ; 3.19] 
0.13 
0.88 
[0.48 ; 1.56] 
0.67 
0.90 











*All values are adjusted for age, sex and BMI for NZ European plus with the estimates of grand-parental ancestry for NZ Polynesian. EP: East Polynesian, WP: West Polynesian, EPWP: 
Mixture of East and West Polynesian, NPH: Ngati Porou Hauora, EUR: NZ Europeans, NU: Normouricaemic, HU: Hyperuricaemic, rs ID: Reference SNP cluster ID, var: Variant, OR: 
Odds ratio for the alternate allele, 95% CI: 95% confidence interval, P: p-value for odds ratio. 
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ß [95% CI] P ß [95% CI] P 
rs111360923 
EP 0.003 [-0.017 ; 0.022] 0.77 -0.011 [-0.028 ; 0.005] 0.17 
WP -0.001 [-0.027 ; 0.025] 0.94 -0.008 [-0.031 ; -0.015] 0.49 
EPWP 0.046 [-0.024 ; 0.117] 0.19 0.028 [-0.034 ; 0.090] 0.37 
NPH -0.020 [-0.061 ; 0.022] 0.35 -0.020 [-0.059 ; -0.019] 0.32 
var170115626 
EP -0.001 [-0.020 ; -0.018] 0.93 -0.014 [-0.031 ; 0.002] 0.08 
WP -0.002 [-0.029 ; 0.024] 0.86 -0.01 [-0.033 ; -0.013] 0.39 
EPWP 0.049 [-0.027 ; 0.125] 0.21 0.033 [-0.034 ; 0.100] 0.33 
NPH -0.014 [-0.054 ; 0.026] 0.48 -0.015 [-0.053 ; 0.024] 0.45 
rs2302694 
EP -0.012 [-0.028 ; 0.005] 0.17 -0.014 [-0.015 ; 0.005] 0.04 
WP -0.009 [-0.036 ; -0.018] 0.52 -0.021 [-0.045 ; 0.004] 0.10 
EPWP 0.027 [-0.036 ; 0.090] 0.40 0.022 [-0.037 ; 0.081] 0.46 
NPH -0.014 [-0.069 ; 0.041] 0.62 -0.015 [-0.076 ; 0.046] 0.62 
EUR 0.008 [-0.015 ; 0.031] 0.51 0.007 [-0.012 ; 0.025] 0.48 
rs4667596 
EP -0.022 [-0.067 ; 0.022] 0.32 -0.029 [-0.066 ; 0.008] 0.12 
WP 0.004 [-0.077 ; 0.085] 0.92 -0.032 [-0.104 ; 0.040] 0.38 
EPWP 0.003 [-0.214 ; 0.219] 0.98 -0.011 [-0.207 ; 0.185] 0.91 
NPH 0.104 [-0.010 ; 0.198] 0.03 0.136 [-0.013 ; 0.258] 0.03 
EUR -0.013 [-0.033 ; 0.059] 0.58 0.006 [-0.031 ; 0.043] 0.74 
rs2075252 
EP -0.005 [-0.017 ; 0.006] 0.36 -0.005 [-0.015 ; 0.005] 0.33 
WP -0.015 [-0.033 ; 0.003] 0.11 -0.014 [-0.030 ; 0.003] 0.11 
EPWP 0.008 [-0.039 ; 0.054] 0.76 0.029 [-0.020 ; 0.078] 0.26 
NPH -0.014 [-0.045 ; -0.017] 0.37 -0.017 [-0.022 ; 0.056] 0.37 
EUR -0.008 [-0.024 ; 0.007] 0.28 -0.007 [-0.019 ; 0.006] 0.30 
rs4667591 
EP -0.002 [-0.013 ; 0.009] 0.75 -0.002 [-0.012 ; 0.007] 0.62 
WP 0.001 [-0.016 ; -0.018] 0.93 0.008 [-0.008 ; 0.023] 0.34 
EPWP -0.017 [-0.062 ; 0.028] 0.46 -0.005 [-0.047 ; 0.036] 0.80 
NPH -0.006 [-0.039 ; 0.026] 0.69 -0.012 [-0.024 ; 0.048] 0.50 
EUR -0.016 [-0.032 ; -0.001] 0.04 -0.008 [-0.021 ; 0.004] 0.20 
rs41268685 
EP -0.018 [-0.098 ; 0.135] 0.76 -0.013 [-0.110 ; 0.084] 0.79 
WP - - - - 
EPWP -0.120 [-0.334 ; 0.095] 0.28 - - 
NPH 0.171 [-0.012 ; 0.331] 0.04 0.192 [0.047 ; 0.337] 0.01 
EUR -0.021 [-0.072 ; 0.029] 0.41 -0.019 [-0.061 ; 0.024] 0.39 
EP: East Polynesian, WP: West Polynesian, EPWP: Mixture of East and West Polynesian, NPH: Ngati Porou Hauora, 
EUR: NZ Europeans, rs ID: Reference SNP cluster ID, var: Variant, ß: Beta/effect estimates for the alternate allele, 
95% CI: 95% confidence interval, P: p-values for effect estimates. *All values are adjusted for age, sex and BMI for 
NZ European plus with the estimates of grand-parental ancestry for NZ Polynesian. 
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Gout (case/control) Hyperuricaemia (NU/HU) Serum urate (mmol L-1) 
OR [95% CI] POR PHet OR [95% CI] POR PHet ß [95% CI] Pß PHet 
rs111360923 POLY 0.646 [0.491; 0.851] 0.002 0.52 0.828 [0.650; 1.054] 0.13 0.85 -0.010 [-0.022; 0.003] 0.12 0.61 
var170115626 POLY 0.736 [0.561; 0.966] 0.03 0.65 0.814 [0.638; 1.039] 0.10 0.69 -0.012 [-0.023; 0.001] 0.06 0.59 
rs2302694 
POLY & EUR 0.859 [0.712; 1.035] 0.11 0.82 0.857 [0.718; 1.022] 0.08 0.34 -0.015 [-0.025; -0.003] 0.01 0.78 
POLY 0.801 [0.632; 1.015] 0.06 0.89 0.797 [0.641; 0.991] 0.04 0.35 -0.015 [-0.026; -0.003] 0.01 0.63 
rs4667596 
POLY & EUR 1.069 [0.718; 1.591] 0.74 0.48 0.936 [0.637; 1.373] 0.74 0.78 -0.008 [-0.031; 0.016] 0.53 0.09 
POLY 1.339 [0.778; 2.301] 0.29 0.56 0.803 [0.480; 1.341] 0.40 0.81 -0.018 [-0.049; 0.013] 0.27 0.07 
rs2075252 
POLY & EUR 1.035 [0.909; 1.176] 0.61 0.15 0.879 [0.777; 0.993] 0.03 0.12 -0.006 [-0.012; 0.001] 0.12 0.37 
POLY 0.979 [0.828; 1.156] 0.79 0.12 0.833 [0.715; 0.969] 0.01 0.11 -0.005 [-0.013; 0.003] 0.23 0.24 
rs4667591 
POLY & EUR 1.003 [0.883; 1.139] 0.95 0.10 0.828 [0.732; 0.936] 0.002 0.39 -0.002 [-0.008; 0.004] 0.61 0.54 
POLY 0.880 [0.751; 1.032] 0.11 0.92 0.794 [0.685; 0.919] 0.002 0.38 0.001 [-0.007; 0.008] 0.86 0.65 
rs41268685 
POLY & EUR - - - - - - 0.036 [-0.067; 0.139] 0.50 0.02 
POLY - - - - - - 0.083 [-0.117; 0.283] 0.42 0.02 
POLY: NZ Polynesian, EUR: NZ European, NU: Normouricaemic, HU: Hyperuricaemic, rs ID: Reference SNP cluster ID, var: Variant, OR/ß: Odds ratio/beta or effect estimates for the 
alternate allele, 95% CI: 95% confidence interval, P; p-values, POR/ß: p-value for odds ratio/beta estimates, Het: Heterogeneity. All values are adjusted for age, sex and BMI for NZ 
European plus with the estimates of grand-parental ancestry for NZ Polynesian. 
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SECTION 5.3 DISCUSSION 
 The findings of this study are four fold. First, the characterisation of exonic 
variants within LRP2 and A1CF identified 11 Polynesian-specific variants in total, with 7 
variants having an allele frequency > 0.05 (common) for both genes (Table 5.5). The 
Discovery-phase association analyses revealed the presence of common, low-frequency 
and rare variants within both genes, carrying both risk and protection for hyperuricaemia 
and gout (Table 5.5 and Table 5.6). Two Polynesian-specific variants showing protection 
against hyperuricaemia and gout were also identified in this analysis (rs111360923 and 
var170115626) (Table 5.5 and Table 5.6). Second, calculating the burden for rare and 
non-synonymous variants within LRP2 and A1CF indicated a burden of hyperuricaemia 
risk variants in European individuals within LRP2 (Table 5.8). Third, assigning functional 
annotations to exonic variants via four different annotation programs showed that at least 
53% of the variants within coding regions of LRP2 could have damaging (functional) 
effects on the proteins (Table 5.8). Overall, the Discovery-phase results from LRP2 came 
out to be more interesting than A1CF, with a number of variants showing an association 
with hyperuricaemia and gout in Europeans and Polynesians (Table 5.5 and Table 5.6). 
Several variants were, therefore, selected from LRP2 for validation of their association 
with hyperuricaemia and/or gout in a larger independent Replication Cohort, which 
represents the fourth finding of this study (detailed below). 
 Multiply-adjusted regression analysis of the seven prioritised variants from the 
Discovery-phase successfully replicated five variants for an association with either 
hyperuricaemia or gout (Table 5.12 to Table 5.14). The genotype and allele frequencies in 
the Replication-phase were similar to that observed in the Discovery-phase for all 
replicated variants (Table 5.12). Two Polynesian-specific variants, rs111360923 and 
var170115626 were replicated for an association with gout (rs111360923; OR = 0.64, 
POR = 0.002, var170115626 = OR = 0.73, POR = 0.03) but not hyperuricaemia (Table 
5.14), while var170115626 indicated a trend of negative association with urate in 
otherwise healthy (control) Polynesian individuals (ß (mmol L-1) = -0.012, P = 0.06) 
(Table 5.14). The similar results and population specificity for these two variants were 
validated via LD that indicated both of these variants to be in strong LD (r2 = 83%) 
(Figure 5.8). Similar but very low LD (5%) with the previously reported variant at LRP2: 
rs2544390 that showed Polynesian-specific association with gout (Rasheed et al., 2013a) 
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further indicated that association signals from these two variants in my study are 
independent of rs2544390. Both of these variants have been reported as having extremely 
low frequencies in the ExAC (The Exome Aggregation Consortium) database 
(http://exac.broadinstitute.org/) for other populations. However, no homozygotes have 
been reported for either variant. The C allele frequency reported for rs111360923 was 
8.9E-04 (108 out of 121,016 alleles), predominantly reported in Africans (C allele 
frequency = 0.008) and South Asians (C allele frequency = 0.001). The C allele 
frequency for the var170115626 was 6.05E-05 (1 out of 165,08 alleles), reported only in 
South Asian population in ExAC. However, this variant was not reported for any other 
population in ExAC (total allele record: 121,232). Moreover, there is no previous report 
available for both of these variants in the context of a pathologic condition (to my 
knowledge). The absence of these variants in other populations, their rarity in South 
Asians and frequent occurence in NZ Polynesian (rs111360923 = 0.07, var170115626 = 
0.07) is likely linked to the settlement processes in the Polynesian region. While people 
moving out of East Asia and speaking Austronesian languages (reaching Polynesia with 
the Lapita culture around 3000 years ago) seem to have contributed to a great extent to 
the genetic variation present in Polynesians, there was also admixture with the earliest 
inhabitants of the New Guinea and Solomon Islands en route. Most of the Y chromosome 
present in Polynesian populations can be traced back to original inhabitants of the Sahul 
continent (which comprised what is now Australia and New Guinea) rather than the East 
Asian ancestors, which indicates some significant admixture (Kayser, 2010). The first 
people to settle the Sahul continent probably arrived via South Asia as part of one of the 
earliest movements of people out of Africa (Hudjashov et al., 2007; Kayser, 2010; 
O'Connell and Allen, 2004; Summerhayes et al., 2010). This is likely where these 
variants originated and became higher in frequency in Polynesians as a result of founder 
effect, genetic drift and population expansion. Due to the scarcity of information 
available in the literature and no functional annotations assigned on any platform for 
rs111360923 and due to the var170115626 being annotated as having a neutral effect on 
protein function in three (PolyPhen-2, SIFT and PROVEAN) out of four annotation 
programs, it is hard to elucidate an effect on protein function. However, the protective 
effect (for hyperuricaemia and gout) of rs111360923 and var170115626 variants in the 
resequencing data and its successful replication through TaqMan genotyping (for gout 
only) represents a novel Polynesian-specific variant known to influence gout risk. 
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 Another common missense variant that showed significant associations with 
hyperuricaemia and gout is rs4667591. The G allele was only nominally associated with 
hyperuricaemia in Europeans (OR = 0.61, P = 0.05) and gout in Polynesians (OR = 0.72, 
P = 0.04) with a protective effect in Discovery-phase analysis (Table 5.5 and Table 5.6). 
Following replication through TaqMan PCR genotyping, the G allele successfully 
replicated the strong protective association with hyperuricaemia in the combined NZ 
Polynesian group (OR = 0.79, P = 0.002) but not NZ Europeans (OR = 0.91, P = 0.43) 
(Table 5.12 and Table 5.14). However, the Replication-phase revealed that addition of 
each G allele increased the risk of gout in NZ Europeans by 26% (OR = 1.26, P = 0.02) 
(Table 5.12). The variant has been reported to be common in other populations in 
Genome Reference Consortium human genome build 37 (GRCh37) on Ensembl 
(http://grch37.ensembl.org/) with the G allele frequency of 0.49 for East Asian and 0.79 
for European (consistent with this study) populations. The frequency of the G allele was 
little different between the East and West Polynesians and Māori individuals from Ngati 
Porou Hauora (0.46, 0.44 and 0.48, respectively). The association of this variant with 
increased risk of gout in NZ European data set is consistent with the recent GWAS data 
from Pattaro et al. (2016) that reported the other (T) allele of rs4667591 to be associated 
with increased eGFR (ß (mL/min/1.73m2) = 0.003, P = 0.006) in the European population 
(Appendix B Figure 5.3). The fact that a decrease in eGFR has been associated with an 
increase in urate concentration (Johnson et al., 2013a; Mohandas and Johnson, 2008; 
Suliman et al., 2006) and higher prevalence of gout (Krishnan, 2012), the allele T should 
be ideally associated with decreasing a risk of gout by decreasing urate concentrations. So, 
the G allele can be expected to have opposite effects on urate concentration and, thus, the 
risk of developing gout in Europeans. 
 Another common (nonsense/stop) variant within LRP2 that indicated significant 
associations in this study is rs2075252. The analysis of sequencing data in the Discovery-
phase showed a protective association of the C allele of rs2075252 with hyperuricaemia 
in Europeans only (OR = 0.65, P = 0.05) (Table 5.5). However, genotyping in the larger 
Replication Cohort did not follow the same trend in NZ Europeans (OR = 0.97, P = 0.78) 
(Table 5.12) but the C allele indicated a protection against hyperuricaemia in the 
combined NZ Polynesian dataset (OR = 0.83, P = 0.01) (Table 5.14). Similar to the 
results for rs4667591, the data presented in large European GWAS from Pattaro et al. 
(2016) indicated a positive association of the opposite (T) allele of the rs2075252 with 
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increased eGFR (ß (mL/min/1.73m2) = 0.004, P = 4.5E-06) (Appendix B Figure 5.3). The 
protective effect of C alleles of both of these variants (rs4667591 and rs2075252) for 
hyperuricaemia in the NZ Polynesian dataset may be supported by ancestral differences 
between these populations. However, in the absence of literature reporting these two 
variants in the context of Polynesian population, it would be naive to comment on 
protective findings in my study. 
 Both rs4667591 and rs2075252 are in the same haplotype block with LD (r2) 
values of 0.39 in European and 0.82 in Han Chinese populations (Table 5.11). In a recent 
GWAS including 2,640 European individuals from the FHS Offspring Cohort, the A 
alleles of rs2075252 and rs4667591 were found to be positively associated with urinary 
levels of Trefoil Factor-3 (rs2075252: ß = 0.22, P = 1.62E-16; rs4667591: ß = 0.19, P = 
0.01) (McMahon et al., 2014). Higher urinary levels of TFF3 have been recognised as 
indicators of renal tubular injury (Yu et al., 2010), acute and/or chronic kidney disease 
(Lebherz-Eichinger et al., 2015) and/or process of kidney damage repair (Astor et al., 
2011; Taupin and Podolsky, 2003). Given that rs2075252 and rs4667591 (the A alleles) 
have been positively associated with higher urinary TFF3 levels, these variants might be 
playing a role in determining the change in urate concentrations. In addition, rs2075252 
and the haplotype GA of rs4667591 were found to be associated with variation in bone 
mineral density in Chinese females (Wang et al., 2011b). Higher bone mineral density 
has been associated with higher urate levels and has been attributed to protect bone health 
in primary osteoporotic patients (Chen et al., 2015b). Although this may present a 
connecting role of these two variants in determining bone health via a change in serum 
urate concentrations, an opposite relationship has also been reported between the two 
metabolic pathways (Zhang et al., 2015). Although none of these two variants have been 
functionally characterised so far, rs4667591 was annotated as having a damaging effect 
on protein function in PolyPhen-2 and SIFT with a high CADD score (31) (Appendix A 
Table 5.6), which may possibly be one of the explanations describing the role of this 
variant in influencing hyperuricaemia and gout in NZ Polynesian and European 
population. 
 The Replication-phase analysis successfully replicated rs2302694 for an 
association of the A allele with hyperuricaemia in NZ Polynesian (OR = 0.79, P = 0.04), 
showing a trend of protective association with gout (OR = 0.80, P = 0.06) and negative 
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association with serum urate concentrations (ß (mmol L-1) = -0.015, P = 0.01) (Table 
5.14). The same allele A was also reported to be negatively associated with increased 
eGFR in European individuals (ß (mL/min/1.73m2) = -0.004, P = 0.005) in a recent 
GWAS (Pattaro et al., 2016) (Appendix B Figure 5.4). However, the A allele did not 
show any association with either hyperuricaemia (OR = 1.14, P = 0.66) or serum urate 
concentrations (ß (mmol L-1) = -0.007, P = 0.30) in the NZ European population (Table 
5.12 and Table 5.13). One reason that can expalin this difference could be the small 
sample size in my study compared to the Pattaro et al. (2016) GWAS. In addition, the 
individuals included in the Replication Cohort were not from the extreme spectrum of 
serum urate (Table 5.3), which may have caused the insignificant outcome in NZ 
European dataset. 
 The study has also found a significant burden of rare non-synonymous variants 
within LRP2 that increases the risk of developing hyperuricaemia in Europeans (PBurden 
(Risk) = 0.009) (Table 5.8). The allele collapsing method revealed a significantly higher (P 
= 0.04) frequency of the altered allele in hyperuricaemic cases (allele frequency = 0.28) 
compared to normouricaemic controls (allele frequency = 0.18) in the European 
population (Table 5.8). Previous research indicated that more common variants within 
LRP2 is inconsistently associated with serum urate and gout in other populations 
(Kamatani et al., 2010; Nakayama et al., 2014; Rasheed et al., 2013a) but no such 
common variant risk associations have been replicated in Europeans. Only a GWAS 
including data from European individuals (FHS Offspring Cohort: n = 2,640) found 
common variants within LRP2 to be associated with urinary biomarker TFF3. An exon 
sequencing follow-up burden analysis in their study also found that rare SNPs within 
LRP2 together explain 3.1% of the variance (P = 2.9×10-4) in TFF3 levels (McMahon et 
al., 2014). The findings of the present study are consistent with the fact that rare (and 
non-synonymous) variant clusters within LRP2 are involved in determining the risk of 
various kidney-related conditions in European individuals. This study presents the first 
evidence of rare variants within LRP2 conferring a risk of hyperuricaemia in the NZ 
European population. 
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5.3.1 Strengths and Limitations of the Study 
 The exon sequencing of LRP2 and A1CF and their follow-up replication indicated 
some interesting results for two populations under study. However, the study also has 
strengths and limitations presented below as a summary. 
 The ReSequencing Cohort was only adequately powered to detect a moderate or 
weaker effect for both European and Polynesian populations (Figure 5.2). This means that 
results from the Discovery-phase analysis could have small study biases in terms of 
having false positive associations and elevated effect sizes. Such underpowered studies 
have low reproducibility and replication success rate (Button et al., 2013). The underlying 
genetic architecture of any trait determines the best-powered design to detect an 
association (Laird and Lange, 2006). For complex traits like gout and hyperuricameia, 
where the genetic architecture is partially known, it is not possible to predict a priori the 
most powerful study design (Auer and Lettre, 2015). However, the study had several 
other complementary factors which could overcome the low detection power to some 
extent. First, the phenotypes assessed were extreme or binary i.e., hyperuricaemic vs 
normouricaemic and gout case vs control. The binary characterisation is described to be 
better than having a continuous phenotype (e.g., serum urate) while carrying out an 
analysis of sequencing data, especially rare variant analysis (Auer and Lettre, 2015; 
Button et al., 2013; Do et al., 2012). Second, a burden analysis approach was used to 
combine the effect of all rare and non-synonymous variants within LRP2 and A1CF. This 
analysis is specialised to calculate the effect of all variants together considering them as 
one unit and is more powerful than testing the effect of each variant separately (Lee et al., 
2014). 
 Follow-up genotyping of the interesting results from the Discovery-phase 
represents the major strength of this study. It is essential to replicate the outcomes of a 
whole genome/exome sequencing analysis via one of several follow-up replication 
strategies (Auer and Lettre, 2015) to confirm the true and false associations. The study 
Replication Cohort was designed by choosing larger and well-characterised data sets from 
two populations. Also, the Replication-phase analysis was able to reproduce similar 
associations for at least one of the two phenotypes (hyperuricaemia and gout) with a total 
success rate of 75%. However, there were some findings from Discovery-analysis that 
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were not replicable and/or were not significant in the Replication-phase. One potential 
limitation could be the average serum urate levels in hyperuricaemic group in the 
Replication Cohort were only marginally hyperuricaemic and were not from extreme ends 
of the urate spectrum as for the Discovery Cohort. Use of individuals with average urate 
levels matching the Discovery Cohort may provide better replication results, but such 
individuals were not available. 
 Another strength of the study is the selection of two different approaches to 
calculate a burden of rare and non-synonymous variants. The selection, however, could 
also be a likely limitation of the study. Falling within five major categories, many 
different burden testing designs are now available (Lee et al., 2014). The burden testing 
approach used in this study was based on the simplicity of computing and the ability of 
the weighted sum statistic test to calculate the burden in two (risk and protective) 
directions. Other approaches (e.g., SKAT) may or may not be more efficient in picking 
up rare variants than the present approach. Additionally, no other methodolodgy is yet 
available to test the burden for risk and protective variants separately. 
5.3.2 Conclusion and future directions 
 The work described in this section provides a detailed characterisation of exonic 
regions of two genes, LRP2 and A1CF. Overall in both genes, 12 common, low frequency 
and rare variants were detected to be associated with hyperuricaemia in Europeans and 
hyperuricaemia or gout or both in NZ Polynesians. Two non-synonymous Polynesian-
specific variants (i.e., alleles) have been identified within the coding region of the gene 
LRP2 showing protection for gout. The confirmation of this association through follow-
up genotyping in a larger cohort presents a novel finding of this study exploring 
population-specific variants in NZ Polynesian individuals indicating a real effect 
associated with gout. The study for the first-time reports rare non-synonymous variants 
within LRP2 to carry a significant risk burden for hyperuricaemia in European individuals. 
The study, however, was unable to find any potentially interesting associations for the 
gene A1CF in the context of hyperuricaemia and gout for European and Polynesian 
populations. A few inconsistent results in the discovery-phase analysis for an association 
with hyperuricaemia and gout in NZ Polynesian population may indicate an independent 
involvement of these variants in either urate transport or the inflammatory pathway. The 
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failure of replication of sequencing associations could be a result of the small sample size 
(low power) of the study (Button et al., 2013). Increasing the sample size of Discovery 
and Replication Cohorts and broadening by including hyperuricaemic individuals with 
urate levels at extreme ends of the hyperuricaemia spectrum would be helpful in 
explaining the associations that were not replicable in my study. The replicated non-
synonymous variants can be further tested for their functional consequences using gene 
cloning and expression approaches in human/animal cell lines. Using such in vitro 
techniques, the effect of variants on the expression of the respective gene, mRNA 
expression and protein activity can be tested. Following the expression assays, the 
proteins encoded by these genes (especially LRP2) can be purified via chromatography to 
further test for their binding to appropriate ligands (e.g., LDL for LRP2), which would be 
beneficial in explaining the role of these genes in the underpinning pathway between lipid 
































SECTION 6.1: CONCLUSIONS 
6.1.1 Summary 
 The need to disentangle the intricate pathophysiology of gout in a country like 
New Zealand with an isolated geographical location and markedly high prevalence of this 
complex phenotype is discernible. My study was an attempt to shed light on the potential 
relationship of gout with other coexisting metabolic conditions with a focus of “which is 
driving which”. Through the implementation of cross-disciplinary research methods, I 
have been able to explore and report as novel findings the genetic/causal associations of 
urate, hyperuricaemia and gout with a set of several metabolic conditions that has more 
often than not been ignored in previous studies of the kind. 
 The first two research chapters (Chapter 2 and Chapter 3) of this thesis aimed out 
to explore a possible causal relationship between gout and imbalanced iron metabolism as 
its co-existing complication. Chapter 2 reports a successful replication of a previously 
reported (Ghio et al., 2005) positive association of urate with serum levels of ferritin (iron 
storage protein that directly reflects total body iron) and transferrin saturation in 
Europeans and/or African Americans using the data in the NHANES III and the JHS 
cohorts (Table 2.5). The ferritin-urate associations were extended from Europeans and 
African Americans to New Zealand Polynesian males (P = 2.53E-04) (Table 2.5). To 
ensure that the observed positive associations were not aggravated by an inflammatory 
condition e.g., hyperuricaemia and/or gout, the robustness of association was validated 
via adjusting for serum levels of CRP as an indicatory marker for acute inflammation. 
This study for the first time reported an association of increased serum ferritin with the 
risk for gout (OR = 1.03, P = 1.76E-03) and frequency of gout flares (ß (flares/year) = 
0.09, P = 0.04) in the New Zealand Polynesian and European male populations, 
respectively (Table 2.7 and 2.8). Results of this study also showed that the levels of 
ferritin were significantly higher in New Zealand Polynesian gout cases (P = 2.29E-04) 
compared to non-gout controls (Appendix A Table 2.4). 
 The observational study in Chapter 2 was primarily conducted to elaborate a 
biochemical association and was not aimed to elucidate the exact mechanism of iron-
urate relationship. However, the results of this study along with the data reported in the 
previous literature suggested a possible role of change in blood levels of ferritin in 
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increasing the risk of gout via hyperuricaemia, especially in New Zealand Māori and 
Pacific Island individuals. Evidence reporting a possible relationship of iron and urate are 
not recent (Green and Mazur, 1957; Mazur et al., 1958; Muirden and Senator, 1968). 
Urate being an antioxidant in humans has been reported as reducing the oxidative stress 
of free floating iron by acting as a metal chelator (Aust et al., 1985; Davies et al., 1986). 
Increased exposure to iron has been shown to upregulate the activity of xanthine oxidase 
resulting in the increased production of urate (Ghio et al., 2002; Martelin et al., 2002; 
Stonehuerner et al., 1998). Additionally, the presence of iron deposits in the synovial 
membrane in people with rheumatoid arthritis (Muirden and Senator, 1968), and the 
reduction in the severity of gout flares following the depletion of the metal via 
phlebotomy are supportive of my observational findings in Chapter 2 (Facchini, 2003). 
My study also reports a preliminary finding of increased serum ferritin in New Zealand 
Polynesians (P = 0.04) who self-reported the consumption of iron-rich food (seafood, fish 
and red meat) as a trigger for gout (Table 2.10). This finding, along with the results from 
previous research conducted in the Merriman Laboratory (Flynn et al., 2015), further 
provoked the idea for a possible role of iron-rich food in increasing, both the frequency 
and severity of gout flares. 
 Albeit the outcomes of Chapter 2 presented an interesting theme of the 
involvement of iron metabolism in gout aetiology via hyperuricaemia, although the 
results were still prone to biases due to the presence of possible confounders (Mann and 
Wood, 2012). To confirm the observational data an initial genetic association analysis 
was done using two iron-related variants (rs1799945 and rs1800562) within the HFE 
(haemochromatosis) gene. In the adjusted analyses (adjusted for age, body mass 
index/BMI and estimates of grand-parental ancestry in Polynesians), the G allele of 
rs1799945 was found to be positively associated with serum urate in the New Zealand 
population sub-groups and with a 28% increase in the risk of developing gout in New 
Zealand European females (OR = 2.28, P = 0.03) (Table 2.12). These results not only 
provided support to my observational data but also a logical base to design the research in 
Chapter 3. 
 The research in Chapter 3 was designed to validate the observational findings in 
Chapter 2 using the robust ‘Two-sample Mendelian randomisation’ approach to infer the 
causal association between iron and urate metabolism/metabolic pathways in the larger 
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population datasets of European descent. My study, for the first time, exploited summary 
statistics data from two large GWAS (Benyamin et al., 2014; Köttgen et al., 2013) to 
investigate the iron-urate causality in a population. Mendelian randomisation is a 
statistical approach to infer a cause-effect relationship via using the appropriate genetic 
instrument(s) (Smith and Ebrahim, 2003). The analysis provided an evidence for a causal 
role for serum iron (ß (SD) = 0.11, P = 1.96E-04) and ferritin (ß (SD) = 0.14, P = 0.03) to 
raise serum urate levels in European individuals (Table 3.4). Given that the study 
included effect estimate data from > 240,000 Europeans, it was presumed to have high 
power to detect a weaker effect. Since the outcomes of Mendelian randomisation studies 
require selection of instruments with ‘no pleiotropy’, a thorough search via literature 
review and the use of bioinformatics tools/platforms was carried out to rule out this 
possibility of any such pleiotropic effects. The results were reported only after removing 
all possible ambiguities (to my knowledge). However, it is impossible to remove the 
effect from any unknown confounders and such studies thus merit further exploration. 
Overall, result from my study in Chapter 3 provides evidence of a causal role of exposure 
iron and ferritin in increasing urate concentration as an outcome. However, my study does 
not report a causal effect of exposure of urate to influence iron homeostasis, which in turn, 
suggested that an increase in blood levels iron (or ferritin) is causative for an increase in 
urate concentration as an outcome. 
 The prevalence of gout is high in the New Zealand population (~7% in 
Polynesians and ~3% in Europeans) (Winnard et al., 2012) and so is the prevalence of its 
comorbidities (detailed in Chapter 1). Most of these comorbidities (IR, T2D, hypertension 
and CVDs) are collectively referred to as components of or ‘metabolic syndrome (MetS)’ 
per se. Seldom has MetS been studied for its genetic relationship with gout and 
hyperuricaemia with most of the studies reporting only its prevalence in the New Zealand 
population. The research in Chapter 4 was, therefore, designed to explore the shared 
genetic basis between gout and the components of MetS in the New Zealand based 
ancestral groups. TaqMan genotyping was used to collect genotype information for > 
4,600 New Zealanders. The data from large publicly-available European populations 
were also sourced from the UK Biobank, ARIC, FHS, CHS and CARDIA cohorts. The 
variants that have primarily been reported for their association with the components of 
MetS and/or serum urate in other populations were selected including ADRB3: rs4994, 
MC3R: rs3827103, MC4R: rs17700633 and rs17782313 and ADTRP: rs6903956. The 
6| Conclusions 
 258 
genotype association analyses were adjusted for baseline confounders (age, sex, BMI and 
estimates of grand-parental ancestry for New Zealand Polynesian datasets) plus with 
other comorbid conditions (hypertension, renal dysfunction, T2D and dyslipidaemia) of 
hyperuricaemia and gout. The analysis successfully replicated the previously reported 
positive associations (Huang et al., 2013; Morcillo et al., 2010; Rho et al., 2007; Wang et 
al., 2011a) of the insulin resistance-related G allele of rs4994 with increased serum urate 
in the New Zealand Polynesians (WP:  (mmol L-1) = 0.036, P = 0.004) (Table 4.8). The 
analysis further revealed a possible pleiotropic effect of the G allele in Western 
Polynesian sub-group, showing a protective effect against gout (OR = 0.62, PUnadjusted = 
0.04) (Table 4.6). The protective association of the G allele with gout was also observed 
in the much larger European dataset from the UK Biobank Cohort (OR = 0.88, P = 0.04) 
(Table 4.6) and was consistent with my previously published data for the G allele of 
ADRB3: rs4994 in Western Polynesian (described above) (Fatima et al., 2016) and 
suggests a possible positive relationship of insulin-resistance and hyperuricaemia. 
 The research in Chapter 4 also reports interesting results for variants within/near 
the obesity-related melanocortin receptor genes (MC3R and MC4R) with gout in the New 
Zealand Polynesian and European populations. While the A allele of MC3R: rs3827103 
indicated a protective association with gout in the overall New Zealand population (OR = 
0.92, P = 0.03) (Table 4.9), the C allele of MC4R: rs17782313 was found to be associated 
with an increased risk for gout in New Zealand Europeans (OR = 1.03, P = 0.02) and the 
combined NZ European and Polynesian datasets (OR = 1.06, P = 0.03) (Table 6.9). The C 
allele of rs17782313 was also associated with increased serum urate in the non-gout 
European plus Polynesian individuals ( (mmol L-1) = 0.002, P = 0.006) (Table 4.9). 
Collectively these findings are consistent with the previously reported genetic/causal 
association of MC3/4R (for the same alleles of variants under study) with serum urate in 
Europeans (Köttgen et al., 2013; Lyngdoh et al., 2012; Palmer et al., 2013). The C allele 
of rs17782313 has been abundantly reported as a genuine signal for obesity and increased 
BMI in several populations (Beckers et al., 2011; Chambers et al., 2008; Loos et al., 
2008; Zobel et al., 2009). Given that the melanocortin system is involved in the anti-
inflammatory response (via MC3R) and in food uptake regulation (via MC4R) (Getting et 
al., 2002; Huszar et al., 1997; Lu et al., 1994), my findings in Chapter 4 not only depicts 
obesity and insulin resistance to have causal relationship with gout but also are suggestive 
of an unknown shared metabolic pathway between gout and MetS. Put together, these 
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findings hence constructed a bridge between gout and MetS via the genetic association 
analyses in New Zealand-based populations. 
 The research in Chapter 5 dealt with ‘dyslipidaemia’ as the third and last 
comorbid condition for gout among the comorbidities included in my PhD project via 
replication-based rare variant association analysis approach. Two lipid-related genes, 
LRP2 and A1CF, were assessed for their association with hyperuricaemia and/or gout in 
the European and NZ Polynesian individuals using exon sequencing data for these 
particular genes from the information available in the ReSequencing Cohort. Exploring 
the genetic association of non-urate transporter genes with hyperuricaemia and gout was 
the major purpose of this research. The results of the Discovery-phase showed several 
novel population-specific association signals for gout and hyperuricaemia from common 
(via single variant analyses) and rare (via non-synonymous burden) variants within the 
coding regions of the LRP2 gene (Table 5.5 and Table 5.6). The C alleles of two 
Polynesian-specific variants, rs111360923 and var170115626, were successfully 
replicated for an association with gout (rs111360923; OR = 0.64, P = 0.002, 
var170115626 = OR = 0.73, P = 0.03) when validated in a larger Replication Cohort that 
included the data from > 3,300 New Zealand-based Polynesian and European individuals 
(Table 5.12 to Table 5.14). Owing to the presence of similar allele frequencies of 
rs111360923 (MAF = 0.07) and var170115626 (MAF = 0.07) LD was calculated, which 
indicated a strong LD (r2 = 83%) between rs111360923 and var170115626 in the New 
Zealand Polynesian population (Figure 5.8). The association signals of these two variants 
(the C alleles) were, however, found to be independent of the T allele of LRP2: 
rs2544390 (r2 = 5%) that was previously reported for its Polynesian-specific association 
with gout (Rasheed et al., 2013a). Both of these variants have been reported as having 
extremely low frequencies in other populations (rs111360923 MAF = for Africans 
(0.008) and South Asians (0.001); var170115626 MAF = 6.05E-05 only in South Asians). 
A thorough literature search also revealed that these two variants have never been 
described in relation to any pathophysiologic condition, which further ascribed the 
novelty of my findings in Chapter 5. The allelic associations of three more common 
variants, rs4667591, rs2075252 and rs2302694, were also replicated for gout and/or 
hyperuricaemia in the New Zealand European and/or Polynesian ancestral groups. The G 
allele of rs4667591 was significantly associated with hyperuricaemia, albeit in opposite 
direction, in the New Zealand Polynesian (OR = 0.79, P = 0.002) and European (OR = 
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1.26, P = 0.02) groups (Table 5.14). The C allele of rs2075252 and the A allele of 
rs2302694 were found to have a protective effect for hyperuricaemia in the New Zealand 
Polynesians (rs2075252: OR = 0.83, P = 0.01; rs2302694: OR = 0.79, P = 0.04) (Table 
5.14). Further to these, the rare non-synonymous variants within the LRP2 gene showed a 
significant burden risk of developing hyperuricaemia in European individuals (PBurden (Risk) 
= 0.009) (Table 5.8). The combined rare variant allele frequency was significantly higher 
(P = 0.04) in hyperuricaemic cases compared to controls (Table 5.8). While the previous 
literature provided evidence for the involvement of more common variants within the 
LRP2 gene in increasing the risk of hyperuricaemia and/or gout in other populations 
(Kamatani et al., 2010; Nakayama et al., 2014; Rasheed et al., 2013a), my findings in 
Chapter 5 are suggestive for a protective role of common variants within the LRP2 gene 
for hyperuricaemia. The replicated protective findings of LRP2 in my study are of interest 
and are not supportive for a role of LRP2 in increasing the risk of hyperuricaemia and/or 
gout in Polynesian individuals. It is also notable that the sample size for the Discovery-
phase indicated a lower power and the individuals in the Replication Cohort did not have 
their urate levels from extreme spectrum of hyperuricaemia. Admitting that these 
limitations could have caused a difference in the direction of association for LRP2 
variants, the protective findings in my study merits further exploration e.g., use of larger 
data set with hyperuricaemic individuals having higher average urate levels than the 
Replication Cohort. 
6.1.2 Study limitations 
The limitations of the work presented in this thesis are detailed below; 
1. The observational data provided in Chapter 2 suggested a positive association of 
imbalanced iron homeostasis with urate and gout with an initial suggestion of an 
involvement of iron-rich food in gout pathophysiology. However, it was not 
possible to further investigate the relationship between iron-rich diet and gout and 
frequency of gout flares due to the small sample size used. 
2. Mendelian randomisation analyses in Chapter 3 represent three major limitations 
of my study. First, the causal effect estimates described by the single variant as 
well as the sensitivity analyses were of limited magnitude and therefore may not 
retain causality if summary data encompassing a wider range of iron biomarkers 
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were used. Second, the causal role of iron and ferritin in increasing serum urate 
was confirmed in Europeans only due to the unavailability of GWAS data for 
Polynesian individuals. These findings, therefore, cannot guarantee the existence 
of a similar causal relationship between iron and urate in the New Zealand 
Polynesian individuals. And finally, the causality was described for ferritin/iron-
urate only, again, due to the absence of GWAS data for gout-related loci, which 
means the causality may or may not retain significance if measured for an iron-
gout relationship. 
3. The associations presented in Chapter 4 were collectively assessed in large New 
Zealand Polynesian and European datasets. However, the data presented for 
individual Polynesian sub-groups could possibly have small-study biases. 
4. The rare variant association analyses using sequencing data resulted in several 
positive significant associations that were not replicable in the larger cohort. The 
failure of replication presents a limitation of these analyses i.e., the Discovery-
Cohort was only adequately powered to detect an intermediate effect (Figure 5.4) 
due to its small size and may have overrepresented some false-positive 
associations. 
6.1.3 Future directions 
 The limitations detailed above need to be addressed appropriately to further 
confirm the false positive association(s) in my study, if any. A few suggestions to extend 
this research are detailed below; 
1. The observational associations between ferritin and gout should be replicated in a 
larger data set from New Zealand individuals. In addition, detailed information 
about the involvement of iron-rich diet in triggering gout flares and the frequency 
of flares should be gained to elaborate the aspects of and further extend the 
research presented in Chapter 2. 
2. A GWAS study detecting gout-related loci in the New Zealand European and 
Polynesian populations will facilitate analysing and validating of the iron/ferritin-
urate causal associations via Mendelian randomisation. Also, the data covering a 
wider range of serum iron biomarkers and urate would be beneficial to assess if 
the causality still exists. 
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3. The recruitment of a larger New Zealand cohort to replicate the association in 
Chapter 4 and the Discovery-phase findings in resequencing analyses (Chapter 5) 
will be beneficial. In addition to increasing the sample size, choosing individuals 
from extreme ranges of hyperuricaemia would be desirable to investigate as to 
why replication of some variants failed. 
6.1.4 Concluding remarks 
 The initially stated overarching aim of this research was to identify the potential 
causal relationship between gout and its comorbidities in the New Zealand population. 
While recognising the limitations, I believe that my study represents an original 
contribution to fill in the substantial gap in literature explaining the cause-effect 
relationship between gout, iron homeostasis, metabolic syndrome and dyslipidaemia. My 
study for the first time reports the association of ferritin with gout and the frequency of 
gout flares in the New Zealand individuals. It is also the first to describe a causal 
contribution of iron homeostasis in hyperuricaemia and gout pathophysiology in 
Europeans. My study is one of a few that addresses several components of the metabolic 
syndrome simultaneously while explaining their genetic relationship in gout. Its is also so 
far the only study reporting two Polynesian-specific common variants within the LRP2 
gene that influence any pathophysiological condition per se, hyperuricaemia and gout in 
this case. Finally, the study is the only one of its kind to report rare variants within the 
coding regions of LRP2 to carry a significant burden of risk of hyperuricaemia in the 
European population. 
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APPENDIX A 





ß [95% CI] P ß [95% CI] P 
NZ European 
Serum iron -4.44e-05 [-6.58e-04 ; 5.69e-04] 0.885 1.74e-05 [-6.04e-04 ; 6.391e-04] 0.955 
Transferrin -0.013 [-0.0607 ; 0.0338] 0.571 -0.008 [-0.0564 ; 0.0396] 0.726 
TIBC -5.35e-04 [-0.0024 ; 0.0013] 0.571 -3.36e-04 [-0.0022 ; 0.0016] 0.726 
TSAT 1.35e-04 [-0.0019 ; 0.0022] 0.898 2.45e-04 [-0.0018 ; 0.0026] 0.816 
NZ Polynesian 
Serum iron -3.86e-04 [-7.66e-04 ; -5.97e-06] 0.046 -3.40e-04 [-7.05e-04 ; 2.52e-05] 0.068 
Transferrin 0.029 [0.0037 ; 0.054] 0.024 0.023 [-0.0018 ; 0.048] 0.069 
TIBC 0.0012 [1.51e-04 ; 2.17e-03] 0.024 9.20e-04 [-7.47e-05 ; 0.0019] 0.069 
TSAT -0.0021 [-0.0033 ; -7.16e-04] 0.002 -1.69e-03 [-0.0029 ; -3.91e-04] 0.011 
JHS (All) 
Serum iron 1.11e-04 [4.08e-05 ; 2.63e-04] 0.152 -8.91e-05 [2.21e-04 ; 4.27e-05] 0.185 
TIBC -1.82e-04 [-2.82e-04 ; -8.19e-05] 3.77e-04 3.31e-05 [-5.45e-05 ; 1.21e-04] 0.459 
TSAT 5.62e-04 [1.28e-04 ; 9.96e-02] 0.011 3.35e-04 [7.19e-04 ; 4.96e-05] 0.087 
JHS (Males) 
Serum iron 2.71e-04 [4.82e-04 ; 5.91e-05] 0.012 -1.63e-04 [3.72e-04 ; 4.54e-05] 0.125 
TIBC 1.29e-04 [-3.47e-05 ; -2.93e-04] 0.122 1.07e-04 [-5.17e-05 ; 2.66e-04] 0.185 
TSAT -9.57e-04 [-1.56e-03 ; 3.51e-04] 0.002 -6.32e-04 [-1.23e-03 ; 3.31e-05] 0.038 
JHS (Females) 
Serum iron -2.15e-04 [3.95e-04 ; 3.39e-05] 0.02 -5.98e-05 [-2.28e-04 ; 1.08e-04] 0.487 
TIBC -6.06e-05 [-1.68e-04 ; 4.67e-05] 0.268 2.49e-05 [-7.89e-05 ; 1.28e-04] 0.637 
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TSAT -4.75e-04 [-8.53e-03 ; 5.79e-05] 0.081 -2.31e-04 [-7.34e-04 ; 2.71e-04] 0.366 
NHANES III: EUR (All) 
Serum iron 0.209 [0.149 ; 0.269] 7.78e-12 0.159 [0.109 ; 0.208] 3.33e-10 
TIBC -0.296 [-0.514 ; -0.077] 0.008 0.306 [0.121 ; 0.491] 0.001 
TSAT 0.681 [0.489 ; 0.873] 3.98e-12 0.358 [0.199 ; 0.5180] 1.07e-05 
NHANES III: EUR (Males) 
Serum iron 0.135 [0.055 ; 0.216] 9.22e-04 0.135 [0.058 ; 0.212] 5.76e-04 
TIBC 0.931 [0.619 ; 1.242] 5.2e-09 0.548 [0.244 ; 0.852] 4.03e-04 
TSAT 0.156 [-0.096 ; 0.409] 0.225 0.265 [0.025 ; 0.506] 0.030 
NHANES III: EUR (Females) 
Serum iron 0.022 [-0.046 ; 0.091] 0.519 0.171 [0.108 ; 0.233] 1.12e-07 
TIBC 0.042 [-0.198 ; 0.284] 0.727 0.192 [-0.031 ; 0.416] 0.0925 
TSAT 8.53e-03 [-0.219 ; 0.236] 0.942 0.411 [0.204 ; 0.618] 1.01e-04 
NHANES III: AA (All) 
Serum iron 0.235 [0.159 ; 0.312] 1.49e-09 0.164 [0.097 ; 0.232] 1.5e-06 
TIBC -1.015 [-1.272 ; -0.757] 1.33e-14 0.197 [-0.031 ; 0.425] 0.09 
TSAT 0.950 [0.699 ; 1.202] 1.47e-13 0.378 [0.155 ; 0.601] 8.71e-04 
NHANES III: AA (Males) 
Serum iron -0.029 [-0.135 ; 0.075] 0.577 0.131 [0.029 ; 0.233] 0.011 
TIBC 0.417 [0.018 ; 0.816] 0.041 0.485 [0.105 ; 0.865] 0.012 
TSAT -0.244 [-0.593 ; 0.104] 0.17 0.252 [-0.083 ; 0.587] 0.14 
NHANES III: AA (Females) 
Serum iron -0.037 [  -0.135 ; 0.059] 0.447 0.163 [0.075 ; 0.252] 2.9e-04 
TIBC -0.783 [-1.078 ; -0.487;] 2.21e-07 0.165 [-0.118 ; 0.449] 0.252 
TSAT 0.036 [-0.290 ; 0.362] 0.828 0.361   [0.063 ; 0.657] 0.017 
NZ; New Zealand, JHS; Jackson Heart Study, NHANES III; US Third National Health and Nutrition Examination Survey, EUR; White Caucasian/European, AA; African American, 
TIBC; Total iron binding capacity, TSAT; Transferrin saturation. *Adjusted for age, sex, BMI and number of self-reported Polynesian grandparents for the NZ Polynesian group. 
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OR [95% CI] P OR [95% CI] P 
JHS (All) 
Serum iron 1.005 [0.999 ; 1.009] 0.067 1.002 [0.994 ; 1.006] 0.958 
TIBC 0.984 [0.966 ; 1.003] 0.108 1.006 [0.983 ; 1.029] 0.607 
TSAT 1.016 [1.001 ; 1.031] 0.034 0.996 [0.979 ; 1.014] 0.735 
JHS (Males) 
Serum iron 0.997 [0.990 ; 1.003] 0.379 0.998 [0.991 ; 1.005] 0.713 
TIBC 1.013 [0.987 ; 1.041] 0.330 1.012 [0.985 ; 1.040] 0.396 
TSAT 0.987 [0.968 ; 1.006] 0.186 0.992 [0.972 ; 1.012] 0.432 
JHS (Females) 
Serum iron 0.999 [0.986 ;1.011] 0.976 1.004 [9.88e-01 ; 1.016] 0.577 
TIBC 0.988 [0.948 ; 1.029] 0.587 1.001 [9.55e-01 ; 1.046] 0.981 
TSAT 1.001 [0.962 ; 1.036] 0.953 1.007 [9.645e-01 ; 1.048] 0.714  
NHANES III: EUR (All) 
Serum iron 1.003 [1.002 ; 1.004] 5.05e-06 1.002 [1.001 ; 1.004] 6.4E-04 
TIBC 0.994 [0.989 ; 0.999] 0.026 1.013 [1.008 ; 1.019] 1.07e-06 
TSAT 1.009 [1.005 ; 1.013] 9.4e-06 1.002 [0.997 ; 1.007] 0.302 
NHANES III: EUR (Males) 
Serum iron 1.001 [0.999 ; 1.002] 0.252 1.002 [1.001 ; 1.004] 0.00646 
TIBC 1.015 [1.008 ; 1.021] 4.51e-06 1.019 [1.012 ; 1.026] 2.71e-08 
TSAT 0.998 [0.993 ; 1.003] 0.526 1.001 [0.996 ; 1.006] 0.607 
NHANES III: EUR (Females) 
Serum iron 0.996 [0.993 ; 0.999] 0.016 1.001 [0.998 ; 1.005] 0.413   
TIBC 0.986 [0.977 ; 0.995] 0.00345 1.006 [9.9e-01 ; 1.016] 0.183 
TSAT 0.992 [0.983 ; 1.002] 0.147 1.001 [0.989 ; 1.011] 0.899 
NHANES III: AA (All) 
Serum iron 1.003 [1.001 ; 1.005] 4.44e-04 1.005 [1.002 ; 1.006] 1.29e-04 
TIBC 0.977 [0.971 ; 0.985] 1.12e-09 1.005 [0.996 ; 1.013] 0.241 
TSAT 1.016 [1.009 ; 1.023] 6.63e-07 1.012 [1.004 ; 1.019] 2.77e-03 
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NHANES III: AA (Males) 
Serum iron 0.999 [0.996 ; 1.002] 0.6 1.004 [1.001 ; 1.007] 0.003 
TIBC 0.992 [0.983 ; 1.002] 0.1509 1.004 [0.993 ; 1.015] 0.407 
TSAT 0.999 [0.991 ; 1.007] 0.908 1.012 [1.002 ; 1.021] 0.013 
NHANES III: AA (Females) 
Serum iron 0.999 [0.995 ; 1.003] 0.724 1.005 [1.001 ; 1.009] 0.024 
TIBC 0.974 [0.961 ; 0.987] 9.3e-05 1.009 [0.995 ; 1.024] 0.176 
TSAT 1.004 [0.991 ; 1.017] 0.503 1.011 [0.994 ; 1.025] 0.19 
JHS; Jackson Heart Study, NHANES III; US Third National Health and Nutrition Examination Survey, EUR; White Caucasian/European, AA; African American, TIBC; Total iron binding 
capacity, TSAT; Transferrin saturation. *Adjusted for age, sex, BMI and number of self-reported Polynesian grandparents for the NZ Polynesian group. 
 
 




OR [95% CI] P OR [95% CI] P 
NZ European 
Serum iron 0.991 [0.981 ; 1.002] 0.115 0.994 [0.981 ; 1.008] 0.459 
Transferrin 1.393 [0.606 ; 3.307] 0.440 1.318 [0.045 ; 3.801] 0.602 
TIBC 1.013 [0.981 ; 1.048] 0.440 1.011 [0.097 ; 1.054] 0.602 
TSAT 0.968 [0.934 ; 1.003] 0.077 0.096 [0.092 ; 1.013] 0.171 
NZ Polynesian 
Serum iron 0.995 [0.984 ; 1.005] 0.354 0.993 [0.981 ; 1.005] 0.263 
Transferrin 1.708 [0.934 ; 3.252] 0.090 1.663 [0.839 ; 3.476] 0.156 
TIBC 1.021 [0.997 ; 1.048] 0.090 1.020 [0.099 ; 1.051] 0.156 
TSAT 0.964 [0.925 ; 1.003] 0.074 0.960 [0.916 ; 1.004] 0.082 
NZ; New Zealand, TIBC; Total iron binding capacity, TSAT; Transferrin saturation. *Adjusted for age, sex, BMI and number of self-reported Polynesian grandparents for the NZ 
Polynesian group. 
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Appendix A Table 2.4: Comparison of average values of iron profile markers in gout 
case-control groups 
Population P [95% CI] for difference 
NZ European 
Serum iron (μg dL-1) 0.114 [-1.96 ; 18.06] 
Serum ferritin (ng mL-1) 0.213 [-97.46 ; 22.02] 
Transferrin (g L-1) 0.446 [-0.17 ;  0.07] 
TIBC (μmol L-1) 0.446 [-4.42 ; 1.96] 
TSAT (%) 0.074 [-0.27 ; 5.64] 
NZ Polynesian 
Serum iron (μg dL-1) 0.342 [-5.09 ; 14.57] 
Serum ferritin (ng mL-1) 2.29E-04 [-211.88 ; -66.31] 
Transferrin (g L-1) 0.073 [-0.32 ; 0.014] 
TIBC (μmol L-1) 0.073 [-8.05 ; 0.36] 
TSAT (%) 0.071 [-0.21 ; 5.01] 
US 
Serum ferritin (ng mL-1) 6.60E-17 [-167.19 to -107.16] 
NZ; New Zealand, TIBC; Total iron binding capacity, TSAT; Transferrin saturation. 
 
 
Appendix A Table 2.5 Association of serum ferritin with gout (Transformed data) 
Population OR [95% CI] P OR [95% CI]* P* 
NZ European 1.19 [0.81 ; 1.76] 0.37 0.88 [0.49 ; 1.52] 0.64 
NZ Polynesian 1.76 [1.12 ; 2.84] 1.63E-02 2.24 [1.27 ; 4.17] 7.41E-03 
US 2.42 [1.79 ; 3.39] 7.02E-08 2.31 [1.65 ; 3.31] 2.26E-06 
NZ; New Zealand, US; United States of America. *Adjusted for age, sex, BMI, C-reactive protein and number of self-




Appendix A Table 2.6 Association of serum ferritin with gout flares/year 
(Transformed data) 
Population ß [95% CI] P ß [95% CI]* P* 
NZ European 1.74 [0.17 ; 3.32] 0.030 1.94 [0.24 ; 3.63] 0.025 
NZ Polynesian -4.42 [-9.750 ; 0.90] 0.10 -4.68 [-10.11 ; 0.75] 0.090 
US 0.38 [0.11 ; 0.64] 0.0063 0.37 [0.10 ; 0.63] 0.0066 
NZ; New Zealand, US; United States of America. *Adjusted for age, sex, BMI and number of self-reported Polynesian 
grandparents in the NZ Polynesian analyses. All ß-estimates represent a change per unit log of ferritin. 
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Appendix A Table 2.7 Association of serum ferritin with gout flares/year 
Population 
^Unadjusted *Adjusted †Adjusted 
ß [95% CI] P ß [95% CI] P ß [95% CI] P 
NZ European 0.08 [0.001 ; 0.16] 0.045 0.09 [0.003 ; 0.17] 0.042 0.069 [-0.005 ; 0.144] 0.067 
NZ Polynesian -0.11 [-0.24 ; 0.03] 0.13 -0.11 [-0.24 ; 0.03] 0.14 -0.091 [-0.22 ; 0.034] 0.15 
US 0.02 [0.01 ; 0.04] 0.003 0.02 [0.01 ; 0.04] 0.002 0.018 [0.001 ; 0.036] 0.043 
^Unadjusted; *Adjusted for age, BMI and number of self-reported Polynesian grandparents in the NZ Polynesian analyses; †Adjusted for age, BMI, allopurinol usage and number of self-
reported Polynesian grandparents in the NZ Polynesian analyses. 
 
Appendix A Table 2.8 Association of serum ferritin (ng mL-1) with gout excluding those ‘not taking allopurinol’ 
Population 
All Taking allopurinol 
OR [95% CI] P OR [95% CI]* P* OR [95% CI] P OR [95% CI]* P* 
NZ 
European 
1.011 [0.993 ; 1.031] 0.22 0.997 [0.971 ; 1.023] 0.84 1.009 [0.987 ; 1.033] 0.42 0.993 [0.961 ; 1.025] 0.67 
NZ 
Polynesian 
1.026 [1.011 ; 1.045] 1.71E-03 1.032 [1.013 ; 1.055] 1.76E-03 1.039 [1.013 ; 1.0725] 6.83E-03 1.061 [1.024 ; 1.112] 3.93E-03 
US 1.115 [1.071 ; 1.170] 1.47E-06 1.112 [1.066 ; 1.170] 7.41E-06 1.149 [1.086 ; 1.233] 1.57E-05 1.270 [1.148 ; 1.469] 8.89E-05 
^Unadjusted; *Adjusted for age, BMI, C-reactive protein and number of self-reported Polynesian grandparents in the NZ Polynesian analyses. All OR values represent change in risk for 
per 10 ng mL-1 increase in serum ferritin. 
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Appendix A Table 2.7 Association of ferritin (ng mL-1) with serum urate (μmol L-1) (Transformed data) 
Population ß [95% CI] P ß [95% CI]* P* 
NZ European 21.97 [-2.452 ; 46.389] 0.076 20.027 [-6.174 ; 46.229] 0.13 
NZ Polynesian 22.031 [7.465 ; 37.151] 3.35E-03 22.824 [8.098 ; 37.551] 2.5E-03 
US 22.98 [-3.882 ; 49.836] 0.092 19.326 [-9.281 ; 47.933] 0.18 
JHS (males) 10.921 [2.642 ; 19.200] 9.82E-03 9.476 [1.457 ; 17.495] 2.06E-02 
JHS (females) 17.48 [11.863 ; 23.093] 1.64E-09 9.527 [3.765 ; 15.288] 1.22E-03 
JHS (combined) 31.470 [27.021 ; 35.919] 7.16E-41 10.850 [6.249 ; 15.452] 4.11E-06 
NHANES III EUR (Males) 8.663 [5.215 ; 12.111] 8.91E-07 5.118 [1.816 ; 8.419] 2.39E-03 
NHANES III EUR (Females) 17.814 [15.342 ; 20.286] 9.27E-44 11.571 [9.074 ; 14.068] 2.07E-19 
NHANES III EUR (Combined) 28.779 [26.779 ; 30.777] 6.12E-163 10.645 [8.655 ; 12.634] 1.76E-25 
NHANES III AA (Males) 13.809 [9.425 ; 18.193] 7.93E-10 7.389 [3.135 ; 11.643] 6.70E-04 
NHANES III AA (Females) 22.585 [19.856 ; 25.313] 2.62E-56 12.526 [9.658 ; 15.394] 1.91E-17 
NHANES III AA (Combined) 31.375 [29.188 ; 33.562] 4.51E-160 12.347 [9.994 ; 14.701] 1.53E-24 
NZ; New Zealand, JHS; Jackson Heart Study, NHANES III; US Third National Health and Nutrition Examination Survey, EUR; White Caucasian/European, AA; African American. 




Appendix A Table 2.8 Association of serum ferritin with hyperuricaemia (Transformed data) 
Population OR [95% CI] P OR [95% CI]* P* 
JHS (Males) 1.31 [1.01 ; 1.72] 4.22E-02 1.30 [1.00 ; 1.70] 5.74E-02 
JHS (Females) 2.40 [1.55 ; 3.84] 1.41E-04 2.12 [1.31 ; 3.61] 3.029E-03 
JHS (Combined) 2.17 [1.78 ; 2.68] 7.22E-14 1.52 [1.20 ; 1.92] 4.65E-04 
NHANES III EUR (Males) 1.40 [1.31 ; 1.51] 1.22E-20 1.18 [1.09 ; 1.27] 2.31E-05 
NHANES III EUR (Females) 2.21 [1.99 ; 2.46] 2.81E-48 1.52 [1.36 ; 1.71] 2.1E-12 
NHANES III EUR (Combined) 1.97 [1.86 ; 2.08] 3.89E-126 1.35 [1.27 ; 1.44] 6.00E-21 
NHANES III AA (Males) 1.65 [1.49 ; 1.84] 3.82E-20 1.31 [1.16 ; 1.47] 9.14E-06 
NHANES III AA (Females) 2.36 [2.05 ; 2.72] 2.15E-32 1.74 [1.48 ; 2.05] 3.35E-11 
NHANES III AA (Combined) 2.21 [2.04 ; 2.39] 7.91E-83 1.50 [1.37 ; 1.65] 2.41E-17 
NZ; New Zealand, JHS; Jackson Heart Study, NHANES III; US Third National Health and Nutrition Examination Survey, EUR; White Caucasian/European, AA; African American. 
*Adjusted for age, sex, BMI, C-reactive protein and number of self-reported Polynesian grandparents in the NZ Polynesian analyses.  All odds ratios represent a change per unit log of 
ferritin. 
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Appendix A Table 3.1 Details of study cohorts included in GWAS used in MR-analysis 
Köttgen et al. (2013) Benyamin et al. (2014) data 
Name of the study 
Number of 
individuals 
Name of the study 
Number of 
individuals 
AGES Reyjavik Study 3219 Australia-Adult 9148 
Amish 1193 Autralia-Adolescent 2544 
ARIC 9049 BHS 877 
ASPS 845 Cambridge  2419 
AUSTWIN 11520 CoLAUS 5409 
BLSA 521 ERF/Rotterdam 871 
BRIGHT 1743 Estonian Biobank (Original) 893 
CARDIA 1713 Estonian Biobank (Replication) 1017 
CHS 3252 FENLAND 1402 
CoLaus 5409 InCHIANTI 1206 
CROATIA-CORCULA 895 INTERACT 9294 
CROATIS-VIS 490 KORA F3 1634 
CROATSIS-SPLIT 912 KORA F4 1809 
DESIR 716 Micros/EURAC 1218 
ERF 1835 NBS 1791 
EPIC-Norfolk cohort 889 PREVEND 3644 
Estonian Biobank (Original) 931 SardiNIA 4694 
Family Heart Study (FamHS) 7837 Val Borbera 1659 
FHS 7699 Total number 51529 







INGI-CLIENTO 859   
INGI-FVG 1018 
  
INGI-Val Borbera 1658 
  
KORA F3 1643 
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Appendix A Table 5.1: Sixty-seven Genomic control SNPs genotyped to calculate 
estimates of individual Eastern Polynesian ancestry 
TaqMan Genotyped Sequenom MassArray Genotyped PCR-RFLP 
rs1183201 rs10025373 rs7725 
rs9358890 rs1143634 rs573816 
rs3799344 rs11536879  
rs12664474 rs1205  
rs2075876 rs2812378  
rs1816532 rs3014875  
rs13419122 rs344542  
rs12401573 rs40401  
rs6945435 rs452204  
rs743777 rs4780884  
rs10511216 rs4781011  
rs12745968 rs4804221  
rs1539438 rs4845622  
rs729749 rs4889640  
rs3738919 rs507879  
rs1130214 rs6005863  
rs755622 rs6819597  
rs7901695 rs6835636  
rs7578597 rs7811892  
rs2043211 rs7842  
rs10733113 rs795467  
rs900865 rs8075846  
rs2059606 rs8122  
rs4129148 rs9639436  
rs831628 rs9882205  
rs1929480 rs11078855  
rs12917707 rs11119568  
 rs1184835  
 rs12535365  
 rs12877336  
 rs2683764  
 rs35958249  
 rs4256629  
 rs4571803  
 rs493430  
 rs615204  
 rs693916  
 rs7108425  
 rs7118682  
 rs730275  
 rs9294168  
 rs9690688  
PCR-RFLP: Polymerase Chain Reaction-Restriction Fragment Length Polymorphism 
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Appendix A Table 5.2: *Brief summary of the 19 renal cell samples used to identify 





Sex Age Tissue Type Marker Type Protocol 
GSM621648 Male 67 (Years) Adult Kidney Histone Methylation ChIP-Seq 
GSM701494 Male 15 (Weeks) Foetal Renal Cortex DNase-Hypersensitivity DNase-Seq 
GSM701502 Male 15 (Weeks) Foetal Renal Cortex DNase-Hypersensitivity DNase-Seq 
GSM701511 Male 16 (Weeks) Foetal Renal Cortex DNase-Hypersensitivity DNase-Seq 
GSM701517 Male 15 (Weeks) Foetal Renal Cortex DNase-Hypersensitivity DNase-Seq 
GSM701519 Male 15 (Weeks) Foetal Renal Cortex DNase-Hypersensitivity DNase-Seq 
GSM701529 Male 13 (Weeks) Foetal Renal Cortex DNase-Hypersensitivity DNase-Seq 
GSM701532 Female 17 (Weeks) Foetal Renal Cortex DNase-Hypersensitivity DNase-Seq 
GSM772811 Male 67 (Years) Adult Kidney Histone Acetylation Chip-Seq 
GSM773005 Male 50 (years) Adult Kidney Histone Methylation ChIP-Seq 
GSM773006 Male 50 (years) Adult Kidney Histone Acetylation ChIP-Seq 
GSM817176 Male 18 (Weeks) Foetal Renal Cortex DNase-Hypersensitivity DNase-Seq 
GSM817190 Male 15 (Weeks) Foetal Renal Cortex DNase-Hypersensitivity DNase-Seq 
GSM817202 Male 17 (Weeks) Foetal Renal Cortex DNase-Hypersensitivity DNase-Seq 
GSM817203 Male 17 (Weeks) Foetal Renal Cortex DNase-Hypersensitivity DNase-Seq 
GSM817210 Male 15 (Weeks) Foetal Renal Cortex DNase-Hypersensitivity DNase-Seq 
GSM817211 Male 15 (Weeks) Foetal Renal Cortex DNase-Hypersensitivity DNase-Seq 
GSM878629 Male 14 (Weeks) Foetal Renal Cortex DNase-Hypersensitivity DNase-Seq 
GSM878667 Female 13 (Weeks) Foetal Renal Cortex DNase-Hypersensitivity DNase-Seq 
*Modified from Flynn (2016) 
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Appendix A Table 5.3: Meta-analysis results of single variant association analysis within LRP2 and A1CF for hyperuricaemia 
Exon Chr: location rs ID/var number POR PHet OR [95% CI] 
LRP2 
2 2:170177382 rs144829356 0.198 1.000 1.27 [0.88; 1.83] 
3 2:170175334 rs2229263 0.841 0.577 0.97 [0.73; 1.29] 
4 2:170163816 rs34104660 0.191 0.984 0.62 [0.30; 1.27] 
6 2:170150671 rs2229266 0.401 0.481 0.90 [0.70; 1.16] 
8 2:170147502 rs34693334 0.094 0.096 1.76 [0.91; 3.39] 
13 2:170131548 rs111360923 0.019 1.000 0.54 [0.32; 0.90] 
14 2:170129474 rs145709922 0.850 1.000 0.76 [0.05; 12.42] 
14 2:170129547 rs34291900 0.583 0.318 1.30 [0.51; 3.36] 
14 2:170129528 rs830994 0.151 0.051 0.82 [0.62; 1.08] 
15 2:170115588 rs2241190 0.735 0.479 1.04 [0.82; 1.32] 
15 2:170115672 rs33954745 0.625 0.703 0.85 [0.45; 1.61] 
15 2:170115626 var170115626 0.029 1.000 0.56 [0.34; 0.94] 
16 2:170127559 rs141180155 0.298 0.982 2.45 [0.45; 13.23] 
19 2:170103471 rs17848143 0.582 1.000 0.67 [0.16; 2.82] 
19 2:170103351 rs2075249 0.314 0.614 1.14 [0.88; 1.47] 
19 2:170103336 rs831043 0.664 0.355 1.05 [0.83; 1.34] 
21 2:170100011 rs150552608 0.429 1.000 0.38 [0.03; 4.23] 
22 2:170099473 rs831042 0.605 0.301 1.07 [0.84; 1.35] 
23 2:170097707 rs17848149 0.693 0.755 1.11 [0.65; 1.91] 
26 2:170096095 rs34915742 0.429 0.979 0.38 [0.03; 4.23] 
27 2:170094756 rs146289506 0.850 1.000 0.76 [0.05; 12.42] 
28 2:170093726 var170093726 0.249 1.000 0.35 [0.06; 2.07] 
29 2:170092439 rs151079411 0.668 1.000 1.97 [0.09; 43.53] 
29 2:170092395 rs2229267 0.910 0.612 0.99 [0.76; 1.28] 
29 2:170092504 var170092504 0.345 1.000 1.78 [0.54; 5.86] 
30 2:170089934 rs145384264 0.943 0.361 1.05 [0.26; 4.31] 
31 2:170088351 rs2302694 0.001 0.291 0.54 [0.37; 0.79] 
32 2:170082936 rs138070797 0.725 0.000 1.54 [0.14; 17.36] 
36 2:170070348 rs11886219 0.565 0.948 0.80 [0.37; 1.73] 
36 2:170070172 rs4667596 0.033 0.308 0.36 [0.14; 0.92] 
39 2:170063263 rs149367019 0.850 0.982 0.76 [0.05; 12.42] 
39 2:170063471 rs35114151 0.623 0.948 1.14 [0.67; 1.94] 
39 2:170062977 rs61995915 0.387 0.982 2.00 [0.42; 9.62] 
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41 2:170062078 rs13397109 0.083 0.152 0.71 [0.49; 1.05] 
42 2:170060603 rs17848169 0.854 0.398 1.09 [0.44; 2.72] 
44 2:170058345 var170058345 0.250 1.000 0.41 [0.09; 1.88] 
46 2:170053505 rs2228171 0.234 0.368 0.86 [0.68; 1.10] 
48 2:170048482 rs149148763 0.510 0.000 0.45 [0.04; 4.79] 
50 2:170042245 rs35734447 0.668 0.000 1.97 [0.09; 43.53] 
54 2:170032989 rs2229265 0.027 0.809 1.32 [1.03; 1.69] 
55 2:170031824 rs17848184 0.399 0.000 1.17 [0.81; 1.69] 
57 2:170029657 rs34355135 0.543 0.000 1.98 [0.22; 17.85] 
58 2:170028529 rs199528723 0.375 1.000 0.56 [0.15; 2.04] 
60 2:170026248 var170026248 0.668 1.000 1.97 [0.09; 43.53] 
61 2:170025083 rs2229268 0.336 0.408 1.18 [0.84; 1.67] 
64 2:170013904 rs79723119 0.482 0.981 1.71 [0.38; 7.60] 
66 2:170010985 rs2075252 0.028 0.415 0.75 [0.58; 0.97] 
67 2:170009390 rs142934522 0.429 1.000 0.38 [0.03; 4.23] 
69 2:170003432 rs4667591 0.012 0.430 0.72 [0.56; 0.93] 
70 2:170002412 var170002412 0.607 1.000 0.48 [0.03; 7.79] 
72 2:169997051 rs990626 0.201 0.470 0.85 [0.67; 1.09] 
73 2:169996070 rs41268685 0.045 0.980 3.85 [1.03; 14.38] 
77 2:169989127 rs142245618 0.682 1.000 0.67 [0.10; 4.45] 
79 2:169985338 rs34564141 0.718 1.000 1.38 [0.24; 8.11] 
A1CF 
5'UTR 10:52645424 rs10994860 0.272 0.487 1.22 [0.86; 1.73] 
5'UTR 10:52645409 var_52645409 0.362 1.000 0.62 [0.22; 1.74] 
3 10:52603874 rs142969066 0.576 0.982 0.65 [0.14; 2.99] 
3 10:52603754 rs35967725 0.857 0.534 0.86 [0.16; 4.51] 
6 10:52587964 rs143315865 0.850 1.000 0.76 [0.05; 12.42] 
7 10:52580318 rs372408821 0.237 0.426 3.31 [0.45; 24.17] 
7 10:52576068 rs4245008 0.263 0.980 3.40 [0.40; 29.06] 
8 10:52576025 rs142026324 0.935 1.000 0.90 [0.08; 10.72] 
9 10:52573772 rs41274050 0.317 0.355 1.18 [0.86; 1.61] 
3'UTR 10:52566049 rs10821846 0.529 0.833 1.08 [0.85; 1.37] 
3'UTR 10:52559634 rs10994507 0.701 0.715 0.91 [0.56; 1.47] 
3'UTR 10:52560658 rs10994521 0.850 1.000 0.76 [0.05; 12.42] 
3'UTR 10:52563898 rs112824128 0.885 1.000 1.17 [0.14; 9.71] 
3'UTR 10:52561919 rs12571156 0.543 0.994 1.11 [0.79; 1.57] 
3'UTR 10:52563981 rs150545950 0.707 0.980 0.61 [0.05; 7.93] 
3'UTR 10:52563196 rs16751 0.529 0.833 1.08 [0.85; 1.37] 
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3'UTR 10:52565132 rs185182715 0.068 1.000 0.72 [0.50; 1.03] 
3'UTR 10:52563051 rs4282939 0.317 0.355 1.18 [0.86; 1.61] 
3'UTR 10:52564065 rs4619096 0.093 0.547 0.82 [0.65; 1.03] 
3'UTR 10:52565951 rs4619097 0.364 0.293 1.16 [0.84; 1.59] 
3'UTR 10:52561643 rs59030524 0.429 1.000 0.38 [0.03; 4.23] 
3'UTR 10:52560557 rs6479731 0.745 0.990 1.46 [0.15; 14.23] 
3'UTR 10:52561829 rs7072584 0.364 0.293 1.16 [0.84; 1.59] 
3'UTR 10:52559843 rs7084132 0.364 0.293 1.16 [0.84; 1.59] 
3'UTR 10:52561803 rs74352101 0.364 0.293 1.16 [0.84; 1.59] 
3'UTR 10:52564700 rs74874346 0.723 0.695 0.92 [0.57; 1.49] 
3'UTR 10:52565377 rs75583477 0.830 0.598 0.95 [0.58; 1.54] 
3'UTR 10:52564421 rs80080606 0.543 0.994 1.11 [0.79; 1.57] 
3'UTR 10:52559853 var52559853 0.850 1.000 0.76 [0.05; 12.42] 
3'UTR 10:52561920 var52561920 0.357 1.000 2.07 [0.44; 9.70] 
3'UTR 10:52562642 var52562642 0.668 1.000 1.97 [0.09; 43.53] 
3'UTR 10:52563862 var52563898 0.850 1.000 0.76 [0.05; 12.42] 
3'UTR 10:52564524 var52564700 0.530 1.000 0.47 [0.04; 5.00] 
3'UTR 10:52565940 var52565951 0.850 1.000 0.76 [0.05; 12.42] 
3'UTR 10:52566333 var52566417 0.207 1.000 0.64 [0.32; 1.28] 
Exon: Exon number, UTR: Un-translated region, rs ID: Reference SNP cluster ID, Chr: Chromosome, var: Variant, Ref: Reference, Alt: Alternate. Normo: Normouricaemic, Hyper: 
Hyperuricaemic, OR: Odds ratio for the alternate allele, 95% CI: 95% confidence interval, POR: p-value for odds ratio. PHet: p-value for intra population heterogeneity. *Odds ratios are 
adjusted for sex, age, BMI and estimates of grand-parental ancestry for Polynesian dataset. Exons numbers and variant positions are sourced from the Genome Reference Consortium 
human genome build 37 (GRCh37) on Ensembl (http://grch37.ensembl.org/). 
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Appendix A Table 5.4: Summary of single variant association analysis within LRP2 for eGFR in NZ Polynesians 
Exon rs ID/var number 




Ref Alt Normouricaemic Hyperuricaemic 
n f n f Lower Upper 
2 rs144829356 G A 70 0.164 1 0.211 -2.169 -5.84 1.50 0.247 
3 rs2229263 T C 66 0.155 187 0.143 0.774 -3.42 4.97 0.718 
4 rs34104660 G T 3 0.007 5 0.000 -6.026 -30.86 18.81 0.635 
4 var170163808 G T 0 0.000 1 0.002 -11.914 -54.92 31.09 0.587 
6 rs2229266 G A 154 0.362 362 0.363 0.516 -2.67 3.70 0.751 
7 var170148871 T C 0 0.000 1 0.002 9.949 -33.00 52.90 0.650 
8 rs34693334 C G 4 0.009 0 0.000 3.953 -11.37 19.28 0.613 
8 var170147408 A G 0 0.000 0 0.000 -3.109 -46.07 39.85 0.887 
13 rs111360923 T C 47 0.110 0 0.000 -3.600 -8.71 1.51 0.168 
14 rs34291900 C T 2 0.005 0 0.000 -2.618 -33.06 27.82 0.866 
14 rs830994 A G 95 0.223 0 0.000 -1.845 -5.58 1.88 0.333 
15 rs2241190 T C 169 0.397 39 0.388 0.367 -2.65 3.39 0.812 
15 rs33954745 A G 7 0.016 43 0.011 -5.523 -18.66 7.61 0.410 
15 var170115626 T C 46 0.108 0 0.000 -3.473 -8.61 1.66 0.186 
16 rs141180155 G A 0 0.000 0 0.000 -16.177 -59.54 27.19 0.465 
16 rs147621120 T A 0 0.000 0 0.000 0.909 -42.05 43.87 0.967 
16 var170127497 A G 0 0.000 0 0.000 -7.127 -50.08 35.83 0.745 
18 var170104017 A C 2 0.005 0 0.000 -3.404 -33.80 26.99 0.826 
19 rs17848143 C T 5 0.012 0 0.000 9.363 -5.10 23.82 0.205 
19 rs2075249 G T 101 0.237 0 0.000 1.487 -1.92 4.90 0.393 
19 rs831043 T C 169 0.397 175 0.385 0.220 -2.81 3.25 0.887 
19 var170103219 T A 1 0.002 0 0.000 -0.095 -43.05 42.86 0.997 
22 rs144723964 G A 0 0.000 0 0.000 0.909 -42.05 43.87 0.967 
22 rs831042 T C 169 0.397 76 0.385 0.220 -2.81 3.25 0.887 
23 rs138030034 G A 0 0.000 55 0.002 0.909 -42.05 43.87 0.967 
23 rs17848149 T G 26 0.061 4 0.064 0.381 -5.62 6.38 0.901 
26 rs34915742 C G 0 0.000 4 0.002 0.909 -42.05 43.87 0.967 
28 var170093726 T G 5 0.012 10 0.004 -1.066 -17.42 15.29 0.898 
29 rs2229267 A G 128 0.300 165 0.284 -1.222 -4.53 2.08 0.469 
29 var170092504 C T 5 0.012 0 0.000 3.401 -7.88 14.68 0.555 
30 rs145384264 C T 2 0.005 0 0.000 -11.735 -36.55 13.08 0.355 
31 rs144054579 C G 0 0.000 0 0.000 0.909 -42.05 43.87 0.967 
31 rs149469954 G A 0 0.000 0 0.000 -7.997 -51.00 35.01 0.716 
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31 rs2302694 G A 64 0.150 176 0.095 -2.902 -7.47 1.66 0.213 
36 rs11886219 T C 7 0.016 0 0.000 -5.665 -18.26 6.93 0.378 
36 rs4667596 C T 10 0.023 155 0.009 4.447 -7.66 16.56 0.472 
39 rs149367019 G A 1 0.002 0 0.000 -44.147 -86.96 -1.34 0.044 
39 rs35114151 A G 26 0.061 1 0.062 -0.687 -6.73 5.36 0.824 
39 rs35413340 T C 0 0.000 28 0.002 28.626 -14.37 71.63 0.193 
39 rs61995915 T C 0 0.000 4 0.002 -7.127 -50.08 35.83 0.745 
41 rs13397109 G C 72 0.169 5 0.121 -1.675 -5.91 2.56 0.438 
42 rs17848169 T C 2 0.005 29 0.002 -2.618 -33.06 27.82 0.866 
42 rs199593393 C T 0 0.000 5 0.002 -12.078 -55.45 31.30 0.586 
44 var170058345 C A 5 0.012 0 0.000 3.756 -11.56 19.07 0.631 
45 var170055385 T C 1 0.002 0 0.000 11.254 -31.75 54.26 0.608 
46 rs2228171 T C 182 0.427 131 0.412 0.305 -2.65 3.26 0.839 
51 var170038806 C T 0 0.000 0 0.000 4.318 -39.07 47.71 0.845 
54 rs2229265 T C 320 0.751 65 0.797 0.292 -3.16 3.75 0.868 
55 rs17848184 C T 85 0.200 1 0.218 1.626 -2.06 5.31 0.387 
56 rs142549310 C T 0 0.000 0 0.000 13.541 -29.83 56.91 0.541 
56 var170030556 G A 0 0.000 0 0.000 -7.114 -26.35 12.12 0.469 
58 rs199528723 G A 5 0.012 99 0.011 4.400 -9.36 18.17 0.531 
61 rs2229268 A G 28 0.066 129 0.086 0.673 -4.93 6.28 0.814 
62 var170022511 T C 1 0.002 1 0.000 11.254 -31.75 54.26 0.608 
64 rs79723119 A C 1 0.002 0 0.000 -18.965 -61.94 24.02 0.388 
64 var170013979 A G 0 0.000 0 0.000 1.244 -42.15 44.63 0.955 
66 rs2075252 T C 139 0.326 120 0.289 0.124 -3.06 3.31 0.939 
69 rs4667591 T G 170 0.399 0 0.000 0.887 -2.15 3.92 0.567 
70 var170002412 T C 1 0.002 0 0.000 -12.650 -43.05 17.75 0.415 
72 rs990626 G A 180 0.423 175 0.394 0.717 -2.26 3.69 0.637 
74 rs370978040 G A 0 0.000 0 0.000 13.320 -29.82 56.46 0.545 
rs ID: Reference SNP cluster ID, Chr: Chromosome, var: Variant, Ref: Reference, Alt: Alternate.n: Total number of altered alleles, f: Altered allele frequency, Beta: Effect estimates 
(mL/min/1.73m2) for the alternate allele, 95% CI: 95% confidence interval, PBeta: p-value for effect estimates. *Values are adjusted for sex, age, BMI and estimates of grand-parental 
ancestry. Exons numbers and variant positions are sourced from the Genome Reference Consortium human genome build 37 (GRCh37) on Ensembl (http://grch37.ensembl.org/). Note: 
eGFR was calculated using CKD-EPI formula (mL/min/1.73m2) (https://www.qxmd.com/calculate/calculator_251/egfr-using-ckd-epi). 
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Appendix A Table 5.5: List of the variants selected for rare-variant burden analyses 
for LRP2 and A1CF 
LRP2 A1CF 
rs ID/var position CAF rs ID/var position CAF rs ID/var position CAF 
rs114460450 0.003 rs34564141 0.009 rs10994521 0.003 
rs114842875 0.003 rs34592807 0.001 rs112824128 0.007 
rs116332504 0.001 rs34693334 0.034 rs141891504 0.001 
rs11886219 0.028 rs34915742 0.002 rs142026324 0.007 
rs138030034 0.001 rs35114151 0.047 rs142968717 0.001 
rs138070797 0.005 rs35413340 0.003 rs142969066 0.006 
rs138269726 0.001 rs35734447 0.003 rs143123872 0.003 
rs139514301 0.003 rs35942532 0.003 rs143315865 0.003 
rs140272085 0.003 rs370978040 0.001 rs146662131 0.001 
rs140586887 0.001 rs371966515 0.001 rs150441974 0.001 
rs140918583 0.003 rs374368151 0.001 rs150545950 0.003 
rs141068435 0.001 rs375394006 0.001 rs16909156 0.001 
rs141180155 0.006 rs41268685 0.011 rs181769526 0.003 
rs141305635 0.001 rs4667596 0.017 rs183260900 0.001 
rs142093111 0.001 rs61995915 0.007 rs185182715 0.001 
rs142221587 0.001 rs7598640 0.001 rs34190540 0.004 
rs142245618 0.007 rs79723119 0.009 rs35967725 0.006 
rs142549310 0.002 var169995201 0.001 rs372408821 0.001 
rs142934522 0.004 var169995769 0.001 rs41274050 0.004 
rs143150497 0.001 var169996058 0.001 rs4619097 0.004 
rs143893803 0.001 var170002291 0.001 rs59030524 0.001 
rs144054579 0.001 var170002412 0.002 rs61742973 0.001 
rs144451000 0.001 var170012798 0.001 rs61856570 0.007 
rs144723964 0.001 var170013979 0.001 rs75583477 0.001 
rs145201961 0.003 var170022511 0.001 rs80080606 0.001 
rs145365776 0.001 var170026248 0.003 rs9073 0.001 
rs145384264 0.009 var170029656 0.001 var52559596 0.003 
rs145709922 0.004 var170030458 0.001 var52559853 0.001 
rs146149181 0.003 var170031714 0.001 var52559869 0.001 
rs146289506 0.003 var170038795 0.001 var52559874 0.001 
rs146783211 0.001 var170038806 0.001 var52560181 0.001 
rs147267007 0.001 var170042056 0.001 var52561178 0.001 
rs147287428 0.001 var170050399 0.001 var52561212 0.001 
rs147621120 0.001 var170055385 0.001 var52561680 0.010 
rs148356370 0.005 var170058345 0.009 var52561920 0.001 
rs148503556 0.001 var170060706 0.001 var52562339 0.001 
rs149148763 0.007 var170062881 0.001 var52562434 0.003 
rs149367019 0.004 var170063080 0.001 var52562642 0.001 
rs149469954 0.001 var170063503 0.001 var52563248 0.001 
rs149558767 0.001 var170066058 0.001 var52563513 0.001 
rs149853330 0.001 var170068592 0.001 var52563650 0.001 
rs150552608 0.004 var170092504 0.017 var52563845 0.001 
rs150752263 0.001 var170093726 0.008 var52563862 0.003 
rs151079411 0.003 var170096262 0.001 var52563898 0.001 
rs17848143 0.01 var170101294 0.001 var52563981 0.006 
rs17848149 0.046 var170103219 0.001 var52564700 0.001 
rs17848169 0.02 var170103416 0.001 var52565100 0.001 
rs199528723 0.011 var170103488 0.001 var52565132 0.004 
rs199593393 0.001 var170104017 0.002 var52566417 0.001 
rs200475391 0.004 var170115652 0.001 var52595864 0.001 
rs200587303 0.001 var170127497 0.001 var52619722 0.001 
rs201490492 0.001 var170135946 0.001 var52623804 0.019 
rs202154723 0.001 var170137024 0.001 var52645409 0.001 
rs33954745 0.041 var170147408 0.001 
  
rs34104660 0.043 var170148871 0.001 
  
rs34291900 0.018 var170163808 0.001 
  
rs34355135 0.008 
    
CAF: Combined frequency of altered allele in NZ Polynesian and European populations, rs ID: Reference SNP cluster 
ID, var; Variant. 
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Appendix A Table 5.6: List of all exonic variants/ SNPs for LRP2 and A1CF exported from Ensembl Variant Effect Predictor (Ve!P) 
and their functional consequences with annotation scores 
Sr. # Exon Location Conseq rs/var number CADD PolyPhen2 SIFT POVEAN Protein 
     
Score Score Prediction Score Prediction Score Prediction Pos Ref|Alt 
LRP2 
1 2 2:170177325 MV rs114460450 20.4 Not scored Not scored Not scored Not scored Not scored Not scored 50 S|T 
2 2 2:170177382 MV rs144829356 Not scored Not scored Not scored Not scored Not scored Not scored Not scored 31 G|E 
3 3 2:170175334 MV rs2229263 0.001 Not scored Not scored Not scored Not scored Not scored Not scored 83 I|T 
4 4 2:170163816 MV rs34104660 2.735 - - - - - - 134 P 
5 4 2:170163827 SL rs34592807 0.245 - - - - - - 131 *|R 
6 4 2:170163808 SV var170163808 Not scored Not scored Not scored Not scored Not scored Not scored Not scored 137 G|V 
7 6 2:170150671 SV rs2229266 12.22 - - - - - - 213 E 
8 7 2:170148871 MV var170148871 Not scored Not scored Not scored Not scored Not scored Not scored Not scored 221 S|P 
9 8 2:170147502 MV rs34693334 10.32 Not scored Not scored Not scored Not scored Not scored Not scored 259 R|G 
10 8 2:170147368 SReV rs375394006 7.89 - - - - - - 303 T 
11 8 2:170147408 SV var170147408 - - - - - - - 290 * 
12 11 2:170136871 SG rs148503556 7.379 - - - - - - 444 L 
13 11 2:170137024 SV var170137024 0.021 - - - - - - 393 Q|* 
14 12 2:170136059 MV rs202154723 9.236 Not scored Not scored Not scored Not scored Not scored Not scored 463 I|T 
15 12 2:170135946 MV var170135946 26.7 Not scored Not scored Not scored Not scored Not scored Not scored 501 G|R 
16 13 2:170131548 MV rs111360923 Not scored Not scored Not scored Not scored Not scored Not scored Not scored 589 F|S 
17 13 2:170134324 MV rs141305635 13.99 - - - - - - 568 W|* 
18 13 2:170134385 MV rs201490492 31 3.583 Deleterious 0.02 Deleterious -4.29 Deleterious 548 G|S 
19 13 2:170131729 SG rs374368151 24.8 2.077 Deleterious 0.5 Neutral -3.44 Deleterious 529 R|C 
20 14 2:170129529 MV rs116332504 24 1.423 Deleterious 0 Deleterious -3.8 Deleterious 606 D|G 
21 14 2:170129474 MV rs145709922 8.443 - - - - - - 624 L 
22 14 2:170129547 SV rs34291900 33 2.385 Deleterious 0.07 Neutral -6.41 Deleterious 600 A|V 
23 14 2:170129528 SV rs830994 - - - - - - - 606 V 
24 15 2:170115588 MV rs2241190 0.34 - - - - - - 683 T 
25 15 2:170115672 MV rs33954745 8.978 - - - - - - 655 E 
26 15 2:170115706 MV rs371966515 7.774 0.647 Neutral 0.9 Neutral -1.05 Neutral 644 I|T 
27 15 2:170115626 SV var170115626 Not scored -0.12 Neutral 0.33 Neutral -0.44 Neutral 671 F|L 
28 15 2:170115652 SV var170115652 28.7 3.458 Deleterious 0 Deleterious -8.28 Deleterious 662 F|S 
29 16 2:170127559 MV rs141180155 12.92 - - - - - - 725 T 
30 16 2:170127556 MV rs144451000 12.96 0.879 Neutral 0.08 Neutral -2.31 Neutral 726 F|L 
31 16 2:170113671 MV rs147621120 Not scored 0.386 Neutral 0.25 Neutral -2.4 Neutral 731 S|T 
32 16 2:170113670 MV rs150752263 19.02 0.386 Neutral 0.25 Neutral -2.4 Neutral 731 S|T 
33 16 2:170127497 SV var170127497 Not scored 1.757 Deleterious 0.01 Deleterious -3.39 Deleterious 746 N|S 
34 18 2:170104017 MV var170104017 Not scored 1.583 Deleterious 0 Deleterious -4.57 Deleterious 790 I|L 
35 19 2:170103472 MV rs114842875 15.16 2.966 Deleterious 0.18 Neutral -2.35 Neutral 841 R|K 
36 19 2:170103471 MV rs17848143 - - - - - - - 841 T 
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37 19 2:170103351 SV rs2075249 0.593 - - - - - - 881 T 
38 19 2:170103336 SV rs831043 0.126 - - - - - - 886 T 
39 19 2:170103219 SV var170103219 - - - - - - - 925 T 
40 19 2:170103416 SV var170103416 27.2 - - - - - - 860 L 
41 19 2:170103488 SV var170103488 13.07 1.462 Deleterious 0.65 Neutral -0.42 Neutral 836 P|S 
42 20 2:170101269 MV rs149853330 3.687 0.171 Neutral 0.11 Neutral -0.59 Neutral 985 F|L 
43 20 2:170101294 SV var170101294 0.008 - - - - - - 976 H 
44 21 2:170100011 MV rs150552608 10.62 1.605 Neutral 0.5 Neutral -3.42 Deleterious 1014 R|H 
45 22 2:170099474 MV rs144723964 Not scored 0.464 Neutral 0.32 Neutral -0.73 Neutral 1083 G|E 
46 22 2:170099473 SV rs831042 10.6 - - - - - - 1083 A 
47 23 2:170097655 MV rs138030034 - - - - - - - 1159 W|* 
48 23 2:170097707 SG rs17848149 0.758 0.684 Neutral 0.74 Neutral -3.97 Deleterious 1142 V|G 
49 23 2:170097508 SV rs200587303 10.16 - - - - - - 1208 S 
50 26 2:170096095 MV rs34915742 11.14 - - - - - - 1412 R 
51 26 2:170096262 SV var170096262 24.6 1.634 Deleterious 0.37 Neutral -3.03 Deleterious 1357 Y|H 
52 27 2:170094756 MV rs146289506 12.52 1.642 Neutral 0.04 Deleterious -1.63 Neutral 1451 L|I 
53 28 2:170093726 SV var170093726 - - - - - - - 1526 T 
54 29 2:170092467 MV rs141068435 11.62 - - - - - - 1601 W|* 
55 29 2:170092439 MV rs151079411 11.52 Not scored Not scored Not scored Not scored Not scored Not scored 1611 V|M 
56 29 2:170092395 SG rs2229267 6.06 - - - - - - 1625 *|W 
57 29 2:170092504 SL var170092504 Not scored 2.726 Deleterious 0 Deleterious -4.85 Deleterious 1589 P|L 
58 30 2:170089947 MV rs145365776 13.38 0.476 Neutral 1 Neutral 0.15 Neutral 1691 G|E 
59 30 2:170089934 SV rs145384264 14.25 - - - - - - 1695 S 
60 31 2:170088328 MV rs142221587 18.15 0.471 Neutral 0.22 Neutral -0.68 Neutral 1708 P|L 
61 31 2:170088296 MV rs144054579 Not scored 1.042 Neutral 0.54 Neutral -0.86 Neutral 1719 R|G 
62 31 2:170088242 MV rs149469954 11.88 1.621 Neutral 0.06 Neutral -0.01 Neutral 1737 V|I 
63 31 2:170088351 SRV rs2302694 3.454 - - - - - - 1700 S 
64 32 2:170082936 MV rs138070797 9.969 1.557 Deleterious 0.77 Neutral -1.53 Neutral 1797 I|T 
65 36 2:170070348 MV rs11886219 4.612 - - - - - - 1953 R 
66 36 2:170070172 SV rs4667596 17.88 0.496 Neutral 0.99 Neutral -0.13 Neutral 2012 T|I 
67 37 2:170068598 MV rs138269726 23.7 1.943 Deleterious 0.62 Neutral -1.85 Neutral 2054 H|Y 
68 37 2:170068502 MV rs146149181 23 -0.021 Neutral 0.07 Neutral 0.64 Neutral 2086 S|T 
69 37 2:170068592 MV var170068592 34 3.621 Deleterious 0.02 Deleterious -3.34 Deleterious 2056 G|R 
70 38 2:170066058 MV var170066058 23.1 2.726 Deleterious 0.54 Neutral -1.05 Neutral 2125 P|L 
71 39 2:170063372 MV rs140918583 15.51 0.49 Neutral 0.26 Neutral -3.83 Deleterious 2286 L|F 
72 39 2:170063339 MV rs143893803 25 2.277 Deleterious 0.24 Neutral -3.53 Deleterious 2297 F|L 
73 39 2:170063223 MV rs147287428 11.29 1.72 Deleterious 0.69 Neutral -0.32 Neutral 2336 P|L 
74 39 2:170063263 MV rs149367019 6.299 Not scored Not scored Not scored Not scored Not scored Not scored 2323 V|I 
75 39 2:170063471 MV rs35114151 1.78 - - - - - - 2253 E 
76 39 2:170063380 MV rs35413340 5.194 0.548 Neutral 1 Neutral 0.06 Neutral 2284 S|P 
77 39 2:170062977 MV rs61995915 0.016 0.053 Neutral 0.54 Neutral -0.96 Neutral 2418 V|A 
78 39 2:170062881 MV var170062881 9.935 1.599 Neutral 0.14 Neutral -2.45 Neutral 2450 S|N 
79 39 2:170063080 SG var170063080 3.326 0.043 Neutral 0.67 Neutral -0.02 Neutral 2384 F|L 
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80 39 2:170063503 SV var170063503 7.804 - - - - - - 2243 G|* 
81 41 2:170062078 SV rs13397109 9.831 - - - - - - 2542 R 
82 42 2:170060631 MV rs139514301 11.51 - - - - - - 2622 E 
83 42 2:170060750 SV rs145201961 11.03 - - - - - - 2583 L 
84 42 2:170060603 SV rs17848169 0.307 1.407 Deleterious 0.87 Neutral -1.73 Neutral 2632 Y|H 
85 42 2:170060619 SV rs199593393 - - - - - - - 2626 H 
86 42 2:170060706 SV var170060706 10.98 - - - - - - 2597 G 
87 44 2:170058345 MV var170058345 Not scored 1.267 Neutral 0.83 Neutral 0.2 Neutral 2749 P|T 
88 45 2:170055416 MV rs140586887 24.6 1.637 Deleterious 0.48 Neutral -1.67 Neutral 2820 G|C 
89 45 2:170055385 MV var170055385 Not scored -0.216 Neutral 0.41 Neutral 0.02 Neutral 2830 L|P 
90 46 2:170053505 MV rs2228171 0.003 -1.003 Neutral - Not scored - - 2872 S|P 
91 47 2:170050399 MV var170050399 0.001 0.143 Neutral 0.37 Neutral -1.19 Neutral 2901 L|P 
92 48 2:170048482 SV rs149148763 13.31 - - - - - - 2964 S 
93 49 2:170044768 MV rs142093111 23.9 0.848 Neutral 0.13 Neutral -3.9 Deleterious 3014 G|R 
94 50 2:170042208 MV rs143150497 10.43 2.151 Deleterious 0.06 Neutral -1.54 Neutral 3217 F|S 
95 50 2:170042495 MV rs146783211 7.817 - - - - - - 3121 G 
96 50 2:170042245 SL rs35734447 27.8 1.634 Deleterious 0.01 Deleterious -4.96 Deleterious 3205 Y|H 
97 50 2:170042056 SV var170042056 6.843 - - - - - - 3268 *|R 
98 51 2:170038694 MV rs149558767 2.376 - - - - - - 3327 A 
99 51 2:170038795 MV var170038795 25 2.199 Deleterious 0.01 Deleterious -3.22 Deleterious 3294 V|I 
100 51 2:170038806 SV var170038806 Not scored -0.937 Neutral 0.6 Neutral 2.84 Neutral 3290 P|L 
101 52 2:170037962 SV rs140272085 23.5 - - - - - - 3389 L 
102 53 2:170034424 MV rs147267007 26.6 1.765 Deleterious 0.06 Neutral -5.06 Deleterious 3428 W|R 
103 54 2:170032989 SV rs2229265 2.762 - - - - - - 3501 H 
104 55 2:170031824 MV rs17848184 - - - - - - - 3549 P 
105 55 2:170031714 SV var170031714 12.34 -0.087 Neutral 0.27 Neutral 0.4 Neutral 3586 P|L 
106 56 2:170030506 MV rs142549310 19.26 0.514 Neutral 0.12 Neutral -3.05 Deleterious 3646 P|L 
107 56 2:170030458 MV var170030458 28.1 2.023 Deleterious 0 Deleterious -7.67 Deleterious 3662 V|G 
108 56 2:170030556 SV var170030556 - - - - - - - 3629 Q 
109 57 2:170029657 MV rs34355135 13.06 - - - - - - 3698 L 
110 57 2:170029656 SV var170029656 13.97 1.423 Deleterious 0.51 Neutral -2.02 Neutral 3698 E|G 
111 58 2:170028529 SV rs199528723 - - - - - - - 3753 K 
112 59 2:170027153 MV rs200475391 32 2.148 Deleterious 0 Deleterious -6.94 Deleterious 3763 V|E 
113 59 2:170027095 SV rs7598640 12.18 - - - - - - 3782 K 
114 60 2:170026248 MV var170026248 23 1.657 Deleterious 0.58 Neutral -1.59 Neutral 3821 P|S 
115 61 2:170025083 SL rs2229268 4.949 - - - - - - 3867 *|W 
116 62 2:170022511 MV var170022511 Not scored 0.186 Neutral 0.44 Neutral -0.64 Neutral 3897 F|L 
117 64 2:170013904 MV rs79723119 0.005 0.759 Neutral 0.42 Neutral -0.34 Neutral 3999 D|A 
118 64 2:170013979 MV var170013979 Not scored 1.665 Deleterious 0.62 Neutral -0.53 Neutral 3974 K|R 
119 65 2:170012798 MV var170012798 22.4 0.253 Neutral 0.59 Neutral -0.15 Neutral 4046 P|L 
120 66 2:170010985 SL rs2075252 16.49 - - - - - - 4094 *|Q 
121 67 2:170009390 MV rs142934522 11.96 2.116 Deleterious 0.22 Neutral 0.78 Neutral 4127 P|L 
122 67 2:170009391 MV rs148356370 5.278 -0.329 Neutral 0.8 Neutral 0.58 Neutral 4127 G|C 
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123 69 2:170003335 MV rs35942532 22.1 1.609 Deleterious 0.51 Neutral -3.63 Deleterious 4242 V|A 
124 69 2:170003432 MV rs4667591 31 0.922 Deleterious 0.03 Deleterious -1.91 Neutral 4210 F|V 
125 70 2:170002291 MV var170002291 5.035 - - - - - - 4318 V 
126 70 2:170002412 SV var170002412 Not scored 1.853 Deleterious 0.01 Deleterious -6.15 Deleterious 4278 V|A 
127 72 2:169997051 MV rs990626 14.46 Not scored Not scored Not scored Not scored Not scored Not scored 4371 M|I 
128 73 2:169996070 MV rs41268685 23 2.095 Deleterious 0.11 Neutral -2.58 Deleterious 4417 A|V 
129 73 2:169996058 MV var169996058 29.7 2.1 Deleterious 0.03 Deleterious -3.15 Deleterious 4421 A|V 
130 74 2:169995880 MV rs370978040 - - - - - - - 4423 T 
131 74 2:169995769 SRV var169995769 25.3 1.991 Deleterious 0.01 Deleterious -2.13 Neutral 4460 N|K 
132 75 2:169995201 SV var169995201 9.565 - - - - - - 4468 V 
133 77 2:169989127 MV rs142245618 6.369 0.076 Neutral 0.79 Neutral -1.31 Neutral 4562 D|G 
134 79 2:169985338 SRV rs34564141 22.9 - - - - - - 4601 I 
A1CF 
1 5' 10:52645409 5' UTR var52645409          
2 5' 10:52645424 5' UTR rs10994860 - - - - - - - - - 
3 5' 10:52619722 5' UTR var52619722 - - - - - - - - - 
4 2 10:52623804 NCT var52623804 - - - - - - - - - 
5 3 10:52603754 SL rs35967725 - - - - - - - 76 *|W 
6 3 10:52603874 SV rs142969066 - - - - - - - 36 G 
7 4 10:52601702 SV rs141891504 - - - - - - - 95 K 
8 5 10:52595853 SV rs61742973 - - - - - - - 195 A 
9 5 10:52595864 MV var52595864 Not scored Not scored Not scored 0 Deleterious -1.99 Neutral 192 P|S 
10 5 10:52595978 MV rs143123872 10.73 1.545 Deleterious 0.03 Deleterious -1.99 Deleterious 154 T|A 
11 6 10:52587964 MV rs143315865 12.64 2.381 Deleterious 0.77 Tolerated -1.99 Neutral 232 M|I 
12 6 10:52588045 SV rs146662131 - - - - - - - 205 H 
13 7 10:52576068 NCT rs4245008 - - - - - - - - - 
14 7 10:52580318 SV rs372408821 - - - - - - - 287 K 
15 8 10:52576025 SV rs142026324 - - - - - - - 294 S 
16 9 10:52573772 MV rs41274050 23.8 1.792 Deleterious 0.24 Tolerated -1.99 Neutral 390 R|C 
17 12 10:52566594 SV rs34190540 - - - - - - - 552 L 
18 12 10:52566611 SV rs9073 - - - - - - - 547 L 
19 3' 10:52559291 3' UTR rs61856570 - - - - - - - - - 
20 3' 10:52559596 3' UTR var52559596 - - - - - - - - - 
21 3' 10:52559634 3' UTR rs10994507 - - - - - - - - - 
22 3' 10:52559843 3' UTR rs7084132 - - - - - - - - - 
23 3' 10:52559853 3' UTR var52559853 - - - - - - - - - 
24 3' 10:52559869 3' UTR var52559869 - - - - - - - - - 
25 3' 10:52559874 3' UTR var52559874 - - - - - - - - - 
26 3' 10:52560181 3' UTR var52560181 - - - - - - - - - 
27 3' 10:52560476 3' UTR rs75907017 - - - - - - - - - 
28 3' 10:52560557 3' UTR rs6479731 - - - - - - - - - 
29 3' 10:52560658 3' UTR rs10994521 - - - - - - - - - 
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30 3' 10:52560693 3' UTR rs142968717 - - - - - - - - - 
31 3' 10:52561178 3' UTR var52561178 - - - - - - - - - 
32 3' 10:52561212 3' UTR var52561212 - - - - - - - - - 
33 3' 10:52561643 3' UTR rs59030524 - - - - - - - - - 
34 3' 10:52561680 3' UTR var52561680 - - - - - - - - - 
35 3' 10:52561803 3' UTR rs74352101 - - - - - - - - - 
36 3' 10:52561829 3' UTR rs7072584 - - - - - - - - - 
37 3' 10:52561919 3' UTR rs12571156 - - - - - - - - - 
38 3' 10:52561920 3' UTR var52561920 - - - - - - - - - 
39 3' 10:52562099 3' UTR rs150441974 - - - - - - - - - 
40 3' 10:52562339 3' UTR var52562339 - - - - - - - - - 
41 3' 10:52562434 3' UTR var52562434 - - - - - - - - - 
42 3' 10:52562642 3' UTR var52562642 - - - - - - - - - 
43 3' 10:52563051 3' UTR rs4282939 - - - - - - - - - 
44 3' 10:52563196 3' UTR rs16751 - - - - - - - - - 
45 3' 10:52563248 3' UTR var52563248 - - - - - - - - - 
46 3' 10:52563345 3' UTR rs16909156 - - - - - - - - - 
47 3' 10:52563513 3' UTR var52563513 - - - - - - - - - 
48 3' 10:52563650 3' UTR var52563650 - - - - - - - - - 
49 3' 10:52563707 3' UTR rs184644838 - - - - - - - - - 
50 3' 10:52563725 3' UTR var52563845 - - - - - - - - - 
51 3' 10:52563845 3' UTR var52563862 - - - - - - - - - 
52 3' 10:52563862 3' UTR var52563898 - - - - - - - - - 
53 3' 10:52563898 3' UTR rs112824128 - - - - - - - - - 
54 3' 10:52563904 3' UTR var52563981 - - - - - - - - - 
55 3' 10:52563981 3' UTR rs150545950 - - - - - - - - - 
56 3' 10:52564065 3' UTR rs4619096 - - - - - - - - - 
57 3' 10:52564421 3' UTR rs80080606 - - - - - - - - - 
58 3' 10:52564524 3' UTR var52564700 - - - - - - - - - 
59 3' 10:52564700 3' UTR rs74874346 - - - - - - - - - 
60 3' 10:52564768 3' UTR var52565100 - - - - - - - - - 
61 3' 10:52565100 3' UTR var52565132 - - - - - - - - - 
62 3' 10:52565132 3' UTR rs185182715 - - - - - - - - - 
63 3' 10:52565377 3' UTR rs75583477 - - - - - - - - - 
64 3' 10:52565903 3' UTR rs4078160 - - - - - - - - - 
65 3' 10:52565940 3' UTR var52565951 - - - - - - - - - 
66 3' 10:52565951 3' UTR rs4619097 - - - - - - - - - 
67 3' 10:52566049 3' UTR rs10821846 - - - - - - - - - 
68 3' 10:52566057 3' UTR rs183260900 - - - - - - - - - 
69 3' 10:52566333 3' UTR var52566417 - - - - - - - - - 
MS: Missense variant, NS: Non-synonymous variant, SRV: Splice region variant, SReV: Splice retained variant, *: Stop, SL/G: Stop lost/gained, NCT: Non-coding transcript, Ref|Alt: 
Reference|Alternate amino acid, Conseq: Functional consequence, Pos: Position, UTR: Untranslated region. 
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APPENDIX B 
Appendix B Figure 2.1: Histograms indicating non-linear distribution of ferritin data in US (A) Control and (B) Gout, NZ Polynesian (C) Control and (D) Gout 
and NZ European (E) Control and (F) Gout case groups. 
 
























Appendix B Figure 2.2: Histograms indicating non-linear distribution of ferritin data in (A) NHANESIII European, (B) NHANESIII African American and 
(C) JHS African American non-gout (control) groups.  
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Appendix B Figure 2.3: Histograms indicating log-transformed distribution of ferritin data in US (A) Control and (B) Gout, NZ Polynesian (C) Control and 
(D) Gout and NZ European (E) Control and (F) Gout case groups. 
  




Appendix B Figure 2.4: Histograms indicating log-transformed distribution of ferritin data in (A) NHANESIII European, (B) NHANESIII African American 
and (C) JHS African American non-gout (control) groups. 
 
 






























Appendix B Figure 3.1: Venn diagram representing total sample overlap between the two GWAS (Benyamin et al., 2014; Köttgen et al., 2013) selected for two-
sample Mendelian randomisation analysis. 
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Appendix B Figure 3.2: Locus zoom plot indicating two HFE gene variants (A) rs1800562 (P = 0.001) 
and (B) rs1799945 (P = 2.94E-06) having an LD with variants within/near SLC17A1-3 loci in a recent 
GWAS (Köttgen et al., 2013). Plots were created online (http://locuszoom.sph.umich.edu/).  
A 
B
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Appendix B Figure 4.1: Meta-analysis of (A) NZ Polynesian, (B) European and (C) All sample sets 









Appendix B Figure 4.2: Meta-analysis of (A) NZ Polynesian, (B) European and (C) All sample sets 
combined for association of rs4994 (G allele) with serum urate. Values on x-axis represent effect size 
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Appendix B Figure 4.3: Meta-analysis of (A) NZ Polynesian, (B) European and (C) All sample sets 








Appendix B Figure 4.4: Meta-analysis of (A) NZ Polynesian, (B) European and (C) All sample sets 
combined for association of rs3827103 (A allele) with serum urate. Values on x-axis represent effect 









Appendix B Figure 4.5: Meta-analysis of (A) NZ Polynesian, (B) European and (C) All sample sets 








Appendix B Figure 4.6: Meta-analysis of (A) NZ Polynesian, (B) European and (C) All sample sets 
combined for association of rs17700633 (A allele) with serum urate. Values on x-axis represent effect 








Appendix B Figure 4.7: Meta-analysis of (A) NZ Polynesian, (B) European and (C) All sample sets 








Appendix B Figure 4.8: Meta-analysis of (A) NZ Polynesian, (B) European and (C) All sample sets 
combined for association of rs17782313 (C allele) with serum urate. Values on x-axis represent effect 








Appendix B Figure 4.9: Meta-analysis of (A) NZ Polynesian, (B) European and (C) All sample sets 








Appendix B Figure 4.10: Meta-analysis of (A) NZ Polynesian, (B) European and (C) All sample sets 
combined for association of rs6903956 (A allele) with serum urate. Values on x-axis represent effect 
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Appendix B Figure 5.1: An overview of coding (exonic) and non-coding (intronic) regions of (A) LRP2 gene: total length – 235.58 kb, exons – 79, coding exons – 
79, transcript length – 15,808 bps, introns – 78, and (B) A1CF gene: total length – 86.27 kb, exons – 12, coding exons – 11, transcript length – 9,221 bps, introns 
– 11. Sourced from Genome Reference consortium human genome build 37 (GRCh37) on Ensembl (http://grch37.ensembl.org/). 
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Appendix B Figure 5.2: Locus zoom plot indicating association signals for two lipid-related genes (A) 
LRP2 and (B) A1CF with eGFR (mL/min/1.73m2) in a recent GWAS (Pattaro et al., 2016). Plots were 
created online (http://locuszoom.sph.umich.edu/).  
A 
B 
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Appendix B Figure 5.3: Locus zoom plot indicating association signals for two LRP2 variants (A) 
rs4667591 (P = 0.006) and (B) rs2075252 (P = 0.004) with eGFR (mL/min/1.73m2) in a recent GWAS 
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Appendix B Figure 5.4: Locus zoom plot indicating association signals for two LRP2 variant 
rs2302694 with eGFR (mL/min/1.73m2) in a recent GWAS (P = 0.005) (Pattaro et al., 2016). Plots 
were created online (http://locuszoom.sph.umich.edu/). 
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